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The major clinical challenge in the treatment of glioblastoma is the inability of 
chemotherapeutic agents to pass the blood-brain barrier (BBB). Docetaxel a hydrophobic 
anticancer drug used alone and in combination with other drugs to treat tumours is a P-
glycoprotein substrate and suffers from the drawback of non-specific cytotoxicity and limited 
accumulation in the brain. To address these clinical challenges and enhance therapeutic 
potential for glioblastoma treatment and penetration of BBB, the project investigated 
nanostructured lipid carrier (NLC) for encapsulation of docetaxel and explored two 
polyunsaturated fatty acids (PUFAs) gamma-linolenic acid (GLA) and Alpha-linolenic acid 
(ALA), and a novel selective aptamer (SA43) as targeting ligands for specific glioblastoma 
targeting. 
A novel, simple and sensitive HPLC method was developed and validated for quantification 
of docetaxel from BBB cell culture medium. The method exhibited high precision and 
accuracy with sample recovery ranging from 90.03- 100.02% and was used to determine the 
permeated drug in the 3D in-vitro BBB model. Validated HPLC methods with high precision 
and accuracy were also developed for quantification of docetaxel from the NLCs and release 
media. Docetaxel-NLC were formulated using biodegradable materials combining Dynasan 
114 as solid lipid with three liquid lipids and surfactants employing hot homogenisation 
technique on probe sonicator. A 32 factorial design was used for optimisation of critical 
factors to get docetaxel-NLCs with particles size (136.8 nm), relatively low polydispersity 
index (PDI 0.231), high entrapment efficiency (99.1%) and high total drug content (80.6%) 
with zeta potential of -32.4 mV contributing to the stability of the docetaxel-NLC over a six 
months period. Docetaxel-NLCs was successfully lyophilised with an only a small increase in 
particle size (13nm) using 10% trehalose as a cryo-protectant. All three ligands (GLA, ALA and 
SA43) were successfully conjugated to Docetaxel-NLCs and covalent bonding was confirmed 
with reduction of surface free amines, FTIR and Raman spectroscopy. DSC and XRD confirmed 
the presence of docetaxel in an amorphous state within the NLCs.  
In-vitro cell lines studies revealed the high efficacy of PUFAs surface modified docetaxel-NLCs 
(GLA-docetaxel-NLC and ALA-docetaxel-NLC) where IC50  showed ~ 6.5 fold increase in 
docetaxel activity at 24h towards glioblastoma (U87MG) cells and ~ 10 fold higher 
cytotoxicity in patient-derived short-term culture obtained from Brain Tumour North West 
organisation (BTNW911) glioblastoma cells at 24 and 48 h. Aptamer surface modified 
docetaxel-NLC (SA43-docetaxel-NLC) showed high selectivity towards glioblastoma cell lines 
with high potency as compared to non-cancerous brain cells (SVG P12) with a preferable 
lower toxicity. Moreover, all developed formulations showed significantly higher cellular 
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uptake by U87MG and BTNW911 cells as compared to SVG P12 cells. Active transport through 
endocytosis was determined as the internalisation mechanism for the all surface modified 
docetaxel-NLCs. Furthermore, bare and surface modified docetaxel-NLCs exhibited cell cycle 
arrest at G2/M phase with the highest percentage of distribution in G2/M phase obtained 
with SA43-docetaxel-NLCs. Docetaxel-NLC also showed high toxicity and penetration in 3D 
U87MG spheroids in comparison to native docetaxel though surface modification of 
docetaxel-NLCs did not enhance the uptake by 3D U87MG spheroids. 
Docetaxel encapsulation within the NLCs exhibited enhanced permeability when studied in 
all human 3D in-vitro BBB model. Notably, functionalisation of docetaxel-NLC with GLA and 
ALA further enhanced the permeation across the BBB while SA43-docetaxel-NLC displayed 
similar permeability as docetaxel-NLC. Distinctive increase in the apparent permeability 
through the BBB and uptake by U87MG cells was observed for all the surface modified 
docetaxel-NLCs when studied in diseased in-vitro BBB model in the presence of a tumour 
monolayered cell line (U87MG).  
The aforementioned research has demonstrated that docetaxel-NLCs is a viable potential 
product for use in the treatment of glioblastoma, exhibiting selective uptake and BBB 
permeability when conjugated with appropriate targeting ligands. This research could 
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Figure 3.61 Stability study over six months and the effect of storing the DTX-NLCs at 
-20, 4, 25, and 40°C (a) the plot of 1/r2 with respect to time, (b) the plot of r3 as a 
function of time. Data are mean ± SD, N=3. (r) refers to the radius of NLCs. 
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Figure 4.1 Cell cycle phase distributions.   157 
Figure 4.2 Images of monolayer cell lines under the microscope (a) U87MG cell line; 
(b) SVG P12 cell line, (c) Primary BTNW911 cell line. 
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Figure 4.3 Mean percentage cell viability relative to control cells with no drug 
treatment for DTX, DTX-NLC, and B-NLC when incubated with U87MG cell line at (a) 
24, (b) 48, and (c) 72 h. Data mean values ±SD, (N=3), and all formulations were 
compared to standard treatment docetaxel alone.    
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 Figure 4.4 Mean percentage cell viability for DTX, DTX-NLC, and B-NLC when 
incubated with SVG P12 cell line at (a) 24, (b) 48, and (c) 72 h. Data mean values 
±SD, (N=3), and all formulations were compared to standard treatment docetaxel 
alone.    
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Figure 4.5 Mean percentage cell viability for DTX, DTX-NLC, and B-NLC when 
incubated with BTNW911 cell line at (a) 24, (b) 48, and (c) 72 h. Data mean values 
±SD, (N=3), and all formulations were compared to standard treatment docetaxel 
alone.    
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Figure 4.6 Mean percentage cell viability for DTX, GLA-DTX-NLC, and ALA-DTX-NLC 
when incubated with U87MG cell line at (a) 24, (b) 48, and (c) 72 h. Data mean 
values ±SD, (N=3), and all formulations were compared to standard treatment 
docetaxel alone.    
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Figure 4.7 Mean percentage cell viability for DTX, GLA-DTX-NLC, and ALA-DTX-NLC 
when incubated with SVG P12 cell line at (a) 24, (b) 48, and (c) 72 h. Data mean 
values ±SD, (N=3), and all formulations were compared to standard treatment 
docetaxel alone. 
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Figure 4.8 Mean percentage cell viability for DTX, GLA-DTX-NLC, and ALA-DTX-NLC 
when incubated with BTNW911 cell line at (a) 24, (b) 48, and (c) 72 h. Data mean 
values ±SD, (N=3), and all formulations were compared to standard treatment 
docetaxel alone.    
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Figure 4.9 Mean percentage cell viability for DTX and SA43-DTX-NLC when 
incubated with U87MG cell line at (a) 24, (b) 48, and (c) 72 h. Data mean values ±SD, 
(N=3), and all formulations were compared to standard treatment docetaxel alone.    
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Figure 4.10 Mean percentage cell viability for DTX and SA43-DTX-NLC when 
incubated with SVG P12 cell line at (a) 24, (b) 48, and (c) 72 h. Data mean values 
±SD, (N=3), and all formulations were compared to standard treatment docetaxel 
alone.    
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Figure 4.11 Mean percentage cell viability for DTX and SA43-DTX-NLC when 
incubated with BNTW911 cell line at (a) 24, (b) 48, and (c) 72 h. Data mean values 
±SD, (N=3), and all formulations were compared to standard treatment docetaxel 
alone.   
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Figure 4.12 showing U87MG spheroids morphology when treated at a range of 
concentration between 2.5-1000 ng/ml and incubated for 72 h. with (a) DTX, (b) 
DTX-NLC. Data are N=3, and all formulations compared with the control untreated 
U87MG spheroids. 
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Figure 4.13 showing U87MG spheroids morphology when treated at a range of 
concentration between 2.5-1000 ng/ml and incubated for 72 h. with (a) GLA-DTX-
NLC, (b) ALA-DTX-NLC. Data are N=3, and all formulations compared with the 
control untreated U87MG spheroids. 
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Figure 4.14 showing U87MG spheroids morphology when treated at a range of 
concentration between 2.5-1000 ng/ml and incubated for 72 h. with SA43-DTX-NLC. 
Data are N=3, and all formulations compared with the control untreated U87MG 
spheroids. 
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Figure 4.15 Mean percentage cell viability for (a) DTX and DTX-NLC, (b) DTX and GLA-
DTX-NLC, (c) DTX and ALA-DTX-NLC, (d) DTX and SA43-DTX-NLC, and (e) % cell 
viability overlay of DTX, DTX-NLC, GLA-DTX-NLC, ALA-DTX-NLC, and SA43-DTX-NLC 
when incubated with U87MG spheroids cell line at 72 h. Data mean values ±SD, 
(N=3), and all formulations were compared to standard treatment docetaxel alone.    
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Figure 4.16 Cellular internalisation, where the blue colour refers to the stained 
nucleus with a fluorescence dye (DAPI) and the green fluorescence dye refers to the 
R-DTX-NLC (Rhodamine 123 (R) loaded within the DTX-NLC). (a) U87MG control 
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untreated cells only stained with DAPI, (b) U87MG incubated for 2 h with R-DTX-
NLC and the nuclei were stained with DAPI, (c) U87MG incubated for 4 h with R-
DTX-NLC and the nuclei were stained with DAPI, (d) SVG P12 control untreated cells 
only stained with DAPI. (e) SVG P12 incubated for 2 h with R-DTX-NLC and the nuclei 
were stained with DAPI, (f) SVG P12 incubated for 4 h with R-DTX-NLC and the nuclei 
were stained with DAPI. Data are N=3. 
Figure 4.17 Cellular internalisation, where the blue colour refers to the stained 
nucleus with a fluorescence dye (DAPI) and the green fluorescence dye refers to the 
R-GLA-DTX-NLC (Rhodamine 123 (R) loaded within the DTX-NLC). (a) U87MG control 
untreated cells only stained with DAPI, (b) U87MG incubated for 2 h with R-GLA-
DTX-NLC and the nuclei were stained with DAPI, (c) U87MG incubated for 4 h with 
R-GLA-DTX-NLC and the nuclei were stained with DAPI, (d) SVG P12 control 
untreated cells only stained with DAPI. (e) SVG P12 incubated for 2 h with R-GLA-
DTX-NLC and the nuclei were stained with DAPI, (f) SVG P12 incubated for 4 h with 
R-GLA-DTX-NLC and the nuclei were stained with DAPI. Data are N=3. 
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Figure 4.18 Cellular internalisation, where the blue colour refers to the stained 
nucleus with a fluorescence dye (DAPI) and the green fluorescence dye refers to the 
R-ALA-DTX-NLC (Rhodamine 123 (R) loaded within the DTX-NLC). (a) U87MG control 
untreated cells only stained with DAPI, (b) U87MG incubated for 2 h with R-ALA-
DTX-NLC and the nuclei were stained with DAPI, (c) U87MG incubated for 4 h with 
R-ALA-DTX-NLC and the nuclei were stained with DAPI, (d) SVG P12 control 
untreated cells only stained with DAPI. (e) SVG P12 incubated for 2 h with R-ALA-
DTX-NLC and the nuclei were stained with DAPI, (f) SVG P12 incubated for 4 h with 
R-ALA-DTX-NLC and the nuclei were stained with DAPI. Data are N=3. 
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Figure 4.19 Cellular internalisation, where the blue colour refers to the stained 
nucleus with a fluorescence dye (DAPI) and the green fluorescence dye refers to the 
R-SA43-DTX-NLC (Rhodamine 123 (R) loaded within the DTX-NLC). (a) U87MG 
control untreated cells only stained with DAPI, (b) U87MG incubated for 2 h with R-
SA43-DTX-NLC and the nuclei were stained with DAPI, (c) U87MG incubated for 4 h 
with R-SA43-DTX-NLC and the nuclei were stained with DAPI, (d) SVG P12 control 
untreated cells only stained with DAPI. (e) SVG P12 incubated for 2 h with R-SA43-
DTX-NLC and the nuclei were stained with DAPI, (f) SVG P12 incubated for 4 h with 
R-SA43-DTX-NLC and the nuclei were stained with DAPI. Data are N=3. 
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Figure 4.20 Standard plots of best fit demonstrating the time-dependent uptake of 
cell lines treated with DTX-NLC and surface modified DTX-NLC formulations 
(Rhodamine 123 (R) loaded within the DTX-NLC). (a) R-DTX-NLC incubated with 
U87MG, (b) R-DTX-NLC incubated with SVG P12, (c) R-GLA-DTX-NLC incubated with 
U87MG, (d) R-GLA-DTX-NLC incubated with SVG P12, (e) R-ALA-DTX-NLC incubated 
with U87MG, (f) R-ALA-DTX-NLC incubated with SVG P12. Data are mean and ±SD, 
(N=3). 
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Figure 4.21 Gradient MFI demonstrating the time-dependent uptake of U87MG and 
SVG P12 cell lines treated with R-DTX-NLC, R-ALA-DTX-NLC, and R-GLA-DTX-NLC 
formulations. Data are mean and ± SD, (N=3). *** p ˂ 0.001, refers to the significant 
difference. 
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Figure 4.22 MFI over time-dependent uptake of U87MG and SVG P12 cell lines 
treated with R-DTX-NLC, R-ALA-DTX-NLC, and R-GLA-DTX-NLC formulations at (0.5, 
1, 2, 4, 6, and 24) hr. Data are mean and ± SD, (N=3). 
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Figure 4.23 Flow cytometer histograms for the time-dependent uptake when R-
DTX-NLC were incubated for (0.5, 1, 2, 4, 6, and 24) h with (a) U87MG cell lines, (b) 
SVG P12 cell lines. R4 representing a region around the untreated control cells, and 
R3 representing a region around the shifted peaks as the fluorescence intensity 
increases the peaks shifting more to the right over time as evidence of increased 
uptake with time. Data are N=3. 
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Figure 4.24 Flow cytometer histograms for the time-dependent uptake when cell 
lines incubated for (0.5, 1, 2, 4, 6, and 24) h with (a) U87MG cell lines, incubated 
with R-GLA-DTX-NLC (b) SVG P12 cell lines incubated with R-GLA-DTX-NLC. (c) 
U87MG cell lines, incubated with R-ALA-DTX-NLC (d) SVG P12 cell lines incubated 
with R-ALA-DTX-NLC R4 representing a region around the untreated control cells, 
and R3 representing a region around the shifted peaks as the fluorescence intensity 
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increases the peaks shifting more to the right over time as evidence of increased 
uptake with time. Data are N=3. 
Figure 4.25 MFI demonstrating the concentration-dependent uptake of U87MG cell 
lines treated with R-DTX-NLC, R-ALA-DTX-NLC, R-GLA-DTX-NLC, and R-SA43-DTX-
NLC formulations. Data are mean and ± SD, (N=3). * p ˂ 0.05, refers to a significant 
difference when formulations were compared to R-DTX-NLC as the control in this 
case. 
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Figure 4.26 MFI demonstrating the concentration-dependent uptake of SVG P12 cell 
lines treated with R-DTX-NLC, R-ALA-DTX-NLC, R-GLA-DTX-NLC, and R-SA43-DTX-
NLC formulations. Data are mean and ± SD, (N=3). * p ˂ 0.05, refers to a significant 
difference when formulations were compared to R-DTX-NLC as the control in this 
case. 
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Figure 4.27 Flow cytometer histograms for the concentration-dependent uptake 
when R-DTX-NLC were incubated with 1, 2, 3, and 5 µg/ml (a) U87MG cell lines, (b) 
SVG P12 cell lines. R4 representing a region around the untreated control cells, and 
R3 representing a region around the shifted peaks as the fluorescence intensity 
increases the peaks shifting more to the right when the concentration was 
increased as evidence of increased uptake with the concentration. The control, in 
this case, was the untreated cell lines. Data are N=3. 
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Figure 4.28 Flow cytometer histograms for the concentration-dependent uptake 
when incubated with 1, 2, 3, and 5 µg/ml (a) U87MG cell lines treated with R-GLA-
DTX-NLC, (b) SVG P12 cell lines treated with R-GLA-DTX-NLC. (c) U87MG cell lines 
treated with R-ALA-DTX-NLC, (d) SVG P12 cell lines treated with R-ALA-DTX-NLC. R4 
representing a region around the untreated control cells, and R3 representing a 
region around the shifted peaks as the fluorescence intensity increases the peaks 
shifting more to the right when the concentration was increased as evidence of 
increased uptake with the concentration. The control, in this case, was the 
untreated cell lines. Data are N=3. 
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Figure 4.29 Flow cytometer histograms for the concentration-dependent uptake 
when R-SA43-DTX-NLC were incubated with 1, 2, 3, and 5 µg/ml (a) U87MG cell 
lines, (b) SVG P12 cell lines. R4 representing a region around the untreated control 
cells, and R3 representing a region around the shifted peaks as the fluorescence 
intensity increases the peaks shifting more to the right when the concentration was 
increased as evidence of increased uptake with the concentration. The control, in 
this case, was the untreated cell lines. Data are N=3. 
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Figure 4.30 MFI demonstrating the BTNW911 uptake with one level concentration 
of 1 µg/ml of R-DTX-NLC, R-ALA-DTX-NLC, R-GLA-DTX-NLC, and R-SA43-DTX-NLC 
formulations at 6 h incubation time. Data are mean and ± SD, (N=3). *** p ˂ 0.001, 
refers to a very significant difference when formulations were compared to R-DTX-
NLC as the control in this case. 
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Figure 4.31 Flow cytometer histograms of the BTNW911 uptake with one level 
concentration 1 µg/ml of R-DTX-NLC, R-ALA-DTX-NLC, R-GLA-DTX-NLC, and R-SA43-
DTX-NLC formulations  , respectively. At 6 h incubation 
time. R4 representing a region around the untreated control cells, and R3 
representing a region around the shifted peaks as the fluorescence intensity 
increases the peaks shifting more to the right when the cells were incubated with 
different formulation at one concentration as evidence of increased uptake with 
different types of unmodified and surface modified R-DTX-NLCs. The control, in this 
case, was the untreated cell lines . Data are N=3. 
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Figure 4.32 MFI demonstrating the 3D U87MG spheroids uptake at 1 µg/ml of R-
DTX-NLC, R-ALA-DTX-NLC, R-GLA-DTX-NLC, and R-SA43-DTX-NLC formulations at 6 
h incubation time. Data are mean and ± SD, (N=3). *** p ˂ 0.001, refers to a very 
significant difference when formulations were compared to R-DTX-NLC as the 
control in this case. 
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Figure 4.33 Flow cytometer histograms of the 3D U87MG spheroids uptake at 1 
µg/ml of R-DTX-NLC, R-ALA-DTX-NLC, R-GLA-DTX-NLC, and R-SA43-DTX-NLC 
formulations , respectively at 6 h incubation time. R4 
representing a region around the untreated control cells, and R3 representing a 
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region around the shifted peaks as the fluorescence intensity increases the peaks 
shifting more to the right when the cells were incubated with different formulation 
at one concentration as evidence of increased uptake with different types of 
unmodified and surface modified R-DTX-NLCs. The control, in this case, was the 
untreated cell lines . Data are N=3. 
Figure 4.34 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) 
and the green fluorescence dye refers to the R-DTX-NLC (Rhodamine 123 (R) loaded 
within the DTX-NLC). (a) U87MG control untreated cells only stained with DAPI, (b) 
U87MG incubated for 2 h with R-DTX-NLC at 4 °C and the nuclei were stained with 
DAPI, (c) U87MG incubated for 4 h with R-DTX-NLC at 4 °C and the nuclei were 
stained with DAPI, (d) U87MG incubated with sucrose pre and during incubation 
with R-DTX-NLC for 4 h at 37 °C, (e) U87MG incubated with Cyto. B (cytochalasin B) 
pre and during incubation with R-DTX-NLC for 4 h at 37 °C, (f) U87MG incubated 
with Nystatin pre and during incubation with R-DTX-NLC for 4 h at 37 °C. Data are 
N=3. 
  214 
Figure 4.35 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) 
and the green fluorescence dye refers to the R-DTX-NLC (Rhodamine 123 (R) loaded 
within the DTX-NLC). (a) SVG P12 control untreated cells only stained with DAPI, (b) 
SVG P12 incubated for 2 h with R-DTX-NLC at 4 °C and the nuclei were stained with 
DAPI, (c) SVG P12 incubated for 4 h with R-DTX-NLC at 4 °C and the nuclei were 
stained with DAPI, (d) SVG P12 incubated with sucrose pre- and during incubation 
with R-DTX-NLC for 4 h at 37 °C, (e) SVG P12 incubated with Cyto. B (cytochalasin B) 
pre- and during incubation with R-DTX-NLC for 4 h at 37 °C, (f) SVG P12 incubated 
with Nystatin pre and during incubation with R-DTX-NLC for 4 h at 37 °C. Data are 
N=3. 
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Figure 4.36 MFI for U87MG and SVG P12 cell lines treated with endocytosis 
pathways inhibitors pre and during incubation with R-DTX-NLC. Data are mean and 
± SD, (N=3). *** p ˂ 0.000, refers to a very significant difference when all data were 
compared to R-DTX-NLC incubated at 37 °C, as the control in this case. 
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Figure 4.37 Flow cytometer histograms for U87MG and SVG P12 cell lines treated 
with endocytosis pathways inhibitors pre and during incubation with R-DTX-NLC 
where (a) U87MG treated with sucrose, Cyto. B, and Nystatin, (b) SVG P12 treated 
with sucrose, Cyto. B and Nystatin, (c) U87MG incubated with R-DTX-NLC at 4 °C 
and 37 °C, (d) SVG P12 incubated with R-DTX-NLC at 4 °C and 37 °C. The control, in 
this case, is the untreated cell lines. Data are N=3. 
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Figure 4.38 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) 
and the green fluorescence dye refers to the R-GLA-DTX-NLC (Rhodamine 123 (R) 
loaded within the DTX-NLC). (a) U87MG control untreated cells only stained with 
DAPI, (b) U87MG incubated for 2 h with R-GLA-DTX-NLC at 4 °C and the nuclei were 
stained with DAPI, (c) U87MG incubated for 4 h with R-GLA-DTX-NLC at 4 °C and the 
nuclei were stained with DAPI, (d) U87MG incubated with sucrose pre- and during 
incubation with R-GLA-DTX-NLC for 4 h at 37 °C, (e) U87MG incubated with Cyto. B 
(cytochalasin B) pre- and during incubation with R-GLA-DTX-NLC for 4 h at 37 °C, (f) 
U87MG incubated with Nystatin pre and during incubation with R-GLA-DTX-NLC for 
4 h at 37 °C. Data are N=3. 
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Figure 4.39 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) 
and the green fluorescence dye refers to the R-GLA-DTX-NLC (Rhodamine 123 (R) 
loaded within the DTX-NLC). (a) SVG P12 control untreated cells only stained with 
DAPI, (b) SVG P12 incubated for 2 h with R-GLA-DTX-NLC at 4 °C and the nuclei were 
stained with DAPI, (c) SVG P12 incubated for 4 h with R-GLA-DTX-NLC at 4 °C and 
the nuclei were stained with DAPI, (d) SVG P12 incubated with sucrose pre- and 
during incubation with R-GLA-DTX-NLC for 4 h at 37 °C, (e) SVG P12 incubated with 
Cyto. B (cytochalasin B) pre- and during incubation with R-GLA-DTX-NLC for 4 h at 
37 °C, (f) SVG P12 incubated with Nystatin pre and during incubation with R-GLA-
DTX-NLC for 4 h at 37 °C. Data are N=3. 
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Figure 4.40 MFI for U87MG and SVG P12 cell lines treated with endocytosis 
pathways inhibitors pre and during incubation with R-GLA-DTX-NLC. Data are mean 
and ± SD, (N=3). *** p ˂ 0.000, refers to a very significant difference when all data 
were compared to R-GLA-DTX-NLC incubated at 37 °C, as the control in this case. 
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Figure 4.41 Flow cytometer histograms for U87MG and SVG P12 cell lines treated 
with endocytosis pathways inhibitors pre and during incubation with R-GLA-DTX-
NLC where (a) U87MG treated with sucrose, Cyto. B, and Nystatin, (b) SVG P12 
treated with sucrose, Cyto. B and Nystatin, (c) U87MG incubated with R-GLA-DTX-
NLC at 4 °C and 37 °C, (d) SVG P12 incubated with R-GLA-DTX-NLC at 4 °C and 37 °C. 
T control, in this case, is the untreated cell lines. Data are N=3. 
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Figure 4.42 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) 
and the green fluorescence dye refers to the R-ALA-DTX-NLC (Rhodamine 123 (R) 
loaded within the DTX-NLC). (a) U87MG control untreated cells only stained with 
DAPI, (b) U87MG incubated for 2 h with R-ALA-DTX-NLC at 4 °C and the nuclei were 
stained with DAPI, (c) U87MG incubated for 4 h with R-ALA-DTX-NLC at 4 °C and the 
nuclei were stained with DAPI, (d) U87MG incubated with sucrose pre- and during 
incubation with R-ALA-DTX-NLC for 4 h at 37 °C, (e) U87MG incubated with Cyto. B 
(cytochalasin B) pre- and during incubation with R-ALA-DTX-NLC for 4 h at 37 °C, (f) 
U87MG incubated with Nystatin pre- and during incubation with R-ALA-DTX-NLC for 
4 h at 37 °C. Data are N=3. 
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Figure 4.43 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) 
and the green fluorescence dye refers to the R-ALA-DTX-NLC (Rhodamine 123 (R) 
loaded within the DTX-NLC). (a) SVG P12 control untreated cells only stained with 
DAPI, (b) SVG P12 incubated for 2 h with R-ALA-DTX-NLC at 4 °C and the nuclei were 
stained with DAPI, (c) SVG P12 incubated for 4 h with R-ALA-DTX-NLC at 4 °C and 
the nuclei were stained with DAPI, (d) SVG P12 incubated with sucrose pre- and 
during incubation with R-ALA-DTX-NLC for 4 h at 37 °C, (e) SVG P12 incubated with 
Cyto. B (cytochalasin B) pre- and during incubation with R-ALA-DTX-NLC for 4 h at 
37 °C, (f) SVG P12 incubated with Nystatin pre and during incubation with R-ALA-
DTX-NLC for 4 h at 37 °C. Data are N=3. 
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Figure 4.44 MFI for U87MG and SVG P12 cell lines treated with endocytosis 
pathways inhibitors pre and during incubation with R-ALA-DTX-NLC. Data are mean 
and ± SD, (N=3). *** p ˂ 0.000, refers to a very significant difference when all data 
were compared to R-ALA-DTX-NLC incubated at 37 °C, as the control in this case. 
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Figure 4.45 Flow cytometer histograms for U87MG and SVG P12 cell lines treated 
with endocytosis pathways inhibitors pre and during incubation with R-ALA-DTX-
NLC where (a) U87MG treated with sucrose, Cyto. B, and Nystatin, (b) SVG P12 
treated with sucrose, Cyto. B and Nystatin, (c) U87MG incubated with R-ALA-DTX-
NLC at 4 °C and 37 °C, (d) SVG P12 incubated with R-ALA-DTX-NLC at 4 °C and 37 °C. 
The control, in this case, is the untreated cell lines. Data are N=3. 
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Figure 4.46 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) 
and the green fluorescence dye refers to the R-SA43-DTX-NLC (Rhodamine 123 (R) 
loaded within the DTX-NLC). (a) U87MG control untreated cells only stained with 
DAPI, (b) U87MG incubated for 2 h with R-SA43-DTX-NLC at 4 °C and the nuclei were 
stained with DAPI, (c) U87MG incubated for 4 h with R-SA43-DTX-NLC at 4 °C and 
the nuclei were stained with DAPI, (d) U87MG incubated with sucrose pre- and 
during incubation with R-SA43-DTX-NLC for 4 h at 37 °C, (e) U87MG incubated with 
Cyto. B (cytochalasin B) pre- and during incubation with R-SA43-DTX-NLC for 4 h at 
37 °C, (f) U87MG incubated with Nystatin pre and during incubation with R-SA43-
DTX-NLC for 4 h at 37 °C. Data are N=3. 
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Figure 4.47 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) 
and the green fluorescence dye refers to the R-SA43-DTX-NLC (Rhodamine 123 (R) 
loaded within the DTX-NLC). (a) SVG P12 control untreated cells only stained with 
DAPI, (b) SVG P12 incubated for 2 h with R-SA43-DTX-NLC at 4 °C and the nuclei 
were stained with DAPI, (c) SVG P12 incubated for 4 h with R-SA43-DTX-NLC at 4 °C 
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and the nuclei were stained with DAPI, (d) SVG P12 incubated with sucrose pre- and 
during incubation with R-SA43-DTX-NLC for 4 h at 37 °C, (e) SVG P12 incubated with 
Cyto. B (cytochalasin B) pre- and during incubation with R-SA43-DTX-NLC for 4 h at 
37 °C, (f) SVG P12 incubated with Nystatin pre and during incubation with R-SA43-
DTX-NLC for 4 h at 37 °C. Data are N=3. 
Figure 4.48 MFI for U87MG and SVG P12 cell lines treated with endocytosis 
pathways inhibitors pre and during incubation with R-SA43-DTX-NLC. Data are mean 
and ± SD, (N=3). *** p ˂ 0.000, refers to a very significant difference when all data 
were compared to R-SA43-DTX-NLC incubated at 37 °C, as the control in this case. 
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Figure 4.49 Flow cytometer histograms for U87MG and SVG P12 cell lines treated 
with endocytosis pathways inhibitors pre and during incubation with R-SA43-DTX-
NLC where (a) U87MG treated with sucrose, Cyto. B, and Nystatin, (b) SVG P12 
treated with sucrose, Cyto. B and Nystatin, (c) U87MG incubated with R-SA43-DTX-
NLC at 4 °C and 37 °C, (d) SVG P12 incubated with R-SA43-DTX-NLC at 4 °C and 37 
°C. The control, in this case, is the untreated cell lines. Data are N=3. 
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Figure 4.50 Percentage cell cycle distribution for U87MG cell lines following 24 h 
incubation with DTX, DTX-NLC, GLA-DTX-NLC, ALA-DTX-NLC, and SA43-DTX-NLC 
formulations. Data are mean and ± SD, (N=3). *** p ˂ 0.000, refers to a very 
significant difference when formulations were compared to untreated U87MG as 
the control in this case. 
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Figure 4.51 showing flow cytometer histograms for U87MG cell cycle following 24 
h incubation with (a) control U87MG untreated cell lines (b) DTX (c) DTX-NLC (d) 
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1.1. Brain tumour  
A brain tumour is a disease in which cells grow uncontrollably in the brain. Brain tumours 
can be broadly categorised into two types, benign and malignant. First, benign tumours 
are unable to spread beyond the brain, itself. It is not essential for benign tumours in the 
brain to be treated and progress is often self-limited. Sometimes benign tumours can 
progress to malignant brain tumours or cause complications because of the position but 
surgery or radiation can be helpful. Second, malignant tumours are typically called brain 
cancer. These tumours can extend outside of the brain (Abinaya et al., 2017).  
Malignant brain tumours represent some of the most devastating diagnoses a clinician 
may ever deliver to a patient. There are over 130 different types of brain tumours, but the 
most common malignant tumours of the brain are glioblastomas, accounting for over 80% 
of all primary brain malignancies (Ostrom et al., 2015; Osswald et al., 2015). These cancers 
are aggressive, invasive, and destructive tumours, considered among the deadliest forms 
of human cancers (Maher et al., 2001).  
1.2.  Glioblastoma  
Glioblastoma (GB) is a general term used to characterise a tumour that originates from 
glial brain cells that represent a heterogeneous group of malignancies of the central 
nervous system (Hands et al., 2014). Approximately 50% of primary brain tumours are 
GBs (Louis et al., 2007). 
There are three main cell types of glial origin with the potential to produce tumours. These 
include astrocytes leading to astrocytomas (including glioblastomas), oligodendrocytes 
giving rise to oligodendrogliomas, and ependymal cells forming ependymomas. Recent 
advances have rendered this method of classification obsolete, and the World Health 
Organisation (WHO) 2016 4th edition classification standards include further separation 
of the subsections based on molecular and genetic traits (Louis et al., 2016).  
1.2.1. Glioblastoma classifications and grades 
Pre-2016 literature, the classification of tumours of the central nervous system (CNS), 
according to WHO 2007, was largely based on histological concepts, where tumours were 
classified according to microscopic similarities with different putative cells of origin and 
presumed levels of differentiation (Louis et al., 2007). At present, glioblastomas are 
classified by cell type, location, grade, and molecular markers according to updated 2016 
WHO guidelines.  
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Recently, many subtypes of glioblastomas were categorised by distinct molecular markers 
and graded by clinical, histological and molecular appearance as defined (Louis et al., 
2016). The molecular characterisation and the presence of isocitrate dehydrogenase (IDH) 
mutation and 1p/19q (codeletion of chromosome arms 1p for petite, small arm of the 
chromosome and the 19q for chromosome arm 19)  codeletion were included and 
reported by Louis et al., (2016). In this new classification, the histologic subtype of grade 
II mixed oligoastrocytoma has also been eliminated. Now, the genotype plus phenotype 
is used to define these tumours (Louis et al., 2016). 
Glioblastomas that has progressed from lower grade diffuse or anaplastic astrocytomas is 
now identified as IDH mutants (Louis et al., 2016; Ohgaki and Kleihues, 2013; Ohgaki et 
al., 2014). IDH sequencing is recommended for distinguishing glioblastomas, if 
immunohistochemistry for mutant R132H IDH1 protein and sequencing for IDH1 codon 
132 and IDH2 codon 172 gene mutations are both negative, or if sequencing for IDH1 
codon 132 and IDH2 codon 172 gene mutations alone is negative, then the lesion can be 
diagnosed as IDH-wildtype (Louis et al., 2016). The classification of diffuse glioblastomas 
was based on both phenotype and genotype expressed in a number of ways (Figure 1.1). 
Grading a glioblastoma biopsy by a neuropathologist is the most important classification 
for determining the overall severity of malignancy. Generally, low-grade glioblastomas 
(WHO Grade I and II) are slower growing and are associated with better prognosis, while 
a high-grade glioblastoma (WHO Grade III or IV) grow faster and have a poor prognosis 
(Louis et al., 2016). In this project grade III and IV of GBs were chosen for the study due to 
the patient outcome since it is the most common and aggressive grades. 
 
Figure 1.1 Classification of the glioblastomas based on histological and genetic features 
(Louis et al., 2016). 
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1.2.2. Glioblastoma incidence and survival rates 
Glioblastoma is the most common primary malignant brain tumour among the adult 
population, making up 46% of all the malignant brain and central nervous system tumours 
and 15% of all primary brain tumours (Ostrom et al., 2015). It is almost always fatal in 
adults (Khan et al., 2009). Patients with GBs have a life expectancy of six to four months 
after diagnosis (Brodbelt et al., 2015). The median life expectancy for patients with GB is 
in the range of 12-15 months, dropping to 3-5 months in older patients ˃ 70 years old 
(Brodbelt et al., 2015). Reasons, for decreased life expectancy with age are probably 
multi-factorial, including aggressive tumour biology, under-treatment and co-morbidities 
and frailty reducing treatment tolerance. 
There were 10,743 patients registered with GBs in England from 2007 to 2011 (6451 male, 
4292 female), giving an overall national incidence of 4.64/100,000/year. Incidence 
increases with age. One, two and five-year survivals, were 28.4%, 11.5% and 3.4% 
respectively. Age-stratified median survivals decreased significantly (p< 0.0001) with 
increasing age from 16.2 months for the 20–44-year age group, to 7.9 months for the 45–
69 years, and 3.2 months for 70+ years. In the maximal treatment subgroup, patients aged 
up to 69 years had a median survival of 14.9 months. Patients over 60 years were less 
likely to receive maximal combination treatment, but median survival was better with a 
maximal treatment at all ages (Brodbelt et al., 2015). 
1.2.3. Glioblastoma treatment  
Treatment for GB and its histological variants typically involves radiation and 
chemotherapy using temozolomide (TMZ) (Stupp et al., 2005; Karsy et al., 2012). High-
grade glioblastomas are particularly insensitive to radiation and genotoxic drugs (Mehta 
et al., 2011). Therapeutic effect of glioblastoma is often limited due to the low 
permeability of delivery systems across the blood-brain barrier (BBB) and poor 
penetration into the tumour tissue (Xin et al., 2012). Moreover, drug penetration is only 
one of several major challenges (Preusser et al., 2011). GB is a grade IV brain tumour 
characterised by a heterogeneous population of cells that are highly infiltrative, 
angiogenic and resistant to chemotherapy (Alves et al., 2011), also the presence of GB 
stem cells (GSCs) is another cause of GB heterogeneity (Jiang et al., 2017). GSCs are highly 
resistant to current cancer treatments, which ultimately fail in GB treatment because they 
do not eliminate GSCs, which survive to regenerate new tumours (Alves et al., 2011). 
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1.2.3.1. Surgical intervention 
Surgery is the first-line therapy for glioblastoma, however, glioblastomas recur in the 
resection margins of 90% of patients (Hamard et al., 2016). Surgical intervention is 
essential for the initial treatment of GB. The surgery, ranging from biopsy to subtotal 
resection to gross-total resection, can affect overall patient survival (Anton et al., 2012; 
Urbanska et al., 2014). Although surgical resection can greatly reduce tumour bulk, 
complete excision is virtually impossible due to the infiltrative nature of these tumours 
(Venkatesh et al., 2015; Price et al., 2012).  
1.2.3.2. Chemotherapy treatment 
Chemotherapy is the most common treatment option for recurrent malignant 
glioblastomas (Kreisl 2009; Combs et al., 2005). Although traditionally reserved for 
treatment of recurrent GB, chemotherapy agents such as temozolomide and carboplatin 
have shown a wide range of efficacy, either when administered alone or as a supplement 
to cytoreductive surgery (Karsy et al., 2012). 
To treat the infiltrating tumour cells, there has been much interest in using local therapies 
inserted at the time of surgery. Carmustine wafers (Gliadel®) are biodegradable polymers 
that release 7.7 mg of carmustine over a few weeks directly into the resection cavity. A 
phase III study in patients, which were newly diagnosed with high-grade glioblastomas 
showed that carmustine wafers were well tolerated and associated with a survival 
advantage (Westphal et al., 2003). Guidelines were developed according to the UK 
National Institute of Clinical Excellence (NICE) for people with brain and other CNS 
tumours (NICE, 2006). NICE issued guidance and recommended the use of carmustine 
wafers as an option for the treatment of newly diagnosed high-grade glioblastomas (WHO 
Grade III and IV) (NICE Technology Appraisal Guidance TA121, NICE 2007). The NICE 2016 
recommendation has been updated and reviewed in March 2016, the NICE technology 
appraisal guidance TA23 on carmustine implants and temozolomide for the treatment of 
newly diagnosed high-grade glioblastoma (NICE 2016). 
1.2.3.3. Radiation  
Radiotherapy has emerged as an indispensable component of therapy to overcome the 
limitation of other treatments. It is delivered primarily by external-beam radiotherapy to 
treat glioblastoma (Snider and Mehta, 2016). To improve local control and limit toxicity 
to normal brain tissue with these infiltrating tumours, novel imaging techniques such as 
(CT, augmented frequently with MRI and PET) are actively being explored to better define 
tumour extent and to map associated radiotherapy treatment fields (Dawson and Sharpe, 
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2006). Hyper fractionated radiotherapy has been associated with a survival detriment. 
Current standard-of-care treatment involves the concurrent use of temozolomide and 
radiotherapy to 6,000 c Gy over 30 days, photon radiation therapy is measured in gray 
(Gy) followed by adjuvant temozolomide treatment for 6 months (Barani and Larson 
2015). Radiotherapy and chemotherapy improve survival, but death is inevitably from 
either recurrent or progressive disease (Stephen et al., 2012). 
1.2.3.4. Stereotactic radiosurgery and brachytherapy 
Stereotactic radiosurgery (SRS) is a non-invasive method of localised irradiation, 
particularly for smaller recurrent GB lesions (Combs et al., 2005; Minniti et al., 2011), 
using iodine-125 seeds in anaplastic astrocytoma, oligoastrocytoma or oligodendroglioma 
(Suchorska et al., 2016). SRS has gained widespread popularity in part because of its use 
as an outpatient procedure and its relatively decreased recovery period. In a study by 
Combs et al., (2005) the median survival of patients undergoing single-fraction SRS 
(median dose of 15 Gy) for recurrent GB was 10 months (Combs et al., 2005). 
Brachytherapy (BT) for glioblastoma, involves the use of radioactive isotopes to deliver 
ionizing radiation directly into the tumour bed. It was introduced as a therapy to prolong 
survival in GB patients, but over the past few decades, it has come with variable success 
(Barbarite et al., 2017). It was reported that brachytherapy and stereotactic radiosurgery 
are effective therapies for relapsed GB but tend to be associated with notable toxicity 
(Barani and Larson 2015). 
Due to unsuccessful current GB treatments including limitation of drug penetration to the 
BBB, recurrence, toxicity and inability to remove a tumour completely by surgical 
intervention, it was essential for the research here in this thesis, to investigate a new 
approach for chemotherapeutic formulation treatment and to overcome some of the side 
effects that prevent maximal treatment in the elderly population in particular. This thesis 
will focus on developing nanoparticles for chemotherapeutic delivery to glioblastoma that 
potentially can penetrate and pass through the BBB, also the mechanism of internalisation 
and uptake will be explored.  
1.3.  Blood-brain barrier 
The BBB acts as a physical barrier, regulating the passage of molecules from the 
bloodstream to the brain, making it impossible for some types of drugs to reach the brain 
upon systemic administration. More than 98% of potential new therapeutic molecules are 
unable to cross the BBB (Pardridge 2002). The BBB consists of endothelial cells connected 
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together by tight junctions (TJ), in contact with the pericytes as well as astrocytes 
(Pardridge 2005) (Figure 1.2).  
If there were no BBB, the brain microvasculature would provide an extraordinary way to 
access the brain. This microvasculature has a total surface area of 20 m2 and a total length 
of 640 km. This massive vascularisation theoretically would give the brain the possibility 
to be permeated by small molecules (by simple diffusion) in half a second (Pardridge 
2003), however, unlike peripheral capillaries, those of the brain present no fenestrae. In 
addition, few pinocytosis vesicles, and tight junctions, also known as zonula occludens 
closely regulate the movement of molecules through the paracellular pathway comprising 
of an almost impermeable barrier for drugs administered through the peripheral 
circulation (Blasi et al., 2007). A further contribution to the BBB functions is given by the 
astrocytes. These have a multitude of functions important for brain homeostasis 
(maintenance of potassium ion levels, inactivation of neurotransmitters, regulation and 
production of growth factors and cytokines) (Blasi et al., 2007). 
 
Figure 1.2 The neurovascular unit of the Blood-brain barrier (BBB) (Cambridge University 





1.3.1. Transport mechanisms across the blood-brain barrier  
The transport of solute molecules across the BBB membrane takes place by four different 
mechanisms (Georgieva et al., 2014). The proposed mechanisms are shown in Figure 1.3. 
 
 
Figure 1.3 Potential transport mechanisms across the blood-brain barrier, diffusion and 
active transport are the main transport mechanisms. Adapted and modified from 
Nature Publishing group (2005). 
 
1.3.1.1. Paracellular diffusion 
Paracellular diffusion is a non-saturable and non-competitive process occurring between 
cells, the presence of TJs in brain endothelial cells greatly affects para-cellular diffusion, 
only small size, water-soluble molecules can diffuse through the BBB, apparently by 
passing through the tight junctions (Patel et al., 2013; Yuan et al. 1995; Georgieva et al., 
2014). 
1.3.1.2. Transcellular diffusion 
Transcellular diffusion takes place across cells and is a non-saturable and non-competitive 
process. The properties of the substances required for trans-cellular transport are high 
lipophilic nature and low molecular weight (around < 450 Da) that will facilitate transport 
of the molecule into the brain (Patel et al., 2013), and not be a substrate for active efflux 
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transporters (Pardridge 2012). The efflux transporters at the BBB, ATP-binding cassette 
(ABC) transporters (ABCB1 or P-glycoprotein (P-gp), that includes the multidrug 
resistance-associated proteins (MRPs or ABCC), and ABCG or breast cancer resistance 
protein (BCRP) (Qosa et al., 2015) play a crucial role by limiting the brain tissue exposure 
to a variety of therapeutic agents, including compounds that are highly lipophilic and 
would easily permeate through the BBB in the absence of efflux transport (Loscher and 
Potschka, 2005) (Figure 1.3). 
1.3.1.3. Carrier-mediated transport 
The exchange of substances between the blood and the brain, including nutrients, occurs 
actively by selective membrane-bound carrier systems. This process of active carrier-
mediated transport involves the development of transient narrow pores, induced by 
binding the substrate to the carrier. These, in turn, allow the passage of specific substrate 
molecules (Blasi et al., 2007). Several carrier systems have been described in brain 
capillaries enabling the specific transport to facilitate the transfer of nutrients, including 
glucose, galactose, amino acids, nucleosides, lactates and pyruvates, adenine and 
guanine, choline, vitamins and hormones (Ricci et al., 2006). Glucose provides the main 
energy source for the brain and glucose transporters (GLUT1 and GLUT3) are of great 
significance as mediated transporters (Zlokovic 2008). Equally important is the mono-
carboxylate (lactate; pyruvate) transporter system (MCT1) (Ohtsuki and Terasaki 2007). 
Moreover, specialised carriers exist for essential amino acids and vitamins (Zlokovic 2008). 
The protein transporters organic anion transporting polypeptides (OATPs) are expressed 
in a variety of different tissues including the brain (König 2010). It is thought to be involved 
in the cellular uptake of various organic compounds (Kovacsics et al., 2016). And organic 
cation transporters (OCTs) achieve important function within the brain for drug 
transportation (Couroussé and Gautron, 2015). 
1.3.1.4. Receptor-mediated endocytosis 
Some large endogenous proteins and hormones are able to cross the BBB by endocytosis, 
mediated by certain receptors present on the luminal side of the barrier. Specific 
receptors have been identified for insulin, insulin-like growth factors, angiotensin II, 
folates and transferrin (Bickel et al., 2001). Lipids can also be internalised in the brain in 
the form of low-density lipoproteins (LDL), which are recognised and endocytosed by the 
endothelial cells, due to the expression of various apo-lipoproteins (especially ApoE) on 
the surface of the LDL (Blasi et al., 2007). 
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Poly-cationic proteins (e.g. cationised albumins or immunoglobulin) can be transported 
across the BBB by means of absorptive transcytosis, without the plasma-membrane 
receptors involvement. In this situation, endocytosis is initiated through the association 
of poly-cationic substances with the negative charges present on the plasma membrane 
of endothelial cells (Smith and Gumbleton 2006) (Figure 1.3). 
1.4.  Nanotechnology for brain drug delivery 
In recent years, with the advent of nanomedicine, engineered tunable devices with a size 
in the order of a billionth of meters have been proposed as an intriguing tool, potentially 
able to solve the unmet problem of drug transport across the BBB (Holmes 2013). Among 
other devices, nanoparticle (NPs) technology is rapidly advancing. NPs are objects sized 
between 1 and 100 nm (Youns et al., 2011). Different types of NPs have been introduced 
as a carrier system (Agrahari 2017). (Figure 1.4).  
What makes NPs even more attractive for medical applications is the possibility of 
conjoining features such as high chemical and biological stability, lipophilic nature 
enabling disposition across membranes, feasibility of incorporating both hydrophilic and 
hydrophobic pharmaceuticals and the ability to be administered by a variety of routes 
(including oral, inhalational, and parenteral) (Petkar et al., 2011).  
 
 
Figure 1.4 Schematic illustration of various nanoparticles classified based on their 




Moreover, NPs can be functionalised by covalent conjugation to various ligands (such as 
antibodies, proteins, or aptamers) for targeted delivery to the site of action. The large 
surface-area-to-volume ratio of NPs permits multiple copies of a ligand to be attached, to 
dramatically increase binding affinity via the multivalent functionalisation (Montet et al., 
2006). The tailoring of NPs to enhance drug delivery to the brain does not necessarily 
imply an ability to cross the BBB. It is predictable that NPs could play the role of increased 
brain permeation in at least in two ways: 
1. By increasing the drug concentration inside, or at the luminal surface of BBB cells, 
thereby establishing a locally high concentration gradient between blood and brain, 
higher than that obtainable after systemic administration of the free drug. The gradient 
should then favour the enhanced passive diffusion of the free drug (Figure 1.3). This task 
could be realised by synthesising NPs functionalised to target brain capillary endothelial 
cells. This feature can be followed or not by measuring subsequent uptake of free drug 
from targeted cells (Haque et al., 2012). 
2. By transport of the NPs into the CNS, together with drug cargo. This task can be realised 
by enabling NPs to target brain capillary endothelial cells and measure the subsequent 
trans-cellular passage of NPs across the BBB (Martin-Banderas et al., 2011), as previously 
explained in section 1.3 and as shown in Figure 1.3.  
Some examples of nanomedicines for cancer treatment approved by the Food and Drug 






Table 1.1 Examples of Nanomedicines for cancer treatment approved by FDA and those undergoing clinical trials (Pillai 2014). 
Drug product Active 
ingredient 



























































Drug product Active 
ingredient 
Manufacturer Indications FDA approved date/clinical trial 
status 
EndoTAG-I Paclitaxel Medigene /SynCore 
Biotechnology 
Breast cancer/Pancreatic cancer In clinical phase II 
Marqibo Vincristine 
liposome 





Celsion Hepatocellular carcinoma In clinical phase III 
Lipoplatin Liposomal 
Cisplatin 
Regulon Pancreatic/ Head and Neck/breast cancer In clinical phase III 
Aurimmune                                                                           






Head and Neck Cancer cancer In clinical phase IIphase II  









Ovarian cancer Phase III  




1.5.  NPs can cross the BBB 
Many medicines are not able to reach the brain due to the lack of drug-specific transport 
systems through the BBB (Miller 2010). The development of new strategies based on NPs 
to enhance the brain drug delivery is of great importance in the therapy and diagnosis of 
CNS diseases and it is based on the interactions between NPs and the BBB and on their 
intracellular traffic pathways (Jain 2012). 
1.5.1.  Crossing the BBB without functionalisation 
Although almost all nanomaterials fall into the class of BBB impermeable, some 
exceptions have been reported in recent years. For instance, gold and silica NPs have been 
shown to reach the brain and accumulate in neurons even in the absence of any specific 
functionalisation, with a mechanism that substantially is still unknown (Wu et al., 2011). 
It was reported that gold NPs mainly accumulate in the hippocampus, thalamus, 
hypothalamus, and the cerebral cortex. The same finding was reported for titanium 
dioxide NPs, furthermore, these NPs were found to cross the BBB in mice particularly 
when smaller than 40 nm in diameter (Ze et al., 2013). 
1.5.2.  Adsorptive-mediated transcytosis 
The concept of adsorptive-mediated transcytosis through the BBB was originally 
suggested by the observation that cationic proteins can bind to the endothelial cell 
surface but also cross the BBB (Broadwell 1989) (Figure 1.3). The mechanism applied to 
NPs is based on the proper functionalisation of their surface allowing electrostatic 
interaction with the luminal surface of BBB due to the presence of negative charges on 
endothelial cells (Masserini 2013). This interaction can be promoted by NPs bearing a 
positive surface charge. 
Different procedures can be followed to measure this phenomenon. The first is 
developing NPs made of components that bear a positively charged surface at 
physiological pH (7.4). This is the case of nano-sized vesicles made of bola amphiphilic 
molecules that, following intravenous administration to mice, showed a marked 
accumulation in the encapsulated fluorescent cargo, whereas the non-encapsulated 
probe was detected only in peripheral tissues but not in the brain (Dakwar et al., 2012). 
A second procedure is to functionalised the NPs surface with positively charged 




been extensively used for NPs decoration, facilitating the BBB passage of drugs (Tian et 
al., 2012). 
1.5.3. Receptor-mediated transcytosis 
One of the most recently applied strategies for drug delivery across the BBB endothelium 
using functionalised NPs is the exploitation of the transcytosis physiological mechanism 
of transport of macromolecules, relying on the presence of specific receptors on the 
luminal surface of cells. Transcytosis is the process by which extracellular cargo 
internalised at the apical plasma membrane domain of a polarised cell is transported via 
vesicular intermediates to the contralateral (basolateral) plasma membrane. For example, 
transferrin, apolipoproteins, and 2-macroglobulin are some of the proteins that reach the 
brain following the path across endothelial cells (Muro et al., 2004).  
1.5.3.1.  Lipoprotein receptors 
Apolipoprotein E (Apo-E) is a 34- kDa protein constituent of both very low-density 
lipoprotein (VLDL) and high-density lipoprotein (HDL), which transports cholesterol and 
other lipids in the plasma and in the CNS (Laskowitz et al., 2001). The lipoproteins were 
taken up by the brain through the recognition of apo E by specific receptors at the BBB, 
which include the low-density lipoprotein receptor (LDLR) and the LDLR-related protein 
(LRP). Taking into consideration that LRP has been reported to be highly expressed on 
endothelial brain microvessels, the LDLR is an ideal target to exploit for transport into the 
brain (Bell et al., 2007). 
1.5.3.2. Transferrin receptor (TfR) 
The transferrin receptor (TfR) is the most widely studied receptor for BBB targeting. TfR 
is a transmembrane glycoprotein, consisting of two linked 90-kDa subunits, each one 
binding a transferrin molecule. The receptor is highly expressed on hepatocytes, 
immature erythroid cells, placental tissue, and rapidly dividing cells, both normal and 
malignant (Ponka and Lok 1999). Furthermore, it is expressed on endothelial cells of the 
BBB. The role of the receptor is the regulation of cellular uptake of iron via transferrin; a 
plasma protein which transports iron in the circulation. Cellular uptake starts with the 
binding of transferrin to the transferrin receptor followed by endocytosis (Moos et al., 
2007). Ironbound transferrin has a high affinity for the TfR, therefore it has been used 
with success as a ligand for functionalisation and targeting of liposomes to cultured brain 




1.5.4. Retrograde transport 
Trans-synaptic retrograde transport could enable some types of nanocarriers to travel 
from peripheral nerve terminals to neuronal cell bodies in the CNS (Cui et al., 2007). 
Studies in this regard have shown that NPs modified with polyethyleneimine (PEI) and 
other polyplexes display active retrograde transport along neurites but are unable to 
mediate efficient biological actions upon reaching the neuronal body (Bergen and Pun 
2008). 
1.5.5. BBB breakdown 
BBB breakdown occurs in neuroinflammatory diseases (Vries et al., 1997). NPs can 
transiently and reversibly open the tight junctions located at the BBB and other sites, thus, 
increasing paracellular permeability (Sadekar and Ghandehari 2012). Using intra-arterial 
injection of mannitol arabinose, lactamide, saline, urea and several radiographic contrast 
agents were found to be conventional for reversibly disrupt the BBB (Bellavance et al., 
2008). These agents are hyperosmolar in nature and cause shrinkage of the endothelial 
cells, thus causing a transit opening of tight junction (TJ). The BBB disruption therapy is an 
intensive and effective way of delivering medication to brain tumours (Treat et al., 2012). 
Nevertheless, it is known that tight junctions can be opened only to a limited extent 
(Adamson et al., 2004) making only small NPs 20nm in diameter use this pathway to 
penetrate the brain through the BBB (Adamson et al., 2004). 
1.5.6. Exploiting Monocyte/Macrophage Infiltration in the CNS 
Monocyte/macrophage infiltration in the CNS plays a key role in neuroinflammation, as 
well as in lesion development and brain injury in neurological diseases such as multiple 
sclerosis (MS) and stroke (Adamson et al., 2004). The role of active phases of cell 
infiltration during CNS disorders is important because anti-inflammatory treatments can 
target cell adhesion molecules and chemokines guiding cellular trafficking (Stoll et al., 
1998). This strategy could be realised at least in two ways as listed below. 
1.5.6.1. Trojan monocytes for NPs delivery to the brain 
NPs drug delivery systems have been used to avoid the reticuloendothelial system (RES) 
clearance and achieve longer circulation time for enhanced tissue uptake. After 
phagocytosis of NPs, monocytes work just like Trojan horses, may transport their cargo 
into the brain (Afergan et al., 2008). This technique has been used for serotonin, a BBB 




its brain uptake was analysed in rats and rabbits. The performance of liposomal serotonin 
was significantly better, leading to two-fold higher drug concentration in brain than the 
free drug. The Trojan monocyte approach provides a new possibility of more effective 
treatment of brain-associated inflammatory disorders, including multiple sclerosis and 
Alzheimer’s disease, which are characterised with increased passage of immune cells 
across the BBB (Park 2008). 
1.5.6.2. NPs mimicking activated monocytes 
The therapeutic efficacy of drug loaded NPs systemically administered depends on the 
ability to attack the immune system, to cross the biological barriers of the body, and to 
localise at target tissues. (Parodi et al., 2013). The nano-porous silicon particles can 
successfully perform all these actions when they are coated with cellular membranes 
purified from leukocytes, avoiding being cleared by the immune system. Furthermore, 
they can be attached to endothelial cells through receptor-ligand interactions and 
transport and release a doxorubicin payload across an inflamed endothelial barrier in an 
in-vitro study (Parodi et al., 2013). 
1.6.  Solid Lipid Nanoparticles 
Solid lipid nanoparticles (SLNs) are nanospheres made from solid lipids, with a diameter 
of approximately 50–1000 nm. SLNs consist of a solid lipid matrix, for example, glycerides, 
fatty acids, or waxes stabilised by physiologically compatible emulsifiers (e.g. 
phospholipids, bile salts, Tween_80, polyoxyethylene ethers, or polyvinyl alcohol 
(Battaglia and Gallarate 2012; Lasa-Saracibar et al., 2012).  
SLNs are usually produced by the hot homogenisation method, which generally entails 
using high-pressure homogenisation (HPH) (Müller et al., 2000; Joshi and Müller 2009; 
Souto et al., 2004). SLNs have been reported as a promising anticancer drug delivery 
system to the brain after IV injection. This is due to the ability of SLNs to cross the blood-
brain barrier and deliver drugs to the brain when coated with proper surfactants, such as 
polysorbates (Blasi et al., 2007). Thus, SLNs have high potential in brain tumour treatment. 
The advantages of SLN are the ability to immobilise hydrophilic or hydrophobic drugs in 
the solid matrix (Figure 1.5), sustain the drug release, and the prevention of premature 
degradation of the incorporated drug. In addition, the matrix is composed of physiological 
components and/or excipients of accepted status (FDA-approved constituents), 






Figure 1.5 Nanostructure of SLN compared with the nanostructured lipid carrier (NLC), 
taken from (Radtke and Müller 2001). 
 
1.6.1. Nanostructure lipid carrier (NLC) 
NLCs were introduced as the next generation of SLNs at the end of the 1990s, to overcome 
the difficulties of previous SLNs (Mehnert et al., 2001; Müller et al., 2014) NLCs improve 
the stability, capacity of drug loading and prevent the drug expulsion during storage. They 
are distinguished from SLNs by the composition of the solid matrix. Lipidic phase in NLCs 
contains both solid and liquid lipids at the ambient temperature (Pardeike et al., 2009). 
Formless, imperfect and multiple types are the three forms of NLCs (Kaur et al., 2015), as 
shown in (Figure 1.6). 
The drug re-partitions into the lipids while the lipids increase structural perfection during 
the cooling, leading to the embedding of drug molecules onto the particle surface and 
formation of a drug-enriched shell. This unfavourable drug incorporation mode limits the 
drug loading capacity and leads to drug expulsion during storage and burst release. To 
overcome this potential issue, Muller et al., (2002) proposed a novel lipid nano-system 
called “nanostructured lipid carriers” (NLC) (Muller et al., 2002). The NLC is a modification 
of the conventional SLN by making the solid lipid core a less organised nanostructure. The 
lipid cores with imperfect crystal structure can be realised by either using spatially 
different lipids, such as mono-, di-, triglycerides with different chain lengths, or mixing 
some liquid lipids (oils) with the solid lipid. The space between different fatty acid chains 
and crystal imperfections provide more accommodation for drug molecules. In addition, 
some drugs have higher solubility in oils than in solid lipids, therefore, the NLC as a new 
generation of SLN increases the drug payload and decreases drug expulsion and burst 




different production method (warm or cool) or modifying surfactant concentration. 
(Muller et al., 2002). 
There are several production techniques for SLNs such as high-pressure homogenization 
(HPH), solvent emulsification /evaporation, supercritical fluid extraction of emulsions 
(SFEE), ultra-sonication or high-speed homogenization (Blasi et al., 2007; Naguib et al., 
2014) and spray drying (Kakadia and Conway, 2014). Two processes of the HPH, hot and 
cold processes have been developed. These are two basic production methods in which, 
the drug is dissolved or solubilised in the lipid being melted at around 5-10 °C above its 
melting point (Blasi et al., 2007). 
1.6.1.1. NLC classes 
NLCs differ from SLNs by the following: more drug loading capacity, less water in the 
dispersion, prevention or minimization of the drug expulsion during storage. No 
significant difference between the bio-toxicity of SLNs and NLCs has been reported 
(Tamjidi et al.,2013; Doktorovova et al., 2014a). The different classes of NLCs are 
summarised in the sections below and Figure 1.6. 
1.6.1.2. Class one imperfect 
The class one NLCs are formed when solid and liquid fats (oil) are mixed in various lipid 
structures. Specific conditions in the crystallisation procedure lead to an extremely 
disordered structure. Imperfect lipid matrix structures present a gap between triglyceride 
fatty acid chains in crystal and thus increase the ability of the drugs to enter the matrix 
(Kaur et al., 2015). 
1.6.1.3. Class two formless 
Non-crystalline matrix is a type of NLCs that has no crystalline structure and thus prevents 
the expulsion of the loaded drug, which is known as an amorphous type (Kaur et al., 2015). 
1.6.1.4. Class three multiple types 
In class three multiple types of NLCs, drug solubility in liquid lipid is greater than in solid 
lipid, thus it is present as a dissolved drug in nano-compartments of oil in solid lipid thus 
preventing it from decomposition. This form of NLCs is similar to w/o/w emulsions (Feng 





Figure 1.6 Structures of NLCs Class I (imperfect type), class II (formless type), class III 
(multiple types). (Selvamuthukumar and Velmurugan 2012). 
 
1.7.  Targeted drug delivery using NPs 
Delivering effective quantities of the drug into the right target cells through clinically 
feasible methods represents a major challenge for the successful development of cancer 
nanomedicines (Alonso 2004). Nano-delivery platforms were designed to overcome such 
barriers and can be divided into two ways: passive targeting and active targeting. 
1.7.1. Passive targeting 
Blood vessels in tumours may have a leaky endothelium, failing the normal barrier 
function thus allowing entry of macromolecules up to 400 nm in size (Yuan et al., 1995). 
NPs passively diffuse into tumour tissue through the leaky vasculature, accumulate in a 
tumour, and release therapeutic payloads into the tumour cells. This process is known as 
the enhanced permeability and retention (EPR) effect (Matsumura and Maeda 1986). A 
limitation of the passive targeting is that it is dependent on the diffusion of drugs (Jain 
1994). 
1.7.2. Active targeting 
To overcome the limitation of EPR, active targeting strategies were incorporated into NPs 
using affinity molecules such as antibodies, peptides, or aptamers that bind to antigens 
or receptors on the target cells to enhance the therapeutic efficacy by increasing cellular 
uptake and accumulation (Peer et al., 2007; Bamrungsap et al., 2012). 
1.8.  Evaluation of permeation of NPs through the BBB  
Crossing the BBB is a very challenging goal in drug delivery. Different methods have been 




these methods involve the use of in vitro models, while others use in vivo models in rats 
or mice. Among in vitro methods, the most important are models of the BBB (Grant et al., 
1998). These generally comprise of cultured brain microvasculature, which can be grown 
in either the absence or in the presence of glial cells. Although primary cultures of brain 
endothelium alone may form tight intercellular junctions, co-culture with astrocytes 
generally leads to increased formation and complexity of endothelial tight junctions 
(Gastaldi et al., 2014). In turn, these induce expression of specific BBB markers. Currently, 
the development of immortalised endothelial cell lines that preserve a stable BBB 
phenotype is of great interest.  
The trans-well system consists of cultured brain microvessel endothelial cell monolayers, 
grown on a microporous membrane submerged in culture medium. Cultured cortical 
astrocytes are compartmentalised below the endothelial monolayer, and they release 
soluble factors, which preserve the BBB properties. This system affords the study of 
bidirectional transport across the BBB. It is an advantageous and well-established way of 
artificially evaluating the crossing of NPs across the BBB in-vitro (Smith 1996).  
1.9.  Cellular uptake pathways  
After crossing the blood-brain barrier the next important question is whether the 
SLNs/NLCs can be internalised by the tumour cell and whether anticancer drugs are 
released from the SLNs/NLCs intracellularly. Nano-particles located in the external 
environment of a cell can interact with the plasma membrane. This can lead to the uptake 
of these nanoparticles by the cells through a process named “endocytosis” (Sahay et al., 
2010). If the nanoparticles cannot be internalised, the drug can still enter cells after being 
released from the nanoparticles, however, the drug can also disperse to the surrounding 
normal tissues rather than be delivered mainly to the cancer cells. In fact, in-vitro and in-
vivo studies reveal that the intracellular concentration of the drug is much higher when it 
is released from nanoparticles into the cytoplasm than from the concentration of non-
capsulated drug with nanoparticles after internalisation (Chen et al., 2004; Jain et al., 
2010). The form of endocytosis involved in nanoparticles uptake can be expected to affect 
the nanoparticles intracellular localisation and trafficking, understanding endocytic 
mechanisms is then crucial for the development of nanoparticles for clinical therapies 
(Martins et al., 2012). 
Furthermore, most nanoparticles have been shown to exploit more than one pathway to 
gain cellular entry (Sahay et al., 2010). The endocytosis of nanoparticles also depends on 




defining the nanoparticle entry and its destination in the cells. Endocytosis is known as a 
general entry mechanism for various extracellular materials. It is divided into two main 
categories, phagocytosis (uptake of large particles) and pinocytosis (uptake of fluids and 
solutes) (Doherty and McMahon 2009; Sahay et al., 2010). Phagocytosis is followed by 
specialised professional phagocytes, such as macrophages, monocytes, or dendritic cells. 
The phagocytic pathway of cellular entry consists of recognising the particles followed by 
the adhesion of the opsonised particles onto the cell membrane and ingestion of the 
particle by the cells. Pinocytosis, in contrast, is present in all types of cells and has multiple 
forms depending on the cell origin and function. Pinocytosis can be classified as clathrin-
mediated endocytosis, caveolae-mediated endocytosis, clathrin- and caveolae-
independent endocytosis, and macropinocytosis (Conner and Schmid 2003). 
Internalisation through clathrin-dependent endocytosis normally happens when the 
clathrin coat on the plasma membrane develops invaginations in the membrane leading 
to the budding of clathrin-coated vesicles (Figure 1.7), (Sahay et al., 2010). Nano-particles 
localised on the cell membrane could be trapped within the vesicles and brought within 
the cells. Receptor-mediated endocytosis through clathrin-coated pits is the most 
common pathway of endocytosis (Martins et al., 2012). 
Alternatively, clathrin-independent endocytosis can happen through the caveolae or lipid-
raft pathway. Caveolae are flask-shaped membrane invaginations on cell surfaces that 
have high amounts of cholesterol and sphingomyelin. Caveolae are found in muscle, 
endothelial cells, fibroblasts and adipocytes and absent in neurons and leukocytes 
(Conner and Schmid 2003; Sahay et al., 2010). In the macro-pinocytosis, the macro-
pinosomes are larger (0.5–10 µm) and distinct from other vesicles formed during 
pinocytosis (Figure 1.7). This pathway is possible for virtually any cell (such as 
macrophages and brain microvessel endothelial cells) with only a few exceptions. 
Macropinocytosis can internalise large particles with submicron and greater sizes in cells, 








Figure 1.7 Endocytosis mechanism and pathway mediators (Oh and Park, 2014). 
Attempt to clarify endocytic uptake mechanisms have been published (Conner and 
Schmid 2003). Coumarin-6 marked SLNs were internalised into A30 cells at 37 °C. The 
uptake was decreased, but not completely stopped at 4°C incubation. This suggested that 
energy-dependent processes (endocytosis) might be involved in SLNs uptake (Rivolta et 
al., 2011). By pre-incubation with specific uptake mechanism inhibitors, two independent 
research groups have specified that clathrin-mediated endocytosis might be the 
preferential uptake mechanism of SLNs, while caveolae-mediated endocytosis seems to 
play an only minor role or not involved at all (Martins et al., 2012; Zhang et al., 2012). 
Martins et al., (2012) also found out that macro-pinocytosis might be involved to a smaller 
extent in some cell types. 
1.10. Docetaxel 
Docetaxel (DTX) is a second-generation taxane derived from the needles of the European 
yew tree, Taxus baccata (Bissery et al., 1995). Early in vitro studies revealed that docetaxel 
has a wide spectrum of antitumor activity (Bissery et al., 1995). It was demonstrated that 
DTX could significantly inhibit brain tumour growth by local injection (Sampath et al., 
2006). Docetaxel (Taxotere) is a novel, semi-synthetic, the anticancer agent, structurally 
related to paclitaxel (Taxol) (Figure 1.8) (Musumeci et al., 2006). Unlike paclitaxel, 
docetaxel exhibits linear pharmacokinetics and, due to differences in drug efflux, is 
retained intracellularly for a longer period (Bissery et al., 1995). DTX has shown efficacy 
in clinical trials against a variety of human tumours (Kaye and Vase 2002). It has also been 
reported to act as a potent radiosensitiser against systemic malignancies (Baker et al., 




Sampath et al., (2006) found that following local injection in a mouse brain tumour model, 
only low levels were found in the brain. 
 
Figure 1.8 The chemical structure of docetaxel (Musumeci et al., 2006). 
1.10.1. Mechanism of action of DTX 
DTX mechanism of action is through inhibition of tubulin depolymerisation resulting in 
microtubule aggregation and cell death (Sparreboom et al., 1998). The central role of 
microtubules in cell division and other relevant cellular functions makes it a target for 
anticancer drug development (Fanale et al., 2015). The primary mechanism of action for 
the taxanes (docetaxel and paclitaxel) is to promote microtubulin assembly and stabilise 
the polymers against depolymerisation, thereby inhibiting microtubule dynamics (Ringel 
et al., 1991). This mechanism of action employed by taxanes is distinct from that of other 
anti-microtubule agents, which prevent microtubule assembly (Rowinsky, Donehower, 
1996). The consequences of blocking microtubule dynamics are complex; a number of 
vital cellular functions in which microtubules play a critical role are compromised. 
Impairment of mitotic progression leading to cell cycle arrest is considered to be a 
principal component of docetaxel’s mechanism of action. This blocks the progression of a 
cell through its natural division cycle and, consequently, inhibits cell proliferation (Herbst 
and Khuri, 2003). Disruption of microtubules not only affects progression through the cell 
cycle but may also alter signalling pathways involved in processes such as apoptosis (Wang 
et al., 1999). Apoptosis, also known as ‘programmed cell death, is a physiologic process 
involving the activation of certain signalling pathways and genetic programs. Defects in 
this process are believed to contribute to a number of human diseases and decreased or 
inhibited apoptosis is a feature of many malignancies (Renehan et al., 2001). Several 
studies have demonstrated that docetaxel and other microtubule-targeting agents 




1.11. Aim and objectives of the project  
1.11.1. Aim 
The aim of this thesis was to enhance selectivity and therapeutic efficacy of an anticancer 
drug docetaxel (DTX) for targeting and treating glioblastomas, by examining the 
glioblastoma cell lines proliferation, internalisation, uptake, cell cycle distribution and 
permeation through 3D in-vitro BBB model that was set up from human origin cell lines. 
 This was achieved by enhancing permeation through the BBB of the poorly water-soluble 
drug DTX, by incorporating it into nanostructure lipid carrier (NLC) as a delivery system 
composed of biodegradable excipients and increasing its selective uptake by glioblastoma 
cells by use of novel aptamer and polyunsaturated fatty acids (PUFAs) as targeting ligands. 
1.11.2. Specific objectives: 
• To develop and validate a high-performance liquid chromatography method for 
quantification of DTX from NLC, release media and a biological matrix. 
• To develop NLC with high drug content and entrapment efficiency of DTX. 
• To study the physicochemical characterisation of the developed DTX-NLCs. 
• To functionalise DTX-NLC with two PUFAs (Gamma-linolenic acid (GLA) and Alpha-
linolenic acid (ALA) and one novel aptamer SA43 as ligands for enhancing DTX-NLC 
selectivity and efficacy. 
• To examine the potential effects of DTX-NLC and functionalised DTX-NLCs in an in-
vitro study of treatment of glioblastoma cell lines, non-cancerous brain cells, and short-
term culture glioblastoma cells. 
• To explore the anti-cancer efficiency and uptake of DTX-NLC and functionalised DTX-
NLCs using a diseased/tumour 3D in-vitro BBB model in the presence of monolayer 
glioblastoma cell line (U87MG). 
• To evaluate the potential mechanism of cellular uptake for DTX-NLC and 
functionalised DTX-NLCs. 
• To investigate the potential permeation of DTX-NLC and functionalised DTX-NLCs 






































2.1. Introduction  
2.1.1. High-performance liquid chromatography (HPLC)  
HPLC is a fast, reliable and commonly used technique for qualification and quantification 
of pharmaceutical and biological materials (Bansal et al., 2010; Shabir 2003; Rao et al., 
2006). One of the most critical factors in developing pharmaceutical drug substances and 
drug products today is ensuring that the analytical test methods that are used to analyse 
the products generate reliable and meaningful data, therefore this chapter reports 
development and validation of separate analytical methods for quantification of DTX in 
the DTX-NLCs to determine drug loading (DL), entrapment efficiency (EE), and in-vitro drug 
release in these formulations to provide assurance on the quality of products.  
2.1.2. HPLC method for analysing sample permeation through a 
physiological in-vitro BBB model  
Assessing BBB penetration is an essential and evaluative step at the early phase of the 
CNS drug discovery process and formulation development for CNS therapeutics (Doan et 
al., 2002; Kikuchi et al., 2013). As DTX-NLCs have been developed for brain targeting, it is 
necessary to evaluate their performance and determine their BBB permeability which was 
carried out by using a 3D in-vitro BBB model. Previous examples of HPLC analysis of 
various drugs permeation across an artificial BBB (human and animal) have been reported 
in the literature (Nakagawa et al., 2009; Jahne et al., 2014; Moradi-Afrapoli et al., 2016). 
A quantitative analytical HPLC method was developed and validated to assess the DTX in 
the biological media to determine drug permeated across the in-vitro BBB model derived 
from cells of human origin. 
In addition, prior to HPLC analysis, an extraction procedure was developed to separate 
the drug of interest from biological media based on previously published protocols (Jahne 
et al., 2014; Moradi-Afrapoli et al., 2016).  
2.1.3. HPLC validation  
The US Food and Drug Administration (FDA, 1995 and 2001) recognised the importance 
of HPLC to the drug development process and have increased validation requirements in 
recent years. Moreover, the International Conference on Harmonization (ICH 1996), has 
added to the FDA requirements to create an acceptable and professional validation 
process for all developed drug as detailed in this section (Shabir 2003; Polagani et al., 




 Analytical method validation is created to ensure that the analytical methodology is 
accurate, specific, reproducible and robust over the duration of time in which the product 
will be usually analysed. All laboratories must perform the method of validation, at least 
every 3-months to be in line with the US FDA regulation and the ICH guidelines. In 
addition, for analytes that need to be resolved from a biological matrix need additional 
validation to be performed according to the European Medicines Agency (EMA). The 
following sections summarise all the validation requirements from the regulatory 
agencies FDA, ICH and EMA.  
2.1.3.1. Specificity   
Specificity involves separation and correct identification of a specific analyte from all 
potential sample components. It is very important in the chromatographic method 
development to demonstrate the ability of the method to accurately measure the analyte 
response and give a specific peak.  
2.1.3.2. Precision  
Precision is the measure of the degree of repeatability of an analytical method under 
normal operation and is normally expressed as the percent relative standard deviation 
(RSD %) for a statistically significant number of samples, for example, three levels, three 
repetitions each. Precision may be performed at three different levels: repeatability, 
intermediate precision, and reproducibility. 
2.1.3.2.1. Repeatability  
Repeatability (intra-day precision) is the measure of variation of the method operating 
over a short time interval under the same conditions. It should be determined from a 
minimum of nine determinations covering the specified range of the procedure (for 
example three levels, three repetitions each). The acceptable precision criterion for an 
assay method is that the instrument precision (RSD) will be ≤ 1%, and for the impurity 
assay and biological samples, at the limit of quantitation, the instrument precision 
(repeatability) will be ≤ 5%. 
2.1.3.2.2. Intermediate precision 
Intermediate precision means inter-day variation and is the measure of variation within 
laboratories, due to random events, such as different days, analysts and equipment. In 
determining intermediate precision, experimental design should be employed, so that the 




method are that the inter-assay precision will be ≤ 2%, and for impurity assay, at the limit 
of quantitation, and the inter-assay precision will be ≤ 10%. 
2.1.3.2.3. Reproducibility  
Reproducibility is normally not expected if intermediate precision was previously 
performed. Reproducibility is determined by testing homogeneous samples in multiple 
laboratories, where the mean results will be within 2% of the value obtained by the 
primary testing lab. For an impurity method, the mean results will be within 10%.  
2.1.3.3. Accuracy 
The accuracy of an analytical method is the closeness of the measured results to the actual 
value (normally a reference standard). Accuracy criteria for an assay method (FDA) are 
that the mean recovery will be 100 ± 2% at each concentration over the range of 80 -120% 
of the target concentration. The ICH recommends collecting data from a minimum of nine 
determinations over a minimum of three concentration levels covering the specified 
range (for example three concentrations, three replicates each), and for extraction of an 
analyte from a biological matrix, the acceptable limit of accuracy should be within 10 % 
RSD. 
2.1.3.4. Recovery 
Recovery is defined as comparing the ratio of mean peak area obtained from a biological 
sample spiked with the analyte of interest before the extraction process, with those mean 
peak areas from the biological sample to which the analyte of interest was added after 
the extraction process, this ratio should be less than 15%.   
2.1.3.5. Matrix effect  
Matrix effect defined for the analyte extraction from different types of biological media, 
by comparing peak area of the analyte of interest in the presence of the biological media 
with the peak area in absence of the biological media (reference standard). This ratio will 
be defined as a matrix factor, this ratio should be less than 15%.   
2.1.3.6. Limit of detection and quantification   
The HPLC Limit of detection (LOD) is the lowest amount of analyte that can be detected 
above baseline noise; typically, three times the noise level. And the limit of quantitation 
(LOQ) is defined as the lowest amount of analyte which can be reproducibly quantitated 




2.1.3.7. Samples stability  
Samples and standards should be tested over at least a 48 h period (depends on intended 
use), and quantitation of components should be determined by comparison to freshly 
prepared standards. A stability criterion for assay methods is that sample and standard 
solutions and the mobile phase will be stable for 48 hours under defined storage 
conditions. Stability is acceptable when the change in the standard or sample response is 
within 2 % relative to freshly prepared standards, and within 15 % according to EMA 





















2.2. Aim and Objectives 
The aim of this Chapter was to develop and validate HPLC methods for the quantification 
of DTX. This was achieved by the following objectives: 
2.2.1. Objective 1 
Quantification DTX in DTX-NLCs and surface modified DTX-NLCs, to determine DTX loading 
and entrapment efficiency of DTX in all developed formulations.  
2.2.2. Objective 2 
Quantification of DTX that is been released from DTX-NLC and DTX-NLC surfaced modified 
formulations in two release media to study the kinetics of DTX release over a period of 
time in an in-vitro environment.  
2.2.3. Objective 3  
Extraction and quantification of DTX in a biological matrix comprising a mixture of three 
primary cell media consisting of proteins and human serum. This analytical method 
enabled quantification of DTX and DTX-NLC that permeated through the physiological in-
vitro BBB model. This method will contribute to access the ability to use DTX-NLCs as a 















2.3. Materials and equipment 
2.3.1. Equipment 
High-Performance Liquid Chromatography (HPLC) analysis was performed using the 
Agilent HPLC 1260 Infinity from Agilent Technologies, USA and data were studied with 
Agilent’s software OpenLAB CDS CS Workstation (Agilent Technologies, USA). Reversed-
phase HPLC C18 column (Luna 5µm, PFP(2), 100Å, 250 x 4.6 mm (Phenomenex, UK). 
Benchtop centrifuge (Spectrafuge 24D, Jencons-Pls, UK).  
2.3.2. Materials  
Tetrahydrofuran (THF), methanol, acetonitrile, acetone, ethanol, dichloromethane, 
dimethyl sulfoxide (DMSO) and chloroform were of HPLC grade and purchased from 
Fisher Scientific, UK.  Transparent and amber HPLC glass vials; orthophosphoric acid and 
Amicon 3 kDa molecular cut-off centrifugal filters were purchased from Fisher Scientific, 
UK. Docetaxel (DTX) and paclitaxel (PTX) were purchased from Kemprotec, UK. Phosphate 
buffer saline (PBS) 1 tablet dissolved in 200 ml water yields buffer containing 0.1 M 
phosphate buffer, 0.0027 M potassium chloride (KCl), and 0.137 M sodium chloride 
(NaCl), pH 7.4 at 25°C (Fisher, UK). Endothelial Basal Medium (EBM) and the following 
growth supplements: 0.5 ml rhEGF, 0.2 ml Hydrocortisone, 0.5 ml GA-1000 (Gentamicin, 
Amphotericin-B), 0.5 ml VEGF,  2ml rhFGF-B, 0.5 R3-IGF-1, 0.5 ml Ascorbic Acid, 0.5 ml 
Heparin, and 2% human serum (HS)/ 1 ml to form EGM-2; Astrocyte Basal Medium 
(ABM™) and the following growth supplements: rhEGF, 0.5 ml; Insulin, 1.25 ml; Ascorbic 
Acid, 0.5 ml; GA-1000, 0.5 ml, L Glutamine, 5.0 ml and 3 % HS/ 1 ml to form AGM-2 
purchased from Lonza, UK and Pericyte Basal Medium (PM) with growth supplements of 
5 ml of Pericyte Growth Supplement (PGS), 5 ml of penicillin/streptomycin solution (P/S) 









2.4.1. HPLC method for quantification of DTX from NLCs 
Drug content and drug entrapment are important pharmaceutical parameters to evaluate 
the success of NLCs as drug delivery systems. Therefore, a rapid and efficient analytical 
method is essential for the evaluation of these parameters. To quantify DTX, reversed 
phase HPLC was used which is a bonded phase chromatographic technique that uses 
water as the base solvent. Separation of compounds is based on solvent strength and 
selectivity and may also be affected by column temperature and pH. In general, the more 
polar components elute faster than the less polar components (Loffe et al., 2002). The 
method that has been used in this study was adopted and modified from previous 
literature (Muthu et al., 2011). Chromatographic conditions for DTX quantification were 
adjusted to an isocratic mobile phase, which consisted of acetonitrile and water (50:50, 
v/v). The mobile phase flow rate (FR) was 1.0 ml/min, the sample injection volume was 
20 µl and the UV detection wavelength was 230 nm. A Phenomenex column Luna 5µm, 
PFP(2), 100Å, 250 x 4.6 mm (Phenomenex, UK) was used throughout the experiment. The 
column temperature adjusted to 40 °C for the total analytical period of 15 min. A standard 
reference sample of DTX at 4 µg/ml was injected for all analytical studies to ensure that 
the HPLC system was working properly. All samples were injected three times, and 
experiments were carried out in triplicate. The mean and standard deviation were 
calculated, and standard calibration curves were generated. 
2.4.1.1. Organic solvents used for dissolving DTX-NLC 
Before the method validation, it was necessary to prove that an appropriate and 
optimised method had been used for the separation of DTX from other sample 
components by dissolving the sample appropriately.  Ideally, the mobile phase should be 
used to dissolve the samples, however, if the sample is not soluble in the mobile phase a 
different solvent should be tested (ICH guidelines, 1996). In this experiment, to determine 
the DTX encapsulation efficiency, DTX loading and total DTX entrapped in the  DTX-NLC 
accurately, it was essential to dissolve the formulation completely to overcome 
interference, peak tailing and poor symmetry in the HPLC chromatogram. However, as the 
NLCs were not soluble in the mobile phase, further optimisations were carried out. 
For dissolving the DTX-NLC formulation, the following organic solvents were evaluated in 
different ratios, acetone: ethanol (4.5:4.5, v/v); THF: DCM (7:2, v/v); THF: chloroform (5:5, 
v/v); THF: acetonitrile (3:7, v/v); methanol: THF (4.5:5.5; 5.5:5.5; 5.5:7.5; 4:6; 7:3; 7:4; 7:5; 




respectively were also evaluated. Only completely soluble samples were injected and 
analysed by the HPLC system as described in section 2.4.1.  
2.4.1.1.1. Sample preparation 
Once the solubility of DTX-NLC was achieved using THF and acetonitrile: water mixture 
(50:50, v/v) as solvents of choice, then samples were tested for the specificity of the 
method to quantify DTX. For DTX detection and quantification, DTX (20 µg/ml) 
concentration was prepared in a mixture of (20: 80 v/v) THF then injected into the HPLC 
system to confirm that there was no interference with DTX peak.  
A standard stock solution of DTX (100 µg/ml) was prepared in THF. Six working standards 
(ICH guidelines) were prepared by dilution of the stock in THF: mobile phase (20:80, v/v) 
to give DTX concentrations of 10, 8, 6, 4, 2 and 1 µg/ml. Samples were vortexed for 1 min, 
and a 1 ml solution of each sample was placed in an HPLC vial for analysis.  All samples 
were injected three times, and the experiment was carried out in triplicate.  
2.4.1.2. HPLC method validation for quantification of DTX from NLCs 
The validation of the analytical methods for DTX quantification in DTX-NLC was carried 
out as per FDA and ICH regulations. The following validation parameters were addressed: 
specificity, linearity, precision, accuracy, LOD, LOQ, and stability. 
2.4.1.2.1. Specificity 
 A 20 µg/ml DTX was prepared as described in section 2.4.1.1.1, and injected into the HPLC 
system, along with three other samples M.P, THF, and Blank-NLC (B-NLC). All samples 
were examined for DTX peak presence and symmetry. 
2.4.1.2.2. Linearity  
A linear regression analysis was achieved by examining a range of DTX concentrations (1, 
2, 4, 6, 8, 9, 10 µg/ml) that were prepared as described in section 4.2.1.1.1, and a linear 
calibration plot was acquired. 
2.4.1.2.3. Precision 
2.4.1.2.3.1. Repeatability 
As per the FDA and ICH guidelines, one level concentration was examined for the 
repeatability test. DTX at 4 µg/ml concentration was prepared as described in section 





2.4.1.2.3.2. Intra-day and inter-day precision 
The intra-day analysis was carried out by preparing three concentrations with three 
injections under the same experimental conditions. 4, 6, and 10 µg/ml DTX concentrations 
were prepared as described in section 2.4.1.1.1 and examined for their standard deviation 
(SD) and % RSD, while for inter-day precision, one concentration of DTX (2 µg/ml) was 
prepared as described in section 2.4.1.1.1 and injected on three different days and the SD 
and % RSD were calculated. 
2.4.1.2.4. Accuracy 
Three DTX concentrations (6, 8, 10 µg/ml) were prepared as described in section 2.4.1.1.1 
and examined for their accuracy and % RSD. 
2.4.1.2.5. LOD and LOQ 
The LOD and LOQ were obtained by examining one concentration of DTX (10 µg/ml) 
prepared as detailed in section 2.4.1.1.1, and LOD and LOQ were calculated. 
2.4.1.2.6. Solution stability 
One level concentration of DTX 3.5 µg/ml was prepared as described in section 2.4.1.1.1 
and evaluated for its stability for up to six weeks, and the mean, SD, and %RSD were 
calculated. 
2.4.2. HPLC method for quantification of DTX in two release media  
In-vitro drug release studies were performed to quantify DTX released from the developed 
DTX-NLCs at 37 °C into two different release media, release medium I consisted of 
absolute ethyl alcohol and phosphate buffer saline (PBS), pH 7.4) (30:70, v/v) (Zhang et 
al., 2017), while release media II consisted of 0.1 M PBS at pH 7.4 (Tan et al., 2017). 
Chromatographic conditions were used for the HPLC were as detailed in section 2.4.1.  
2.4.2.1. Sample preparations  
For quantification of DTX in the release medium I, a standard stock solution of DTX (100 
µg/ml) was prepared in ethanol. Five working standards were prepared by dilution with a 
mixture of (30:70, v/v) of ethanol and PBS pH 7.4 (release media I) to give a DTX 
concentration of 5, 2.5, 1, 0.5 and 0.25 µg/ml. For the release medium II, a standard stock 
solution of DTX (100 µg/ml) was prepared in ethanol. Five working standards were 
prepared by dilution with PBS, pH7.4 (release media II) to give DTX concentrations of 5, 
2.5, 1, 0.5 and 0.25 µg/ml. All samples were vortexed for 1 min, and a 1 ml solution of 




2.4.2.2. HPLC method validation for quantification of DTX from release 
media  
The validation of the analytical methods for DTX quantification in release media was 
carried out as per FDA and the ICH regulations. The following validation parameters were 
addressed: specificity, linearity, precision, accuracy, LOD, LOQ, and stability. 
2.4.2.2.1. Specificity 
 A 1 µg/ml DTX was prepared in both the release media as described in section 2.4.2.1. 
and injected into the HPLC system, along with blank release media. All samples were 
examined for the presence of DTX peak and its symmetry. 
2.4.2.2.2. Linearity  
A linear regression analysis in two different media was achieved by examining a range of 
DTX concentrations (0.25, 0.5, 1, 2.5, and 5) µg/ml that were prepared as described in 
section 2.4.2.1. and linear calibration plots were acquired. 
2.4.2.2.3. Precision 
2.4.2.2.3.1. Repeatability 
As per the FDA and ICH guidelines, one concentration was examined for the repeatability 
test. DTX at 0.25 µg/ml concentration was prepared in the two-release media as described 
in section 2.4.2.1 and injected ten times, then the percentage relative standard deviation 
(% RSD) was calculated. 
2.4.2.2.3.2. Intra-day and inter-day precision 
The intra-day analysis was carried out by preparing three concentrations with three 
injections under the same experimental conditions. Three DTX concentrations (0.25, 1, 
and 2.5 µg/ml) were prepared in both the media as described in section 2.4.2.1 and 
examined for their SD and % RSD, while for inter-day precision, one concentration of DTX 
5 µg/ml was prepared in both the media as described in section 2.4.2.1, and injected in 
three different days, and the SD and % RSDs were calculated. 
2.4.2.2.4. Accuracy 
Three DTX concentrations (0.25, 2.5, and 5 µg/ml) were prepared in two different media 
as described in section 2.4.2.1 and examined for their accuracy and % RSD. 
2.4.2.2.5. LOD and LOQ 
The LOD and LOQ were obtained by examining one concentration of DTX (1 µg/ml) 





2.4.2.2.6. Solution stability 
One concentration of DTX (2.5 µg/ml) was prepared as described in section 2.4.2.1 and 
evaluated for its stability for up to three days for the purpose of this analytical method, 
and the mean, SD, and %RSD were calculated. 
2.4.3. HPLC method development for DTX quantification and 
extraction from biological matrices 
Only a few HPLC methods for drug quantitation after permeation through a physiological 
in-vitro BBB model have been reported in the literature. In previous studies, the drug of 
interest was extracted and quantified from Ringer HEPES buffer (RHB) and/or  Hank’s 
balanced salt solution (HBSS, pH7.4) plus bovine serum albumin (BSA) as corresponding 
matrices (Jahne et al., 2014; Moradi-Afrapoli et al., 2016). To our knowledge, no method 
has been developed for DTX quantification in a biological matrix consisting of a mixture of 
biological media and human serum (HS). As the in-vitro BBB model comprised of three 
type of cells (endothelial, astrocytes and pericytes) and therefore a combination of three 
media along with human serum is required for their growth. Our study aimed to quantify 
DTX permeated in this biological matrix consisting of a mixture of three biological media 
and their growth supplements in equal ratio (1:1:1) as follows, EBM+ 2% HS/ 1 ml, ABM 
+3 % HS/ 1 ml PM+ 2% HS/1 ml. The serum addition is essential as a source of growth and 
adhesion factors and plays a crucial role as a cell membrane permeability regulator, and 
serves as a carrier for lipids, enzymes, micronutrients and trace elements for a basic cell 
culture environment (Invitrogen, Life Technologies). Therefore an HPLC method was 
developed and optimised specifically for DTX quantification in biological media consisting 
of serum. Isocratic and gradient mobile phases were explored, and mobile phase pH was 
adjusted to 5 by using orthophosphoric acid as recommended in the literature (Choudhury 
et al., 2013).  
2.4.3.1. HPLC Method optimisation 
Various combinations of different reversed-phase columns flow rates and different 
mobile phases were evaluated to achieve a good resolution, symmetrical peaks, shorter 
retention time and better peak shape by improving peak separation of the drug of interest 
from sample components peaks (Rigo-Bonnin et al., 2016). 
2.4.3.1.1. Stationary phase optimisation  
For the stationary phase optimisation, the methods by Schmidt et al., (2017) and Khan et 




columns were utilised during method development: Kromasil 3.9 x 150 mm, (Waters, UK); 
Kinetex, 2.64 x B-C18 100Å, 75x4.60 mm, (Phenomenex, UK) and Luna 5µm, PFP(2) 100Å, 
250 x 4.6 mm (Phenomenex, UK), under the same chromatographic conditions with 
mobile phase acetonitrile: water (50:50, v/v) at 1 ml/min flow rate. 
2.4.3.1.2. Flow Rate (FR) 
The method of Khan et al., (2016) was adopted and optimised further. Mobile phase flow 
rates at 0.8, 0.9, and 1 ml/min were examined under the same experimental conditions 
acetonitrile: water (50:50, v/v) mobile phase and C18 Luna Column 5u PFP (2) 100A, 250 
x 4.6 mm (Phenomenex) was selected for further studies. The flow rate that showed the 
best peak shape, symmetry and resolution were selected for validation studies.  
2.4.3.1.3. Mobile phase  
Isocratic and gradient mobile phase were tested using varying ratios of acetonitrile: water 
as shown in Table 2.1.  The mobile phase that gave the target peak of DTX with no peak 
interference, acceptable peak symmetry and good separation from the sample 
component was selected for further validation according to ICH and FDA guidelines.  
2.4.3.1.3.1. Isocratic mobile phase 
Different mobile phases were tested (Table 2.1), for quantification of DTX in a biological 
sample. 
Table 2.1 Isocratic mobile phase used for quantification of DTX in a biological sample. 
Solvent A Solvent B  Solvent 
C 
pH Ratio  
Acetonitrile H2O - - 50:50 
Acetonitrile H2O - - 40:60 
Acetonitrile H2O - - 60:40 
Acetonitrile H2O - - 70:30 
Acetonitrile H2O - - 65:30 
Acetonitrile  1% acetic acid in H2O - 5 60:40 
Acetonitrile 1% acetic acid in H2O - 5 40:60 
Acetonitrile The orthophosphoric acid in 
H2O 
THF 5 40:50:10 
 
2.4.3.1.3.2. Gradient mobile phase 
A gradient mobile phase was evaluated, and the pH was adjusted to 5 by using 
orthophosphoric acid (Choudhury et al., 2013) as shown in Table 2.2. According to Rigo-
Bonnin et al., (2016) when a gradient mobile phase was used with lower pH it gave better 






Table 2.2 Table showing a gradient mobile phase with pH 5. 
Time (min) %B H2O %C THF %D Acetonitrile FR (ml/min) 
0 50 10 40 1 
10 20 10 70 1 
10 50 10 40 1 
12 50 10 40 1 
 
2.4.3.2. Optimisation of DTX extraction from biological samples and 
sample preparation 
Precipitation of biological proteins by using acetonitrile prior to bioanalysis has been 
widely reported (Khan et al., 2016; Jahne et al., 2014; Moradi-Afrapoli et al., 2016). 
Acetonitrile was therefore used to evaluate its suitability to extract DTX from biological 
samples in a combination with two other organic solvents THF  and DMSO. 
2.4.3.2.1. THF/acetonitrile for DTX extraction  
DTX standard stock (100 µg/ml) was prepared in THF. Five working standards were 
prepared by diluting with (20: 80, v/v) THF: M.P (water: acetonitrile) to give a DTX 
concentration of 5, 4, 3, 2 and 1 µg/ml. A volume of 50 µl was placed in a 1.5 ml tube 
(Eppendorf) from each working standard, and 450 µl of biological media mixture was 
added to the working standard solution. A volume of 500µl of ice-cold acetonitrile was 
added to the mixture. All samples were vortexed for 1 min, the samples were centrifuged 
at 16300 x g for 30 min, then 800 µl supernatant was transferred to an HPLC vial for 
analysis. A further 300 µl supernatant was diluted with 200 µl acetonitrile and transferred 
to the HPLC for analysis. 
2.4.3.2.2. DMSO/ acetonitrile for DTX extraction  
A standard DTX stock solution concentration (500 µg/ml) was prepared in DMSO. Six 
working standards were prepared by dilution with a mixture of (20:80, v/v) of DMSO: M.P 
(acetonitrile: water, 50:50, v/v) to give DTX concentrations 40, 30, 20, 15, 10 and 4 µg/ml 
respectively. Samples were vortexed for 1 min and a volume of 50 µl was taken from each 
working standard and placed in a 1.5 ml tube (Eppendorf), 450 µl of primary cells media 
mixture was added to the working standard solution. The samples were vortexed for 1 
min. Finally, 500 µl of ice-cold acetonitrile was added to give a DTX concentration of 2, 
1.5, 1, 0.75, 0.5, and 0.2 µg/ml that contain 1% DMSO. The samples were centrifuged at 




2.4.3.2.3. DMSO/ acetonitrile for DTX extraction by using paclitaxel as an 
internal standard   
A similar extraction method was used as detailed in section 2.4.3.2.2, with the presence 
of 0.1 µg/ml paclitaxel (PTX) as an internal standard (IS). After samples were vortexed for 
1 min, 50 µl was taken from each working standard and placed in a 1.5 ml tube 
(Eppendorf), then 50 µl of PTX (0.1 µg/ml) was added, followed by addition of  400 µl of 
biological media. Finally, the samples were vortexed for 1 min and 500 µl of ice-cold 
acetonitrile was added to give a DTX concentration of 2, 1.5, 1, 0.5, 0.25, 0.1 and 0.05 
µg/ml) that contained 1% DMSO. The samples were centrifuged at 16300 x g for 30 min 
and 800 µl was taken from the supernatant solution from each sample and placed in an 
HPLC vial and analysed.   
2.4.3.3. HPLC method validation for DTX quantification and extraction 
from biological matrices 
There are separate EMA and FDA guidelines for validation of the analytical methods for 
analytes that need to be resolved from a biological matrix. The validation was therefore 
performed considering these guidelines, whereby the following validation parameters 
were addressed: specificity, linearity and range, precision, accuracy, recovery, LOD, LOQ, 
matrix effect and stability and freeze throwing stability evaluation. 
2.4.3.3.1. Specificity 
DTX at 2 µg/ml and PTX (IS) at 0.1 µg/ml were prepared separately and in combination (2 
µg/ml DTX and PTX 0.1 µg/ml) as described in section 2.4.3.2.3 and injected into the HPLC 
system along with two other samples M.P and blank-biological matrix (without DTX and 
PTX) to examine for any peak interference.  
2.4.3.3.2. Linearity  
A linear regression analysis was achieved by examining a range of DTX concentrations 
(0.05, 0.1, 0.25, 0.5, 1, 1.5, and 2) µg/ml that were prepared as described in section 
2.4.3.2.3 and a linear calibration plot was acquired. 
2.4.3.3.3. Precision 
2.4.3.3.3.1. Repeatability 
As per the FDA and ICH guidelines, one concentration of DTX 2 µg/ml was prepared as 
described section 2.4.3.2.3 and examined for repeatability by injecting nine times and the 




2.4.3.3.3.2. Intra-day and inter-day precision 
The intra-day analysis was carried out by preparing three concentrations of DTX 0.05, 0.5, 
and 1 µg/ml (section 2.4.3.2.3) with three injections under the same experimental 
conditions and examined for their SD and % RSD; while for inter-day precision, one 
concentration of DTX 1.5 µg/ml was prepared and injected on three different days and 
the SD and % RSD were calculated. 
 
2.4.3.3.4. Accuracy 
Three DTX concentration 0.05, 0.5, and 1 µg/ml were prepared as described in section 
2.4.3.2.3 and examined for their accuracy and % RSD. 
2.4.3.3.5. Recovery 
For evaluation of the extraction recovery method from biological matrices, a method was 
adopted and modified from Moradi-Afrapoli et al., (2016). Four sets of standards were 
prepared as described in section 2.4.3.2.3, where: (set I) included DTX concentrations (low 
0.05 µg/ mL, medium 0.5 µg/ mL and high 2 µg/ mL) extracted, then spiked with IS (0.1 
µg/ mL PTX); (set II) a batch of blank samples were extracted and then afterwards were 
spiked with IS plus and DTX concentrations (low, medium and high). The absolute recovery 
of the extraction process was calculated by comparing the ratio of peak area obtained in 
the set I to peak area obtained from set II. Moreover, to calculate the absolute recovery 
for the IS, set III was prepared by extracting the IS with 0.1 µg/ml medium concentration 
and then afterwards was spiked with DTX (high concentration). Later, set IV was prepared 
by taking a blank sample replicate and extracting, then afterwards was spiked with IS plus 
high DTX concentration. By comparing the ratio of peak area for those of set III to those 
of set IV, an absolute recovery of the IS was calculated. 
2.4.3.3.6. Matrix effect 
DTX concentration of 1 µg/ml was prepared as described in section 2.4.3.2.3 in the 
presence and absence of a biological matrix and injected to determine the matrix factor. 
2.4.3.3.7. LOD and LOQ 
The LOD and LOQ were obtained by examining DTX at 2 µg/ml as detailed in section 
2.4.3.2.3. 
2.4.1.2.8. Solution stability 
Three level concentrations of DTX (0.05, 0.5, and 2 µg/ml) were prepared as described in 




and one concentration of DTX (0.5 µg/ml) was examined for its stability during three cycles 





















2.5. Results and Discussion 
2.5.1. HPLC method development for DTX quantification in DTX-NLC 
The key objective of the chromatographic method is to achieve separation of the impurity 
from the peak of interest (ICH guidelines). Well-separated peaks are essential for 
quantitation. This is a very useful parameter if potential interference peak(s) may be of 
concern. Previous studies have attempted to dissolve DTX from lipid microspheres using 
a combination of acetonitrile, water and methanol, where methanol was reported as the 
solvent of choice (Du et al., 2013). In the present study, DTX-NLC solubility was 
investigated in a combination of the common organic solvents where the formulation 
failed to dissolve in the listed solvents (Table 2.3).  








It was found out that a combination of THF with either methanol or ethanol dissolved 
DTX-NLC samples successfully (Tables 2.4 and 2.5). Including methanol/ ethanol as 
solvents resulted in dissolving DTX-NLC yielding a clear solution. However, the 
chromatograms were causing a split in the DTX peak. Furthermore, when the volume of 
THF was increased to more than twice than ethanol a single sharp peak with good 
symmetry was obtained. Therefore, THF was used to dissolve the DTX-NLC and then a 
serial dilution with a combination of THF and mobile phase (acetonitrile: water 50:50, v/v) 








Organic solvent Composition  Findings 
1 Ethanol: acetone  4.5: 4.5 Lipid does not dissolve. 
1 DMC: THF 2: 7 Lipid does not dissolve. 
1 Chloroform: THF 5: 5 Lipid does not dissolve.  

























2.5.1.1. HPLC method validation for quantification of DTX from NLCs 
2.5.1.1.1. Specificity  
As per ICH guidelines method, specificity and peak separation is a critical step for 
developing a new method for quantification of an analyte. A well separated DTX peak with 
good shape and symmetry were obtained when 20 µg/ml DTX was prepared in (20: 80, 
v/v) THF: M.P and the DTX peak was detected at a retention time (RT) of 8.6 min (Figure 
2.1 a). Moreover, the absence of any peak at RT of 8.6 min confirmed that there was no 
excipient or impurity interference at the RT of DTX as is evident from chromatograms of 
B-NLC in M.P and THF (Figures 2.1 b, 2.1 c and 2.1 d). This method was found to be specific 








1 4.5 5.5 Clear solution and peak splitting  
1 5.5 5.5 Clear solution and peak splitting 
1 5.5 7.5 Clear solution and peak splitting 
1 4 6 Clear solution. Peak splitting 
1 7 3 Lipid does not dissolve 
1 7 4 Not Clear solution 
1 5 7 Clear solution and peak splitting 
1 3 9 Clear solution and peak splitting 








1 5 5 Clear solution. Peak splitting 
1 5 7 Clear solution. Peak splitting   
1 7 3 Clear solution. Peak splitting 
1 9 9 Clear solution. Peak splitting. 
1 3 7 Clear solution. Peak splitting 










Figure 2.1 HPLC chromatograms (a) concentration 20 µg/ml of DTX dissolved in THF: 
M.P; (b) B-NLC dissolved in THF: M.P. (c) M.P peak; (d) THF peak. The peak of interest 
DTX had a retention time of 8.6 min. 
 
2.5.1.1.2. Linearity 
A linear calibration curve was acquired by plotting the mean area under the curve (MAUC) 
against DTX concentrations ranging from 1 to 10 μg/ml (Figure 2.2). The assessment of 
linearity was achieved by linear regression analysis using R2 values. A correlation 
coefficient R2 of 0.9994 was obtained demonstrating linearity of DTX for the studied 
concentration range. Similar findings were reported in the literature, where a standard 




0.999 (Kumar et al., 2010) and R2 > 0.990 (Muthu et al., 2011) were considered an 
excellent demonstration of the relationship between peak area and drug concentration. 
The respective linear regression was calculated by the equation below:  
Y= 21.504x+0.2972  (Equation 2.1) 
 
Figure 2.2 DTX standard plot showing a linear relationship between DTX concentration 
and average AUC obtained by HPLC analysis. Data are mean ± SD, (N=3).  
 
2.5.1.1.3. Precision 
The injection (system) precision of an analytical method is related to the repeatability and 
reproducibility of the technique and can be represented as % RSD. 
2.5.1.1.3.1. Repeatability  
The ICH and FDA guidelines propose injection of the same sample ten times under the 
same chromatographic conditions. This experiment established repeatability by 
performing ten replicates for independently prepared DTX concentration (4 µg/ml) where 
RSD was 0.709 % (Table 2.6). All data were considered acceptable for the injection 






















Table 2.6 HPLC data obtained for the injection repeatability (instrumental precision) 
using the same concentration of DTX. 











Average  3.608 
SD 0.025 
RSD (%) 0.709 
 
2.5.1.1.3.2. Intra-day and Inter-day precision 
Intra-day precision was established by analysing three concentrations with three 
injections under the same experimental conditions following the ICH guidelines. The % 
RSD values for the nominated three DTX concentrations 4, 6 and 10 µg/ml were 1.497, 
0.470 and 0.088 % respectively (Table 2.7). Intra-assay precision was considered 
acceptable when the % RSD ≤ 2. The ICH guidelines suggest inter-day precision should be 
determined by the injection of one sample on three different days. A 2µg/ml was the 
nominated DTX concentration for this experiment. The obtained % RSD was (0.753 %) 
(Table 2.8) which was well within the acceptable limits of ≤ 2 %. All generated data were 
within the acceptable limits of the ICH guidelines.  











































The accuracy of an analytical method is the closeness of the measured results to the actual 
concentration of the standard. The following equation was used to calculate the accuracy: 
Accuracy = 100*(calculated data/ actual data) (Equation 2.2) 
For DTX concentrations, 6, 8 and 10 µg/ml, the recovery of DTX in samples ranged from 
99 % to 100.6 % (Table 2.9). The method was found to be accurate as the % RSD was well 
within the acceptable limits 100 ± 2 % following ICH and FDA guidelines.  
Table 2.9 Results obtained for method accuracy. 
DTX labelled  
concentration (µg/ml) 
DTX actual 
 Concentration (µg/ml) 
Accuracy (%) RSD 
(%) 
6 6.15 100.6 0.090 
8 7.97 99.6 1.069 
10 9.90 99.0 0.099 
 
2.5.1.1.5. LOQ and LOD 
The LOQ is the lowest quantity that can be quantified by HPLC system; while the LOD is 
the lowest quantity that can be detected (ICH and FDA guidelines). The two parameters 
were calculated as described in the equations below:  
LOQ= (10X % SD)/Slope (Equation 2.3) 
LOD= (3.3x % SD)/Slope (Equation 2.4) 
The LOQ of DTX was obtained at 0.041 µg/ml and the LOD was 0.013 µg/ml under the 
same conditions.  
DTX labelled  
concentration (µg/ml) 




Day 1 2.01 
Day 2 1.997 
Day 3 1.980 
Mean 1.995 
SD 0.015 




2.5.1.1.6. Solution stability  
The RSD of the assay of DTX during solution stability experiments was < 1.0 % (Table 2.10). 
No change was observed in the content of the solution during stability experiments. The 
experimental data confirmed that sample solutions used during the assay were stable up 
to six weeks and were suitable for the intended purpose of the developed HPLC method 
(ICH guidelines). 
Table 2.10 Sample stability. 
DTX labelle 
Concentration (µg/ml) 
















% RSD 0.658 
The development and validation of this HPLC method according to ICH and FDA guidelines 
for the DTX quantification, demonstrated the HPLC method was suitable for measurement 
of DTX content, encapsulation efficiency and total DTX entrapped in DTX-NLC. 
2.5.2. HPLC method for quantification of DTX from release media 
2.5.2.1. HPLC method validation for quantification of DTX from release 
media  
2.5.2.1.1. Specificity  
The chromatographic separation was achieved by using the HPLC method as described 
2.3.1. An acceptable DTX peak with good shape and symmetry were obtained in both 
release media. The DTX peak was detected at RT of 8.9 min (Figure 2.3 a and b). Moreover, 
the absence of the peak at RT of drug (8.9 min) when only blank release media was 
injected (Figure 2.3 c and d) confirmed that there was no interference of release media 
components with the DTX peak demonstrating the specificity of the method and was 













Figure 2.3 HPLC chromatograms (a) concentration 1 µg/ml of DTX dissolved in release 
media (30:70, v/v, ethanol: PBS pH7.4) (b) concentration 1 µg/ml of DTX dissolved in 
release media (100%, PBS pH7.4), (c) blank release media (30:70, v/v, ethanol: PBS 
pH7.4), (d) blank release media (100%, PBS pH7.4). 
 
2.5.2.1.2. Linearity 
Linear calibration curves were acquired by plotting the mean area under the curve 
(MAUC) against DTX concentrations ranging from 5 to 0.25μg /ml (Figure 2.4 a, b) for the 
two-release media respectively. The assessment of linearity was achieved by linear 
regression analysis using R2 values.  
The correlation coefficients R2 obtained were 0.9999 for the release media I and II. This 




the studied concentrations range was acceptable (Muthu et al., 2011; Shabir 2004) as ICH 
guidelines recommend when the value of R2 is close to or equal to 1, the developed HPLC 
method is within the acceptable limits. The equations of the linear curves were as below:  
 Y=20.687x-0.2672 (Equation 2.5) 






Figure 2.4 DTX standard plots showing (a) linear relationship of DTX concentration and 
average AUC obtained for the release media I (30:70, v/v, ethanol: PBS pH7.4) and (b) 
linear relationship of DTX concentration and average AUC obtained for the release 
media II (100 % PBS pH7.4) HPLC analysis. Data are mean ± SD, (N=3). 


































2.5.2.1.3.1. Repeatability  
The ICH and FDA guidelines propose injection of the same sample ten times under the 
same chromatographic conditions. This experiment established repeatability by 
performing the ten replicates for independently prepared DTX concentration (0.25 µg/ml) 
for both the release media. A low % RSD (0.741 % and 0.907 %) was obtained for both 
release media respectively (Table 2.11). All data were considered acceptable for the 
injection repeatability when the % RSD ≤ 1 % (ICH and FDA guidelines). 
Table 2.11 HPLC data obtained for the injection repeatability (instrumental precision) 
using same concentration of DTX for release media (30:70, v/v ethanol: PBS pH7.4) I and 
II (100 % PBS pH7.4) release media II. 
DTX labelled 
 Concentration (µg/ml) 
DTX actual  
Concentration (µg/ml) 
Release Media I 
DTX actual  
Concentration (µg/ml) 














Average 0.253 0.251 
SD        0.001 0.002 
RSD (%)        0.741 0.907 
2.5.2.1.3.2. Intra-day and Inter-day precision 
Intra-day precision was established by analysing three concentrations with three 
injections under the same experimental conditions following the ICH guidelines. The % 
RSD values for nominated DTX concentrations 0.25, 1 and 5 µg/ml were 0.84, 0.446 and 
0.79 % (Table 2.12) for the release media I, and 0.624, 0.881 and 0.264 % for release media 
II respectively (Table 2.12). Intra-assay precision was considered acceptable when the % 
RSD ≤ 2 (ICH and FDA guidelines). The ICH guidelines suggest the injection of one sample 
on three different days for inter-day precision. A 5 µg/ml was used in both release media 
as the nominated DTX concentration for this experiment. The % RSD obtained were (0.718 
and 0.313 %) for the two-release media respectively (Table 2.13). The % RSD values were 




Table 2.12 HPLC data obtained for intra-day method precision for release media I (30:70, 
v/v, ethanol: PBS Ph7.4) I and release media II (100 % PBS Ph7.4) II. 
 
Table 2.13 HPLC data obtained for inter-day method precision for release media (30:70, 
v/v ethanol: PBS Ph7.4) I and for the release media (100 % PBS Ph7.4) II. 
 
2.5.2.1.4. Accuracy 
The accuracy of an analytical method is the closeness of the measured results to the actual 
data; equation 2.2 was used to calculate the accuracy. For DTX concentrations 0.25-5 
µg/ml, the recovery of DTX in samples was ranging from 100 % to 101.6 % (Table 2.14) for 
the release media I, and 99.99 % to 100.7 % for the release media II (Table 2.14). The 
method was found to be accurate as the % RSD values were well within the acceptable 
limits 100 ± 2 % of the ICH and FDA guidelines. 
Table 2.14 Results obtained for method accuracy for release media (30:70, v/v and 
















0.25 0.256 0.002 0.840 0.253 0.001 0.624 
0.252 0.250 
0.253 0.252 
1 0.959 0.004 0.446 0.991 0.008 0.881 
0.952 0.993 
0.960 1.007 


















Day 1 5.050  Day 1 5.007  
Day 2 4.993 Day 2 4.981 
Day 3 4.984 Day 3 5.010 
Mean 5.00 4.99 
SD 0.035 0.015 




2.5.2.1.5. LOQ and LOD 
The LOQ and LOD were calculated as described in equations 2.3 and 2.4, respectively. The 
LOQ of DTX was obtained at 0.216 and 0.42 µg/ml for release media I and II respectively 
while LOD was 0.071 and 0.138 µg/ml respectively for the two media under the same 
conditions. 
2.5.2.1.6. Solution stability  
The RSD of the assay of DTX during solution stability experiments were 0.872 and 0.275 
% for the first and second release media, respectively when 2.5 µg/ml was assessed as 
nominated concentration to test the stability of both release media (Table 2.15). No 
changes were observed in the content of the solution during stability experiments. The 
experimental data confirmed that sample solutions used in the assay were stable up to 
three days and were suitable for the intended purpose of the developed HPLC method.  
Table 2.15 Sample stability for release media (30:70, v/v and ethanol: PBS pH7.4) I and 
release media (100% PBS pH7.4) II.  
 
The HPLC methods developed and validated according to ICH and FDA guidelines for 
quantification of free DTX in release media were thus found suitable for the purpose. 
2.5.3. HPLC method development for quantification of DTX from the 
biological matrix  
HPLC method for the extraction and quantification of DTX from the biological sample was 
established as described in section 2.4.3.2.3. This method was required to quantify a low 
concentration of DTX in the biological matrix when samples were collected from the 
basolateral side of a physiological 3D in-vitro BBB model. This matrix consisted of a 
combination of three primary cells media prepared as per recommended manufacturer 
directions (supplements, protein and human serum) (Lonza, UK). No previous method has 



















1 2.494   
2.5 
1 2.208  
2 2.514 2 2.210 
3 2.470 3 2.219 
Mean 2.493   2.212 
SD 0.021 0.006 




BBB model. Earlier methods have employed, RHB and HBSS as matrices for such 
quantification (Jahne et al., 2014; Moradi-Afrapoli et al., 2016). 
2.5.3.1. HPLC method optimisation  
2.5.3.1.1. Optimisation of stationary phase 
The selection of a suitable HPLC column is a major step to achieve a good analyte peak. 
Four reversed phase C18 columns were investigated, shows that DTX could not be 
detected at a low concentration of 1 µg/ml when HPLC was performed using Kinetex, 2.64 
x B-C18 100A, 75x4.60 mm column (Phenomenex), the peak tailing and poor symmetry 
was the reason behind disregarding this column. The high concentration of DTX at 10 and 
100 µg/ml were quantified by using the C18, 150 mm, Kromasil column, but there was an 
interference between the diluent and the DTX peak. In addition, the peak symmetry was 
not acceptable. A high concentration of DTX at 10 and 100 µg/ml were quantified using 
C18, 3.9 x 150 mm, Waters column, but this column was not used due to peak interference 
with the diluent. According to ICH guidelines the accuracy of quantification decreases with 
increase in peak tailing because of the difficulties encountered during integration in 
determining where and when the peak ends, hence the calculation of the area under the 
peak will not be accurate. All columns described above have very short column length, 
which may have contributed to peak tailing and/or peak interference. Column choice is a 
critical step in acquiring a good shape peak with no interference (Schmidt et al., 2017; 
Khan et al., 2016). Moreover, a new column with longer length and presence of 
pentafluoro phenyl (PFP) in column packing, Luna 5u PFP(2) 100A, C18, 250 x 4.6 mm 
(Phenomenex) was used specifically for separation of hydrophobic compounds. The 
chromatogram (Figure 2.5 c, d, e) reveals an acceptable peak with good symmetry and no 
interference.  Also, a lower concentration could be detected using this particular column 
after further optimisation. This column was therefore used for quantification of DTX in 
biological matrices.  
2.5.3.1.2. Optimisation of flow rate (FR) 
Three mobile phase flow rates were explored, as described in section 2.4.3.1.2.  The  FR 
of 0.8 and 0.9 ml/min did not show any peak at lower DTX concentration of 1 µg/ml. Poor 
peak symmetry and peak tailing were obtained with this FR at high concentrations of DTX. 
The HPLC chromatogram obtained at a flow rate of 1 ml/ min (figure 2.5 c, d, e), showed 
acceptable DTX peak with good peak symmetry and no interference. Importantly, lower 




further HPLC method development for quantification of DTX in biological matrices. This 
finding was in line with another previous study (Sathyamoorthy et al ., 2014). 
2.5.3.1.3. Optimisation of mobile phase 
Different mobile phases were examined for quantification of DTX in a biological matrix as 
described in section 2.4.3.1.3. Initially, isocratic mobile phases were investigated for 
quantification of DTX, which caused interference of the diluent with the DTX peak, 
unacceptable peak tailing, the peaks symmetry was not acceptable. According to Agilent 
technical support, a lower pH might improve the peak shape and symmetry, further 
orthophosphoric acid was used (Choudhury et al., 2014) to bring the preferred pH in a 
gradient mobile phase as described in Table 2.2. Chromatogram (figure 2.5 d) displayed 
DTX peak with good shape, by using this M.P a low DTX concentration (0.2 µg/ml) was 
quantified with acceptable peak symmetry and no peak tailing when ortho-phosphoric 
acid was selected to bring the preferred pH to the gradient mobile phase. This gradient 
mobile phase was used for the quantification of DTX in biological matrices. Further 
optimisation was carried out for the quantification of DTX from the biological matrix. 
 
2.5.3.2. Optimisation of sample preparation  
Extraction of DTX from the biological matrix was carried out investigating acetonitrile with 
two organic solvents THF and DMSO as described in section 2.4.3.2. only the use of 
DMSO/acetonitrile and extracting the DTX using ice-cold acetonitrile were found to be a 
suitable method, as no peak interferences from the biological matrix with the DTX peak 
were found and the peak symmetry was found to be acceptable with no peak tailing 
(Figure 2.10 c and d). This method was therefore selected for the DTX extraction and 
quantification of biological matrices in the presence of PTX, which was used as IS and 
validated according to ICH, FDA and EMA guidelines.   
2.5.3.3. HPLC method validation for DTX extraction and quantification 
from the biological matrix  
2.5.3.3.1. Specificity  
This method demonstrated specificity for quantification of DTX in a biological matrix, due 
to the absence of any interfering peak at RT of DTX (7.2 min) when blank biological matrix 
and gradient mobile phase were injected in HPLC as evident by chromatograms shown in 
figure 2.5 a and b. DTX peak eluted at RT 7.2 min (Figure 2.5 c and d) when extracted from 
biological samples with symmetrical peak shape and good baseline resolution. The PTX 




interference from other sample components (Figure 2.5 c, d and e). The absence of any 
interfering peaks from the blank biological matrix and gradient mobile phase (Figure 2.5 








Figure 2.5 HPLC chromatograms (a) blank biological matrix, (b) gradient mobile phase, 
(c) docetaxel and internal standard paclitaxel extracted from the biological matrix, (d) 





A linear calibration curve was acquired (Figure 2.6), using the standard solutions ranging 
from 0.05 to 2 µg/ml. The calibration curve was generated by a linear fit of the DTX/PTX 
standard area ratio versus DTX concentration. The assessment of linearity was performed 
by linear regression analysis using R2 values.  
In this study, the correlation coefficient R2 obtained was 0.9987. Similar results were 
obtained previously (Moradi-Afrapoli et al., 2016). Since the acquired R2 value was 
acceptable, this demonstrated that the linearity of the DTX quantification within the 
studied concentration range for the newly developed method was acceptable. It was 
calculated according to the following equation: 
Y = 3.4588x-0.0247 (Equation 2.8)  
 
 
Figure 2.6 DTX standard plot for DTX from the biological matrix. Data are mean ± SD, 
(N=3). 
2.5.3.3.3. Precision 
The % RSD was generated by calculating the DTX/PTX ratio as described below: 
2.5.3.3.3.1. Repeatability  
Repeatability precision was evaluated by injecting one concentration nine times. The % 
RSD value obtained for the instrumental precision for DTX at a nominated concentration 
of 2 µg/ml was 2.099 % (Table 2.16). Samples were acceptable if the assay value was 
























within the acceptable limits (±5 % RSD) following EMA guidelines, it is worth to mention 
that this result is in line with the FDA and ICH guidelines as well.  
2.5.3.3.3.2. Intra and inter-day precision 
Intra-day precision was assessed by three injections for three different concentrations. 
The % RSD values for the nominated three DTX concentrations of 0.05, 0.5 and 1 were 
1.081, 1.890 and 0.988 % respectively (Table 2.17). Moreover, the ICH guidelines suggest 
the injection of one sample on three different days to examine the inter-day precision. 
The % RSD value was 1.615 % for the nominated concentration of DTX 1.5 µg/ml (Table 
2.18). Acceptable limits within the % RSD values ≤ 10% according to EMA guidelines, FDA 
and ICH guidelines as well. Thus, the newly developed method for DTX quantification from 
the biological sample was within the acceptable limits. 
 
Table 2.16 HPLC data obtained for the injection repeatability (instrumental precision) 
using the same concentration of DTX. 
 DTX labelled  
concentration (µg/mL) 
















Average  1.970 
SD 0.041 
RSD (%) 2.099 
 
Table 2.17 HPLC data obtained for intra-day method precision. 























Table2.18 HPLC data obtained for inter-day method precision. 
DTX labelled  
Concentration (µg/ml) 
Time (day)  DTX/PTX  
Actual concentration (µg/ml) 
 
1.5 
Day 1 1.528  
Day 2 1.546 
Day 3 1.578 
Mean 1.551 
SD 0.025 
% RSD 1.615 
2.5.3.3.4. Accuracy  
The accuracy of an analytical method is the closeness of the measured results to the actual 
data. It can be calculated using accuracy method equation 2.2. 
The % accuracy for DTX in samples ranging from 0.05 to 1 µg/ml ranged from 98.6 to 99.5 
% with RSD in range of 0.988 to 1.890 (Table 2.19). These findings were in line with the 
ICH, FDA and EMA guidelines. Acceptable limit of accuracy is ±10 % RSD. Therefore, the 
method can be said to be accurate 








The extraction recovery was determined as described in section 2.4.3.3.5 for three 
nominated DTX concentrations 0.05, 0.5 and 1 µg/ml, in three replicates plus medium 
concentration of PTX as IS 0.1 µg/ml by comparing the ratio of the set I (Figure 2.7 a) to 
the ratio of set II (Figure 2.7 b). The obtained % recovery was 100.02 %, 101.90 % and 
90.03 % for the nominated DTX concentrations (Table 2.20) and the % recovery for the IS 
was 99.59 %, by calculating the ratio when peak area from set III (Figure 2.7 c) was 
compared to those peak area obtained in set IV (Figure 2.7 d) as tabulated in table 2.21. 
All obtained data showed acceptable extraction recovery with respect to ICH, FDA and 













0.05 0.049 98.6 1.081 
0.5 0.497 99.41 1.890 




this experiment. Moreover, the obtained extraction recovery % were better than data 
reported by Jahne et al., (2014) and Moradi-Afrapoli et al., (2016).  This might be due to 
their method employs buffers as a matrix, and lower centrifugation time and speed during 
the extraction. We have used a centrifugation time of 30 min at 16300 x g to ensure high 






Figure 2.7 HPLC chromatogram showing the peak resolution for (a) 1 µg/ml docetaxel 
extracted and then unprocessed IS added in biological matrix (set I), (b) extraction of 
blank biological matrix then adding unprocessed 1µgm/ml docetaxel and IS 0.1 µg/ml 
(set II), (c) 0.1 µg/ml IS extracted and then unprocessed 1µg/ml docetaxel was added in 
biological matrices (set III), (d) extraction of blank biological matrices then adding 



























2.5.3.3.6. Matrix effect 
To determine the effect of the presence of biological matrix on the DTX concentration, it 
was essential to measure the matrix factor by comparing peak area response for DTX in 
the presence of matrix to the peak area in the absence of the biological matrix. In this 
experiment, the obtained matrix factor was equal to 1.130 for the nominated DTX 
concentration (Table 2.22). 
If the factor is greater than 1 it might be due to ion enhancement, and less than 1 might 
be due to ion suppressant (Rigo-Bonnin et al., 2016). Our results reveal ion enhancement 
in the tested biological matrix. Also, the results fall well within the acceptable values given 
by EMA guidelines, whereby the variation must be less than 15 %. 
 
DTX labelled concentration (µg/ml) Set I Set II % Recovery 
0.05 0.279 0.245 100.02 
0.273 0.281 
0.236 0.266 
Average  0.2634 0.264 
SD 12.944 
%RSD 12.941 
         0.5 1.524 1.557 101.90 
1.729 1.582 
1.578 1.600 
Average 1.610 1.580 
SD 6.392 
%RSD 6.273 
1 2.959 3.656 90.03 
2.920 3.115 
2.722 2.852 
Average 2.867 3.208 
SD 7.934 
%RSD 8.812 
DTX labelled concentration (µg/ml) Set III Set IV % Recovery 
0.1  2.861 2.837 99.59 
2.889 2.716 
2.942 2.96 

















2.5.3.3.7. LOQ and LOD 
 LOQ is the lowest value that can be quantified. In this study, the LOQ of DTX was 0.04 
µg/ml Furthermore, the LOD was explained as the lowest value that can be detected by 
the HPLC system. In this experiment, the LOD was 0.01 µg/ml. The LOQ and LOD were 
both calculated using equations 2.3 and 2.4, respectively. These findings were similar to a 
previous study (Patel et al., 2011) where acceptable LOQ and LOD must be within ±20 % 
of the nominal concentration.  
2.5.3.3.8. Solution stability  
The % RSD values of DTX nominated concentrations 0.05, 0.5 and 2 µg/ml during solution 
stability experiments carried out for 21 days at -20 °C was well within the acceptable limits 
15 % of EMA guidelines (Table 2.23). No changes were observed in the content of the 
solution during stability experiments. Moreover, the experimental data confirmed that 
sample solutions used during the assay for three freeze/thaw cycles were stable for DTX 
nominated concentration 0.5 µg/ml according to EMA guidelines as reported in table 2.24 
the % RSD equal to 7.720 %, the result was within 15 %. These results demonstrated the 


























96.5 87.7  1.137  
97.7 86.6 1.151 
105.0 90.5 1.102 
AV 99.73 88.26 1.130 
SD 4.60 2.010 0.025 




Table 2.23 Sample stability at -20 °C. 
DTX labelled 
 Concentration (µg/ml) 


































% RSD 14.605 
 
Table 2.24 Sample stability at -20 ° for three freeze/thaw cycles. 
DTX labelled 
 concentration (µg/ml) 








Fresh sample 0.052 
 
Cycle 1 0.497 
 
Cycle 2 0.470 
 




% RSD 7.720 
 
Hence to summarise the HPLC method to quantify free DTX in a biological matrix 
comprising a combination of three cell growth media and serum could be successfully 
developed and validated. This method would be useful to quantify DTX during 
permeability studies of DTX and DTX-NLC through a physiological 3D in-vitro BBB model 






In summary, for quantification of DTX concentration within the NLCs a serial dilution of 
acetonitrile and THF were used to dissolve the DTX-NLCs and an isocratic mobile phase 
consisting of acetonitrile and water (50:50, v/v) was used throughout this method 
wherein the HPLC method developed was found to be acceptable and accurate.  Another 
HPLC method was developed with the same isocratic mobile phase for quantification of 
DTX in two release media consisting of PBS 100% and PBS 70%+ 30% Ethanol, this method 
was found to be precise.  Both HPLC methods were validated according to the FDA and 
ICH guidelines. Additionally, for quantification and extraction of DTX in a biological matrix, 
a third HPLC method was developed where a gradient mobile phase with pH 5 was used 
throughout this method and an ice-cold acetonitrile was used as a solvent of choice to 
extract the DTX from the biological matrix, this method was also validated according to 

























3.1.1. Docetaxel for brain cancer treatment  
Docetaxel has long been used to treat various types of cancers (Breast, head and neck, 
prostate and gastric carcinoma) with the commercial dosage form Taxotere® licensed by 
Sanofi-Aventis and approved by the FDA (Fauzee et al., 2011). However, DTX has not been 
applied to treat brain metastases or primary tumours as it is subject to P-gp efflux at the 
BBB and consequently it is unable to accumulate in the brain at adequate concentrations 
(Loscher and Potschka, 2005) 
Moreover, DTX is practically insoluble in water and thus the clinically used product 
Taxotere® is formulated with ethanol and Tween 80 to solubilise the drug as described by 
the manufacturer (Sanofi-Aventis, Canada), the high content of polysorbate 80 is believed 
to cause hypersensitivity hemolysis and cholestasis (Ten et al., 2003). It has been reported 
that DTX inhibits brain tumour growth following local injection in a mouse brain tumour 
model (Sampath et al., 2006). Thus, a novel formulation of DTX, which would permit BBB 
permeation and avoid usage of polysorbate 80 in such high concentration, would be a 
useful alternative for treatment of brain tumours. 
3.1.2. Nanostructure lipid carrier 
Nanostructure lipid carrier (NLC) is a new generation of solid lipid carrier (SLN), was 
proposed to overcome the limitations of SLN (Muller et al., 2002a) by making the structure 
of solid lipid core less organised by mixing a variety of liquid lipid with solid lipid as 
previously discussed in chapter one. Higher drug payloads could be incorporated in these 
amorphous structures with decreased drug expulsion upon storage (Radtke and Muller, 
2001). Moreover, the non-uniform structure of NLCs might contribute to why NLCs have 
a more controlled drug release than SLNs (Muller et al., 2002a). It was reported that 
entrapment of PTX in solid NPs significantly increased the PTX brain uptake, by either 
shielding the drug from direct interaction with P-gp by the encapsulation inside the NPs 
or by modulating of BBB P-gp function by the surfactant (Koziara et al., 2004). These data 
open the potential for brain delivery of chemotherapeutic drugs loaded in lipid NPs. The 
aim of this study was to determine whether NLCs could be used as a delivery system for 
DTX for treatment of a brain tumour and whether anticancer properties are achieved with 




3.1.2.1. Influence of surfactants on NPs brain drug delivery 
A major obstacle for drug delivery to treat diseases of the CNS is the inability of the drug 
to reach the site of action due to the presence of BBB. The BBB prevents most treatments 
from entering brain tissue because of its tight junctions (Masserini 2013; Tunblad 2004). 
Surface properties of nanoparticles have a great impact on their interaction with living 
cell and tissues, previous studies have shown successful BBB passage of NPs when 
fabricated with cationic stabilisers and/or non-ionic surfactants, but not when anionic 
compounds were used. Interestingly, the size and surface charge of NPs have shown little 
influence on BBB permeation (Voigt et al., 2014). 
Improved brain uptake after an intravenous (IV) administration has been reported for 
nitrendipine (Ntd) loaded SLNs prepared from triglycerides and surfactants (soy lecithin 
and poloxamer188) as compared to Ntd suspension. This might be attributed due to the 
encapsulation of Ntd within the SLN, which makes it consequently delivered to the brain 
bypassing the BBB by endocytosis pathway (Manjunath and Venkateshwarlu 2006). 
Incorporation of soy lecithin probably improved brain therapeutic uptake for the drug 
loaded in the SLNs and it showed effective targeting for the brain drug delivery by enabling 
the SLNs passing through the BBB. Also, NLC developed by Miglyol 812 increased the drug 
level in the brain due to fast onset of action (Singh et al., 2013).  Another surfactant 
Solutol® HS15 which is a mixture of free PEG 660 and PEG 660 hydroxy stearate has been 
recently approved as novel and a safe parenteral excipient for human use. It has been 
used as a solubiliser for poorly soluble drugs (Kasongo et al., 2011). Moreover, Solutol® 
HS15 improved neuronal immune response when combined with soy lecithin (Singh et al., 
2013).  
An important requirement for all NPs chosen for brain delivery system is that NPs should 
be prepared from rapidly biodegradable particles, as the non-degradable particles might 
cause a potential risk to the delivery system (Wohlfart et al., 2012). Tween 80 (T80), 
lecithin, poloxamer 188 (P188) and sodium glycocholate are all considered as acceptable 
surfactants for IV route (Muller et al., 2000). Additionally, surfactants can overcome drug 
resistance by inhibition of P-gp as has been demonstrated by the previous study whereby 
edelfosine-loaded SLN coated with T80 showed higher uptake by C6 glioblastoma cells 
(Mendoza et al., 2011). Surfactants, therefore, play a fundamental role in the 





3.1.3. Surface modification for selective and enhanced docetaxel 
delivery 
Functionalisation of NPs surface with different types of ligands is usually desirable to 
achieve selective cellular binding and internalisation through receptor-mediated 
endocytosis. There some challenges of targeting cancers and tumours, as defective cells 
often have similar characteristics to the surrounding non-cancerous cells, to overcome 
this feature the ligands can be designed to have specificity and selectivity for some 
receptors that are overexpressed on cancerous cells but are less expressed on non-
cancerous cells. Ligands that have been widely used for functionalisation of NPs include 
antibodies, small molecules, peptides and aptamers (Wang et al., 2008). In the present 
work, two polyunsaturated fatty acids (PUFAs) gamma-linolenic acid (GLA) and alpha-
linolenic acid (ALA) and one novel aptamer SA43 have been explored as ligands for 
functionalisation of NLC for better targeting and enhanced efficacy.  
3.1.3.1. Polyunsaturated fatty acids and their tumoricidal effect on 
glioblastomas  
It has been reported in the previous literature that gamma-linolenic acid (GLA) an omega 
6 fatty acid has a potential anticancer effect, GLA demonstrated tumoricidal action 
towards glioblastoma cells with less or no neurotoxicity towards non-cancerous brain 
cells. GLA’s tumoricidal effect is due to the induced apoptotic effect on of glioblastoma 
cells (Bell et al., 1999; Madhavi and Das 1994). The study by Bell et al., (1999) also involved 
evaluating the effect of GLA on glioblastoma spheroids cells e.g C6 (rodent glioblastoma 
cell line), U373 and U87MG (glioblastoma) and MOG human cell lines. These studies 
demonstrated the antiproliferation effect on tumour; invasion and impaired spheroid 
growth, suggesting that local delivery of GLA could reduce tumour size and growth. In 
addition, Alpha-linolenic acid (ALA) an omega 3 fatty acid has much potential for 
improving the therapeutic efficacy of anti-cancer drugs for the treatment of breast cancer 
when MCF7 cells were treated with ALA conjugated with doxorubicin (Huan et al., 2009). 
Several studies have demonstrated that ALA sensitises tumour cells to effects of anti-
cancer drugs either in tumour-bearing animals or in-vitro cell culture where ALA can play 
an important role in cancer prevention/progression. These PUFAs induced changes in 
tumour fatty acid composition resulting in increased sensitivity to chemotherapy, 
especially in tumour lines that are resistant to chemotherapy, and cause high cytotoxicity 
to tumour cells and protection of normal cells (Horia and Watkins 2005). 
FABPs are intracellular fatty acid binding proteins involved in the binding and the 




cytoplasmic, for metabolism and energy production, or nuclear, for regulation of gene 
transcription via activation of peroxisome proliferator-activated receptors (PPARs) 
(Forman et al., 1997).  The previous literature showed that FABP or FABP7 are involved in 
the internalisation and intracellular transport of PUFAs which are highly up-regulated in 
glioblastoma cells in comparison with normal brain cells (Liang et al., 2005; Mita et al., 
2007). GLA and other PUFAs also produce mitochondrial depolymerisation, lipid 
accumulation and overexpression of P53 and GMYC, by forming various lipid peroxidase 
(Chung et al., 2003; Cury-Boaventura et al., 2005; Chi et al., 2004). To the best of our 
knowledge there are no reports of these PUFAs being used as ligands for targeting 
glioblastoma cells, therefore in the present work DTX-NLCs are functionalised with GLA 
and ALA for their potential effect on enhancing the anti-cancer effect of the 
chemotherapeutic drug and brain-targeted therapy.  
3.1.3.2. Aptamers are the new trend in selective targeting of glioblastomas  
Aptamers are short single-stranded DNA, RNAs, or modified nucleic acids that can fold 
into complex three-dimensional structures and specifically bind to their targets (Dausse 
et al., 2009; Nimjee et al., 2005). Aptamers can be selected from randomly synthesised 
and easily modified oligonucleotide libraries through the systematic evolution of ligands 
by exponential enrichment (SELEX) (Gopinath, 2007). Their advantages can be due to ease 
of selection and synthesis, high binding affinity and specificity, low immunogenicity and 
versatile synthetic accessibility with high purity (Zhang et al., 2011; Zhou and Rossi 2011). 
Moreover, NPs significantly enhanced intracellular drug delivery and tumour spheroid 
penetration when functionlised with aptamers and could target glioblastoma and 
accumulate at the tumour site (Gao et al., 2012b). Aptamers have also been demonstrated 
to have more specific and higher affinity for the intended target than other ligands for 
example antibodies (Sun et al., 2014). 
Recent studies showed DTX-encapsulated NPs formulated with PLGA-b-PEG copolymer 
and surface functionalised with the A10 RNA aptamers could recognise the extracellular 
domain of the prostate-specific membrane antigen (Chen et al., 2016). Moreover, Gao et 
al., (2012a) found that DTX-loaded PEG-PCL NPs functionalised with GMT8, an aptamer 
with the highest affinity for U87MG cells was used for targeted glioblastoma therapy. In 
addition, SA43-aptamer which has high specificity to glioblastoma cell (U87MG) has been 
demonstrated for its binding to Ku 70 and Ku 80 which probably was responsible for its 
selectivity to cancerous glioblastoma cells rather than non-cancerous cell lines (Aptekar 




model due to a transient opening of the TJ as determined by a temporary reduction in the 
trans-endothelial electrical resistance (TEER) and good apparent permeability (Papp of 
4.32 ± 3.90 x10−9 cm/ min) (Aptekar et al., 2015). Due to the selectivity of SA43-aptamer 
towards glioblastoma cells and its ability to permeate through an in-vitro BBB model, SA43 























3.2. Aim and objectives  
The main aim of this chapter was to develop NLC, that have high encapsulation efficiency 
to incorporate chemotherapeutic drug docetaxel (DTX), and further functionalised the 
DTX-NLC with GLA, ALA, and SA43-aptamer. 
3.2.1. Objective 1 
Development and optimisation of NLC loaded with DTX, and to evaluate the effect of 
process and product parameters on critical quality attributes of NPs, the particle size, 
polydispersity index (PDI), zeta potential (ZP), entrapment efficiency (EE), total drug (TD), 
and drug loading (DL), using one factor at a time and factorial design approach.   
3.2.2. Objective 2  
Functionalisation of DTX-NLCs with three ligands; two PUFAs, (GLA and ALA), and one 
selective aptamer SA43 for the potential effect on targeted brain delivery and enhanced 
selectivity for glioblastoma cells. 
3.2.3. Objective 3 
To carry out the physicochemical characterisation of the developed bare and 
functionalised DTX-NLCs. 
3.2.4. Objective 4 
To assess the stability of the bare DTX-NLC and study the effect of storage temperature 













3.3. Equipment and materials 
 
3.3.1. Equipment 
Probe sonicator (Vibra Cell Sonics, USA), Sigma Centrifuge (Germany). Malvern Zetasizer 
Nano (Malvern Instalment Ltd, Uk). Centrifuge (Spectrafuge 24D, Jencons-Pls, UK). Bruker 
powder X-ray diffractometer (XRD). Differential scanning calorimetry (DSC) Q2000 TA 
(Thermal Analysis Instruments, Elstree, Hertfordshire, UK). Nicolet iS 10 Fourier transform 
infrared spectroscopy (Thermo Scientific, UK). Horiba HR800 Raman with a green 
detector. Centrifuge (3-16PK SCIQUIP). High-Pressure Liquid Chromatography (HPLC) 
system (Agilent 1260 Infinity HPLC instrument Agilent Technologies, USA). Nano-Drop, 
Spectrophotometer (Thermo Scientific, UK). 
3.3.2. Materials 
Docetaxel (DTX) and Paclitaxel (PTX) were purchased from Kemprotec company, UK. 
Dynasan114 (D114) and Miglyol 812N were given as a free sample from CREMER OLEO, 
company, Germany. Sodium cholate was purchased from Sigma Aldrich, UK. 
Phospholipon 90H (PH90), Lipoid S75 and E80 were free samples from Lipoid, Germany. 
Poloxamer188 (P188) was given as a free sample from BASF company, Germany. Solutol 
HS15 (S HS15) was purchased from Sigma. Labrasol (LB), Lauroglycol 90 (LG90) and 
Capryol propylene glycol monocaprylate (CPGMC) were given as a free sample from 
Gattefossé company, France. 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), N-
hydroxysuccinimide (NHS) were purchased from (Fisher, UK). Dimethyl sulfoxide (DMSO), 
Tetrahydrofuran (THF), Methanol, Acetonitrile, and ethanol were purchased from Fisher 
Scientific, UK (all solvents were used were HPLC grade). Ortho-phosphoric acid (Fisher 
Scientific, UK). Amicon 3 kDa molecular cut-off centrifugal filters purchased from (Fisher 
Scientific, UK). Spectra/Por® dialysis membrane (3.5K Da MWCO) was obtained from 
Spectrum Labs, USA. Phosphate buffer saline (PBS) 0.1 M (pH 7.4), purchased from Sigma 
Aldrich. SA43-Aptamer was synthesised by Integrated DNA Technologies (IDT) and 
conjugated at the 5’ end with-COOH functional group (IDT, Glasgow, UK and IDT, US). 
RNase free water purchased from Fisher, UK. Ascorbyl palmitate (AP), and α-Tocopherol 
(Vit E), sodium chloride, and dextrose were purchased from (Sigma, UK). Eagle’s minimum 
essential medium (EMEM) was purchased from Lonza. Double distilled water was used 





3.4.1. Preparation of Docetaxel-loaded nanostructure lipid carrier 
(DTX-NLC) 
NLC loaded with DTX were prepared by hot homogenisation technique (Naguib et al., 
2014). High melting point triglyceride Dynasan 114 (D114) (55-58 °C) as solid lipid (S.L) 
and four liquid lipids (L.Ls), Miglyol 812 N (MG), Labrasol (LB), Lauroglycol 90 (LG90) and 
Capryol propylene glycol monocaprylate (CPGMC) were investigated for fabrication of the 
DTX-NLCs. 
Briefly, anticancer drug DTX (1 mg/ml), solid lipid D114 (4 g), lipophilic surfactant 
Phospholipon 90 H (PH90) (300 mg), three liquid lipids (L.Ls): LB, LG90, and CPGMC (150 
mg each) to give a total 450 mg of L.Ls, and non-ionic solubiliser and an emulsifying agent 
Solutol HS15 (S HS15) (300 mg) were placed in a beaker and dissolved in ethanol (250 µl). 
Lipid-drug mixture was melted using a water bath. The temperature was brought to 65 °C 
(ten degrees higher than the melting point of the solid lipid). Another lipophilic surfactant 
Lipoid S75 (LS75) (2.4 g) was then added to the mixture (lipid phase). The aqueous phase, 
composed of an anionic static bio-surfactant sodium cholate (SC) (374 mg) and any other 
surfactant used during the optimisation in a (100 ml) water, was placed in another beaker 
with continuous stirring using magnetic stirrer, and kept at the same temperature (65°C 
±5) as the lipid phase temperature by using a water bath. The aqueous phase was added 
to the lipid phase under continuous stirring for 20 min to form a pre-emulsion. The 
subsequent oil-in-water pre-emulsion was placed in a glass vial under the controlled 
condition of temperature (ice-bath) and the mixture was sonicated using the probe 
sonicator for an overall time of 40 min at a sonication intensity of 40 %. The hot nano-
emulsion was left to cool down at room temperature to form DTX-NLC. For the blank NLC 
(B-NLCs) the same procedure was followed but DTX was not added during the 
preparation. 
To prepare a Rhodamine123 (R) labelled NLCs, R was added in the lipid phase to form R-
DTX-NLC. To remove the titanium particles (that originated from the titanium probe of 
the ultrasonicator) from the NLC suspensions, nanoparticle formulations were 







3.4.1.1. Optimisation of NLCs 
In order to prepare a uniform stable formulation with a low particle size (PS) and 
polydispersity index (PDI), various parameters affecting the NLCs preparation were 
investigated. The product parameters including surfactant types and their concentrations 
in the aqueous phase, the concentration of solid lipid (S.L) and liquid lipids (L.Ls) in the 
lipid phase were evaluated. Moreover, the process parameters included sonication time, 
and mixing time under high-speed homogeniser (HSH) Ultra-turax were also assessed. 
Previous studies have shown these parameters to have a critical effect on NPs production 
(Zirak and Pezeshki, 2015; Keum et al., 2011). In addition, the effect of process 
temperature was also studied. Various experiments were designed altering one factor at 





3.4.1.2. Optimisation of NLCs by 32 factorial design 
After the preliminary optimisation and changing one factor at the time, a final 
optimisation was performed by factorial design adopted and modified from Gao et al., 
(2011). In this study two factors, three-level central composite rotatable design 32 was 
used to study the effect of two independent variables, surfactant concentration (A) and 
lipid concentration (B), on the five response variable PS, PDI, entrapment efficiency (EE), 
total drug (TD) and drug loading (DL) of DTX-NLCs. Factorial designs generate polynomial 
equations comprised of interacting terms and regression coefficients, which together 
assist in evaluating the responses. An initial 32 full factorial design was created (Table 3.1). 
A total of nine experiments were carried out. Design-Expert® Software was used to design 
this experiment and ANOVA was used for statistical analysis. The data were considered as 
significant when p values were < 0.05. The Design Expert software generates two basic 
models, the particularly full model in which non-significant terms are included and 
reduced model in which non-significant terms are excluded.  
Table 3.1 Independent variables in 32 factorial design and the actual concentrations 
used.  








B38 -1 250 -1 3 
B41 0 375 -1 3 
B43 +1 500 -1 3 
B39 -1 250 0 4 
B20 0 375 0 4 
B44 +1 500 0 4 
B40 -1 250 +1 5 
B42 0 375 +1 5 
B45 +1 500 +1 5 
3.4.2. Functionalisation of DTX-NLCs with PUFAs  
DTX-NLC was prepared as described in section 3.4.1. and it was surface modified with 
either gamma-linolenic acid (GLA) or alpha-linolenic acid (ALA). The coupling process was 
adopted and modified from, Yang and Hu (2015) through forming amide linkage by a 
covalently coupling free amino group of DTX-NLC to the carboxylic acid group of GLA or 
ALA, using EDC and NHS as coupling agents. Briefly, 1 mg/ml of GLA or ALA were placed 
in a glass container and dissolved in ethanol, vortexed for 1 min and then mixed with EDC 
(1:1 molar ratio, PUFA: EDC, pH 7.4,) EDC was dissolved in water (1mg/ml), the mixture 
was flushed with nitrogen gas to maintain the stability of PUFAs. This mixture was stirred 
for 30 min at room temperature. Then NHS (1:1 molar ratio, NHS: EDC) was added, NHS 




temperature. 1 ml DTX-NLC formulation was added to the mixture under a stream of 
nitrogen gas and then allowed to stir for 12 h under the same conditions to form GLA-
DTX-NLC and ALA-DTX-NLC respectively (Figure 3.1). Excessive unbound materials were 
removed from GLA-DTX-NLC and ALA-DTX-NLC using dialysis bag. Briefly, 1 ml formulation 
was placed in a dialysis bag (3.5K Da MWCO), then transferred into a beaker containing 
100 ml of water and stirred for 15 min for two purification cycles. Particle size (PS), PDI 
and zeta potential (ZP) were measured before and after conjugation using Malvern 
Zetasizer Nano.  
As PUFAs are known to oxidise, a combination of antioxidant 0.02%, w/v of Vit.E + 0.05%, 
w/v of AP (Bvg 2009; Pharmaceutical Excipients, 7th edition, 2012), were added and 
evaluated. Both Vit E and AP were added into the lipid phase during the DTX-NLC 
preparation as described in section 3.4.1. When the antioxidants were employed, 
nitrogen flushing was not done during the coupling process, of GLA and ALA. 
 
Figure 3.1 Schematic diagram showing the crosslinking of DTX-NLC with PUFAs by 
covalent bonding in the presence of EDC and NHS to form an amide linkage between a 
free amino group of DTX-NLC and PUFAs carboxylic group. This reaction was carried out 
at room temperature (Chemical structures were adopted from Fisher and Sigma, Uk 
websites, and NLC picture was adopted and modified from Yingchoncharoen et al., 
2016). 
 
3.4.2.1. Optimisation of DTX-NLC functionalised with PUFAs 
DTX-NLCs have free amino groups (FAG) available on their surface due to the presence of 
phospholipids (LS75 and PH90) incorporated in the formulation. The FAG was quantified 
with Trinitrobenzene sulfonic acid (TNBS) reaction as described in section 3.4.4. The 




Bandyopadhyay et al., 2011). Therefore, various ratios of PUFAs to FAG available on the 
DTX-NLC were investigated (1:1, 1:1/2, 1:1/3, 1:1/4, 1:1/5, 1:1/6 and 1:1/7, FAG: PUFAs 
ratio) to prepare varied batches of both GLA-DTX-NLC and ALA-DTX-NLC and their effect 
on PS and PDI were observed. EDC and NHS coupling agents were used equally to the 
molar ratio of the PUFAs in this process (Figure 3.1).  
3.4.3. Functionalisation of DTX-NLCs with SA43-aptamer 
SA43-aptamer was synthesised by IDT company and conjugated at the 5’ end with -COOH 
functional group and was used for functionalisation with DTX-NLC through covalent 
bonding, due to the presence of FAG on the surface of the DTX-NLCs; an amide linkage 
was formed when DTX-NLC was linked with free -COOH group on the SA43-aptamer 
(Farokhzad et al., 2004; Yang and Hu 2015). 
Briefly, 250 µl of RNase free water was added to the SA43 freeze-dried sample to give a 
concentration of 24.73 µM (Stock 1) as measured by Nanodrop. This stock was then either 
freshly used or stored at -20° C for later experiments. From stock 1 a final 1:1/8 ratio (FAG: 
SA43, ratio) was prepared by covalent bonding using coupling agents EDC and NHS in 
equal molar ratios 1:1/8 molar, (SA43: EDC/NHS, ratio), modified from previously 
published methods (Medley et al., 2012). An appropriate volume of stock 1 was placed in 
a glass container and diluted up to 100 µl with RNase free water, then EDC was added to 
the SA43 solution (1:1 molar ratio, SA43: EDC), where EDC was dissolved in RNases free 
water (2mg/ 1ml) the mixture was left stirring for 30 min at room temperature. Then NHS 
(1:1 molar ratio, EDC: NHS) were added (NHS was dissolved in RNases free water 
2mg/1ml) and stirred with the mixture for 30 min under the same conditions. 1 ml DTX-
NLC formulation was added to the mixture (DTX-NLC was prepared with RNase free water 
in all experiments included with SA43-aptamer). This mixture was allowed to stir for 12 h 
under the same conditions to form SA43-DTX-NLC (Figure 3.2). Excessive unbound 
materials were removed by purification of SA43-DTX-NLC using dialysis bag as detailed in 






Figure 3.2 Showing crosslinking of DTX-NLC with SA43-Aptamer by covalent bonding in 
the presence of EDC and NHS to form an amide linkage between a free amino group of 
DTX-NLC and SA43 carboxylic group. This reaction was carried out at room temperature 
(Chemical structures were adopted from Fisher and Sigma, Uk websites, the SA43 
structure adopted and modified from Aptekar et al., 2015 and NLC picture was adopted 
and modified from Yingchoncharoen et al., 2016). 
 
3.4.3.1 Optimisation of DTX-NLC functionalised with SA43-aptamer 
The SA43-DTX-NLC formulation was optimised by testing different ratios of SA43 to the 
FAG available on the surface of the DTX-NLCs that was quantified by TNBS (section 3.4.4). 
The FAG: SA43 ratios that have been assessed in this experiment were (1:1/70, 1:1/35, 
1:1/23, 1:1/12, and 1:1/8, FAG: SA43 ratio), and their effect on PS, PDI, and ZP were 
studied. Appropriate volume of stock 1 (4.04, 8.08, 12.12, 24.27, and 36.4 µl), respectively 
for each ratio was taken and diluted up to 100 µl with RNAs free water, and further 
functionalised with DTX-NLC through forming an amide bond by using EDC and NHS 
mixture equal to the SA43 molar ratio (1:1 ratio, SA43: EDC/NHS) as detailed in section 
3.4.3 (Figure 3.2) to give a range of SA43-DTX-NLC formulations. 
3.4.4. Conjugation efficiency  
Conjugation efficiency was calculated by determining free amino groups (FAG) on DTX-
NLC pre- and post-conjugation with ligands (GLA, ALA, and SA43-aptamer). As FGA react 




on DTX-NLC surface.  Excess TNBS is added to the formulation and the reacted TNBS gives 
a measure of the FAG in the tested samples (Gao et al., 2011).  
Initially, calibration curves were obtained to measure the unreacted TNBS, by 
modification Gao et al., (2011) method, then reacted TNBS was calculated as described in 
equation 3.1. To prepare the calibration curve, TNBS was diluted with a NaHCO3 solution 
(4%, pH8.5) to give a concentration of 4 µmol/ml (Stock1). Two sets were prepared from 
stock1, first set was the active set and samples were prepared by placing 50, 100, 125, 
150, 200, 250 µl of the solution in a 10 ml volumetric flask to give a final concentration of 
0.2, 0.4, 0.6, 0.8 and 1 µmol/ml, respectively. To each volumetric flask, 100 µl of 1% 
trichloracetic acid (TCAA) was added, then 100 µl of L-valine (LV) (40 µmol/ml) was added, 
samples were vortexed for 1 min (Figure 3.3 a). The second set was the blank set, the 
samples were prepared exactly like the first set, but without adding LV to the blank 
samples (Figure 3.3 b). Both sets were then kept in dark to react for 1 h at 40 °C, the 
reaction was terminated by adding 0.5 µmol/ml HCl solution to make the volume up to 
10 ml in each volumetric flask in both sets. The absorbance of all samples was measured 
at 410 nm. For each concentration first, the absorption of the blank sample was 
measured, and the equipment settings auto-zeroed followed by measuring the absorption 
of the active sample. Data were collected, and this experiment was carried out in 
triplicate, mean and SD was calculated, and a calibration curve (concentration of TNBS vs. 
Absorbance) was generated. The unreacted TNBS was quantified from the calibration 
curve. From there, the reacted TNBS was calculated (equation 3.1) which was equivalent 
to the FAG in the tested formulation.  
𝑹𝒆𝒂𝒄𝒕𝒆𝒅 𝑻𝑵𝑩𝑺 = 𝑻𝒐𝒕𝒂𝒍 𝑻𝑵𝑩𝑺 − 𝑼𝒏𝒓𝒆𝒂𝒄𝒕𝒆𝒅 𝑻𝑵𝑩𝑺        (Equation 3.1) 
 
         





      (b) 
Figure 3.3 Showing different concentrations of TNBS for the preparation of the standard 
plot (a) first set was the active set and samples (50, 100, 125 150, 200, 250) µl of TNBS 
solution placed in a 10 ml volumetric flask to give a final concentration of 0.2, 04, 0,6, 
0,8 and 1 µmol/ml, to each volumetric flask 100 µl  of 1% trichloracetic acid  (TCAA) was 
added to each sample and then 100 µl of L-valine (LV) (40 µmol/ml), (b) the second set 
was the blank set, the samples were prepared exactly like the first set, but without 
adding LV to the blank samples, then 0.5 µmol/ml HCl solution was added to make the 
volume up to 10 ml in each volumetric flask. 
 
The process to determine FAG in DTX-NLC is shown schematically in Figure 3.4. For DTX-
NLC formulation, briefly, 0.5 ml of each formulation was placed in a glass container and 4 
ml of TNBS (4 µmol/ml) was added (Total TNBS in this case 16 µmol/4ml). All samples 
were transferred to the incubator, kept in dark for 1 h at 40 °C. Following incubation, 2ml 
was transferred to a centrifuge tube and centrifuged for 30 min at 16300 x g. Then 900 µl 
of the supernatant was placed in two individual 10 ml volumetric flasks one was labelled 
as the active sample, and the second was labelled as a blank sample. For each active 
sample, a 100 µl of 1% TCAA was added followed by adding 100 µl of L-valine (LV) (40 
µmol/ml), samples were then vortexed for 1 min. The blank samples were prepared 
exactly like the active sample, but with one difference in step as the LV was not added to 
the blank samples. Both active and blank samples were transferred to the incubator, kept 
in dark for 1 h at 40 °C for the reaction to take place. Samples were removed from the 
incubator, and the reaction was terminated by adding 0.5 µmol/ml HCl solution to make 
the volume up to 10 ml for each sample. Absorbance then measured using 
spectrophotometer at 410 nm wavelengths. The blank sample was measured first 
followed by its active sample for each specific formulation and the quantity of unreacted 
TNBS was measured using the calibration curve from the equation of the curve. From 




The % ligand conjugation to DTX-NLC was calculated using the following equation 
 
% 𝑪𝒐𝒏𝒋𝒖𝒈𝒂𝒕𝒊𝒐𝒏 = {
𝑻𝒐𝒕𝒂𝒍 𝑭𝑨𝑮 𝒃𝒆𝒇𝒐𝒓𝒆 𝒄𝒐𝒏𝒋𝒖𝒈𝒂𝒕𝒊𝒐𝒏−𝑭𝑨𝑮 𝒂𝒇𝒕𝒆𝒓 𝒄𝒐𝒏𝒋𝒖𝒈𝒂𝒕𝒊𝒐𝒏
𝑻𝒐𝒕𝒂𝒍 𝑭𝑨𝑮 𝒃𝒆𝒇𝒐𝒓𝒆 𝒄𝒐𝒏𝒋𝒖𝒈𝒂𝒕𝒊𝒐𝒏





Figure 3.4 Schematic diagram showing the preparation of the blank and active samples 
to measure the unreacted TNBS of DTX-NLC. 
3.4.5. Freeze-drying of NLCs 
NLCs were freeze-dried using two cryoprotectant agents sucrose and trehalose (Li et al., 
2009; Sun et al., 2016).  Both the cryoprotectants were examined in different percentages 




the particle size distribution after reconstitution with water. The studied sucrose 
percentages were (1, 2, 3, 5, 10, 15 and 20 %). Furthermore, trehalose was assessed in 
different percentages (3, 5, 10, 15, and 20) %. Additionally, sucrose and trehalose were 
used in combination with a 1:1 ratio by using 2.5% of each agent (Sun et al., 2016). 1 ml 
of NLC was placed in a glass container and mixed properly with the cryoprotectant agent 
then covered with parafilm and transferred to -80 °C freezer to be stored for 24 h. A 
number of small holes were made into the parafilm to help water evaporation then all 
glass containers were placed inside the freeze drier for 96 h of the main drying cycle and 
24 h of secondary drying (over all five days freeze drying period).  
3.4.6. Physicochemical characterisation 
Appropriate characterisation of NLCs is crucial for the management of product quality, 
stability, and drug release (Das and Chaudhury, 2011; Mehnert and Mader, 2001). There 
are several important parameters such as particle size (PS), particle distribution (PDI), zeta 
potential (ZP), drug content, drug entrapment efficiency (EE), morphology, crystallinity 
and structural compositions that were evaluated for DTX-NLC formulations are as detailed 
below. 
3.4.6.1. Particle size, polydispersity index and zeta potential of NLCs 
Photon correlation spectroscopy (PCS) was used to obtain the PS, PDI and zeta potential 
(ZP) of all bare and surface-modified DTX-NLCs using Zeta Sizer Instrument at 25° C. PCS 
measures the fluctuation of the intensity of the scattered light caused by particle 
movement (Iqbal et al., 2012; Yoon et al., 2013). Size measurements were obtained by 
measuring 1.5 ml of formulation. The formulations placed in a zeta sizer transparent 
cuvette. All measurements were repeated at least three times from three different 
samples. Mean and standard deviations were calculated. 
3.4.6.2. DTX-NLC Total Drug (TD) and Drug Loading (DL) 
In order to measure the DTX content and loading concentration in DTX-NLC and surface 
modified DTX-NLCs with PUFAs and SA43-aptamer, a specific HPLC method was 
developed and validated with respect to ICH and FDA guidelines. HPLC method was used 
as described in section 2.4.1. After several steps of optimisation, the best organic solvent 
was chosen to completely dissolve DTX-NLC formulations as described in section 2.4.1.1. 
This method was modified from Garanti et al., (2016). A serial dilution of THF and mobile 
phase (acetonitrile and water, 50:50, v/v) were chosen to carry out this experiment. 1 ml 
of each formulation was placed in a 5 ml volumetric flask and the volume made up to 5 




THF was carried out to generate 20 µg/ml concentration (stock 2). From stock 2 a final 
concentration of 4 µg/ml was prepared by placing 1 ml of stock 2 in a volumetric flask, 
and further diluting with mobile phase up to 5 ml. All samples were vortexed for 1 min. 1 
ml of each sample was taken from the final concentration and placed in HPLC vials for 
analytical study. The samples were injected three times and a reference sample of DTX (4 
µg/ml) was injected during all analytical experimentation, as recommended by ICH and 
FDA guidelines. The mean and SD were calculated for the area under the curve. The 
equations below were used to calculate the DL and TD %, respectively.  
% 𝑫𝑳 =  {
𝑴𝒂𝒔𝒔 𝒐𝒇 𝑫𝑻𝑿
𝑴𝒂𝒔𝒔 𝒐𝒇 𝑳𝒊𝒑𝒊𝒅𝒔 𝒊𝒏 𝒕𝒉𝒆 𝑵𝑳𝑪𝒔+𝑴𝒂𝒔𝒔 𝒐𝒇 𝑫𝑻𝑿
} ∗ 𝟏𝟎𝟎           (Equation 3.3) 
% 𝑻𝑫 =  {
𝑫𝑻𝑿 𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝒂𝒇𝒕𝒆𝒓 𝒑𝒓𝒐𝒄𝒆𝒔𝒔𝒊𝒏𝒈
𝑫𝑻𝑿 𝒂𝒅𝒅𝒆𝒅 𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝒃𝒆𝒇𝒐𝒓𝒆 𝒑𝒓𝒐𝒄𝒆𝒔𝒔𝒊𝒏𝒈
} ∗ 𝟏𝟎𝟎   (Equation 3.4) 
3.4.6.3. DTX Entrapment Efficiency 
Entrapment efficiency (EE) of all DTX-NLC and surface modified DTX-NLCs were 
determined by quantifying free DTX concentration, the un-entrapped drug in 
nanoparticles and is separated from NLCs following protocols adopted and modified from 
previous literature (Kasongo et al., 2011; Garanti et al., 2016) by using Amicon 3 kDa 
molecular cut-off centrifuge filters. Briefly, 0.5 ml of each formulation was placed in the 
centrifuge filter and centrifuged at 15600 x g for 60 min. The lipid nanoparticles with 
entrapped drug remained on top of the filter while aqueous phase with the unentrapped 
free drug (FD) passed through the filter membrane as shown in (Figure 3.5). The filtrate 
was used for DTX quantification, by placing 100 µl of the filtrate and the volume made up 
to 1 ml with 100% acetonitrile. Samples were subsequently injected into HPLC and 
analysed, using the HPLC method as described 2.4.1.  Entrapment efficiency (%EE) was 
determined by the equation below:  
% 𝑬𝑬 =  {
𝑻𝑫−𝑭𝑫
𝑻𝑫
} ∗ 𝟏𝟎𝟎      (Equation 3.5) 
                                              
Figure 3.5 Separation of unentrapped drug (free drug) from drug loaded NLCs using 




3.4.6.4. In-vitro DTX-NLCs release study  
The release of DTX from DTX solution (DTX prepared in ethanol 2mg/2ml), Taxotere ® and 
DTX-NLC were evaluated in a pH7.4 PBS. Typically, dialysis bag was used to carry out this 
experiment (dialysis membranes molecular weight cut-off 3.5 kDa). The dialysis bag was 
cut into appropriate sizes, then were kept in water for 1 h prior to the experiment in 
accordance with manufacturer’s instructions; then 2ml samples were placed in the 
dialysis membranes and both ends of the membrane were securely tied with knots and 
thread to prevent any possible leakage of the samples. All samples were immersed in 400 
ml of release media pH7.4 PBS solution at 37 °C under horizontal shaking (100rpm/min) 
(Tan et al., 2017). Samples (1ml) were withdrawn at the predetermined time points (0.5, 
1, 2, 4, 6, 8 and 24) h respectively, and replaced with 1 ml of fresh release media. The 
amount of DTX released was tested using HPLC method that was specifically developed 
and validated for this purpose. 
Another release media (PBS pH 7.4 containing 30 % (v/v) ethanol) was used to evaluate 
the DTX release from DTX solution, DTX-NLC, GLA-DTX-NLC and ALA-DTX-NLC at 37 °C 
(Zhang et al., 2017) respectively. The same method mentioned above was employed, then 
samples were analysed by HPLC method developed and validated as described in section 
2.4.2 and 2.5.2.  
3.4.6.5. Scanning electron microscopy (SEM) 
DTX-NLC particle morphology was observed via scanning electron microscopy (SEM) 
(Melzig et al., 2018) using freeze-dried powder sample. DTX-NLC sample was spread 
evenly on a metallic stub before the analysis with SEM. JFC, the sample was coated with 
1200 Fine Coater that was used to coat the sample with gold for 2 min under vacuum.  
Samples were then studied with SEM microscope at 20 Kv.  
3.4.6.6. X-ray diffractometer (XRD) 
Crystalline structures were tested for surfactants SC and PH90, solid lipid D114, drug DTX, 
physical mixture (DTX+ D114), and DTX-NLC (Freeze Dried). Samples were placed into the 
sample holders and scanned from 5° to 50° with a scanning rate of 5°/minute, with a scan 
type coupled two theta/theta using Scintillation counter and 1-dimensional LYNXEYE 
detector, A Cu-Kα radiation source-detector was used exposing samples to Cu Kα 





3.4.6.7. Thermogravimetric analysis (TGA) 
DTX and D114 pure powdered forms were tested against B-NLC and DTX-NLC in freeze-
dried form, and DTX-NLC in suspension form and was investigated for their thermal 
behaviour.  Stability of GLA-DTX-NLC, ALA-DTX-NLC, and SA43-DTX-NLC, was also 
determined, where each sample was heated from 25-500 °C using TGA Q500. 
Approximately 10 mg of each sample was placed in a platinum pan and analysed for 
weight % loss as a function of temperature. The collected data were analysed using TA 
Universal Analysis software (TA Instruments, Elstree, Hertfordshire, UK). 
3.4.6.8. Differential scanning calorimetry (DSC) 
Thermal behaviour study was employed to evaluate the crystallization and melting 
behaviour of various samples. To identify and determine the possible difference between 
D114 and DTX pure drug in comparison to freeze-dried. DTX-NLC and B-NLC DSC 
thermograms were run for each of these samples. In addition, DTX-NLC, GLA-DTX-NLC, 
ALA-DTX-NLC and SA43-DTX-NLC were also evaluated. A sample of approximately 5mg 
was placed in a hermetically sealed Tzero pan, and an empty pan was used as a reference. 
Samples were analysed using heat/cool/heat run. The heating rate used was 10 °C /min 
and the temperature was cycling between 0-240 °C.  Samples were measured under a 
nitrogen purge of 50 ml/min. The collected data were analysed using TA Universal Analysis 
software (TA Instruments, Elstree, Hertfordshire, UK).  
3.4.6.9. Fourier-Transform Infrared Spectroscopy (FTIR) 
The interaction between the materials and the polymorphic state was measured using 
FTIR. Pure powdered DTX was investigated against DTX-NLC and B-NLC in freeze-dried 
forms. Moreover, the suspension form of DTX-NLC was compared to GLA-DTX-NLC, ALA-
DTX-NLC and SA43-DTX-NLC in suspension forms, and GLA and ALA pure materials were 
also analysed. Samples were measured for % transmittance ranging between 400-4000 
cm-1 using diamond crystal and a resolution of 0.5 cm-1 and accumulation of 150 scan. The 
data were analysed using the OMNIC software (Thermo Scientific, UK). 
3.4.6.10. Raman spectroscopy  
For further characterisation, DTX pure drug was compared with DTX-NLC as a freeze-dried 
form by Raman spectroscopy. The Raman spectroscopy machine was calibrated using high 
purity silica wafer with a distinguishable scattering and at 520 cm-1. The drug and DTX-
NLCs were analysed using the following settings: green laser was used in the analysis (532 
nm) with a grating of 600, 50X magnification was used for the objective lens and laser 
intensity of 0.01 %. The powdered samples were placed evenly on a slide wrapped with 




they were measured using the accessory liquid sample holder with a quartz cuvette 
objective range of 400- 2000 cm-1. All samples were analysed under the same settings and 
parameters. LabSpec 6 software was used to analyse the data. 
3.4.7. Stability study 
DTX-NLCs stability were evaluated in suspension and freeze-dried form using various 
protocols as detailed below: 
3.4.7.1. Colloidal stability  
Colloidal stability was performed on DTX-NLC in different physiological media (PBS, 
EMEM, Dextrose 5%, NaCl 0.9 % and H2O) to assess their stability by placing 1 ml of DTX-
NLC into five individual glass containers and added 30 ml of each of the tested media into 
the containers. Samples were mixed properly then transferred the mixture to the 
incubator and stored all five containers at 37°C. Then 1.5 ml was withdrawn from each 
container at different time intervals (0.5, 1, 2, 4, 6, 8 and 24) h, and evaluated for the 
changes in PS and PDI, as per method modified from Sun et al., (2016). 
3.4.7.2. Short-term stability 
The stability of the developed DTX-NLC and B-NLC samples in suspension form were 
evaluated by storing samples at room temperature for three months. Samples were 
withdrawn periodically after one, two and three months and were compared to the 
freshly prepared samples and characterised for their PS, PDI, ZP, %EE, %TD and % DL. This 
method was adopted and modified from literature (Gao et al., 2008). 
3.4.7.3. Long-term stability  
Freeze dried DTX-NLC where stored at -20, 4, 25, and 40 °C, for up to six months in a glass 
container, sealed properly, and the formulations were assessed and characterised 
periodically after 0, 1, 3 and 6 months for their PS, PDI, ZP, %EE, %TD and % DL after 
reconstitution with water. 
3.4.8. Statistical analysis  
The statistical analysis was performed using the Kolmornov-Smirnov test for normality 
followed by ANOVA (with post-hoc analysis Tukey and Dunnett test) by using statistical 
analyses using the Statistical Package for the Social Sciences SPSS Version 20 software 
(IBM company, USA) and the Microsoft Excel software for Microsoft office 360 (Microsoft 
Corporation, USA).   The analysis of variance was statistically significant difference when 
(*) P < 0.05 with (95% confidence), (**) P < 0.001 (99% confidence), and (***) P < 0.000. 





3.5. Results and discussion 
3.5.1. Preparation of NLCs 
B-NLCs and DTX-NLCs were prepared using the probe sonicator/hot homogenisation 
technique (Naguib et al., 2014) as described in section 3.4.1. The probe sonicator has the 
limitation of heat being released during the sonication process. This heat could affect the 
stability of the drug. Therefore, the temperature was controlled between 50-70 °C, by 
placing the vial that contained DTX-NLC or B-NLC in an ice bath during the sonication 
process and the sonication was carried out alternatively every 5 min with a total 
processing time of 40 min. 
3.5.2. Optimisation of Blank-NLC 
The surface charge of the NPs has been reported to play a critical role in stabilisation of 
NPs, as well as successful passage through the BBB when fabricated with non-ionic and 
cationic surfactants (Voigt et al., 2014). In the present study, various surfactants were 
explored, and initial optimisation was carried out with B-NLCs and then further 
optimisation was performed on DTX loaded NLCs as various product and process 
parameters were studied to shed light on their effect on the PS and PDI of the NLCs. 
3.5.2.1. Effect of high-speed homogenisation (HSH) 
High-speed homogenisation (HSH) has been used for size reduction of NLCs (Singh et al., 
2015). Combining HSH with probe sonication would probably result in obtaining a lower 
particle size of the NLCs. Three different batches (B4, B6 and B7) with varying ration of 
surfactants were fabricated (Table 3.2), to study the effect of HSH time on PS and PDI. All 
three formulations were prepared with and without 15 min of HSH prior to the probe 
sonicator.  
B4 showed a significant difference in both PS and PDI when HSH was used prior to the 
ultra-sonication compared to when HSH was not employed during the fabrication of the 
batch (Figure 3.6 a and b). While B6 showed a significant difference in PS, no significant 
difference on PDI was observed when HSH was used prior to sonication process. 
Moreover, when HSH was used in B7 prior to ultra-sonication, it showed a no significant 
difference in PS as compared to the batch prepared without HSH prior to the ultra-
sonication. It was found that the effect of HSH was variable depending upon the 




 Table 3.2 Compositions of three B-NLCs batches B4, B6, B7, and HSH time. 
 
 
               
(a)                                                                        (b) 
Figure 3.6 (a) Effect of HSH time on PS for (B4, B6, and B7); (b) Effect of HSH time on PDI 
for (B4, B6 and B7). Data are mean ± SD, N=3, * P < 0.05 refers to the significant 
difference. 
3.5.2.2. Effect of surfactants 
According to Voigt et al., (2014), a successful BBB passage could be achieved if NPs were 
fabricated with non-ionic surfactants. To achieve our goal of stable NLCs formulation with 
low PS and uniform distribution that might have a potential to pass the BBB, optimisation 
was carried out with different surfactants. Initially, B-NLCs were prepared with several 
types of anionic and non-ionic surfactants to assess their effect on PS and PDI. 
3.5.2.2.1. Effect of Sodium cholate (SC) on B-NLCs 
As surfactants play an important role to prevent aggregation and reduce the surface 
tension between particles (Blasi et al., 2007), in this study to understand the role of 

























































B4 15 5 300 450 - 250 1.2 1.2 300 
- 
B6 15 5 300 450 1.2 - 1.2 1.2 300 
- 








B6, and B7) as per table 3.3. It was observed that SC as a surfactant played an important 
role in the stabilisation of B-NLCs. This is line with a previous study which has reported SC 
as a better stabiliser than Sodium Dodecyl Sulphate (SDS), which result from higher 
repulsive energy barrier and a shallower attractive energy which could be attributed to 
rigid, bean-like structure of SC (2010; Wei et al., 2016). This could be inferred as 
formulation B6 that did not contain SC showed large particle size with a wide particle size 
distribution in the range of 20-700 nm (Figure 3.7 a). Formulations containing SC (B31, B4, 
B5, and B7) revealed lower PS with a uniform distribution (Figure 3.7 b and c).  





         
      (b)                                                                   (c) 
 
Figure 3.7 Particle size distribution for (a) B6 and effect on PS distribution, Bar charts 
showing the Sodium Cholate (SC) and surfactants (b) effect on PS, (c) effect on PDI. Data 
are mean ± SD, N=3, * P < 0.05 refers to the significant difference in particle size for B6 
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5 300 450 1.2 250 1.2 1.2 300 
B4 5 300 450 - 250 1.2 1.2 300 
B5 5 300 450 1.2 250 - 1.2 300 
B6 5 300 450 1.2 - 1.2 1.2 300 





3.5.2.2.2. Effect of Poloxamer188 (P188) on B-NLCs 
Poloxamer188 is a non-ionic surfactant and previously reported to facilitate the drug 
delivery to the brain (Blasi et al., 2007). In this study, the presence and absence of P188 
were evaluated (Table 3.4), showing a significant increase in PS but reduced PDI when 
P188 was not added (Batch B4) as compared to B31 (Figure 3.8 a and b), indicating that 
through inclusion of P188 might aid in achieving NLCs with lower PS but at the cost of 
wider particle size distribution.  




              
(a)                                                             (b) 
Figure 3.8 Bar charts demonstrating the effect of Poloxamer188 on (a) PS and (b) PDI. 
Data are mean ± SD, N=3, * P < 0.05 refers to the significant difference in PS and PDI for 
B31 when compared with B4. 
 
Further, the concentration of P188 was explored to find if the concentration had any role 
on PS and PDI; therefore, the P188 concentration was reduced from 1.2 g (B31) to 0.3 g 
(B8) and evaluated for its effect on PS and PDI (Table 3.5). Notably, the reduction in P188 
concentration showed no effect on both PS and PDI (Figures 3.9 b and c), which remained 
the same as in the one containing higher concentration. Therefore, P188 was not 
considered suitable and was not considered for further optimisation. Though P188 has 
been widely used as an efficient stabiliser for lipid NPs (Olbrich et al., 2004), our studies 
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(a)                                                         (c) 
Figure 3.9 Poloxamer 188 (P118) effect (a) particle distribution B31, bar charts showing 
Effect of P188 concentration on (b) PS, (c) PDI. Data are mean ± SD, N=3, * P < 0.05 refers 
to significant difference. In this case, there was no significant difference between B31 
and B8 when compared with respect to PS and PDI.  
 
3.5.2.2.3. Effect of Phospholipon H90 (PH90) on B-NLCs 
Phospholipon H90 (PH90) is a widely used lipophilic surfactant in NPs preparation (Blasi 
et al., 2007). The effect of PH90 was investigated by comparing B31 (0.3 g of PH90) with 
B13 (without PH90) (Table 3.6). Though addition of PH90 did not significantly lower the 
PS but notably it did not cause any increase in PS or had any negative impact on the PDI 
(Figure 3.10 a and b), therefore, it was retained as part of the surfactants system as several 
reports have shown PH90 to facilitate the transport of the drug to the brain (Blasi et al., 
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(a)                                                                (b) 
Figure 3.10 B-NLCs with PH90 0.3 % and without PH90 (a) effect of PH90 on PS; (b) effect 
of PH90 on PDI. Data are mean ± SD, N=3, * P < 0.05 refers to significant difference. In 
this case, there was no significant difference between B31 and B13 when compared with 
respect to PS and PDI.  
 
3.5.3. Optimisation of DTX-NLCs  
To evaluate the effect of excipients on PS and PDI when the drug was loaded, further 
optimisations were carried out with DTX loaded NLCs as follows: 
3.5.3.1. Effect of surfactants  
3.5.3.1.1. Effect of Tween 80 (T80) on DTX-NLCs 
Tween 80 (T80) is a well-known non-ionic hydrophilic surfactant and it is widely employed 
in NP fabrication either alone or in combination with lipophilic surfactants (Voigt et al., 
2014). T80 was incorporated with other non-ionic surfactants to assess its effect on both 
PS and PDI (Table 3.7). The presence of T80 in B23 was found to give a very wide particle 
size distribution with two peaks, (Figure 3.11 a).   Even after 15 min of sonication (Figure 
3.11 b and c), PS remained high, therefore, T80 was not continued as part of the 
surfactants combination in our formulation. It is worth mentioning that T80 has previously 
reported enhancing BBB drug delivery though we could not use it to our advantage (Voigt 
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(Taxotere®) which is believed to cause hypersensitivity (Sanofi-Aventis, Canada, 2015) and 
suffer from limitations due to hemolysis effect (Ellis et al., 1996). 






(a)      
    
(b)                                                                      (c) 
Figure 3.11 Size and distribution data (a) mean data showing the effect of T80 on particle 
distribution at 15 min sonication time (b) bar chart showing effect of T80 on MPS at 5,10, 
15 min sonication time; (c) bar chart showing effect of T80 on MPDI at 5, 10, and 15 min 
sonication time. Data are mean ± SD, N=3, ** P < 0.001 refers to the significant 
difference in PS and PDI when B36 compared to B23 at 5, 10, 15 min. 
3.5.3.1.2. Effect of Vitamin E TPGS (d-alpha tocopheryl polyethene glycol 1000 
succinate) on DTX-NLCs 
TPGS is a non-ionic surfactant that enables delivery to the brain (Keum et al., 2011). TPGS 
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PS for B17 (containing 0.5 g of TPGS) was noticeable when compared with the PS of B33 
(without TPGS) at all examined sonication time intervals (Figure 3.12 b). However, PDI of 
the formulations remained high even after 15 min of sonication (Figure 3.12 c). As TPGS 
affected the particle distribution of DTX-NLCs (Figure 3.12 a), therefore it was not used 
for further optimisation.  







                         
(b)                                                                 (c) 
Figure 3.12 DTX-NLCs composed of 0.5 % of TPGS and no TPGS (a) mean data showing 
B17 particles distribution effect of TPGs on PS at 15 min sonication time (b) effect of 
TPGs on PDI at 5, 10, and 15 min sonication time. Data are mean ± SD, N=3, * P < 0.05, 
** P < 0.001 refers to the significant difference in PS for B33 when compared with PS of 
B17 at 5, 10, 15 min. A significant difference was observed for the PDI in B33 when 
compared to the PDI of 17 at 5 min sonication time. 
3.5.3.1.3. Effect of Poloxamer407 (P407) on DTX-NLCs 
Poloxamer407 (P407) is a hydrophilic non-ionic surfactant, which is adsorbed onto 
hydrophobic NPs providing stability for the NPs preventing opsonisation and 
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Additionally, Blasi et al., (2007) have reported high brain uptake by P407 coated NPs. Two 
batches B21 (contain 2 g of P407), and B34 (without P407) were prepared as summarised 
in Table 3.9 and evaluated for their effect on PS and PDI after 15 min sonication. No 
significant effect on PS was observed on the incorporation of P407 (Figure 3.13 b), though 
a significant increase in particle distribution was obtained in the presence of P407 (Figure 
3.13 c). Due to the wide particle distribution (Figure 3.13 a) P407 was also not included in 
the surfactant combination of DTX-NLCs fabrication.   




                   
(b)                                                             (c) 
Figure 3.13 Size and particle distribution (a) mean data showing the DTX-NLC prepared 
with P407 and its effect on particle distribution after 15 min sonication time. DTX-NLCs 
composed of 2 % P407 and without P407 to assess their effect on (b) PS, (c) effect of 
P407 on PDI. Data are mean ± SD, N=3, * P < 0.05 refers to the significant difference. In 
this case, no significant difference was observed in the PS for B21 when compared with 
B34, and a significant increase in the PDI of B21 when compared with the PDI of B34. 
3.5.3.1.4. Effect of Sodium cholate (SC) on DTX-NLCs  
As incorporation of SC showed a significant reduction in particle size when incorporated 
with surfactant combination for the preparation of B-NLC formulations, it was worth 
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considered, B16 (contains 0.5 % of SC) and B32 (contains 0.375 % of SC) (Table 3.10).  SC 
at lower concentration showed a significant reduction in PS, with no effect on particle 
distribution (Figure 3.14 a and b) indicating the vital role of SC in obtaining lower PS of 
DTX-NLC formulation. It is worth mentioning that a previous report has shown egg 
lecithin-SC form a mixed micellar state, which resulted in better stability of nanostructure 
(Walter et al., 1991). Thus, SC was included in the DTX-NLC formulation and further 
optimisation was carried out.  
 Table 3.10 Compositions of two DTX-NLCs batches B16 and B32. 
 
                                         
(a)                                                              (b) 
Figure 3.14 DTX-NLCs composed of Sodium cholate 0.5 % and 0.375% respectively (a) 
effect of hydrophilic surfactant SC on PS, (b) effect of hydrophilic surfactant SC on PDI. 
Data are mean ± SD, N =3, * P < 0.05 refers to the significant increase in PS for B16 when 
compared to PS of B32, and no significant difference in PDI. 
3.5.3.1.5. Effect of Solutol HS15 (S HS15) on DTX-NLCs 
DTX a highly insoluble drug which faces some challenges during incorporation in the lipid 
matrix (Yin et al., 2009; Kintzel et al., 2006; Persohn et al., 2005).  S HS15 is a potent non-
ionic solubiliser and an emulsifying agent which has low toxicity and is approved by FDA 
for parenteral application. S HS15 was used in the fabrication of DTX-NLC (Table 3.11). 
High concentration of S HS15 in B22 (600 mg/100 ml) though had limited effect on the PS, 
increased the PDI significantly (Figure 3.15 a and b) in comparison to the lower 
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(300 mg/100 ml). This concentration was suitable for incorporation of DTX at (1mg/1ml) 
concentration, to enhance the DTX solubility. 
Table 3.11 Compositions of two DTX-NLCs batches B22 and B35. 
 
                      
(a)                                                               (b) 
Figure 3.15 DTX-NLCs composed of 0.6% and 0.3 % of S HS15 (a) effect of S HS15 on PS; 
(b) effect of S HS15 on PDI. Data are mean ± SD, N =3, * P < 0.05 refers to the significant 
increase in PDI of B22 when compared to B35. While no significant difference was 
observed in PS when B22 compared to B35. 
3.5.3.2. Effect of Liquid lipids (L.Ls) on DTX-NLCs 
It is well known that liquid lipids (L.Ls) are present in the NLC as oil nano-compartments 
that enhance the solubility of the drug and also prevent drug leakage (Muller et al., 2002a; 
Das et al., 2012) on storage. The content of the liquid lipid phase incorporated can 
influence the size and surface morphology of the particles (Zhuang et al., 2010). 
Therefore, the effect of four L.Ls was studied. Figure 3.16 a and b demonstrate the effect 
on PS and PDI when three L.Ls in combination were used for fabrication of B20 showing 
not only low PS, but also led to high incorporation of DTX as revealed by high entrapment 
efficiency, total drug (Figure 3.17 a), and high loading capacity (Figure 3.17 b) as compared 
to three other batches prepared with individual L.Ls, B25 contains Miglyol 812 N (MG), 
B26 contains Labrasol (LB), and B27 contains Capryol propylene glycol monocaprylate 
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LB:CPGMC:LG90 in equivalent ratio and SLN formulation B29 (without L.Ls) (Table 3.12). 
DTX showed good solubility in all the selected L.Ls (Quan et al., 2013), but only B20 
resulted in high drug content as well as better stability and uniform particle distribution.  
Three L.Ls were therefore used in combination with the production of the DTX-NLC (B20) 
formulation. 
Table 3.12 Compositions of six DTX-NLCs batches B20, B25, B26, B27, B29, and B30. 
 
         
(a)                                                                 (b) 
Figure 3.16 Solid lipid and liquid lipids effect on the preparation of DTX-NLCs (a) effect 
of S.L and L.L on PS, (b) effect of S.L and L.L on PDI. Data are mean ± SD, N =3, * P < 0.05 
refers to the significant difference. In this case, there was no significant difference in PS 
when B20 compared to all the other batches. While a significant reduction observed in 
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B20 100 4 300 150 150 150 - 375 2.4 300 
B25 100 4 300 - - - 150 375 2.4 300 
B26 100 4 300 - 150 - - 375 2.4 300 
B27 100 4 300 - - 150 - 375 2.4 300 
B29 100 4 300 - - - - 375 2.4 300 






Figure 3.17 Solid lipid and liquid lipids effect on the preparation of DTX-NLCs (a) effect 
of S.L and L.L on %EE and %TD, and (b) effect of S.L and L.L on %DL. Data are mean ± SD, 
N=3, * P < 0.05 refers to the significant difference. In this study, there was no significant 
difference in % EE and % DL when B20 compared to all the other batches, and a 
significant reduction in % TD when B20 compared to B27 and B29. 
 
3.5.4. Optimisation of process parameters on the selected DTX-NLC 
From the above experiments, a prototype composition of DTX-NLC was achieved (Table 
3.12). It was found to be that B20 was the most stable amongst all studied formulations 
with respect to PS and PDI, therefore the process parameters, temperature and sonication 
time were further investigated to evaluate their effect on PS, PDI, %EE, %TD and %DL for 
the selected DTX-NLC formulation (B20). 
3.5.4.1. Effect of process temperature on DTX-NLCs 
Process temperature has a large impact on the stability of the NLCs, DTX is heat sensitive 
drug and therefore processing temperature could affect its stability during DTX-NLC 
fabrication. Probe sonication, when used for a continuous period of time, can lead to a 
rise in sample temperature. This is because, during sonication, the extreme local heating 
cycles that take place on microscale bubble interface due to cavitation results in bulk 
heating of the liquid over time (Hielscher 2005). Excessive bulk heating can cause 
substantial liquid evaporation resulting in a change in sonicated volume or degradation of 
the material. A simple approach to minimise temperature driven heat effect is to avoid 
substantial high-temperature excursion by immersing the container in a cooling ice-bath. 
Additionally, operating pulse mode, ultrasonication intervals are alternated with static 
(sonication off) intervals. Duration of on and off intervals can be regulated. Operating in 
pulse mode reduced the temperature increase, minimising unwanted side effect and 




















It was observed that when the temperature was not controlled during DTX-NLC (Table 
3.13), the drug content resulted in a lower percentage of TD (Figure 3.18 c and d). 
Controlling the temperature was considered important to get the desired drug content in 
the formulation. Not only TD of the DTX-NLC was affected by temperature control, but it 
had an effect on PS and PDI also (Figure 3.18 a and b). Low PS and uniform distribution 
could be obtained when the formulations were prepared under controlled temperature 
environment, which avoided the rise in sample temperature during sonication. Thus a 
significant reduction in PS and PDI were obtained when B20 was prepared by controlling 
the temperature by using an ice bath as compared to uncontrolled or pulsed control 
conditions, Our results are in line with a previous report by Singh et al., (2015).  
Table 3.13 DTX-NLC B20 compositions and temperature variation assessment.  
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      (d)                 
Figure 3.18 Temperature effect on DTX-NLCs B20 (a) effect on PS; (b) effect on PDI; (c) 
%EE and %TD; (d) %DL. Data are mean ± SD, N =3, * P < 0.05 and ** P < 0.001 refers to 
the significant difference in PS, PDI, % EE, % TD and % DL for B20 controlled by ice bath 
when compared to similar batches with two temperature studies. 
 
3.5.4.2. Effect of sonication time and drug loading on B-NLC (B28) and DTX-
NLCs (B20) 
The total energy delivered to a dispersion during sonication is not only dependent on the 
applied power but also on the total time that the dispersion is subjected to an 
ultrasonication treatment (Hielscher 2005). 
𝑬 = 𝑷 𝒙 𝒕  (Equation 3.6) 
Where E = energy, P = Power, and t = time 
The increase in sonication time resulted in lower particles size and PDI, that could be 
achieved at 25 min of sonication (under controlled temperature by ice-bath). It was 
interesting to note that drug-loaded NLCs (Table 3.14) resulted in smaller PS than B-NLCs 
when sonicated for 25 min (Figure 3.19). 
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High sonication time beyond 20 min resulted in high PDI, therefore 20 min was considered 
optimum for processing DTX-NLCs. Keum et al., (2011) reported similar findings, where 
the PS increased at higher sonication intervals.   
             
(a)                                                                      (b) 
Figure 3.19 Drug loading DTX-NLC B20 and B-NLC B28 (a) effect on PS; (b) effect on PDI. 
Data are mean ± SD, N =3, * P < 0.05 refers to the significant difference in PS and PDI for 
both batches when compared with respect to the sonication time. A significant increase 
observed in the PDI and no significant difference in PS between B20 and B28 when 
compared at 20 min sonication time. 
 
3.5.5. DTX-NLCs optimisation by factorial design 
Following the preliminary optimisation studies whereby the effect of various process and 
product parameters were investigated, DTX-NLC (B20) showed desired characteristics and 
was therefore taken up for final optimisation using 32 factorial design. Sodium cholate 
(SC) as a surfactant in the NLC formulation was found to critically impact the size and PDI, 
and the lipid concentration Daynasn  114 (D114) is well documented to affect the 
performance of lipid structure (Naguib et al., 2014). Therefore, those two critical input 
variables were studied on five response variables PS, PDI, %EE, %TD, and %DL. Nine 
formulations were prepared, and the data were statistically analysed by using ANOVA 
(Table 3.15). The contour plots and response surface graphs are given in figures (3.20, 


































Table 3.15 Coefficient Estimate, p-value, Model p-value, for two factors. 
(*) Refers to a significant difference when the p-value ≤ 0.05 and (ns) refers to non-significant 
results. 
3.5.5.1 Effect of inputs variables (surfactant and lipid) on response 
variables 
3.5.5.1.1. Particle size 
For PS response a quadratic model was indicated by Design-Expert software, F-value of 
138.11 implies that the model was significant. There is only 0.01% chance that an F-value 
this large could occur due to noise. Values of "Prob > F" < 0.05 indicate model terms are 
significant. In this case, A, B, AB, A2, B2 are significant model terms. The model P-value 
<0.0001 implies that the model is significant (Table 3.15).  
The final polynomial equation generated by the software, representing the effect of both 
variables on particle size in terms of coded factors is as follows: 
Particle size    =+109.27-7.84A+27.16B-3.76AB+11.85A2+10.40B2       (Equation 3.7) 
The equation in terms of coded factors can be used to make predictions about the 
response for given levels of each factor (Figure 3.20 a). The coded equation is useful for 
identifying the relative impact of the factors by comparing the factor coefficients. Positive 
sign before the factor in the polynomial equation suggests a synergistic effect, signifying 
that the response increase with the factor, whereas for the negative sign, it means 
response and factor have a reciprocal relation. The magnitude of the coefficient indicates 
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the degree of contribution of the factor to the response (Esim et al., 2018). The lipid 
concentration had a positive impact on the particle size, implying increasing the lipid 
concentration lead to increase in PS. In contrast, high surfactant concentration would lead 
to lowering in the PS (Figure 3.20 b and c). Higher concentration of surfactant would result 
in a reduction in the surface tension and production of particles with small sizes whereas 
the lower concentration of surfactant would be insufficient to reduce the interfacial 


































X1 = A: surfactant concentration
X2 = B: lipid concentration


































Figure 3.20 (a) PS response for 32 factorial design predicted VS actual values, (b) PS 
response for 32 factorial design actual values 2D contour plot, (c) PS response for 32 
factorial design response surface 3D graph. 
 
3.5.5.1.2. Polydispersity index  
PDI response is shown in (Figure 3.21 a, b, c). The model F-value of 32.48 implies that the 
model is significant. There is only a 0.01% chance that an F-value this large could occur 
due to noise. Values of "Prob > F" < 0.05 indicate model terms are significant. In this case 
B, B2 are significant model terms. While values greater than 0.1 indicate the model terms 
are not significant. If there are many insignificant model terms not counting those 
required to support hierarchy. The model reduction may improve the model. the model 
P-value less than 0.05 indicate model terms are significant (Table 3.15).  
The final equation representing the effect of both variables on PDI in terms of coded 
factors is as follows: 
Polydispersityindex=+0.23+6.667*A-0.040B-7.500*AB+6.207*A2+0.016B2      
(Equation 3.8) 
Lipid concentration had a negative impact on the PDI. High concentration would lead to 
better homogeneity of PS. The blue rejoins (Figure 3.21 b) shows the presence of 
homogeneous particles. The equation in terms of coded factors can be used to make 
predictions about the response for given levels of each factor. The equation in terms of 
actual factors can be used to make predictions about the response for given levels of each 
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Figure 3.21 (a) PDI response for 32 factorial design predicted vs actual values, (b) PDI 
response for 32 factorial design actual values 2D contour, (c) PDI response for 32 factorial 
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3.5.5.1.3. Entrapment efficiency 
For % EE response, the model F-value of 3.31 implies that there is a 7.50% chance that an 
F-value this large could occur due to noise. Values of "Prob > F" < 0.05 indicate that the 
model terms are significant. Values greater than 0.1 indicate the model terms are not 
significant, the model reduction may improve the model. The p-value of the surfactant 
concentration and the quadric effect of the lipid concentration were not significant (Table 
3.15).  
The final equation representing the effect of both variables on EE in terms of coded factors 
is as follows: 
% EE =+98.36+0.56A+1.50B-1.96AB-2.19A2+0.021B2           (Equation 3.9) 
Both surfactant and lipid concentration had a positive impact on %EE, though the 
coefficient values suggested the lipid concentration have a higher impact on the % EE than 










Figure 3.22 (a) % EE response for 32 factorial design predicted vs actual values, (b) %EE 
response for 32 factorial design actual values 2D contour, (c) %EE response for 32 
factorial design response surface 3D graph. 
3.5.5.1.4. Total drug  
For the TD%, the model F-value of 7.64 implies that the model is significant. There is only 
a 0.97% chance that an F-value this large could occur due to noise. Values of "Prob > F" < 
0.05 indicate that the model terms are significant. In this case, A is a significant model 
term. Values > 0.1 indicate the model terms are not significant. If there are many 
insignificant model terms (not counting those required to support hierarchy), the model 
reduction may improve the model (equation 3.10). 
TD model P-value < 0.05 indicate model terms are significant. In this case, only surfactant 
concentration was a significant model term. Values > 0.1 indicate the model terms are not 
significant (Table 3.15). The final reduced equation representing the effect of both 
variables on TD in terms of coded factors is as follows: 
%  TD =+78.18-10.53A+1.69B               (Equation 3.10) 
From the above equation, it can be concluded that the higher lipid concentration in NLC 
would lead to higher TD content in the NLCs. This could be due to the fact that the 
increased lipid concentration would give more opportunity for the drug to be loaded into 
the lipid matrix. For the surfactant concentration, high concentration causes a negative 
relation with % TD, this might be due to the fact high surfactant concentration might lead 
to high dispersion of the surfactant on the interphase of water and lipid phase, thus 
reducing the interfacial tension resulting in smaller droplet, and consequently lower PS 
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Figure 3.23 (a) %TD response for 32 factorial design predicted vs actual values, (b) %TD 
response for 32 factorial design actual values 2D contour, (c) % TD response for 32 
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3.5.5.1.5. Drug loading  
The % DL response model F-value of 28.26 implies that the model is significant. There is 
only a 0.01% chance that an F-value this large could occur due to noise. Values of "Prob > 
F" < 0.05 indicate that the model terms are significant. In this case A, B are significant 
model terms. Values > 0.1 indicate the model terms are not significant. If there are many 
insignificant model terms (not counting those required to support hierarchy).  
The final reduced equation representing the effect of both variables on DL in terms of 
coded factors is as follows: 
 % DL=+1.41-0.098A-0.17B         (Equation 3.11) 
From the above equation, factors, lipid and surfactant concentration had a negative 
impact on DTX loading. This means higher lipid concentration would lead to lower drug 
loading. For calculation of drug loading as lipid content of NLCs is in denominator its higher 
value will lead to lower drug loading value. Response model p-value < 0.05 indicate model 
terms are significant (Table 3.15). both input factors surfactant and lipid concentrations 












Figure 3.24 (a) % DL response for 32 factorial design predicted VS actual values, (b) % DL 
response for 32 factorial design actual values 2D contour, (c) % DL response for 32 
factorial design response surface 3D graph. 
 
In this study, lower PS and PDI were achieved with surfactant and lipid concentration of 
3.5 g and 375 mg, respectively. Moreover, high %EE, %TD, and %DL were obtained with 
lipid and surfactant concentration > 4.5g  and 375 mg, 4g and 375 mg, 3g and 250 mg, 
respectively. From the factorial design B20 of the DTX-NLC formulation was selected as 
the optimum formulation. The chosen final formulation had lipid and surfactant content 
at 4g and 375 mg respectively. And they were incorporated with 100 mg DTX, 2.4 g lipoid 
S75 (LS75), 300 mg of Solutol HS15 (S HS15), 300 mg Phospholipon 90 H (PH90) and 450 
Drug loading % 
Drug loading % 













mg of three liquid lipids Labrasol (LB), CPGMC, and Lauroglycol 90 (LG90) in a 1:1:1, ratio 
to  obtain DTX-NLC formulation with a stable, uniform distribution and high %EE, %TD, 
and %DL.  
3.5.6.  Functionalisation of DTX-NLCs with PUFAs  
DTX-NLCs were functionalised with either GLA and ALA as described in section 3.4.2. 
through amide bond formation (Figure 3.1). Different ratios of each ligand were evaluated 
for their suitability depending on the effect of the presence of PUFAs ligands and the 
availability of FAG on the surface of the DTX-NLC for conjugation. The ligand density is 
known to impact the PS, particle geometry and surface property (charge and 
hydrophobicity) (Bertrand et al., 2014; Valencia et al., 2011). Therefore, the effect of 
ligand density in terms of different ratios of ligand to FAG  was investigated on PS, PDI, 
and ZP of  GLA-DTX-NLC and ALA-DTX-NLC.  
3.5.6.1. Functionalisation of DTX-NLCs with GLA 
In this experiment the FAG determined for DTX-NLC was 5.91 ± 0.181 µmol/ml pre-
conjugation with GLA, so different ratios were evaluated for GLA functionalisation with 
DTX-NLC (1:1, 1:1/2, 1:1/3, 1:1/4, 1:1/5, 1:1/6 and 1:1/7 ratio, FAG: PUFAs), respectively. 
The data clearly shows that the particle size is significantly higher when GLA was 
conjugated to DTX-NLC as compared to bare DTX-NLC (Figure 3.25 a). Additionally, no 
significant difference in PDI values was observed on conjugation with different GLA ratios 
as compared to bare DTX-NLC (Figure 3.25 b). The data verified the influence of the 
conjugation on PS, notably, when the FAG: GLA ratio increased the PS increased as well. 
For GLA-DTX-NLCs when FAG: GLA, ratio increased 1:1/4 1:1/3, 1:1/2, and, 1:1, PS 
increased from 160-452 nm (Figure 3.26 a). The ligand density had a high impact on the 
PS with almost a linear increase in the PS from lower to higher ratios (1:1/4, 1:1/3, 1:1/2, 
and 1:1 ratio, FAG: GLA). Large PS is known to be opsonised and uptake by macrophages 
and removed from the circulatory system (Liu et al., 2017). Therefore though high ligand 
density is desirable as high ligand concentration can lead to efficient binding to the target 
due to high avidity (Cao et al., 2018; Elias et al., 2013), but not at the cost of very high 
particle size as that would lead to opsonisation of particles. As the following ratios of FAG: 
GLA (1:1/5, 1:1/6 and 1:1/7 ) had limited effect on the PS  ranging from  153 to 160 nm 
(Figures 3.26 a and b), therefore these formulations with two ratios 1:1/5 and 1:1/6 were 






      
(a)                                                                (b) 
Figure 3.25 DTX-NLCs formulation pre- and post-conjugation with GLA when different 
ratios were used to form GLA-DTX-NLCs (a) effect on PS, (b) effect on PDI. Data are mean 
± SD, N=3, * P < 0.05 and *** p ˂ 0.000 refers to the significant increase in PS in all GLA-
DTX-NLCs formulation in all examined ratios when compared to DTX-NLC, while no 






Figure 3.26 Particle size distribution data showing DTX-NLCs compared to GLA-DTX-NLCs 
in different ratios and their effect on PS and PDI (a) DTX-NLC compared with 1:1, 1:1/2 













































The ligand density not only affects the PS but also the surface charge of the DTX-NLCs, 
where a significant reduction was observed with GLA-DTX-NLC 1:1/5 ratio ZP as compared 
to the ZP of  DTX-NLC (Figure 3.27). From the above data we can conclude that when GLA 
is conjugated to DTX-NLC, the PS and ZP can be used as indicating parameters for 
conjugation due to the significant change they bring about on formation of GLA-DTX-NLC.  
 
Figure 3.27 DTX-NLCs conjugation with 1:1/5 GLA (FAG: GLA, ratio) to form GLA-DTX-
NLCs and their effect on ZP. Data are mean ± SD, N =3, *** p ˂ 0.000 refers to the 
significant reduction in ZP for GLA-DTX-NLCs formulation when compared to DTX-NLC 
ZP. 
3.5.6.1.1.  Functionalisation of DTX-NLCs with GLA in the presence of 
antioxidants   
As GLA is highly prone to oxidation, a combination of two antioxidants 0.02 % of α-
Tocopherol (Vit E) and 0.05 % of Ascorbyl palmitate (AP) in a total percentage of 0.07% 
was used to protect the GLA-DTX-NLC from oxidation. Antioxidants were added in the lipid 
phase during the fabrication of DTX-NLC. The formulation of GLA-DTX-NLC in the following 
ratio of FAG: GLA 1:1/5 and 1:1/6 ratio, was studied in the presence of antioxidants and 
their effect on PS and PDI was investigated (Figure 3.28). Figures 3.29 a and b show a 
significant increase in PS and PDI when DTX-NLC prepared with antioxidants Vit. E+ AP 
and then conjugated with GLA in both the tested ratios. As the chosen antioxidants 
combination had an impact on both PS and PDI, these two ratios were further tested on 
glioblastoma cell lines to examine their effect on proliferation of cells (Chapter Four, 





















Figure 3.28 Size distribution data showing DTX-NLC prepared with antioxidants Vit.E+AP 
and compared to GLA-DTX-NLCs in different ratios and their effect on PS and PDI. DTX-
NLC compared with 1:1/5 and 1:1/6, GLA ratios.  
              
(a)                                                          (b) 
Figure 3.29 DTX-NLCs prepared with antioxidants Vit.E+AP then conjugation with GLA 
when 1:1/5 and 1:1/6, ratios were used to form GLA-DTX-NLCs (a) effect on PS, (b) effect 
on PDI. Data are mean ± SD, N=3, *** P ˂ 0.000 refers to the significant increase in PS 
and PDI for both GLA-DTX-NLC formulations in both examined ratios when compared to 
DTX-NLC pre-conjugation. 
 
Out of the all studied ratio, 1:1/5 (FAG: GAL, ratio) was showing acceptable particle size 
and distribution (Figure 3.30), and was further taken up for detailed characterisation as it 
also showed a high tumoricidal activity towards glioblastoma cells as detailed in Chapter 
Four. The inclusion of antioxidants hindered the cell proliferation, therefore the addition 
of antioxidants was not included in the preparation of GLA-DTX-NLC, and the entire 


































Figure 3.30 Particle size distribution of DTX-NLC and GLA-DTX-NLC in 1:1/5 ratio and its 
effect on PS and PDI.  
 
3.5.6.2. Functionalisation of DTX-NLCs with ALA 
As high ratio of the ligand GLA resulted in high particle size, therefore, lower ratios of FAG: 
ALA was investigated for their effect on PS and PDI in ALA-DTX-NLC formulations. In this 
experiment, the FAG for bare DTX-NLC was 5.91 ± 0.181 µmol/ml and it was used for 
conjugation with ALA in the following ratios (1:1/5, 1:1/6 and 1:1/7 ratio, FAG: ALA) 
respectively, and their effect on PS and particle distribution was evaluated (Figure 3.31). 
As anticipated 1:1/6 and 1:1/7 ratios showed less effect on PS, while 1:1/5 ratio showed 
a notable increase in the PS. The data demonstrated a significant increase in PS of  ALA 
ratios 1:1/5 and 1:1/6 and no significant effect on PS for ALA ratio 1:1/7 when all ratios 
were compared to the PS of bare DTX-NLC. Additionally, the PDI showed a significant 
effect between bare DTX-NLC, and ALA conjugated formulation prepared with three FAG: 
ALA ratios (Figure 3.32 a and b). 
 
Figure 3.31 Size distribution data showing DTX-NLC compared to ALA-DTX-NLC in 1:1/5, 





       
(a)                                                               (b) 
Figure 3.32 DTX-NLCs compared to conjugation with ALA when different ratios were 
used to form ALA-DTX-NLCs (a) effect on PS, (b) effect on PDI. Data are mean ± SD, N=3,* 
P ˂ 0.05, ** P ˂ 0.001  and *** P ˂ 0.000 refers to significant difference in PS and PDI for 
DTX-NLC when compared to all ALA-DTX-NLCs formulation in all examined ratios, except 
1:1/7 ALA ratio when there was no significant difference in PS when compared to DTX-
NLC pre-conjugation.  
 
The ALA 1:1/6 ratio (FAG: ALA) was selected as this formulation has a high ligand density 
with minimal increase in PS (Figure 3.32 a). The surface functionalisation of DTX-NLC with 
ALA showed a significant reduction of charge at the particle surface due to the presence 
of hydrophobic ALA on the surface of DTX-NLC (Figure 3.33). The 1:1/6 ratio (FAG: ALA) 
formulation was taken up for detailed characterisation due to reasonably low PS and 
particles distribution (Figure 3.34). Additionally, to evaluate the effect of different ratios 
of ALA on glioblastoma cell lines, 1:1/5 and 1:1/6 ratios, (FAG: ALA) were examined for 
their proliferation impact on glioblastoma cells (Chapter Four, section 4.5.2.2.2).  
 
Figure 3.33 ZP of DTX-NLCs compared to ZP of ALA-DTX-NLCs when ALA 1:1/6 ratio was 
used to form ALA-DTX-NLC. Data are mean ± SD, N=3,** P ˂ 0.001  refers to the 
significant difference in ZP for DTX-NLC when compared to ZP of ALA-DTX-NLCs 
















































Figure 3.34 Size distribution data showing DTX-NLC and compared to ALA-DTX-NLC 
when 1:1/6 ALA ratios were used, and their effect on PS and PDI.  
3.5.6.2.1.  Functionalisation of DTX-NLCs with ALA in the presence of 
antioxidant   
To evaluate the effect of the presence of antioxidants in DTX-NLC on PS and PDI Vit E and 
AP were used during DTX-NLC fabrication, then DTX-NLC were conjugated with ALA. 
Different ratios of ALA were examined (1:1/4, 1:1/5, 1:1/6 and 1:1/7) to produce ALA-
DTX-NLCs (Figure 3.35). A significant increase was obtained in both PS and PDI when DTX-
NLC (prepared with Vit E and AP) compared to ALA-DTX-NLC formulation when different 
ALA ratios were conjugated (Figure 3.36 a and b). These data showed the impact of 
antioxidants presents on both PS and PDI, further studies were vital to evaluate the effect 
of the presence of antioxidants on the glioblastoma cells, two ratios 1:1/5 and 1:1/6 were 
chosen for proliferation test with glioblastoma cells (Chapter Four, section 4.5.2.2.1). 
Similar to GLA, ALA is prone to oxidation, so the functionalisation of DTX-NLC with ALA 
was carried out completely under nitrogen environment when no antioxidants were used.  
 
Figure 3.35 Particle Size distribution data showing DTX-NLC prepared with Vit E and AP 
and compared to ALA-DTX-NLCs when different ratios of ALA were used 1:1/4, 1:1/5 and 





    
(a)                                                                (b) 
Figure 3.36 DTX-NLCs prepared with Vit E and AP compared to conjugation with ALA 
when different ratios (1:1/4, 1:1/5, 1:1/6 and 1:1/7) were used to form ALA-DTX-NLCs 
(a) effect on PS, (b) effect on PDI. Data are mean ± SD, N =3,* P ˂ 0.05, ** P ˂ 0.001  and 
*** P ˂ 0.000 refers to the significant difference in PS and PDI for DTX-NLC when 
compared to all ALA-DTX-NLCs formulation in all examined ratios. 
 
3.5.7. Functionalisation of DTX-NLCs with SA43-aptamer 
SA43 is a novel selective aptamer. To the best of our knowledge, there are no previous 
reports in the literature of conjugation SA43-aptamer with NPs. SA43 was conjugated to 
DTX-NLC to improve its selectivity towards glioblastoma cells. The FAG for DTX-NLC was 
7.04 ±0.18 µmol/ml prior to conjugation with SA43. Five ratios of FAG: SA43 were 
assessed (1:1/8, 1:1/12, 1:1/23, 1:1/35, and 1:1/70) respectively for preparation of SA43-
DTX-NLC. Significant effects on PS, PDI, and ZP were obtained when DTX-NLC was 
compared to SA43-DTX-NLC formulations (Figure 3.37 a, b, and 3.39). Moreover, the data 
showed a uniform distribution with PDI ranging from 0.23-0.27 in all developed SA43-DTX-
NLCs  (Figure 3.38 a). The FAG: SA43 1:1/8 ratio was chosen due to uniform distribution 
of the SA43-DTX-NLC and PS ˂ 93 nm, and high ligand density (Figure 3.38 b). These 
findings were within the PS range of previous literature for Anti-PSMA aptamer that was 
reported by Chen et al., (2016). Notably, ZP of surface modified NPs with aptamers have 
a negative surface charge ˃  -32 mV, as it was anticipated due to aptamers negative charge. 
So successful modification of NPs with the aptamer was indicated using the PS and ZP as 


































          
(a)                                                              (b) 
Figure 3.37 DTX-NLCs compared to conjugation with SA43 when different ratios (1:1/8, 
1:1/12, 1:1/23, 1:1/35, and 1:1/70) were used to form SA43-DTX-NLCs (a) effect on PS, 
(b) effect on PDI. Data are mean ± SD, N=3,** P ˂ 0.001  and *** P ˂ 0.000 refers to the 
significant difference in PS and PDI for DTX-NLC when compared to all SA43-DTX-NLCs 
formulation in all examined ratios. Except there was no significant difference in the PDI 

















































Figure 3.38 Size distribution data showing DTX-NLC and compared to SA43-DTX-NLCs 
when (a) (1:1/8, 1:1/12, 1:1/23, 1:1/35, and 1:1/70) ratios of SA43 were used, (b) the 
ration of 1:1/8 of SA43 was chosen. Their effect on PS and PDI were demonstrated in 
comparison with DTX-NLC pre-conjugation.  
 
 
Figure 3.39 DTX-NLCs compared to conjugation with SA43 when different ratios (1:1/8, 
1:1/12, 1:1/23, 1:1/35, and 1:1/70) were used to form SA43-DTX-NLCs and their effect 
on ZP. Data are mean ± SD, N =3, *P ˂ 0.05, ** P ˂ 0.001  and *** P ˂ 0.000 refers to the 
significant difference in ZP for DTX-NLC when compared to all SA43-DTX-NLCs 
formulation in all examined ratios.  
3.5.8. Conjugation efficiency  
As described in section 3.4.4, and explained in the schematic diagram (figure 3.5) the FAG 
was calculated for all formulation pre and post conjugation with GLA, ALA and SA43 
ligands. The TNBS concentration was calculated by generating a calibration for TNBS 
(Figure 3.40) as described in section 3.4.4, and equation 3.12 was used to calculate the 












DTX-NLC SA43-DTX-NLC 1:1/70 SA43-DTX-NLC 1:1/35








correlates to FAG that is available on DTX-NLCs formulation pre and post conjugation with 
ligands (Table 3.16). 
Y=1.1307x – 0.1366 (Equation 3.12) 
 
Figure 3.40 TNBS standard plot, prepared by using active known concentrations of TNBS 
and their blank samples. Data are mean ± SD, N=3. 
 
Table 3.16 Ratios for different ligands used for surface modification of DTX-NLC, and 
FAG availability for pre and post conjugation. 
 
Name of formulations The ratio of FAG: ligands  FAG concentration µmol/ml  
DTX-NLC - 6.23± 0.69 
GLA-DTX-NLC 1:1/5 3.38± 0.51 
1:1/6 4.44± 0.16 
ALA-DTX-NLC 1:1/5 2.32± 0.33 
1:1/6  4.025± 0.27 
SA43-DTX-NLC 1:1/8 2.93± 0.03 
1:1/12 4.04 ±0.76 
1:1/23 6.19± 1.07 
1:1/35 6.8± 0.32 
1:1/70 6.85± 0.59 
 




















Covalent bonding of ligands on the DTX-NLC surface decreased the free amino groups 
available, confirming the conjugation of ligands to DTX-NLCs. For all three ligands it was 
observed that as the ligand density was increased (as indicated by the higher FAG: ligands 
ratio), the FAG present on the surface of the DTX-NLC decreased. 
For GLA-DTX-NLCs there was almost 10 folds increase in % conjugation when the FAG: 
GLA ratio increased from 1:1/7 to 1:1 (Figure 3.41 a). For ALA-DTX-NLCs similar pattern 
was found (Figure 3.41 b), while SA43 with low ligand density 1:1/70 showed only 2.6 % 
conjugation which could be increased to 50 % by increasing the SA43 ratio up to 1:1/8 



























































Figure 3.41 The % conjugation of DTX-NLCs with ligands (a) GLA-DTX-NLCs when 
different GLA ratios were evaluated, (b) ALA-DTX-NLCs when different ALA ratios were 
evaluated, (c) SA43LA-DTX-NLC when different SA43 ratios were evaluated. Data are 
mean ± SD, N=3 and *** P ˂ 0.000 refers to the significant difference in % conjugation. 
 
3.5.9. Freeze drying  
The freeze-drying process for DTX-NLC was carried out in presence of two cryoprotective 
agents. Low percentage 1-10 % of sucrose did not provide sufficient cryoprotection and 
resulted in aggregation with a highly significant increase in both PS and PDI as compared 
to the DTX-NLC before freeze-drying (Figure 3.42 a and b); while for higher percentage of 
sucrose 15 and 20 %, the PS ˃ 397 and wide range of particle distribution was observed. 
A combination of 1:1 ratio of trehalose and sucrose were used at concentration of 5% 
cryoprotective, that resulted in no significant difference in the PDI in comparison to the 
PDI of the DTX-NLC pre-freeze drying (Figure 3.42 c and d) even though a lower % of 
sucrose was used, that might be attributed to the presence of trehalose.  
Further, trehalose was investigated in variable percentages 3, 5, 10, 15, and 20 %. 
Trehalose was investigated. 10% trehalose was found to be acceptable as a 
cryoprotectant for DTX-NLC as it resulted in the free-flowing stable product (Figure 3.42 
e) which could be reconstituted to give a dispersion with uniform particle distribution PS 
140.4 ± 2.25 and PDI 0.238 ± 0.023. It is worth noting that there was only 13 nm increase 
in PS as compared to original DTX-NLC before freeze drying. This is quite remarkable as 
previous reports have shown 50-100 nm increase in PS on reconstitution after freeze-
drying when 10% trehalose was used as a cryoprotectant (Lozano et al., 2013). Trehalose 






























physical isolation of NPs due to the glassy cryoprotectant reduces the freeze-drying stress 
on the NPs, thus, maintaining the PS during the freeze-drying (Beloqui et al., 2016). 
Additionally, the PDI of 3, 5, and 10 % trehalose exhibited no significant difference when 
compared to the PDI of DTX-NLC before freeze drying. Meanwhile, a higher % of trehalose 
15 and 20 % displayed a significant increase in the PDI (Figure 3.42 c and d). It is worth 
mentioning that our findings showed better PS after freeze-drying when compared to 
previous literature by Li et al., (2009) as SLNs suffer from challenges of high PS (245.3± 
13.6 nm) after reconstitution. Thus 10% was chosen to freeze dry the DTX-NLCs. 
 
          
(a)                                                               (b)  
      












































































Figure 3.42 Effect of cryoprotective agents on DTX-NLCs (a) effect on PS when 1, 2, 3, 5, 
10, 15, and 20 % of sucrose was used, (b) effect on PDI PS when  1, 2, 3, 5, 10, 15, and 20 
% of sucrose was used, (c) effect on PS when  2.5% of sucrose and 2.5 % trehalose were 
used as combination, and 3, 5, 10, 15, and 20 % of trehalose was used, (d)  effect on PDI 
when  2.5% of sucrose and 2.5 % trehalose were used as combination, and 3, 5, 10, 15, 
and 20 % of trehalose was used, (e) DTX-NLC picture showing DTX-NLC pre and post-
freeze drying with 10% trehalose. Data are mean ± SD, N=3, * P < 0.05 and *** P < 0.000 
refers to the significant difference when all examined percentages were compared with 
respect to PS and PDI of DTX-NLC pre-freeze drying. 
 
3.5.10. Physicochemical characterisation 
A detailed characterisation was carried out for final optimised B-NLC, DTX-NLC, GLA-DTX-
NLC, ALA-DTX-NLC and SA43-DTX-NLC formulations. 
3.5.10.1. Size, polydispersity index, zeta potential, %TD, %DL and % EE 
Particles generally affect the biodistribution and pharmacokinetics of NPs (Mehnert and 
Mader, 2001; Xie et al., 2010). It also has an impact on extravasation to the leaky 
vasculature of a tumour, and the BBB passage of the NPs is critically affected by PS apart 
from other factors (Modarres et al., 2018; Patel et al., 2013). It is also important that 
particles should be monodispersed with low PDI (Zhang et al., 2009). 
The B-NLC showed no significant difference in PS in comparison to PS of DTX-NLC, 
indicating that loading DTX into the NLCs had no impact on the PS, and only caused a slight 
increase in PDI (Table 3.17). DTX-NLC of average PS 136.8 ±2.165 nm was achieved with 
low PDI 0.231 ±0.0136  (Table 3.17) indicating a fairly uniform particle distribution. PDI 
values ranging from  0-0.5 are considered to be monodisperse and homogenous, and PDI 
values ˂  0.3 are accepted as a homogenous sample (Zhang et al., 2009; Anton et al., 2007).  
The low PS of DTX-NLC could be attributed to the inclusion of L.Ls and surfactants which 
reduce the interfacial tension and lower the particle size. Previous reports of DTX lipid NPs 




Functionalisation of DTX-NLC with PUFAs (GLA and ALA) resulted in approximately 20 nm 
increase in PS (Table 3.17), confirming the interaction and conjugation of PUFAs with DTX-
NLC. On the contrary, SA43-DTX-NLC  PS was lower than DTX-NLC due to the SA43 -ve 
charge that might have resulted in stronger attraction to the shell and led to smaller PS, 
or simply due to the folding of the aptamer on the DTX-NLC surface as previously 
suggested by Modrejewski et al., (2016). 
The presence of surface charge on the NPs resulted in repulsion and avoid aggregation of 
NPs, ZP ˃ ± 30 mV inputs good stability of the NPs (Caddeo et al., 2008; Mukherjee et al., 
2008). The ZP for B-NLC and DTX-NLC were  -34.4 ±0.742 mV and -32.4 ±0.967 mV, 
respectively, indicating that surface charge did not affect by the addition of DTX since DTX 
does not contain functional groups that can ionize in NLCs as in line with the previous 
report by Gao et al., (2008). Conjugation of DTX-NLC with PUFAs resulted in significant 
reduction in ZP as demonstrated in table 3.17, confirming the conjugation of ligands on 
the surface of the DTX-NLCs. The capping of NPs with fatty acids resulted in a reduction 
of the surface charge (Jaimes-Aguirre et al., 2017). A high %EE were achieved for all tested 
DTX-NLC and surface modified DTX-NLCs. Acceptable %TD and %DL  were determined 
with DTX-NLC, while lower % TD were encountered for all surface modified DTX-NLC due 
to dilution of the DTX-NLC during the conjugation process. 
 
Table 3.17 DTX-NLCs, B-NLCs, DTX-NLCs surface modified formulations mean particle 
size (PS), polydispersity index (PDI), zeta potential (ZP), %EE, %TD, and %DL.  
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3.5.10.2. In-vitro drug release  
The cumulative release profiles of DTX from different samples over 24 h at 37° C and the 




generated through a validated HPLC method as explained in Chapter two (sections 2.4.2 
and 2.5.2). 
The release of DTX from DTX solution, DTX-NLCs and Taxotere, was achieved in a 
controlled pH close to the physiological environmental conditions by assessing all three 
samples in release media PBS, pH7.4 (Figure 3.43 a). All three tested samples suffered 
from delayed release in the buffer due to the absence of the sink condition. Therefore, 
DTX release from NLCs was assessed in 30% ethanol+70% PBS, at pH7.4 to achieve sink 
conditions (Zhang et al., 2017). DTX release from DTX-NLC was faster than the release 
from GLA-DTX-NLC and ALA-DTX-NLC, due to more than 40% of DTX was released from 
DTX-NLC at 2 h presenting a biphasic profile with the initial fast burst release followed by 
a slow sustained release (Lozano et al., 2013) that could be due to diffusion of drug  (DTX) 
molecules on the surface of the DTX-NLCs as previously reported by Koopaei et al., (2014). 
While in case of GLA-DTX-NLC and ALA-DTX-NLC their release pattern showed more than 
12% of DTX released from each formulation under the same conditions followed by very 
slow release profile where more than 40 % was released at 24 h (Figure 3.43 b), 
demonstrating sustained release effect when DTX-NLC were surface modified with GLA 
and ALA, a sustained release effect is more favourable than faster drug release particularly 
for IV.administration. In addition, the slower DTX release when the NLCs were surface 
modified might be attributed to the higher PS of the formed GLA-DTX-NLC and ALA-DTX-
NLC in comparison to PS of the bare DTX-NLC, and that might lead to increasing the 
distance between the surface and the lipid core of the NLCs as previously reported by Xu 



























Figure 3.43 DTX release profile from NLCs over 24 h at 37° C (a) when 100 % PBS, (pH7.4) 
was used as release media to study the release of DTX from DTX, DTX-NLCs and 
Taxotere, (b) when 30% Ethanol+70% PBS, (pH7.4) was used as release media to study 
the release of DTX from DTX, DTX-NLCs, GLA-DTX-NLC, and ALA-DTX-NLC. Data are mean 
± SD, N=3. 
3.5.10.3. Scanning electron microscopy 
SEM images for the freeze-dried DTX-NLC (Figure 3.44) illustrated spherically shaped 
particles and a PS ˃288 nm that might be attributed to the protection effected by 
trehalose as a cryo-protectant. Our finding showed DTX-NLC freeze-dried in nanometre 
range compared to previous results showing increased PS in micrometre range after 








Figure 3.44 SEM images showing freeze dried DTX-NLC in different magnifications (a) 






















3.5.10.4. X-ray diffractometer 
     The X-ray diffractometer (XRD) was used to investigate the crystalline structure of DTX 
and further confirm the status of DTX in NLCs formulation. Figure 3.45 shows the XRD 
pattern of all tested samples where the surfactants SC showed one peak at 2Ɵ value of 
14.36 and PH90 showed a high-intensity peak at 6.29° and medium intensity peaks at 9.5°, 
12.8°, 14.4°, 16.1°, 17.7°, 19.3°, 20.2°, 21,09°, 22.2° and 23.05°. The lipid D114 
demonstrated peaks of low-intensity at 35.06°, the medium intensity at 7.4°, 10.2°, 15.3°, 
16.6°, 17.05°, 17.6° and very high-intensity peak at 19.3°, 22.5°, 24.06°, 24.10°, D114 
obtained diffraction peaks were in line with Severino et al., (2012). Moreover, DTX 
powdered sample showed usual peaks at 2Ɵ values of 5.4°, 8.1°, 10.18°, 11.4°, 12.7°, 14.2° 
and 17.17° in line with previous reports by Fang et al., (2014). In the physical mixture, the 
peaks at 2Ɵ were at 7.4°, 16.7°, 17.3°, 17.9°, 19.4°, 23.29° and 24.14° which could be 
attributed to solid lipid D114. The DTX fingerprint peaks were absent from the physical 
mixture due to the low concentration of DTX used as compared to the D114.  DTX-NLC 
diffraction pattern showed peaks appearing at 2Ɵ of 7.8°, 15.05°, 15.68°,16.8°, 17.4°, 
19.5°, and 24,2° attributed to D114 diffraction peaks, and 9.4°, 12.8°, 18.1°, 17.4°, 19.5° 
and 21.5° which could be attributed to PH90 diffraction peaks. The SC peak did not appear 
in the DTX-NLC due to its low concentration present in DTX-NLC. The absence of DTX 
characteristic peaks in the DTX-NLC formulation might suggest that DTX was in an 
amorphous state within the NLCs (Figure 3.45). 
 
Figure 3.45 XRD structure of SC, PH90, D114, DTX, a physical mixture of DTX and D114, 
and DTX-NLC, expressed in 2Ɵ°.  


















3.5.10.5. Thermogravimetric analysis 
The TGA was performed for thermal stability analysis for DTX, D114, B-NLC, DTX-NLC, GLA-
DTX-NLC, ALA-DTX-NLC and SA43-DTX-NLC. The TGA of DTX showed major degradation 
started at around 204°C with 6% weight loss, our data was in line with Kulhari et al., (2014) 
findings, though mild degradation with approximately 2% loss was observed at initial 
temperature around 53°C, and at 110 °C around 3% loss was observed, revealing the 
importance of controlling the temperature during the processing of DTX-NLC (Figure 
3.46). D114 is relatively stable lipid as shown in Figure 3.46 where a stable degradation 
pattern with 8% weight loss at 320° was notable. The B-NLC showed an early degradation 
at 204 °C, as compared to D114 degradation, that could be due to presence of L.Ls and 
surfactants apart from solid lipid (D114) in the B-NLC structure, followed by increase in 
degradation around 260 °C with 10% weight loss, while DTX-NLC showed higher 
degradation 15% loss at 204 °C in comparison to the B-NLC (8% lost) at 204 °C (Figure 
3.46). The functionalised DTX-NLCs demonstrated an equal stability as compared to DTX-
NLC, where ALA-DTX and SA43-DTX-NLC started degradation around 280 °C and almost 
30% of weight loss, apart from GLA-DTX-NLC which indicated a faster degradation at 
temperature 84.8°C and almost 60% weight loss, that might be attributed to the high 
water content in this formulation or instability of the formulation during extensive heat 
(Hénon et al., 1997; Won et al., 2008) (Figure 3.46). Individual TGA thermographs for each 
sample in Appendix I. 
 
Figure 3.46 TGA thermographs using heat ranging from 25-500 °C for overlay of DTX, 
D114, DTX-NLC, B-NLC, GLA-DTX-NLC, ALA-DTX-NLC, and SA43-DTX-NLC degradation 
pattern. 
3.5.10.6. Differential scanning calorimetry 
To further investigate the physical state of D114, DTX in B-NLC, DTX-NLC, GLA-DTX-NLC, 




a melting endothermic peak at 59.33 °C (Figure 3.47 a), and recrystallisation of lipid during 
the cooling cycle as shown by the exothermic peak detected at 28.57 °C (Figure 3.47 b) as 
demonstrated by (Naguib et al., 2014). The melting endothermic peak for pure DTX was 
observed at 170.46 °C (Figure 3.47 a). This finding was in line with Singh et al., (2015). 
Shifting of D114 was observed in the B-NLC, which exhibited a characteristic lipid D114 
melting peak at 55.61 °C in the first heat cycle (Figure 3.47 a), that might be due to 
incorporation of L.Ls in addition to the D114 (impurity effect), additionally, B-NLC 
exhibited lipids recrystallises during cooling as evident from the exothermic peaks 
detected at 25.18 °C (Figure 3.47 b). DTX-NLC showed melting peak at 54.42° C attributed 
to D114, however, no DTX peaks were observed at 170°C demonstrated that DTX in the 
NLC formulations might be in an amorphous state or in the solid-solution state after 
encapsulation into the NLCs (Figure 3.47 a), and recrystallisation during the cooling cycle 
at 25.4 °C (Figure 3.47 b). A similar finding has been obtained by Tao et al., (2013) and 
Naguib et al., (2014). 
Surface modified formulations GLA-DTX-NLC, ALA-DTX-NLC, and SA43-DTX-NLC showed 
melting peaks at 55.37, 56.08 and 55.34 °C characteristic of D114. It is worth to mention 
that the intensity of the lipid melting endothermic peaks for surface modified NLCs were 
very low in comparison to B-NLC and DTX-NLC peaks that might be attributed to fact that 
the surface modified NLCs have been diluted during the coupling process. These 
formulations also showed recrystallisation of lipid during the cooling cycle as evident by 
peaks detected at 27.84, 27.61 and 27.39 °C for GLA-DTX-NLC, ALA-DTX-NLC, and SA43-
DTX-NLC, respectively (Figure 3.47 b).  
Similarly, to DTX-NLC thermal behaviour, DTX melting endotherm was absent in the 
surface-modified formulations suggesting the amorphous nature of drug in the 
formulations. D114, B-NLC, DTX-NLC, GLA-DTX-NLC, ALA-DTX-NLC, and SA43-DTX-NLC 
were demonstrating melting endothermic peaks at 59.04, 55.05, 55.34, 55.05, 55.91, and 












Figure 3.47 DSC thermograph using method heat/cool/heat, for D114, DTX, DTX-NLC, B-
NLC, GLA-DTX-NLC, ALA-DTX-NLC, and SA43-DTX-NLC (a) first heat phase, (b) cool phase 




3.5.10.7. Fourier-transform infrared spectroscopy 
Fourier-transform infrared spectroscopy (FTIR) involves energy transferred to molecules 
by absorption of IR radiation and this result in covalent bond stretching, twisting, and 
bending in the stationary phase states of the molecule. Each molecule has its own 
characteristic IR spectra, thus changes in structure can be detected by IR (Cantor and 
Schimmel, 1980). FTIR spectroscopy of DTX, B-NLC, DTX-NLC and surface modified DTX-
NLCs was carried out and the vibrational band's assignments are summarised in tables 
3.18, 3.19, 3.20 and 3.21. All band assessments were confirmed with previous literature 
(Shabani et al., 2016; Fang et al., 2014; Rusu and Rusu 2010; Venishetty et al., 2013; Singh 
et al., 2015; Seçilmi and Bardakç, 2011; Mushtaq et al., 2014; Bright et al., 2010; Tugarova 
et al., 2018).  
DTX, DTX-NLC, and B-NLC 
DTX demonstrated the characteristic vibrational band assignments, which are in 
conformation with previous reports (Shabani et al., 2016; Fang et al., 2014) as shown in 
Figure 3.48. DTX-NLC showed the characteristic peaks of DTX positions at (3688, 1700, 
1457 and 1368) cm⁻1 that correlates to OH stretching, C=O stretching, N-H diffraction and 
C-H bending respectively, indicating the presence of DTX within the DTX-NLC (Table 3.18 
and Figure 3.48), however, some DTX peaks are absent due to the interaction between 
DTX and DTX-NLC.  
 
 






The DTX-NLC had all the characteristic peaks that were present in the B-NLC (Figure 3.48 
and Table 3.18), which could be due to the presence of same excipients used in the 
formulations apart from the drug, which includes (solid lipid, liquid lipids, and 
surfactants). A detailed FTIR spectrum in Appendix I.  
Table 3.18 FTIR Vibrational band assignment for DTX, DTX-NLC, and B-NLCs. 
FTIR  
frequency (cm⁻1) 
Vibrational band assignment  DTX DTX-NLC B-NLC  
3688 O-H stretching √ √  
3459 N-H/ O-H stretching  √   
3326 N-H stretching  √ √ shift to 
3351  
2979 C-H stretching  √   
2915 and 2849 CH2 asymmetrical and symmetrical stretching   √ √ 
1734 C=O stretching  √ √ 
1718 C=O stretching  √   
1700 C=O stretching √ √  
1490 C=C stretching  √   
1472 CH2 / CH3 asymmetrical stretching  √ √ 
1457 N-H, CH3, O-H diffraction   √ √  
1452 C-H bending  √   
1368 C-H bending/C-C stretching  √ √  
1273 C-O stretching    √ √ 
1254 C-O stretching    √ √ 
1245 C-O stretching  √   
1228 C-O stretching  √ √ 
FTIR  
frequency (cm⁻1) 
Vibrational band assignment  DTX DTX-NLC B-NLC  
1201 C-O stretching  √ √ 
1179 S=O stretching   √ √ 
1161 C-O stretching √   
1148 S=O stretching  √ √ 
1103 C-N stretching   √ √ 
1077 CH2 twisting/ aromatic ring stretching   √ √ 
1070 C-O stretching/ Aromatic ring stretch/CH2 
twisting  
√   
1028 C-N /C-O stretching   √ √ 
1024 C-O stretching √   
987 C=C bending   √ √ 
978 C-S stretching  √   
942 C-H twisting   √ √ 
848 C-H out of plane bending √   
803 C=C bending  √ √ 
780 C-H bending √   
716 C-H bending  √ √ 
708 C-H out of plane bending √   




DTX-NLC, GLA, and GLA-DTX-NLC 
GLA-DTX-NLC retained all characteristic peaks of DTX-NLC, GLA-DTX-NLC also showed 
characteristic peaks of GLA at (1772, 1775, 1506, 1419, and 917) cm⁻1 that were related 
to (C=O, C=O, N-H bending, CH2 symmetrical, and C=C), respectively, which were absent 
in the DTX-NLC. Additionally, GLA-DTX-NLC showed new peaks at (2991, 1085, 1044 and 
882) cm⁻1 that were characterisation for (N-H stretching, C-O stretching, Aromatic 
deformation, C-O-C and C-H bending) respectively, which were not seen in spectrums of 
either in GLA or DTX-NLC, suggestive of GLA interaction with DTX-NLC, and indicating the 
GLA functionalisation with DTX-NLC. However, the characteristic peaks of amide bond 
formation at C=O at 1653 cm⁻1 and N-H bend at 1558 cm⁻1 (Rusu and Rusu 2010; 
Venishetty et al., 2013; Singh et al., 2015) were masked due to overlapping with the DTX-

















Table 3.19 FTIR Vibrational band assignment for DTX-NLC, GLA and GLA-DTX-NLC. 
 
DTX-NLC, ALA, and ALA-DTX-NLC 
ALA-DTX-NLC also showed the formation of new peaks at 2991, 1085, 1044 and 882) cm⁻1 
that were characteristics for N-H stretching, C-O stretching, Aromatic deformation, C-O-C 
and C-H bending respectively, which were absent in both ALA and DTX-NLC, indicating the 
interaction and conjugation of ALA to the DTX-NLC. Additionally, some of the ALA peaks 
were present in ALA-DTX-NLC, to further suggest the confirmation of the functionalisation 
of DTX-NLC with ALA. Similar observation to GLA-DTX-NLC, the ALA-DTX-NLC 
characteristic amide bond formation at C=O at 1653 cm⁻1 and N-H bend at 1558 cm⁻1 (Rusu 
and Rusu 2010; Venishetty et al., 2013; Singh et al., 2015; Seçilmi and Bardakç, 2011) were 
masked due to overlapping with the DTX-NLC carbonyl group (Figure 3.50 and Table 3.20). 
A detailed FTIR spectrum in Appendix I. 
FTIR frequency (cm⁻1) Vibrational band assignment  DTX-NLC GLA GLA-DTX-NLC  
3011 C-H stretching  √  
2991 N-H stretching   √ 
2915 CH2 asymmetrical and symmetrical 
stretching 
√  √ 
2849 CH2 asymmetrical and symmetrical 
stretching 
√ √ √ 
1772 C=O stretching  √ √ 
1751 C=O stretching  √ √ 
1734 C=O stretching √  √ 
1700 C=O stretching √   
1653 C=C/ C=O amide I stretch √  √ 
1558 N-H bending √  √ 
1506 N-H bending / N-O stretching   √ √ 
1455 N-H, CH3, OH detraction  √  √ 
1419 CH2 symmetrical scissoring  √ √ 
1085 C-O stretching   √ 
1044 Aromatic ring deformation/C-O-C   √ 
917 C=C bending   √ √ 
882 C-H bending    √ 





Figure 3.50 FTIR spectrum overlay of DTX-NLC, ALA and ALA-DTX-NLC, and their band 
assignments.  
 
Table 3.20 FTIR Vibrational band assignments for DTX-NLC, ALA and ALA-DTX-NLC. 
DTX-NLC, SA43 and SA43-DTX-NLC  
As seen in figure 3. 51 and band assignment given in table 3.21, the appearance of two 
bands SA43-DTX-NLC at 1772 cm⁻1 (C=O stretching) and 1505 cm⁻1 (N-H bending) might 
provide a preliminary proof for the amide bond formation. Also, it was noted some mutual 
FTIR  
frequency (cm⁻1) 
Vibrational band assignment  DTX-NLC ALA ALA-DTX-NLC  
3011 C-H stretching  √  
2991 N-H stretching   √ 
2915 CH2 asymmetrical and symmetrical 
stretching 
√  √ 
2849 CH2 asymmetrical and symmetrical 
stretching 
√ √ √ 
1734 C=O stretching √ √ √ 
1700 C=O stretching √ √ √ 
1653 C=C stretching √ √ √ 
1635 Cis C=C /C=O amide I stretch  √ √ 
1558 N-H bending √ √ √ 
1455 N-H, CH3, OH detraction  √ √ √ 
1419 CH2 symmetrical scissoring   √ √ 
1085 C-O stretching   √ 
1044 Aromatic ring deformation/ CO-O-CO 
stretching 
  √ 
935 O-H out of the plane of the carbonyl group   √  
917 C=C bending    




peaks between SA43-DTX-NLC and the DTX-NLC demonstrating the interaction of SA43-
aptamer with the DTX-NLC. A detailed FTIR spectrum in Appendix I. 
 
Figure 3.51 FTIR spectrum overlay of DTX-NLC, SA43 and SA43-DTX-NLC, and their band 
assignments.  
 
Table 3.21 FTIR Vibrational band assignments for DTX-NLC, SA43 and SA43-DTX-NLC. 
 
3.5.10.8. Raman spectroscopy  
Raman spectroscopy is a highly informative nondestructive method of analysis to 
determine the structural and compositional properties of NPs (Gopal et al., 2016). In NPs 
the crystalline Raman peak position is usually downshifted and asymmetrically broadened 
with respect to bulk material (Meilakhs and Koniakhin, 2017). All Raman vibrational band 
assignments summarised in tables 3.22, 3.23 were compared with previous published 
FTIR  
frequency (cm⁻1) 
Vibrational band assignment  DTX-NLC SA43 SA43-DTX-NLC  
2915 CH2 asymmetrical and symmetrical 
stretching 
√  √ 
2849 CH2 asymmetrical and symmetrical 
stretching 
√  √ 
1772 C=O stretching  √ √ 
1734 C=O stretching √ √ √ 
1700 C=O stretching √ √ √ 
1684 C=O stretching, I or III amide √ √ √ 
1653 Cis C=C stretching √ √ √ 
1635  C=C/ C=O stretching √ √ √ 
1558 N-H bending √ √ √ 
1505 N-H bending  √ √ 
1455 N-H, CH3, OH detraction  √   




literature (Torres et al., 2007; Ansari et al., 2018; Yamini et al., 2014; Lo et al., 2009; 
Schaffer et al., 1991) and with the company data analysis handbook for Raman band 
assignment positions by Horiba (2017). 
DTX and DTX-NLC  
Table 3.22 showed band shifting at (1783, 1658, 1626, 1605, 1533, 1261, 1079, 1061, 908, 
and 842) cm⁻1 as evident in Raman spectrum (Figure 3.52) confirmed the encapsulation 
of DTX within the DTX-NLC due to appearing of DTX corresponding peaks in the DTX-NLC 
spectrum. 












Vibrational band assignment  DTX DTX-NLC 
Freeze dried 
1813 C=O stretching  √ √ 
1793 C=O √ √ 
1786 C=C/C=O stretching  √ √ shifted to 1783 
1651 C=O/ C=C stretching √ √ shifted to 1658 high intensity  
1631 C=O/C=C/ C=N stretching √ √ shifted to 1626 
1601 C=N/C=C stretching  √ √ shifted to 1605 
1530 C-N stretching √ √ shifted to 1533 
1357 C-(NO2) √ √ 
1346 C-(NO2) (phospholipids) √ √ 
1275 C=O stretching  √ √ shifted to 1261 
1230 C-N stretching/CH2 twisting  √ √ 
1026 C=S √ √ shifted to 1079 
1003 C=S √ √ shifted to 1061 
960 C=O stretching  √ √ 
950 C-C stretching/ CH2 rocking √ √ 
894 C-C stretching √ √ shifted to 908 
849 C-C stretching √ √ shifted to 842 
702 C-N stretching √ √ 











     DTX-NLC, GLA-DTX-NLC, and ALA-DTX-NLC  
Raman spectrum of functionalised GLA-DTX-NLC and ALA-DTX-NLC were obtained and the 
Raman shift of the main bond are summarised in table 3.23, together with their 
corresponding band assignments. 
GLA-DTX-NLC demonstrated a Raman shift at (1737, 1883, 1937, 1440, 1399, 1383, 1262, 
1207, 1161, 1104, 1017, 980, 967, 920, 586, and 530) cm⁻1 which were a characteristic of 
( C=O stretching, C=O stretching, C=O/ C=N stretching, CH3/CH2 stretching, N-H stretching, 
N-H stretching, C=O stretching/N-H bending, C-N stretching, C-N stretching, C-N 
stretching/CH3 twisting, C=O, C=O stretching, C-C stretching, and C=O bending), 
respectively.  
Raman shift was also used to evaluate the amide bond formation and any changes in the 
Raman spectrum after ligands been linked to the DTX-NLC as shown in Figure 3.53 and 
Table 3.23 that indicates some characteristic peaks that only appeared in the GLA-DTX-
NLC and ALA-DTX-NLC at Raman shifts (1451, 1189, 1101, 945, 905, 773, and 684) cm⁻1 
assigned for (CH3 asymmetrical deformation, C-C/C-N stretching, C-C/C-N stretching/ CH3 
twisting, C-C stretching, , C-C stretching, C-N stretching/ C-H out of plane bend, and C-C 
stretching), respectively, those bands were absent in DTX-NLC, that might suggest the 
interaction and conjugation between the two PUFAs ligand and the DTX-NLC. Though 
some of the amide bond characteristics peaks (C=O at 1653 cm⁻1  and N=H at 1246 cm⁻1). 
were present in both surface modifieds DTX-NLCs and the DTX-NLC pre-conjugation, that 













Table 3.23 Raman Vibrational band assignments for DTX-NLC, GLA-DTX-NLC, and ALA-







DTX-NLC GLA-DTX-NLC ALA-DTX-NLC  
1853 C=C √ √  
1844 C=C √   
1828 C=C √ √  
1793 C=O √   
1773 C=O √ √  
1761 C=O √ √  
1755 C=O   √ 
1741 C=O stretching √  √ shifted to 1743 
1730 C=O stretching √ √ sifted to 1737  
1712 C=O stretching  √  
1706 Ketone  √ √ shifted to 1702  
1688 C=O/C=C/C=N 
stretching  
√ √ shifted 1883 
Amide band  
√ 
1674 C=O/ C=N stretching √  √ shifted to 1676 
1666 C=O stretching/amide I  √  
1653 C=O/C=C stretching 
(amide I) 
√ √ √ 
1639 C=O/C=C/C=N 
stretching 
√ √ shifted 1937 √ 
1625 C=O N-H stretching 
amide bond formation 
 √  
1608 Amide  √  √ 
1600 Amide   √  
1596 C-C / Amide    √ 
1559 Amide   √  
1543 C-N stretching  √  
1521 C-N stretching √ √ Shifted to 1529 
1509 C-N stretching  √  
1496 Aromatic ring  √   
1451 CH3 asymmetrical 
deformation  
 √ √ 
1441 CH3 asymmetrical 
/CH2/ring stretching  
√ √ Shifted to 1440  
1416 CH3/CH2  √  
1396 N-H stretching √  √ shifted to 1399 √ shifted to 1399 
1386 N-H stretching √ √shifted to 1383  
1367 CH3 umbrella mode 
(phospholipids) 
 √  
1299 CH2 twisting/ √ √ √ shifted to 1294 
1266 C=O stretching/N-H 
bending  
√ √ shifted to 1263  
1252 C-N stretching/ N-H 
bending   
 √  
1246 C-N stretching/ N-H 
bending amide III 
stretch  
√   
1233 C-N/C-O stretching, C-
H in-plane bend 
√  √ shifted to 1231 
1228 C-N stretching/CH2 
twisting  
 √  
1200  C-N stretching √ √ shifted to 1207  
1191 C-N / C-C stretching √   















DTX-NLC GLA-DTX-NLC ALA-DTX-NLC  
1163 C-N/ C-C 
stretching/CH3 rocking  
√ very sharp 
and high-
intensity peak  
√ shifted to 1161, low 
intensity  
√ shifted to 1169, low 
intensity  
1124  C-N stretching/CH2 
twisting  
√   
1112 C-N stretching √   
1101 C-N/C-C stretching/ 
CH3 twisting  
 √ shifted to 1104 √ shifted to 1109 
1075  C-C stretching √ √ √ high intensity  
1033 Sulfonic acid  √   
1020 Aromatic ring  √ √ shifted to 1017 √ 
995  Aromatic ring 
breathing  
√ √ √ high intensity  
977 C=O  √ √ shifted to 980 √ 
962 C=O √ √ shifted to 967 √ shifted to 964 
945 C-C stretching/ CH2 
rocking 
 √ √ shifted to 940 
925 C-C stretching √ √ shifted to 920 √ shifted to 920 
905 C-C stretching  √ √ 
895 C-C stretching √   
878 C-C stretching √ √ √ high intensity  
868 C-C ending/ CH2 
twisting  
√   
856 C-C stretching √ √  
773 C-N stretching/ C-H 
out of plane bend 
 √ √ 
724 C-N stretching III 
amide  
 √  
707 C-N stretching III 
amide 
√ √ √ high intensity  
695 C-C/C=O deformation   √  
684 C-C  √ √ 
679 C-C out of the plane  √ high 
intensity  
  
645 C-C √   
633 C-C stretching / C-H 
out of plane bend 
√ √  
595 C=S  √ √ shifted to 598 
582 C=S √ √ shifted to 586 √ shifted to 580 
577 C-Cl  √  
528 C=O bending √ √ shifted to 530  
503 O-H torsion √ √ √ high intensity  












3.5.11. Stability studies  
3.5.11.1. Colloidal stability  
DTX-NLC maintained good stability in water, as well as dextrose 5% over a period of 24 h 
as seen by no significant change in PS and uniform distribution, maintained during this 
study (Figure 3.54 a and b). These results were in agreement with the previous study by 
Rohiwal et al., (2015) when BSA NPs were examined in similar media. However, in the 
presence of  NaCl 0.9 %  and PBS a drastic increase in both PS and PDI were observed 
(Figure 3.54 a and b), that might be attributed to both NaCl 0.9 %  and PBS  have anionic 
moieties which might result in changes in the surface charge of DTX-NLC and consequently 
led to DTX-NLC aggregation or due to potential formation of insoluble salts that might 
lead to precipitation from the colloidal dispersion and co-precipitate colloidal particles 
along with it (Rohiwal et al., 2015). Thus, H2O and dextrose 5% could be a good media for 
reconstitution of freeze-dried NPs and avoiding of anionic physiological solution would be 
preferable.  
EMEM was used during cell culture biology work, involving incubation of EMEM with 
NLCs, thus, it was considered for investigating its effect on the DTX-NLC colloidal stability. 
In the initial time period up to 6 h there was a slight increase in PS, however, beyond 6 h, 
an increase in PS and PDI were observed (Figure 3.54 a and b), that might be due to the 
presence of amino acids, glucose, and FBS. As it is well known that proteins and vitamins 
might adsorb onto the NPs (Goppert et al., 2005), and lead to the formation of a corona 
on the surface resulting in an increase in PS (Barbero et al., 2017). These results were in 




















Figure 3.54 Effect of physiological media on DTX-NLCs over 24 h during different time 
intervals at 37°C (a) effect on PS when PBS, EMEM, Dextrose 5%, NaCl 0.9 % and H2O 
(D.W) were used, (b) effect on PDI when PBS, EMEM, Dextrose 5%, NaCl 0.9 % and H2O 
(D.W) were used. Data are mean ± SD, N=3. 
 
3.5.11.2. Short-term stability  
Stability studies were performed on the liquid dispersion of DTX-NLCs and B-NLCs for up 
to three months at room temperature (Tables 3.24 and 3.25). Both formulations 
demonstrated stable features for all investigated parameters (Figure 3.55 a and b). There 
was no change observed on PS and PDI due to high ZP more than -30 mV which was 
maintained over a period of three months. These findings were in line with Radomska-
Soukharev (2007) and, Radomska-Soukharev and Muller (2006). High ZP plays a crucial 
role to prevent drug aggregation, as the electrostatic repulsion prevents aggregation of 
particles might lead to colloidal stability (Caddeo et al., 2008).  Moreover, 15 % reduction 
in TD was obtained over the same period. Lyophilisation (freeze-drying) of the formulation 
might result in better drug stability with DTX-NLC and overcome drug loss.  
Table 3.24 DTX-NLCs in liquid dispersion stability study for three months at room 
temperature. 
DTX-NLCs PS (nm) PDI ZP (mV) %EE %TD %DC 


































































Table 3.25 B-NLCs in liquid dispersion stability study for three months at room 
temperature.  
B-NLCs PS (nm) PDI ZP (mV) 





























Figure 3.55 Stability study for up to three months at room temperature showing particle 
size and particles distribution for (a) overlay graph for DTX-NLC (b) overlay graph for B-
NLC. Data are mean, N=3. 
3.5.11.3. Long-term stability  
Stability studies were conducted on freeze-dried DTX-NLCs with samples stored at 
different storage temperature over a period of six months (-20, 4, 25 and 40°C), 
respectively. DTX-NLC showed good stability in terms of PS when stored at -20 °C (Figure 
3.56 and 3.57), as no significant increase in PS, was observed for samples stored at -20 °C 




C for up to six months. DTX-NLC PS suffered from a highly significant increase in PS when 
DTX-NLC stored at 25 and 40 °C at all time points, indicating that high temperature might 
not be suitable for storing the DTX-NLC. Interestingly, our data for PS demonstrated better 
results than reported by Fan et al., (2014) at similar storage environments.  








Figure 3.56 Combined graphs showing PS and PDI stability study for DTX-NLC, Stored at 
different temperature (a) at -20 °C, (b) at 4°C, (c) at 25°C, and (d) at 40 °C, respectively. 
     
 
Figure 3.57 Stability study over six months and the effect of storing the DTX-NLCs at -20, 
4, 25, and 40°C on PS. Data are mean ± SD, N=3, * P < 0.05, ** P < 0.001 and *** P < 
0.000 refers to a significant difference when samples stored at variable temperature 



























Figure 3.58 a, demonstrated a significant increase in the size distribution of the PDI when 
DTX-NLCs were stored at -20°C, 4°C, 25 and 40 °C for up to six months. However, storing 
DTX-NLC at -20°C and 4°C were much preferable over higher storage temperature due to 
PDI ˃ 0.5 at six months period.  The ZP of DTX-NLC showed a significant increase at -20, 4, 
and 25 °C, which probably contributed to increasing the stability of these formulations. It 
was reported earlier that ZP ˃ -30.0 mV was good for physical stability (Mukherjee et al., 
2008). In our experiments all DTX-NLCs stored at different temperature were 
characterised by a high zeta potential and/or remain unchanged as ZP was ranging from -
36.1 ± 1.5 to -45.86 ± 0.5 mV during the six months period of storage (Figure 3.58 b) that 
suggests a good long-term physical stability as reported by Mukherjee et al., (2008). and 





Figure 3.58 Stability study over six months and the effect of storing the DTX-NLCs at -20, 
4, 25, and 40°C on (a) PDI and (b) ZP. Data are mean ± SD, N=3, * P < 0.05, ** P < 0.001 
and *** P < 0.000 refers to the significant difference when samples stored at variable 
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The %TD were maintained for up to three months, beyond that %TD was reduced by 10, 
12, 12, and 20 % at the end of six month period at -20, 4, 25, and 40 °C, respectively (Figure 
3.59 a). Additionally, only DTX-NLC stored at -20 °C was showing high %DL with no 
significant reduction for up to six months, and the % DL of DTX-NLC stored at 4 and 25 °C 
was slightly reduced. Notably, a drastic reduction in % DL was observed at 40°C beyond 





Figure 3.59 Stability study over six months and the effect of storing the DTX-NLCs at -20, 
4, 25, and 40°C on (a) %TD and (b) %DL. Data are mean ± SD, N=3, * P < 0.05, ** P < 
0.001 and *** P < 0.000 refers to the significant difference when samples stored at 
variable temperature were compared to a fresh DTX-NLC.  
 
It was evident in figure 3.60 that the DTX-NLC % EE showed a high DTX entrapment within 
the NLCs for all examined samples, preferably DTX-NLC should be stored at -20 and 4°C 








































worth mentioning that our finding demonstrated relatively good PS and %EE when NLCs 
were stored at 25°C when compared with previous literature by Li et al., (2009). 
 
Figure 3.60 Stability study over six months and the effect of storing the DTX-NLCs at -20, 
4, 25, and 40°C on % EE. Data are mean ± SD, N=3, * P < 0.05 refers to the significant 
difference, ** P < 0.001 and *** P < 0.000 refers to a highly significant difference when 
samples stored at variable temperature were compared to a fresh DTX-NLC. In this case, 
no significant difference was observed in all tested samples. 
 
DTX-NLC followed a trend of Oswald ripening for all DTX-NLC stored at -20, 4, 25 and 40°C 
as the r2 versus time demonstrated a relatively linear relation r2 was ranging between 
0.69-0.30 (Witayaudom and Klinkesorn, 2017), this phenomenon occurs due to small 
particle size accumulate and disposed into larger particle size, so the ripening increases 
with time (Figure 3.61 a). However,  DTX-NLC stored at 40 °C  apart from Oswald ripening 
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Figure 3.61 Stability study over six months and the effect of storing the DTX-NLCs at -20, 
4, 25, and 40°C (a) the plot of 1/r2 with respect to time, (b) the plot of r3 as a function of 
time. Data are mean ± SD, N=3. (r) refers to the radius of NLCs. 
In summary, DTX-NLCs were developed and prepared in a temperature-controlled 
environment and organic solvent-free preparation process. Biodegradable excipients that 
were acceptable for IV route administration were used for DTX-NLC fabrication, where a 
combination of surfactants system, solid and liquid lipids were used to produce a 
formulation with low PS 136 nm, uniform distribution PDI 0.23, desirable high surface 
charge -32 mV, drug entrapment 99%, and drug content 88 %. Stable in water and 
dextrose 5% physiological media with up to six months of stability at -20 °C for freeze-
dried form. Followed by a successful surface modification with two PUFAs (GLA and ALA) 
and novel SA43-aptamer. Additionally, DTX-NLCs and surface modified NLCs were 
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4.1.1. Monolayer cell lines as in-vitro model  
The use of in-vitro cell lines as screening models for evaluation of different drugs and 
compounds has great value for overcoming obstacles in the drug development and 
screening processes (Allen et al., 2005). Using tissue culture, it is possible to study cell 
lines derived from humans and animals and to assess the effect of the drug on the desired 
target systems; and examining the mechanism of action and toxicity (Allen et al., 2005).  
After the development of new NLC formulations loaded with anti-cancer drug DTX, as 
previously detailed in chapter three, the evaluation of their efficacy and effect on cell 
proliferation was investigated. Specifically, this involved study of the cellular uptake, 
internalisation mechanism and the effect on cell cycle of the DTX and NLCs loaded with 
DTX and further the effect of surface modification of DTX-NLC with PUFAs (GLA and ALA) 
and SA43-aptamer was studied. Commercially available immortalised glioblastoma cell 
lines and patient-derived short-term cultures of glioblastomas grown in a monolayer were 
used as models for the aforementioned assays.  
4.1.2. Spheroids as a 3D in-vitro model  
Three dimensional (3D) spheroids permit the evaluation of cytotoxic therapeutics under 
specific conditions, which partially represent the tumour microenvironment more so than 
a monolayer (Hamilton, 1998). Spheroids are micro size aspherical cell groups that self-
assemble to form a 3D tumour (Mehta et al., 2012). Spheroids are thought to be produced 
by promoting cell coupling with a neighbour cell and by resisting cell–surface interactions 
with the tissue culture plate (Friedrich et al., 2007). Spheroids have been used for studying 
a variety of treatments as demonstrated by Sha et al., (2015) and Gao et al., (2012). It is 
believed that tumour spheroid models will participate to economic savings in cancer 
research as the physiologically relevant microenvironment as they more closely represent 
the in vivo environment, hence improving the predictive drug efficacy and thereby 
reducing downstream animal tests (Carver et al., 2014; Friedrich et al., 2007). Wherever 
possible, 3D spheroids were used for cell proliferation and uptake assays, but where high 
cell numbers were required, monolayer cultures had to be used. 
4.1.3. Docetaxel mechanism of action and tumoricidal effect 
It is well reported that DTX exerts tumouricidal effects by disrupting microtubule assembly 
and stabilising the polymers against depolymerisation, hence inhibiting the microtubule 




impairment of mitotic progression leading to cell cycle arrest at G2/M phase (Figure 4.1), 
















The aim of this study was to evaluate the efficacy and toxicity of DTX-NLCs for treatment 
of glioblastoma and to explore the effect of surface modification DTX-NLCs (DTX-NLC, 
GLA-DTX-NLC, ALA-DTX-NLC, and SA43-DTX-NLC) with respect to enhanced DTX-NLC 
selective uptake, internalisation and toxicity.   
4.2.1. Objective 1 
Evaluation of the effect of DTX-NLCs on cell proliferation in monolayer U87MG 
glioblastoma cell lines and patient-derived short-term cultures of glioblastoma BTNW911 
and compare to non- cancerous glial cell line SVG P12. 
4.2.2. Objective 2 
Evaluation of the effect of the presence of combined antioxidants (Vit E and AP), used 
during the fabrication of DTX-NLC, GLA-DTX-NLC, and ALA-DTX-NLC on cell proliferation 
of U87MG cell line. 
4.2.3. Objective 3 
Evaluation of the effect of variable ratios of GLA, ALA and SA43-aptamer functionalised 
DTX-NLCs on cell proliferation in monolayer U87MG glioblastoma cell lines, patient-
derived short-term cultures of glioblastoma BTNW911 as compared to non- cancerous 
glial cell line SVG P12. 
4.2.4. Objective 4 
Evaluation of the cell proliferation differential effect of DTX-NLC and surface modified 
DTX-NLCs in U87MG glioblastoma cell lines spheroids. 
4.2.5. Objective 5 
Internalisation and selective uptake analysis of DTX-NLC and surface modified DTX-NLCs 
in monolayer U87MG glioblastoma cell lines and patient-derived short-term cultures of 
glioblastoma BTNW911 (FACS only) compared to non- cancerous glial cell line SVG P12 
measured by fluorescence microscopy and flow cytometry respectively. 
4.2.6. Objective 6 
Selective uptake analysis of DTX-NLC and surface modified DTX-NLCs in spheroid U87MG 





4.2.7. Objective 7 
Elucidation of the uptake pathway of DTX-NLCs and surface modified DTX-NLCs in 
monolayer U87MG glioblastoma cell lines compared to non- cancerous glial cell line SVG 
P12 measured by fluorescence microscopy and flow cytometer in the presence of specific 
pathway inhibitors. 
4.2.8. Objective 8 
Determine the cell cycle phase distribution following treatment with developed 




















4.3. Equipment and materials  
4.3.1. Equipment  
Class II microbiological safety cabinets (Labcaire Systems Limited, UK) were used for 
sterile tissue culture.  Separate class II cabinets were used for immortalised cell line 
culture and short-term culture of patient-derived primary cells to minimise the risk of 
cross-contamination of cell lines. Fluorescence spectroscopy measurements were made 
in a plate reader (Genios Pro microtiter plate reader, Tecan, Austria) and data were 
analysed using GraphPad software Prism version 5.00 for Windows, (San Diego California, 
USA). Fluorescence imaging was captured with a Carl Zeiss fluorescence microscope (Carl 
Zeiss Microscopy GmbH, Germany). Fluorescence images were taken with an AxioCam 
MRm Zeiss camera, (Carl Zeiss Microscopy GmbH, Germany) and processed with Zen blue 
software (Carl Zeiss Microscopy GmbH, Germany). A benchtop flow cytometer was used 
for cellular uptake, internalisation mechanism and cell cycle analysis (Guava, Merck, 
Germany), and the data were analysed with Guava® EasyCyte software 3.1.1 (Guava, 
Merck, Germany), The cells were incubated in a Sanyo CO2 incubator (Sanyo, Japan). Cells 
were visualised with Leica DMIL light microscope from Leica Microsystems GmbH, 
Germany whereas light microscope images were taken with the MShot camera, China and 
processed with MShot Digital Imaging System software, China. Haemocytometer slide 
used for cell counting was obtained from Marienfeld (Marienfeld, Germany). Bench 
centrifuge (ALC, Buckinghamshire, UK) at 179 x g for 5 min. All sterile culture flasks (T25 
and T75 cm3), sterile plates (6-well, 12-well, and 96-well) (Nunc™ MicroWell™), sterile 
centrifuge tubes (15 and 50 ml), serological pipettes and Mr Frosty™ freezing containers 
were purchased from Fisher Scientific, UK. Syringes were obtained and Millex® sterile 
syringe filters (0.45 μm and 0.22 μm pore size) were from Fisher, UK. The slides and cover 
slides from Fisher, UK. Non-tissue culture/ V-shaped 96 well plates were purchased from 
Fisher, UK.  
4.3.2. Materials 
The media, supplements and chemicals were obtained from the following: Eagle’s 
minimum essential medium (EMEM) Lonza, Belgium. Foetal bovine serum (FBS), L-
glutamine, sodium pyruvate, non-essential amino acid (NEAA) and phosphate buffer 
saline (PBS) 0.1 M pH 7.4 at 25°C (Fisher, UK). RNAse free water was from Fisher, UK. 
Propidium iodide, Trypsin solution 10X, Trypan blue, sucrose and agarose were purchased 
from Sigma Aldrich, UK. Presto blue, 16% Formaldehyde, HBSS 1X consists of (Potassium 




Bicarbonate (NaHCO3) 4.166 mM, Sodium Chloride (NaCl) 137.93 mM, Sodium Phosphate 
dibasic (Na2HPO4) anhydrous 0.338 mM and Other Components D-Glucose (Dextrose) 
5.55 mM and Phenol Red 0.026 mM) at pH7.4, 1X TryPLE Express, ethanol, DMSO, RNAs, 
Nystatin and Cytochalasin B, industrial methylated spirit (IMS) were purchased from 
Fisher Scientific, UK. Vectashield mounting medium with DAPI was purchased from Vector 
Labs, UK. Accumax™ Cell Counting Solution in Dulbecco's Phosphate-Buffered Saline 
(DPBS) was provided by Merck Millipore, UK.  
4.3.3. Cell lines  
SVG P12 (human, non-cancerous foetal glial cell line) was cultured with a passage number 
ranging from 9-13, U87MG (human glioblastomas, grade IV cell line), was cultured with a 
passage number ranging from 15-23. Both cell lines were obtained from the European 
Collection of Cell Cultures (ECACC, UK). BTNW911 was a short-term culture derived from 
primary cells obtained from a 60-year-old, male grade IV glioblastomas, used at passage 
number 9 and 10 with written ethical consent from the BTNW (Brain Tumour North West) 

















All the experiments reported in this chapter were performed under sterile conditions and 
by using a class II laminar flow hood. All equipment, materials, pipettes, flasks were 
sterilised prior to place it inside the hood either by spring with 70% industrial methylated 
spirit (IMS) or by autoclaving and spraying with 70% IMS. Unsterile reagents were 
sterilised by filtering the reagents with sterile filters of pore sizes 0.22 μm. All media, PBS 
and media supplements were placed in the water bath at 37°C for at least 30 min before 
starting the experiments. Moreover, all the flasks containing cell suspension and media 
were sprayed with 70% IMS then placed at 37°C in a humidified incubator under 5 % CO2 
atmosphere, all these conditions were kept constant during the course of this studies, to 
maintain a clean, sterile and desirable environment for the cell lines and spheroids to 
grow properly.   
4.4.1. Preparations  
4.4.1.1. Media preparation 
Eagle’s minimum essential medium (EMEM) was used for growing U87MG, U87MG 
spheroids and SVG P12 cells then adding to it 1 mM sodium pyruvate, 1% non-essential 
amino acid (NEAA), 2 mM L-glutamine and 10% foetal bovine serum (FBS) as supplements 
for the cell lines. For BTNW911 the primary culture was maintained in F-12 media, and 1 
mM pen-strep, 2 mM L-glutamine and 10% Foetal bovine serum (FBS) as supplements 
were added. The prepared media were stored at 4 °C. 
4.4.1.2. Trypsin and Phosphate buffer saline (PBS) 
Trypsin 1x (0.25 mM) was used to detach the adherent monolayer cells from the flasks, it 
was prepared by 1:10 dilution with sterile PBS (0.1 M, pH7.4) and the PBS was prepared 
by adding one tablet of PBS in 200 ml H2O to give a final concentration of 0.1 M with 
pH7.4, then sterilised by autoclaving. Additionally, in all the experiments PBS 
concentration 0.1 M, pH7.4 was used for washing the adherent cells prior to detaching 
them by the trypsin, diluting cell suspensions for uptake, and cell cycle experiments. In 
the case of BTNW911, HBSS 1x (pH 7.4) and 1x TrypLE™ ready to use as advised by the 
supplier was used for washing and dissociation, respectively.  
4.4.1.3. Agarose preparation and plate coating 
For the spheroid formation, the agarose coating method was used. A 1 % agarose solution 
was prepared by dissolving 1 g of agarose in 100 ml sterile PBS solution (1 % w/v), and 




stored at room temperature until used. The 1% agarose solution was heated again and a 
50 µl were placed in each 96/well/ tissue culture plates in a sterile laminar flow hood and 
kept inside the hood for 3 h. The plates were sealed using parafilm and covered with 
aluminium foil to protect from light and kept at 4 °C overnight prior to use the following 
day (Garanti 2016). 
4.4.1.4. Coating coverslips with fibronectin 
For the qualitative internalisation study coverslips pre-sterilised with 70 % IMS, were also 
autoclaved, washed with HBSS and placed in 12 well tissue culture plates. For each well, 
5 µg/ml fibronectin diluted with HBSS was added on top of the coverslip and incubated 
for 24 h in a humidified incubator under 5 % CO2 atmosphere. Then prior to the seeding 
day the excess fibronectin was removed by washing the coverslips two times with 1 ml of 
sterile PBS.  
4.4.2. Cell lines thawing 
The cryovial containing the frozen cells were removed from liquid nitrogen storage and 
thawed immediately by gently swirling the vial in a 37° C water bath, for less than 1 
minute. The thawed cells were transferred to a centrifuge tube containing 1 ml (1:1, ratio 
media: cells) of pre-warmed complete growth medium appropriate for each cell line. The 
cell suspension was centrifuged at room temperature at 179 x g for 5 min. The 
supernatant was removed gently without disturbing the cell pellet. The cells were 
resuspended in 10 ml complete growth medium appropriate for each cell line in T75 
flasks, or 5 ml media for T25 flasks. Moreover, all flasks were then placed at 37 °C in a 
humidified incubator under 5 % CO2 atmosphere and cultured until 75-80 % confluent.  
4.4.3. Cell lines sub-culturing  
At 75-80 % confluency, the media were aspirated from each flask and the monolayer cells 
were gently washed with 2 ml PBS (0.1 M, pH7.4), then the PBS discarded. This was 
followed by adding 2 ml pre-warmed trypsin, incubating the flasks at 37 °C for less than 5 
min until the detached cells were observed under the microscope. Flasks were placed 
back into the laminar flow hood and 2 ml of complete growth media was added. The cell 
suspension was transferred to a 15 ml tube and centrifuged at room temperature at 179 
x g for 5 min. The cell pellet was resuspended in complete growth medium and an 
appropriate volume was transferred into new cell culture flasks depending on the split 
ratio/cell concentration required. For each of U87MG, SVG P12, and BTNW911 cell lines 
were split into (1:3, 1:3, and 1:2) ratio, respectively. All new flasks were labelled with cell 




4.4.4. Cell count and viability assessment   
Cell counting was performed after the protocol in section 4.4.3.  After the cell pellet was 
resuspended in media, a 50 µl cell suspension was transferred into 1.5 ml tube 
(Eppendorf), and 50 µl of trypan blue was added and mixed. Then 10 µl of the mixture 
were added on a hemocytometer then covered with a coverslip. A viable cell count was 
performed at 10 X magnification under the light microscope by counting the cells that 
looked bright and colourless and excluding the dead cells that had taken up the trypan 
blue dye, (dark blue appearance) (Louis and Siegel, 2011). The haemocytometer consists 
of 9 large squares with 1 mm length, and four squares were used to count the viable cells, 
and an average was calculated then multiplied by dilution factor and the haemocytometer 
factor 1 x104 to obtain the number of cells per 1 ml of suspension. Cells were seeded in 
different densities depending on the intended use and purpose of the experiment. 
4.4.5. Cell line growth kinetics  
To study the growth pattern of the immortalised (U87MG, SVG P12) and patient-derived 
short-term (BTNW911) cell lines, cell count versus time was determined using Presto 
Blue® dye. Cells were seeded at a density of 500, 1000, 2500, 5000 and 10000 cells/ 90 µl 
well in a 96 well tissue culture plate and cultured at 37 °C and 5 % CO2 in a humidified 
incubator. Every 24 h, for four days, cells were stained with 10 µl Presto Blue ® dye and 
counted using a plate reader (section 4.3.1). For every time point, an average cell count 
from six wells was calculated up to four days because no experiment would last longer 
than this. The growth medium was changed every other day to maintain cells in a healthy 
environment. 
4.4.6. Spheroids formation  
Using the method of Garanti et al., (2016), U87MG were grown into spheroids by seeding 
3 x 103 cells/100 µL in 96-well tissue culture plates that were pre-coated with 1% sterile 
agarose (refer to section 4.4.1.3), then 100 µl of complete EMEM media was added gently 
and dropwise to each well (to give a total volume of 200 µl).  The plates were then 
transferred to a humidified incubator at 37 °C and 5 % CO2 and were incubated for four 
days until the spheroids formation was complete. The spheroid formation was confirmed 





4.4.7. Cell proliferation evaluation  
To determine the effect of DTX, B-NLC, DTX-NLC, GLA-DTX-NLC, ALA-DTX-NLC and SA43-
DTX-NLC on U87MG, SVG P12, BTNW911 monolayers cells and U87MG spheroids, cell 
proliferation was assessed by using Presto Blue® viability reagent; this protocol was 
adapted from Thakor et al., 2017. 
4.4.7.1. Cell proliferation evaluation of docetaxel-loaded nanostructured 
lipid carriers (DTX-NLCs) in monolayer cell lines 
Cells were seeded at a density of 2500 cells/90 µl/well for U87MG and SVG P12, and 5000 
cells/90 µl/well in a 96-well plate for BTNW911. The monolayer cell lines were then 
cultured for 24 hours prior to drug treatment at concentrations 2.5, 5, 10, 25, 50, 100, 
250, 500, 1000 ng/ml from each of the formulation. Media without any cells was used as 
a blank and cells and media without a drug were used as a control. Presto Blue® was used 
to perform the proliferation assay by adding 10 µl/well of Presto Blue at 24, 48 and 72 h, 
after drug treatment. All plates were covered with aluminium foil and transferred to the 
incubator for 1 h incubation in a humidified incubator at 37 °C and 5 % CO2, then the plate 
reader was used for detection of fluorescence response for Presto Blue at an excitation 
wavelength of 535 nm and an emission wavelength of 612nm. This experiment was 
repeated three times and cell proliferation that is corresponding to cell viability was 
calculated using equation 4.1.  
% 𝑪𝒆𝒍𝒍 𝑽𝒊𝒂𝒃𝒊𝒍𝒊𝒕𝒚 =  [
(𝑭𝒍𝒖𝒐𝒓. 𝑫𝒓𝒖𝒈 𝑻𝒓𝒆𝒂𝒕𝒎𝒆𝒏𝒕 − 𝑭𝒍𝒖𝒐𝒓. 𝑩𝒍𝒂𝒏𝒌)
(𝑭𝒍𝒖𝒐𝒓. 𝑪𝒐𝒏𝒕𝒓𝒐𝒍 − 𝑭𝒍𝒖𝒐𝒓. 𝑩𝒍𝒂𝒏𝒌)
] × 𝟏𝟎𝟎 
 
 (Equation 4.1) 
 
Mean cell viability versus drug concentration was plotted using the Prism5 software 
(GraphPad Software, USA). The concentration at which 50 % inhibition (decrease in cell 
proliferation) was achieved (IC50 value) was calculated for all tested formulations. 
4.4.7.1.1. Cell proliferation evaluation of PUFA tagged docetaxel-loaded 
nanostructured lipid carriers 
Two PUFAs (GLA and ALA) were examined as ligands for surface modification of DTX-NLCs 




4.4.7.1.1.1. Cell proliferation evaluation of nanostructured lipid carriers 
composed of antioxidants and surface modified with PUFAs 
A combination of two antioxidants Ascorbyl palmitate (AP) and α-Tocopherol (Vit. E) were 
used (0.05%, w/v of AP+ 0.02%, w/v of Vit. E), during the fabrication of DTX-NLC, which 
was then functionalised with GLA and ALA in two ratios  1:1/5 and 1:1/6 (FAG: PUFAs) as 
detailed in Chapter Three (sections 3.4.2, 3.5.6.1.1, and 3.5.6.2.1). The cell proliferation 
assay was performed on U87MG and SVG P12 monolayers for the same range of 
concentrations and incubation time detailed in section 4.4.7.1, to evaluate the presence 
of antioxidants effect on the cell line when treated with DTX-NLCs, GLA-DTX-NLC, and ALA-
DTX-NLC formulated with the antioxidant combination. This was measured by the Presto 
Blue® assay and a percentage of mean cell viability was calculated as per equation 4.1, 
followed by measuring IC50 values for all tested formulations.  
4.4.7.1.1.2. Cell proliferation evaluation of nanostructured lipid carriers 
composed of variable ratios of PUFAs as ligands 
GLA-DTX-NLC and ALA-DTX-NLC were prepared with varied ligand density of PUFAs as 
detailed in Chapter Three (sections 3.4.2, 3.5.6.1, and 3.5.6.2) and only two ratios  1:1/5 
and 1:1/6 (FAG: PUFAs) were selected for cell proliferation studies with U87MG and SVG 
P12 cells following the same protocol, range of concentrations and incubation time as 
detailed in section 4.4.7.1. Cell proliferation was measured using Presto Blue® assay and 
a percentage of mean cell viability was calculated as per equation 4.1, followed by 
determination of  IC50 values for all the tested formulations.  
4.4.7.1.2. Cell proliferation after treatment with aptamer tagged docetaxel-
loaded nanostructured lipid carriers 
SA43-aptamer was surface modified with DTX-NLC as detailed in Chapter Three (sections 
3.4.3 and 3.5.7) and the ratio of 1:1/8 (FAG: SA43) was chosen to perform cell proliferation 
test with monolayer cell lines. Following the same protocol, the range of concentrations 
and incubation time as detailed in section 4.4.7.1. Cell proliferation was measured using 
Presto Blue® assay and a percentage of mean cell viability was calculated as per equation 
4.1, followed by measuring IC50 values for the tested formulation. 
4.4.7.2. Cell proliferation evaluation of docetaxel-loaded nanostructured 
lipid carriers in U87MG spheroids  
For the proliferation evaluation of the U87MG spheroids, a 3000 cells/90 µl/well in a 96-
well plate were seeded as described in section 4.4.6. The U87MG spheroids were treated 




the treatment for 72 h for the same range of concentrations mentioned in section 4.4.7.1, 
then the spheroids were transferred gently into a new 96 well plate (the plates were not 
coated with agarose at this stage), with 90 µl media. After that, cell proliferation was 
determined as described in section 4.4.7.1.  
4.4.8. Qualitative Cellular internalisation study 
The mechanism of cellular internalisation for entry of fluorescence-labelled DTX-NLCs 
with Rhodamine 123 (R) prepared as described in chapter three section 3.4.1 was 
determined. R-DTX-NLC, R-GLA-DTX-NLC, R-ALA-DTX-NLC and R-SA43-DTX-NLC were 
evaluated in U87MG and SVG P12 cells, this method was adopted and modified from 
Garanti et al., (2016). When cells reached 75-80% confluency they were seeded at 2.5x105 
/well/1 ml on a sterile pre-coated coverslip prepared as described in section 4.4.1.4. The 
coverslips were placed in a 12-well plate and transferred to a humidified incubator at 37 
°C and 5 % CO2 and incubated for 24 h. The plates containing the adherent monolayer 
cells (seeded on the coverslips) were removed from the incubator and washed twice with 
1 ml/well pre-warmed PBS (0.1 M, pH7.4) followed by addition of 1 µg/ml formulations 
diluted with media (R-DTX-NLC, R-GLA-DTX-NLC, R-ALA-DTX-NLC and R-SA43-DTX-NLC), 
and incubated for 2 and 4 h, respectively. The media containing the formulations were 
aspirated from each well and washed three times with PBS to remove the NLCs that had 
not been taken up by the cells. Cells were then fixed by adding 1 ml of 4% 
paraformaldehyde (PFD) diluted with PBS (1:4 ratio, v/v) and then the plates were 
incubated at room temperature for 20 min. The PFD was removed, and each well was 
washed three times with PBS. Finally, mounting medium containing DAPI was used to 
stain the nucleus by placing one drop of mounting medium containing DAPI on the 
microscope slide and the coverslips containing the cells were placed facing down on the 
slide. The slides were sealed with transparent nail polish and stored at 4 °C in a slide box 
for up to 12 h. Images were captured with the Zeiss fluorescence microscope in a 63x 
magnification with an oil lens. 
4.4.9. Quantitative uptake study 
The quantitative uptake studies were performed on U87MG, SVG P12, and BTNW911 
monolayer cell lines. Additionally, U87MG spheroids were evaluated for NLCs uptake. The 
flow cytometer was used to carry out these experiments. Formulations were labelled with 
R123 (R-DTX-NLC, R-GLA-DTX-NLC, R-ALA-DTX-NLC and R-SA43-DTX-NLC) as described in 
chapter three section 3.4.1. After a series of optimisations steps, the cell density was 
adjusted in this study to give no more than 500 cells/1 µl during the analysis. The acquired 




samples were placed in a V-shaped, non-tissue culture 96 well plate. Non treated cells 
were used as a control:  
4.4.9.1. Time-dependent uptake 
The U87MG and SVG P12 were seeded in a 12 well tissue culture plate once they reached 
a confluencey of 75-80%. The seeding densities were optimised through several steps and 
a final density of 150000/1 ml/well and 180000/1 ml/well, respectively, it was used during 
this experiment. The plates were incubated for 24 h in a humidified incubator at 37 °C and 
5 % CO2 then media was aspirated and replaced with 1 µg/ml of each of the formulation 
(R-DTX-NLC, R-GLA-DTX-NLC, and R-ALA-DTX-NLC) diluted with media and the plates were 
placed back in the incubator for a time-dependent course study (0.5, 1, 2,4, 6, and 24 h). 
Following each designated time point the plates were removed from the incubator, and 
the formulation diluted with media was aspirated gently then each well was washed three 
times with 1 ml sterile PBS, and then cells were detached by adding 0.5 ml trypsin and 
placed back into the incubator. After the trypsinisation step, 0.5 ml media was added to 
each well, and the cell suspension was placed in a centrifuge tube and centrifuged at 179 
x g for 5 min. The supernatant was removed, and the cell pellet resuspended with 0.3 ice-
cold PBS. Each sample was placed in a V-shaped, non-tissue culture 96 well plates then a 
30 µl of PI (50 µg/ml stock) was added prior to the analysis and each plate was placed in 
the flow cytometer, the same settings described in section 4.4.9. were followed. Data 
were expressed by plotting mean fluorescence intensity versus time. 
For the BTNW911 cells, a seeding density of 180000/1m/well was used during uptake 
study,  and one-time point 6 h was chosen to evaluate labelled formulation with 1 µg/ml 
R123 (R-DTX-NLC, R-GLA-DTX-NLC, R-ALA-DTX-NLC and R-SA43-DTX-NLC) and the same 
protocol as described above was followed.  
4.4.9.2. Concentration-dependent uptake  
Concentration-dependent uptake of R-DTX-NLC, R-GLA-DTX-NLC, R-ALA-DTX-NLC and R-
SA43-DTX-NLC by U87MG and SVG P12 cells was assessed at four concentrations 1, 2, 3, 
and 5 µg/ml at 6 h following the protocol described in section 4.4.9.1. 
4.4.9.3. 3D tumour spheroids uptake  
Spheroids uptake analysis was performed by adopting and modifying a protocol proposed 
by Garanti et al., (2016). On the fourth day, after the spheroids were formed properly as 
described in section 4.4.6, spheroids were treated with 200 µg/ 200 µl of the labelled 




incubated for 6 h. Following the incubation period, the spheroids were harvested and 
placed in a 15 ml centrifuge tube and washed three times with 1 ml sterile PBS, then 0.75 
ml of AccuMax® cell dissociation solution was added to the tubes and incubated at 37 °C 
for 30 min, to allow proper dissociation of the spheroids.  All tubes were then centrifuged 
for 5 min at 179 x g and the cells resuspended in 0.3 ml ice-cold PBS and spheroids uptake 
was performed following the same protocol described in section 4.4.9.1.  
4.4.10. Quantitative and qualitative endocytosis pathways analysis 
Following the similar protocol mentioned in section 4.4.9.1. for seeding density and 
analysis U87MG and SVG P12 were exposed to different endocytosis inhibitors diluted 
with media as follows: 4° C used for energy-dependent endocytosis, 0.45 M sucrose used 
for clathrin pathway, 5 µg/ml cytochalasin B used for micropinocytosis/phagocytosis, and 
5 µg/ml nystatin used caveolae/ lipid rafts pathway for 90 min. Media containing 
endocytic inhibitors was removed and replaced with 1 µg/ml R123-labelled formulations 
(R-DTX-NLC, R-GLA-DTX-NLC, R-ALA-DTX-NLC and R-SA43-DTX-NLC) diluted with media 
plus the three mentioned inhibitors and then incubated for a further 4 h except for 
samples stored at the 4° C. This method was adopted and modified from Doherty and 
McMahon (2009) and Sahay et al., (2010). Samples were then prepared and analysed for 
internalisation and selective uptake as described in section 4.4.8. and 4.4.9. respectively. 
4.4.11. Cell cycle analysis  
U87MG cell cycle analyses were performed by propidium iodide (PI) staining to evaluate 
the DTX, DTX-NLC, GLA-DTX-NLC, ALA-DTX-NLC, and SA43-DTX-NLC effect on U87MG cell 
cycle. Following the optimisation process, the cells were seeded at a density 50000/well 
in sterile 12 well tissue culture plates, then placed in a humidified incubator at 37 °C and 
5 % CO2 for 24 h. Media was aspirated from each well and 1 ml of each sample diluted 
with media were placed in the well. The plates were then incubated for 24 h with the 
treatments in a humidified incubator at 37 °C and 5 % CO2. Following the treatment 
period, the wells were washed with 1 ml PBS and detached with 0.5 ml trypsin, then 
incubated in a humidified incubator. The trypsin was neutralised with 0.5 ml media and 
the cell suspension was collected from each well and placed in a 15 ml centrifuge tube, 
and centrifuged at 179 x g for 5 min. The supernatant was removed and the cell pellets 
were resuspended and fixed by adding 6 ml of ice-cold 70% ethanol (diluted with PBS) 
dropwise, whilst vortexing to prevent clumping. Then the tubes were stored at -20oC for 
at least at least 24 h. Following the storage period, the fixed samples were centrifuged at 
179 x g for 5 min and washed once by adding 1 ml of ice-cold PBS to each tube, then 




and a 0.225 ml of the fixed cell suspension was transferred to a non-tissue culture 96 well 
plate/ V-shaped, then 22.5 µl of PI concentration (500µg/ml stock) was added to each well 
followed by 2.5 µl of RNAase (10 mg/ml stock) and incubated for 2 h at 37o C and 5 % CO2. 
All plates were processed by using flow cytometry and Guava software for data analysis 
to determine DNA content by fluorescence intensity (488 nm) for each treated 
population. 
4.4.12. Statistical data analysis 
The statistical analysis was performed using the Kolmornov-Smirnov test for normality 
followed by ANOVA (with post-hoc analysis Tukey and Dunnett test) and independent-
samples T test (SPSS, IBM software). The analysis of variance was statistically significant 
difference when (*) P < 0.05 (95% confidence), (**) P < 0.001 (99% confidence), and  (***) 
P < 0.000. The data are presented as the mean ± standard deviation for N=3 experiments 
























4.5. Results and discussion  
4.5.1. Cell line growth kinetics  
To study the growth behaviour of SVG P12, U87MG, and BTNW911, cells were seeded and 
counted with respect to time, to establish the lag phase, log (exponential) phase and a 
plateau phase. This experiment was done using Presto Blue dye® for determining the cells 
number. The exponential phase is where the cell undergoes mitosis and multiply 
exponentially (Mather and Roberts 1998).  
It is essential to study the cell behaviour in the exponential phase (Mather and Roberts 
1998) since data from the exponential phase will give an indication when the cells should 
be treated with the drug of interest. In our case cells were seeded in 2500 cell/90 µl/ well 
for both U87MG and SVG P12 and 5000 cells/ 90 µl/well for BTNW911 cell lines to ensure 
that cells were in exponential phase within 24 h of seeding, as this was when drug 
treatment would commence. Cells were then treated with DTX, B-NLC, DTX-NLC, GLA-
DTX-NLC, ALA-DTX-NLC and SA43-DTX-NLC during the course of the in-vitro evaluation. 
For the analysis of growth kinetics, when cells were seeded at less than 2500 cells/ 90 µl/ 
well, the lag phase lasted until day 3 (Appendix II). To ensure that cells were in the 
exponential growth phase within 24 h of seeding, as required for the DTX-NLCs treatment 
experiments, seeding densities of 2500 cells/ 90µl/ well were chosen for U87MG 
(Appendix II), SVG P12 (Appendix II)  and 5000 cells/ 90µl/ well for BTNW 911 (Appendix 
II), which had slower growth kinetics. The double time for U87MG and SVG P12 was found 
to be approximately 45 h and 50 h respectively, which is in rough agreement with 
commercial specifications and previous reports (Aptekar et al., 2015). A slightly slower 
doubling time of 55 h for BTNW911 was as expected for a short-term primary derived 
culture (Kumar et al., 2014).  
Additionally, the morphology of U87MG, SVG P12, and BTNW911 were observed under a 
light microscope during the study of growth patterns at 10 X magnification as shown in 
figures 4.2 a, b, and c respectively after 3 days of incubation. The data showed that 
U87MG and SVG P12 cell lines were more confluent than BTNW911 as primary cell lines 







Figure 4.2 Images of monolayer cell lines under the microscope (a) U87MG cell line; (b) 
SVG P12 cell line, (c) Primary BTNW911 cell line. 
 
 
4.5.2. Cell proliferation evaluation  
Cell proliferation following treatment with DTX, B-NLC, DTX-NLC, GLA-DTX-NLC, ALA-DTX-
NLC and SA43-DTX-NLC was studied in U87MG, SVG P12, and BTNW911 cells. The data for 
the IC50 values are listed in tables 4.1, 4.2, 4.3, 4.4, 4.5, and 4.6. In all cases, the potency 
of DTX-NLCs and surface modified DTX-NLCs treatments were compared to the potency 
of standard treatment docetaxel alone. 
4.5.2.1. Cell proliferation after treatment with docetaxel-loaded 
nanostructured lipid carriers  
DTX-NLC verses DTX 
DTX-NLC showed significantly higher IC50 values in U87MG than DTX, at 24 and 48 h 
incubation time (Figure 4.3 and Table 4.1). No significant difference in IC50 between DTX-
NLC and DTX alone was observed at 72 h which suggested that DTX-NLC was as cytotoxic 
as DTX alone, but there was a time-dependent delay to reach this equivalent effect, that 
might be attributed to the slow release of DTX from DTX-NLC at initial time in physiological 
pH7.4 as previously determined in Chapter three (section 3.5.10.2) where DTX-NLC 
released only 16 % of DTX at 8 h in comparison to the DTX solution which demonstrated 
30 % release under the same conditions. Additionally, the DTX-NLC PS might lead to 
increasing the distance between the surface and the lipid core of the NLCs as previously 
reported by Xu et al., (2009), since DTX is encapsulated within the NLCs, hence taking 
longer time for the DTX to be released from the NLCs lipid core.  
 A similar pattern of time-dependent toxicity effect was observed for the same treatments 
in SVG P12 (Figure 4.4) and BTNW 911 cells (Figure 4.5). The DTX-NLC  had less toxicity 
towards SVG P12 at 24 and 48 h incubation when compared to the DTX on SVG P12 at 




similar incubation times. No significant difference was encountered at 72 h incubation of 
DTX-NLC with the SVG P12 cells (Figure 4.4), that signified that early time points of 
incubation were less toxic to the non-cancerous cells.  
Our data demonstrated more efficacy towards U87MG cell line with lower IC50 value 
(24.37 ±0.74 ng/ml), and showed 33 folds reduction in IC50 at 48 h incubation with the 
treatment in comparison to previous literature reported by Singh et al., (2015) where their 
DTX-SLN gave an IC50 value of (0.792 ±0.03 µg/ml) when incubated for 48 h with U87MG 
cell lines. These results indicate the potential use of DTX-NLC in glioblastoma therapy; 
encapsulating DTX within the NLCs might also be beneficial for avoidance or reduced 
direct interaction with the blood cells and consequently decrease the DTX haematological 
toxicity (Feng and Mumper, 2013). 
Table 4.1 mean IC50 values for DTX, DTX-NLC, and B-NLC, in U87MG, SVG P12, and 
BTNW911 cell line at 24, 48, and 72 h. Data mean values ±SD, (N=3), and * p ˂0.05, ** p 
˂ 0.001 and *** p ˂ 0.000 refers to the significant difference when all formulations 
















































BTNW911 24 95.16 
±4.95 
N/A N/A 











Duration of incubation 
When comparing the effect of duration of incubation of DTX and DTX-NLC treatments on 
IC50, in all cases (except SVG P12, 48 h when treated with DTX), the IC50 values decreased 






Above a certain concentration, the blank nanostructured lipid carrier was found to cause 
a significant decrease in cell proliferation as compared to the non-drug treated control 
cells which occurred at 0.012 % for 24 h and 0.12 % for 48 h incubation. When the original 
nanoparticle stock solution was diluted with media up to 99.98 and 99.88 %, respectively 
for U87MG cells treated with B-NLC, and all tested B-NLC concentrations were considered 
safe at 72 h incubation. Similarly, SVG P12 and BYNW911 demonstrated the notable effect 
at 24 h incubation (0.012 %) and both 48 and 72 h incubation with B-NLC were considered 
fairly safe for all examined concentrations. This information enabled us to ensure that all 
nanoparticle suspensions need to be diluted at least with 99.98 % media to ensure that 
all cell proliferation changes were related to the release of docetaxel, and since further 
dilution of DTX-NLC more than 99.98 % was reducing the cell proliferation, so this effect 
was considered due to DTX present in the NLCs and not due to B-NLC excipients.  
The B-NLC showed a highly significant increase in IC50 values when compared to the DTX 
IC50 values at similar incubation times towards U87MG cell line at all time points, and 
undetectable cell toxicity when SVG P12 and BTNW911 cell lines were treated with B-NLC 
within the studied concentrations, indicating the empty nanostructured lipid carrier had 
significantly less cytotoxicity (high cell proliferation) compared to the DTX treatment 
alone.  
SVG P12 verses U87MG/ BTNW 911 
To assess the IC50 values between U87MG or BTNW911 and SVG P12 of DTX and  DTX-NLC 
at 72 h revealed that significant increase in IC50 of BTNW911 in comparison to IC50 values 
of SVG P12 when both cell lines treated with DTX at 72 h (p ˂0.05), and no significant 
effect in IC50 (potency) in U87MG cells compared to SVG P12 cells when treated with DTX 
at 72 h. Similarly, no significant difference in IC50 of U87MG and BTNW911 cell lines was 
observed. Interestingly, there seemed to be less efficient (2.1 % difference)  in the short-
term primary derived cultures (BTNW911) as compared to the U87MG cells, indicating 
that there are differences in the cell models that warrant further investigation. 
Additionally, a significant increase in IC50 value at 72 h incubation with DTX-NLC in 
comparison to the IC50 values of SVG P12 and U87MG cell lines (p ˂0.001) was observed, 
suggesting more resistance to treatment in case of patient-derived cells BTNW911. A 
higher concentration or longer incubation time of DTX-NLC might be worth to try. An 
equal potency of DTX-NLC was observed towards both U87MG and SVG P12 due to no 


























































































Figure 4.3 Mean percentage cell viability relative to control cells with no drug treatment 
for DTX, DTX-NLC, and B-NLC when incubated with U87MG cell line at (a) 24, (b) 48, and 
(c) 72 h. Data mean values ±SD, (N=3), and all formulations were compared to standard 






































































































Figure 4.4 Mean percentage cell viability for DTX, DTX-NLC, and B-NLC when incubated 
with SVG P12 cell line at (a) 24, (b) 48, and (c) 72 h. Data mean values ±SD, (N=3), and 











































































































Figure 4.5 Mean percentage cell viability for DTX, DTX-NLC, and B-NLC when incubated 
with BTNW911 cell line at (a) 24, (b) 48, and (c) 72 h. Data mean values ±SD, (N=3), and 






















4.5.2.2. Cell proliferation after treatment with PUFAs tagged docetaxel-
loaded nanostructured lipid carriers 
DTX-NLC was prepared with presence and absence of antioxidant combination (Vit E and 
AP) to preserve the surface modified DTX-NLC with PUFAs (GLA-DTX-NLC and ALA-DTX-
NLC) from oxidation and to evaluate the effect of the presence of antioxidants in the 
formulation on cell proliferation. GLA-DTX-NLC and ALA-DTX-NLC with variable ratios of 
GLA and ALA were evaluated. 
4.5.2.2.1. Cell proliferation after treatment with nanostructured lipid carriers 
composed of antioxidants and surface modified with PUFAs 
DTX-NLCs were first evaluated for their effect on cell proliferation prior to the surface 
modification with PUFAs. 
DTX-NLC with and without antioxidants verses DTX 
A delayed effect on cell proliferation was noted when DTX-NLC were prepared with 
antioxidants on both U87MG and SVG P12 cells (Table 4.2) especially at initial incubation 
time in comparison to DTX and DTX-NLC (without antioxidants). No IC50 values could be 
determined at 24 h incubation, and a highly significant increase in IC50 at 48 h followed by 
similar potency to DTX at 72 h incubation was observed for, DTX-NLC (with antioxidants) 
indicating that the formulations with antioxidants might exhibit longer time to release 
DTX, and the antioxidants acted as a barrier that caused a delayed effect on cell 
proliferation. Similar behaviour was observed with SVG P12 cells treatment (Table 4.2).  
Table 4.2 Mean IC50 values for DTX and DTX-NLC (prepared with and without 
antioxidants combination) in U87MG and SVG P12 following 24, 48, and 72 h 
incubations. Data mean values ±SD, (N=3). * p ˂ 0.05 and   *** p ˂ 0.000 refers to the 











Without antioxidants  
U87MG 24 7.22 
±0.84 
N/A 32.44  
*** 
±2.72 




































GLA-DTX-NLCs verses DTX 
Two ratios of GLA (1:1/5 and 1:1/6, FAG: GLA) were used to prepare GLA-DTX-NLCs (DTX-
NLCs were prepared with antioxidants prior to surface modification). Table 4.3 
summarises the effect of the IC50 values. Both GLA-DTX-NLCs displayed a time-dependent 
increase in toxicity towards U87MG, with low potency towards U87MG (high IC50) 
observed at 24 h incubation in comparison to DTX, followed by similar cytotoxicity effect 
for both ratios as the DTX effect at 48 and 72 h incubation. It is worth noting that GLA-
DTX-NLC displayed more potency than DTX-NLC at 24 and 48 h incubation as indicated by 
low IC50 values (Tables 4.2 and 4.3). GLA has been previously reported for its tumoricidal 
effect towards U87MG cell lines (Leaver et al., 2002b). It was reported by Das (2004) that 
antioxidants especially Vit E might block the tumoricidal effect of the PUFAs (GLA and ALA) 
as it functions as a lipid peroxidase inhibitor (blocking the PUFAs mechanisms of action), 
and consequently decrease the inhibitory effect of the PUFAs in-vitro (Das 2004; 
Menendez et al., 2001). Thus, similar ratios of GLA-DTX-NLCs were examined towards 
U87MG and SVG P12 when DTX-NLCs were not incorporated with antioxidants (section 
4.5.2.2.2).  
Table 4.3 Mean IC50 values for formulations prepared with antioxidants combination 
GLA-DTX-NLC (1:1/5), GLA-DTX-NLC (1:1/6), ALA-DTX-NLC (1:1/5), and ALA-DTX-NLC 
(1:1/6) in U87MG following 24, 48, and 72 h incubations. Data mean values ±SD, (N=3). 
* p ˂ 0.05 and   *** p ˂ 0.000 refers to the significant difference when all formulations 















































ALA-DTX-NLC verses DTX 
Like GLA, ALA was studied in two ratios (1:1/5 and 1:1/6, FAG: ALA), were used to prepare 
ALA-DTX-NLCs (DTX-NLCs were prepared with antioxidants prior to surface modification). A 
higher ratio of FAG: ALA (1:1/5) in the ALA-DTX-NLC exhibited a similar effect on U87MG 
proliferation as the DTX at 48 and 72 h, while lower ratio demonstrated a delayed effect 




surface modification) or due to ligand density. Previous reports have shown that an 
intermediate ligand density provided a statistically significant improvement in cell binding in 
comparison with higher and lower ligand densities in nanoparticles (Elias et al., 2013). 
Overall, it was decided not to continue with the fabrication of DTX-NLCs in the presence of 
antioxidants for PUFAs functionalisation and rather carry out the process in the environment 
of nitrogen, as the presence of antioxidants increased the IC50 values 
4.5.2.2.2. Cell proliferation after treatment with nanostructured lipid carriers 
composed of variable ratios of PUFAs 
DTX-NLCs were prepared and surface modified with variable ratios of PUFAs (GLA and 
ALA). No antioxidants were used, instead, the entire process of surface functionalisation 
was carried out under a nitrogen environment to protect GLA-DTX-NLC and ALA-DTX-NLC 
from oxidation and their effect on cell proliferation was evaluated.  
GLA-DTX-NLC verses DTX 
The GLA-DTX-NLC with high ligand density (1:1/5 FAG: GLA ratio) demonstrated good 
efficacy with low cell proliferation of U87MG  cells as indicated by similar IC50 values to 
DTX alone at all time points (Figure 4.6 and Table 4.4). Low ligand density GLA-DTX-NLC 
(1:1/6 FAG: GLA ratio) exhibited a significant increase in IC50 at 24 h incubation,  followed 
by similar activity as DTX and GLA-DTX-NLC (1:1/5 FAG: GLA ratio) at 48 and 72 h 
incubation (Table 4.4). Lower cell toxicity was observed against the SVG P12 at 24 and 48 
h incubation when the data was compared with the DTX at similar time points (Figure 4.7) 
as revealed by significant increase in IC50 values at incubation time of 24 and 48 h, while 
no significant effect could be seen at 72 h incubation time when data were compared with 
the DTX IC50 values at similar incubation time points. Notably lower ligand density (1:1/6 
FAG: GLA ratio)  of GLA-DTX-NLC  demonstrated low activity towards SVG P12 owing to 
the significant increase in IC50 values at all time point when compared with DTX alone  
(Table 4.4). This is in line with previous reports which have shown that PUFAs have a 
limited effect on normal cells and high cytotoxicity towards cancerous cell lines (Horia and 
Watkins 2005). High ligand concentration can lead to efficient binding to the target 
because of high avidity (Cao et al., 2018; Elias et al., 2013). Therefore, GLA-DTX-NLC with 
high ligand density (1:1/5 FAG: GLA ratio) which has not only displayed good activity but 
also has low PS and fairly uniform particle size distribution (Section 3.5.6.1) was further 






Table 4.4 Mean IC50 values for GLA-DTX-NLC (1:1/5), GLA-DTX-NLC (1:1/6), ALA-DTX-NLC 
(1:1/5), and ALA-DTX-NLC (1:1/6) in U87MG and SVG P12 following 24, 48, and 72 h 
incubations. Data mean values ±SD, (N=3). * p ˂ 0.05 and   *** p ˂ 0.000 refers to the 


















































































ALA-DTX-NLC verses DTX 
It was interesting to note that IC50 values for ALA-DTX-NLC (1:1/6 FAG: ALA ratio) 
demonstrated no significant difference from DTX IC50 values when incubated at 24, 48, 
and 72 h, respectively (Figure 4.6). This suggested that low ligand density in case of ALA-
DTX-NLC was as effective as the DTX treatment alone in toxicity towards U87MG cells and 
the data did not seem to exhibit a time-dependent effect on the cytotoxicity. It has been 
reported earlier by Elias et al., (2013) that high ligand density does not always mean high 
binding to cells, thus it was important to evaluate variable ligand ratios. ALA-DTX-NLC 
(1:1/5 FAG: ALA ratio) exhibited less toxicity towards U87MG and SVP12 at 24 and 72 h of 
incubation (Table 4.4). In case of SVG P12, ALA-DTX-NLC (1:1/6 FAG: ALA ratio) was as 
effective as DTX alone (no significant difference in IC50) at 48 h and 72 h (Figure 4.7). 
Meanwhile, ALA-DTX-NLC (1:1/6 FAG: ALA ratio) showed a significant increase in IC50 value 
at 24 h when the SVG P12 cells were treated in comparison to the IC50 value of DTX at the 
same time point (Figure 4.7). This indicates the less favourable effect of the conjugation 
of ALA with DTX-NLC due to increased toxicity of ALA-DTX-NLC (1:1/6 FAG: ALA ratio) 
towards non-cancerous cells as demonstrated at 48 and 72 h of incubation with the 
treatment (Figure 4.7). Therefore, ALA-DTX-NLC (1:1/6 FAG: ALA ratio) was chosen for the 
further test with patient-derived cell line BTNW911 as it exhibited higher efficacy against 





BTNW911 versus GLA-DTX-NLC/ ALA-DTX-NLC 
For BTNW 911 cells, the ALA-DTX-NLC (1:1/6) was significantly more cytotoxic than DTX 
at 24 h and 48 h (significantly lower IC50), but at 72 h DTX was more effective (Figure 4.8 
and Table 4.5).  To our knowledge, the ALA surface modified NPs had not been tested 
before for the treatment of glioblastoma cells. ALA conjugated with Doxorubicin (DOX) 
have been reported in the literature for the treatment of breast cancer cell lines (MCF-7) 
by Huan et al., (2009), which were reported to show more cytotoxicity towards MCF-7 
cells than free DOX. Interestingly GLA-DTX-NLC (1:1/5 FAG: GLA ratio) exhibited 
significantly lower IC50 than DTX alone at 24 h and similar potency as DTX at 48 h, followed 
by less activity towards BTNW911 cell lines at 72 h when compared with DTX alone (Table 
4.5 and Figure 4.8). A delayed toxicity effect for the DTX alone, and sustained the desirable 
toxicity effect of both GLA-DTX-NLC and ALA-DTX-NLC was observed at all time point when 
treated with BTNW911 cells (Figure 4.8). This could be associated with cell resistance to 
some chemotherapeutic treatments. High activity of PUFAs towards BTNW911 cells might 
be attributed to the particular composition of PUFAs as it has been previously indicated 
that the certain fatty acids result in increased sensitivity to chemotherapy, especially in 
tumour lines that are resistant to chemotherapy, and cause high efficacy of cytotoxicity 
to a tumour (Horia and Watkins 2005). 
In the literature, GLA has been reported to have a tumoricidal effect towards glioblastoma 
cells with lower toxicity towards non-cancerous cells (Das 2007; Das 2004; Bakshi et al., 
2003), it was interesting for us to see similar results when GLA was conjugated with the 
DTX-NLC.  
 
Table 4.5 Mean IC50 values for GLA-DTX-NLC (1:1/5) and ALA-DTX-NLC (1:1/6) in 
BTNW911 following 24, 48, and 72 h incubations. Data mean values ±SD, (N=3). * p ˂ 
0.05 and *** p ˂ 0.000 refers to the significant difference when all formulations 





IC50 Values (ng/ml) 
DTX GLA-DTX-NLC (1:1/5) ALA-DTX-NLC (1:1/6) 























Overall, GLA-DTX-NLC and ALA-DTX-NLC displayed similar activity towards U87MG at 24 
h and highly significant low IC50 than DTX-NLC demonstrating their higher potency. 
ALA-DTX-NLC demonstrated higher potency than GLA-DTX-NLC when U87MG were 
treated for 48 h incubation, and both formulations displayed higher activity than DTX-NLC 
at 48 h. However, GLA-DTX-NLC and ALA-DTX-NLC exhibited similar activity towards 
U8MG at 72 h, as no significant difference in IC50 was observed.  
GLA-DTX-NLC and ALA-DTX-NLC displayed similar activity towards SVG P12 at 24 h due to 
no significant difference observed in IC50 values, though DTX-NLC demonstrated lower 
toxicity towards SVG P12 at 24 and 48 h. Interestingly, GLA-DTX-NLC exhibited less toxicity 
towards SVG P12 at 48 h than the ALA-DTX-NLC, as clearly observed by a significant 
increase in IC50 of GLA-DTX-NLC when compared to ALA-DTX-NLC. All the three 
formulations showed no significant effect on activity towards SVG P12 at 72 h.  
For BTNW911 cell lines, ALA-DTX-NLC displayed higher activity (significantly low IC50) than 
both DTX-NLC and GLA-DTX-NLC at all time points, and GLA-DTX-NLC exhibited more 
potency with significantly lower IC50 than DTX-NLC at all time points on treatment with 
BTNW911 cells. 
In summary, it was obvious that surface modification with both GLA and ALA increased 
the potency of the DTX-NLC as observed by a decrease in IC50 for every incubation 
regardless of duration and in every cell line. Also, the cell proliferation was reduced with 
increasing incubation time for all treatments.  
Since we obtained more potency with DTX-NLC when it was surface modified with PUFAs, 
therefore GLA-DTX-NLC (1:1/5 FAG: GLA ratio) and ALA-DTX-NLC (1:1/6 FAG: ALA ratio) 
were chosen for more detailed study for cellular internalisation, selective uptake, 
endocytosis pathway study and cell cycle analysis, to further investigate the effect of 



























































































Figure 4.6 Mean percentage cell viability for DTX, GLA-DTX-NLC, and ALA-DTX-NLC when 
incubated with U87MG cell line at (a) 24, (b) 48, and (c) 72 h. Data mean values ±SD, 













































































































Figure 4.7 Mean percentage cell viability for DTX, GLA-DTX-NLC, and ALA-DTX-NLC when 
incubated with SVG P12 cell line at (a) 24, (b) 48, and (c) 72 h. Data mean values ±SD, 












































































































Figure 4.8 Mean percentage cell viability for DTX, GLA-DTX-NLC, and ALA-DTX-NLC when 
incubated with BTNW911 cell line at (a) 24, (b) 48, and (c) 72 h. Data mean values ±SD, 





















4.5.2.3. Cell proliferation after treatment with aptamer tagged docetaxel-
loaded nanostructured lipid carriers 
SA43-DTX-NLC verses DTX 
Interestingly SA43-DTX-NLC exhibited significantly lower potency (higher IC50 values) as 
compared with DTX IC50 (Table 4.6) when incubated for 24, 48, and 72 h in U87MG cell 
lines (Figure 4.9). A similar observation was made for SVGp12 (Figure 4.10) and BTNW 911 
cells (Figure 4.11). In addition, it could be seen that conjugating the SA43 ligand to the 
DTX-NLC decreased potency in every cell line for nearly every duration of incubation. That 
might be attributed to the delayed release of DTX from the SA43-DTX-NLC. Though there 
are no previous reports on  SA43-aptamer conjugated NPs,  and our study is the first 
report on application of the SA43- aptamer as a ligand conjugated with DTX-NLC for 
selective glioblastoma therapy, previous reports on other aptamers conjugated to 
docetaxel-loaded NPs Chen et al., (2016), have shown a similar slow release of DTX from 
DTX-apt-NPs, owing to hydrophobic core and hydrophilic shell of the NPs acting as a 
barrier. Additionally, slow release of DTX from SA43-DTX-NLC could be due to low 
solubility, hence causing low toxicity or plausibly due to SA43-aptamer binding to the 
U87MG, resulting in slow diffusion of DTX into the cells. Aptekar et al., (2015) reported  
SA43-aptamer alone was not a therapeutic aptamer, but it displayed a selective uptake 
with differentiation between glioblastoma (U87MG) and non-cancerous cells (SVG P12), 
which is important for all anti-cancer treatments to exhibit a less or no toxicity towards 
the non-cancerous cells. Consequently, the SA43-DTX-NLC was further studied for cell 














Table 4.6 Mean IC50 values for SA43-DTX-NLC (1:1/8) in U87MG, SVG P12, and BTNW911 
following 24, 48, and 72 h incubations. Data mean values ±SD, (N=3). * p ˂ 0.05 and   *** 
p ˂ 0.000 refers to the significant difference when all formulations compared to the 


































BTNW911 24 95.16 
±4.95 
N/A 































































































Figure 4.9 Mean percentage cell viability for DTX and SA43-DTX-NLC when incubated 
with U87MG cell line at (a) 24, (b) 48, and (c) 72 h. Data mean values ±SD, (N=3), and all 









































































































Figure 4.10 Mean percentage cell viability for DTX and SA43-DTX-NLC when incubated 
with SVG P12 cell line at (a) 24, (b) 48, and (c) 72 h. Data mean values ±SD, (N=3), and 










































































































Figure 4.11 Mean percentage cell viability for DTX and SA43-DTX-NLC when incubated 
with BNTW911 cell line at (a) 24, (b) 48, and (c) 72 h. Data mean values ±SD, (N=3), and 






















4.5.2.4. Cell proliferation evaluation in 3D U87MG spheroids  
A 3D tumour spheroid has been used as a tool to evaluate the NPs efficacy (Gao et al., 
2012). In this experiment, from a morphological point of view, when U87MG spheroids 
were treated with DTX there was no reduction in the spheroids size/dimension at all 
tested concentrations (Figure 4.12 a), spheroids diameter was ranging between 500-510 
µm, while the untreated spheroids were around 450-500 µm in diameter (Figure 4.12 a). 
When spheroids were treated with DTX-NLC they demonstrated a slight reduction in the 
spheroids diameter at higher concentration, around 490-350 µm (Figure 4.12 b), due to 
higher uptake of the NLCs as demonstrated by Gao et al., (2014b), that contributed to 
transport the capsulated DTX within the NLC to the core of spheroids, which in turn 
increases the growth-inhibition, and consequently reduces the U87MG spheroids 
diameter.  
 
Figure 4.12 showing U87MG spheroids morphology when treated at a range of 
concentration between 2.5-1000 ng/ml and incubated for 72 h. with (a) DTX, (b) DTX-
NLC. Data are N=3, and all formulations compared with the control untreated U87MG 
spheroids. 
 
In addition, a slight reduction was also encountered with the GLA-DTX-NLC treated 
spheroids ranging between 480-490 µm in diameter (Figure 4.13 a), and a higher 
reduction in diameter was notable when spheroids were treated with ALA-DTX-NLC as the 
spheroids diameters were ranging 380-450 µm (Figure 4.13 b) that might be attributed to 
the high inhibitory-growth effect of PUFAs especially GLA on glioblastoma spheroids as 
reported by Leaver et al., (2002).  
Control                  2.5 ng/ml                  5 ng/ml                     10 ng/ml                   25 ng/ml          
Control                   2.5 ng/ml                 5 ng/ml                    10 ng/ml                   25 ng/ml          
50 ng/ml                100 ng/ml                250 ng/ml                500 ng/ml                 1000 ng/ml 
 










Figure 4.13 showing U87MG spheroids morphology when treated at a range of 
concentration between 2.5-1000 ng/ml and incubated for 72 h. with (a) GLA-DTX-NLC, 
(b) ALA-DTX-NLC. Data are N=3, and all formulations compared with the control 
untreated U87MG spheroids. 
Finally, the U87MG spheroids that were treated with SA43-DTX-NL exhibited little 
reduction in the diameter. The spheroids diameter, in this case, was ranging between 490-
450 µm (Figure 4.14). 
 
 
Figure 4.14 showing U87MG spheroids morphology when treated at a range of 
concentration between 2.5-1000 ng/ml and incubated for 72 h. with SA43-DTX-NLC. 
Data are N=3, and all formulations compared with the control untreated U87MG 
spheroids. 
 
DTX-NLC showed higher efficacy (Figure 4.15 a) with a highly significant reduction in the 
IC50 value when compared to the DTX at 72 h incubation time (Table 4.7). This might be 
attributed to fact that DTX transportation to the spheroid core was extremely difficult as 
50 ng/ml                100 ng/ml                 250 ng/ml                500 ng/ml                1000 ng/ml 
 
50 ng/ml                 100 ng/ml                250 ng/ml                500 ng/ml                1000 ng/ml 
 
50 ng/ml                 100 ng/ml                250 ng/ml                500 ng/ml                1000 ng/ml 
 
Control                    2.5 ng/ml                 5 ng/ml                    10 ng/ml                    25 ng/ml          
 
Control                   2.5 ng/ml                 5 ng/ml                    10 ng/ml                   25 ng/ml          
 







previously demonstrated by Gao et al., (2014b). The direct contact of DTX with the 
spheroids, might harm the cells and cause cell death, which makes the transportation of 
DTX from the surface of dead cells to the core of tumour spheroid impossible (Gao et al., 
2014a). Therefore, the proposed encapsulation of DTX within the NLCs might be the 
reason for enhancing DTX-NLC uptake and consequently, DTX-NLC exhibited high potency 
and penetration in the spheroids core, as further demonstrated in section 4.5.4.3. 
Interestingly GLA-DTX-NLC demonstrated less toxicity towards U87MG spheroids, with a 
significant increase in IC50 when compared to DTX at similar incubation time. This might 
suggest that the DTX that was released from the GLA-DTX-NLC was taking a long time to 
reach the spheroids core resulting in slower penetration and causing less toxic action 
(Figure 4.15 b). While ALA-DTX-NLC and SA43-DTX-NLC exhibited no significant difference 
in toxicity towards U87MG spheroids when compared to DTX as shown in figures 4.15 c 
and d, and indicated in table 4.7. Both formulations were as toxic as the DTX alone, 
probably due to reaching of the released DTX from the formulations to the spheroids core 
at a similar rate as the DTX.  Cells on the surface of spheroids are likely to be killed quicker 
than the cells deeper in the spheroid Gao et al., (2014b). A longer incubation time with 
the treatments might be favourable, as different formulations are exhibiting a variable 
reaction when incubated with the spheroids due to drug taking a long time to penetrate 
the spheroid. Previous reports by Kim et al., (2010) demonstrated that penetration of 
doxorubicin a well known anti-cancer drug was limited to the periphery of the spheroids 
and could not diffuse through the spheroid more than the outer few cell layers.  
Table 4.7 Mean IC50 values for DTX, DTX-NLC, GLA-DTX-NLC, ALA-DTX-NLC, and SA43-
DTX-NLC in U87MG spheroids following 72 h incubation. Data mean values ±SD, (N=3), 
and *** p ˂ 0.000 refers to the significant difference when all formulations compared to 









































































Figure 4.15 Mean percentage cell viability for (a) DTX and DTX-NLC, (b) DTX and GLA-
DTX-NLC, (c) DTX and ALA-DTX-NLC, (d) DTX and SA43-DTX-NLC, and (e) % cell viability 
overlay of DTX, DTX-NLC, GLA-DTX-NLC, ALA-DTX-NLC, and SA43-DTX-NLC when 
incubated with U87MG spheroids cell line at 72 h. Data mean values ±SD, (N=3), and all 
formulations were compared to standard treatment docetaxel alone.    
 
4.5.3. Qualitative internalisation study 
Visualisation of the cellular internalisation of DTX-NLCs was studied for R-DTX-NLC and 
surface-modified R-DTX-NLC in U87MG glioblastomas and non-cancerous brain cells SVG 
P12 by incubating the cells with the proposed formulations for 2 and 4 h as described in 
section 4.4.8. Cells do not fluoresce, therefore observation of fluorescent dye was due to 









The internalisation study of the R-DTX-NLC was an important step to be able to visualise 
the delivered treatment and the localisation of the anti-cancer loaded NLCs within the 
cells. R-DTX-NLC demonstrated a high internalisation at both time points due to a high 
intensive green fluorescence colour mostly around the nucleus (stained with DAPI blue 
fluorescence dye) that referred to the R-DTX-NLC being internalised inside the U87MG 
cell line that was encapsulated with Rhodamine 123 (green fluorescence dye) (Figure 4.16 
b and c). While SVG P12 showed less intense green colour at both time points mostly in 
the cytoplasm, that might suggest a lower uptake of the R-DTX-NLC with the non-
cancerous cells (Figure 4.16 e and f), which was also indicated by a further quantitative 
study using the flow cytometer as detailed in section 4.5.4.1 (Figure 4.22). This finding is 
in agreement with previously published papers by Singh et al., (2015) and Martins et al., 
(2012) where lipidic NPs were evaluated with U87MG cell lines. Additionally, low particle 
size might play a role in the R-DTX-NLC uptake (R-DTX-NLC PS 136.8 nm), in collaboration 
with previous report Albanese et al., (2012) whereby, the particle size had a positive 
impact on cellular uptake of the free surface formulation.  
R-GLA-DTX-NLC 
When R-GLA-DTX-NLC was treated with both the cell lines, higher internalisation with 
U87MG cell lines was observed as compared to SVG P12, especially at 2 h incubation time 
(Figure 4.17 b). As previously reported, GLA alone demonstrated less uptake with the non-
cancerous cells (Das 2004), and consequently, it would show less internalisation (Figure 
4.17 e and f) when conjugated with our DTX-NLCs as our results suggested. Moreover, this 
data was in line with our finding from a quantitative study using the flow cytometer as 
detailed in section 4.5.4.1 (Figure 4.22).  
R-ALA-DTX-NLC 
Interestingly, R-ALA-DTX-NLC also displayed similar behaviour with both the cell lines 
(Figure 4.18) as the internalisation behaviour of R-DTX-NLC. It was proposed by Elsherbiny 
et al., (2013) that long chain fatty acids are transported inside the cells by intracellular 
lipid binding proteins named fatty acid binding protein (FABPs), which are present in most 
tissues, that might explain the higher internalisation of DTX-NLC conjugated with PUFAs.  
R-SA43-DTX-NLC 
R-SA43-DTX-NLC showed more selectivity towards the U87MG cell lines when compared 




reported by Aptekar et al., (2015) the SA43-aptamer selectively binds to Ku 70 and Ku 80 
and as a result of overexpression of Ku 70 and Ku 80 in cancer tissues which could serve 
as a useful strategy for targeting to glioblastoma cells. Thus, when the SA43-aptamer was 
conjugated to the R-DTX-NLC it enhanced its selectivity towards the glioblastoma U87MG 





Figure 4.16 Cellular internalisation, where the blue colour refers to the stained nucleus 
with a fluorescence dye (DAPI) and the green fluorescence dye refers to the R-DTX-NLC 
(Rhodamine 123 (R) loaded within the DTX-NLC). (a) U87MG control untreated cells only 
stained with DAPI, (b) U87MG incubated for 2 h with R-DTX-NLC and the nuclei were 
stained with DAPI, (c) U87MG incubated for 4 h with R-DTX-NLC and the nuclei were 
stained with DAPI, (d) SVG P12 control untreated cells only stained with DAPI. (e) SVG 
P12 incubated for 2 h with R-DTX-NLC and the nuclei were stained with DAPI, (f) SVG 
P12 incubated for 4 h with R-DTX-NLC and the nuclei were stained with DAPI. Data are 
N=3. 













Figure 4.17 Cellular internalisation, where the blue colour refers to the stained nucleus 
with a fluorescence dye (DAPI) and the green fluorescence dye refers to the R-GLA-DTX-
NLC (Rhodamine 123 (R) loaded within the DTX-NLC). (a) U87MG control untreated cells 
only stained with DAPI, (b) U87MG incubated for 2 h with R-GLA-DTX-NLC and the nuclei 
were stained with DAPI, (c) U87MG incubated for 4 h with R-GLA-DTX-NLC and the nuclei 
were stained with DAPI, (d) SVG P12 control untreated cells only stained with DAPI. ( e) 
SVG P12 incubated for 2 h with R-GLA-DTX-NLC and the nuclei were stained with DAPI, 
(f) SVG P12 incubated for 4 h with R-GLA-DTX-NLC and the nuclei were stained with DAPI. 
































   
 
             
 
Figure 4.18 Cellular internalisation, where the blue colour refers to the stained nucleus 
with a fluorescence dye (DAPI) and the green fluorescence dye refers to the R-ALA-DTX-
NLC (Rhodamine 123 (R) loaded within the DTX-NLC). (a) U87MG control untreated cells 
only stained with DAPI, (b) U87MG incubated for 2 h with R-ALA-DTX-NLC and the nuclei 
were stained with DAPI, (c) U87MG incubated for 4 h with R-ALA-DTX-NLC and the nuclei 
were stained with DAPI, (d) SVG P12 control untreated cells only stained with DAPI. ( e) 
SVG P12 incubated for 2 h with R-ALA-DTX-NLC and the nuclei were stained with DAPI, 
(f) SVG P12 incubated for 4 h with R-ALA-DTX-NLC and the nuclei were stained with DAPI. 

































Figure 4.19 Cellular internalisation, where the blue colour refers to the stained nucleus 
with a fluorescence dye (DAPI) and the green fluorescence dye refers to the R-SA43-DTX-
NLC (Rhodamine 123 (R) loaded within the DTX-NLC). (a) U87MG control untreated cells 
only stained with DAPI, (b) U87MG incubated for 2 h with R-SA43-DTX-NLC and the 
nuclei were stained with DAPI, (c) U87MG incubated for 4 h with R-SA43-DTX-NLC and 
the nuclei were stained with DAPI, (d) SVG P12 control untreated cells only stained with 
DAPI. (e) SVG P12 incubated for 2 h with R-SA43-DTX-NLC and the nuclei were stained 
with DAPI, (f) SVG P12 incubated for 4 h with R-SA43-DTX-NLC and the nuclei were 
stained with DAPI. Data are N=3. 
 



























4.5.4. Quantitative uptake study 
In order to confirm the quantitative uptake of DTX-NLCs formulations in cell lines and 3D 
U87MG spheroids, time and concentration-dependent, the study was conducted as 
detailed below: 
4.5.4.1. Time-dependent uptake 
Time-dependent quantitative uptake of all R-DTX-NLCs was performed in U87MG and SVG 
P12 cells, and the results are presented in two ways. First by studying the linear 
relationship (line of best fit) between the mean fluorescence intensity (MFI) and the time, 
for all proposed DTX-NLC formulations that were encapsulated with a fluorescence 
Rhodamine 123 (R ) dye. The uptake rate of R-DTX-NLC, R-GLA-DTX-NLC and R-ALA-DTX-
NLC followed this order from higher to lower uptake rate R-ALA-DTX-NLC ˃ R-GLA-DTX-
NLC ˃ R-DTX-NLC when U87MG were treated and incubated at different time intervals 
(Figure 4.20 a, c, e). In contrast, for the SVG P12, results demonstrated the following order 
from highest to lowest cell uptake R-DTX-NLC ˃ R-GLA-DTX-NLC ˃ R-ALA-DTX-NLC (4.20 b, 
d, f). These results suggest that the increase in the U87MG cell uptake and the reduction 
of SVG P12 uptake, though the uptake of U87MG was improved once the DTX-NLC were 
surface modified with PUFAs, but the efficacy of GLA-DTX-NLC and ALA-DTX-NLC  was as 
effective as DTX alone, that might be attributed to the slow release of DTX from both 
formulations as they exhibited approximately 12% of DTX release at initial time and 
followed by very slow release profile where more than 40 % was released at 24 h as 
(section 3.5.10.2). It is worth mentioning that high U87MG uptake for surface modified 
formulation with PUFAs (ALA and GLA), might be attributed due to the higher binding to 
FABPs receptors (Elsherbiny et al., 2013). Figure 4.20 demonstrates the uptake behaviour 
over a period of time, where all three tested formulations exhibited a highly significant 
increase in U87MG uptake (p ˂ 0.001) due to the lipophilic nature of the formulations 
(Yuan et al., 2008) over the SVG P12 uptake. 
SVG P12 demonstrated slower cellular uptake in comparison to the U87MG cells as shown 
in figure 4.18 when the data are presented secondly as a gradient for MFI over time. 
Additionally, both R-ALA-DTX-NLC and R-GLA-DTX-NLC showed a highly significant 
increase in uptake by the U87MG cells when compared to the bare R-DTX-NLC  under the 






     
(a)                                                                   (b) 
     
(c)                                                                    (d) 
     
(e)                                                                    (f) 
 
Figure 4.20 Standard plots of best fit demonstrating the time-dependent uptake of cell 
lines treated with DTX-NLC and surface modified DTX-NLC formulations (Rhodamine 123 
(R) loaded within the DTX-NLC). (a) R-DTX-NLC incubated with U87MG, (b) R-DTX-NLC 
incubated with SVG P12, (c) R-GLA-DTX-NLC incubated with U87MG, (d) R-GLA-DTX-NLC 
incubated with SVG P12, (e) R-ALA-DTX-NLC incubated with U87MG, (f) R-ALA-DTX-NLC 




























































































Figure 4.21 Gradient MFI demonstrating the time-dependent uptake of U87MG and SVG 
P12 cell lines treated with R-DTX-NLC, R-ALA-DTX-NLC, and R-GLA-DTX-NLC 
formulations. Data are mean and ± SD, (N=3). *** p ˂ 0.001, refers to the significant 
difference. 
 
The MFI for the uptake was demonstrated over a time interval in U87MG and SVG P12 
cells treated with R-DTX-NLC, R-ALA-DTX-NLC and R-GLA-DTX-NLC formulations at 0.5, 1, 
2, 4, 6, and 24 h (Figure 4.22). U87MG cells displayed an early uptake starting at 0.5 h and 
showed maximum uptake at 24 h for all examined formulations. Notably, figure 4.22 also 
show a distinguished lower uptake of all the tested formulations by SVG P12 cells. 
Furthermore, the uptake MFI at 2 and 4 h incubation time results were in line with our 
qualitative uptake findings, when the fluorescence microscopy was used to perform the 
cellular internalisation on both cell lines (section 4.5.3).  
The flow cytometer histograms display the cellular uptake of R-DTX-NLC (Figure 4.23 a, b), 
R-GLA-DTX-NLC (Figure 4.24 a, b), and R-ALA-DTX-NLC (Figure 4.24 c, d) indicating an 
increase in cell uptake with time, as evidenced by the shift in the fluorescence intensities 
to the right over time for both glioblastoma U87MG cell lines and the non-cancerous brain 
cell lines SVG P12. The results suggest high-intensity histogram peak shifting with (p 
˂0.001) when U87MG cell lines were treated with R-GLA-DTX-NLC and R-ALA-DTX-NLC, 
respectively. A similar concept was previously reported by Martins et al., (2012) and 
Garanti et al., (2016). A much lower flow cytometer histogram peaks were observed when 
SVG P12 were treated with the same formulations under the same conditions (Figure 4.24 































Figure 4.22 MFI over time-dependent uptake of U87MG and SVG P12 cell lines treated 
with R-DTX-NLC, R-ALA-DTX-NLC, and R-GLA-DTX-NLC formulations at (0.5, 1, 2, 4, 6, and 
24) hr. Data are mean and ± SD, (N=3). 
 
All the acquired results from the section 4.5.3 and the results that are presented, and 
discussed in this section show significant higher uptake by cancerous cells when the NLCs 
were surface modified over a lower uptake by the non-cancerous cells, which is a much-
desired quality in the anti-cancer drug delivery. Thus surface modification of NPs with 
different ligands demonstrated enhanced internalisation and higher uptake in 
glioblastoma cell lines as previously reported by Gao et al., (2014a) and Singh et al., 
(2015). Also, for other cell lines as indicated by Zhang and Zhang, (2013). The affinity of 
both the PUFAs to bind to cells through lipid binding protein FABPs (Elsherbiny et al., 
2013) could be the plausible reason for higher cellular uptake of GLA-DTX-NLC and ALA-
DTX-NLC. 
 
Figure 4.23 Flow cytometer histograms for the time-dependent uptake when R-DTX-NLC 
were incubated for (0.5, 1, 2, 4, 6, and 24) h with (a) U87MG cell lines, (b) SVG P12 cell 
lines. R4 representing a region around the untreated control cells, and R3 representing 
a region around the shifted peaks as the fluorescence intensity increases the peaks 
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Figure 4.24 Flow cytometer histograms for the time-dependent uptake when cell lines 
incubated for (0.5, 1, 2, 4, 6, and 24) h with (a) U87MG cell lines, incubated with R-GLA-
DTX-NLC (b) SVG P12 cell lines incubated with R-GLA-DTX-NLC. (c) U87MG cell lines, 
incubated with R-ALA-DTX-NLC (d) SVG P12 cell lines incubated with R-ALA-DTX-NLC R4 
representing a region around the untreated control cells, and R3 representing a region 
around the shifted peaks as the fluorescence intensity increases the peaks shifting more 
to the right over time as evidence of increased uptake with time. Data are N=3. 
4.5.4.2. Concentration-dependent uptake  
U87MG and SVG P12 cell lines 
A four-level concentration (1, 2, 3, and 5 µg/ml) uptake was performed at 6 h to establish 
the dose-dependent uptake by the U87MG cell lines. The U87MG cells showed a very 
significant increase in the uptake when the cells were treated with R-GLA-DTX-NLC at 2 
and 3 µg/ml concentration, likewise the cell uptake was significantly increased when 
treated with 1, 2, and 3 µg/ml concentration of R-ALA-DTX-NLC and furthermore, the 
U87MG displayed a very significant increase in the cell uptake at all concentrations levels 
1, 2, 3, and 5 µg/ml when the cells were treated with R-SA43-DTX-NLC; the R-DTX-NLC 
was considered as control in this study and all the formulations uptake was compared 
with it (Figure 4.25). In addition, uptake by the non-cancerous brain cells SVG P12 was 
evaluated under the same conditions. Figure 4.26 demonstrates a significant reduction in 
the SVG P12 uptake when treated with 1 µg/ml of R-GLA-DTX-NLC and R-ALA-DTX-NLC, 
respectively. 
No significant difference was obtained when the cells were treated with 2 µg/ml of R-GLA-
DTX-NLC and R-SA43-DTX-NLC. Furthermore, when the concentration of the R-ALA-DTX-
NLC was increased to 2 µg/ml the SVG P12 uptake was significantly increased. Similar 
(a) (b) 












findings were obtained when the R-GLA-DTX-NLC has increased to 3 and 5 µg/ml, as a 
significant increase in the SVG P12 uptake was noticeable (Figure 4.26). In contrast, the R-
SA43-DTX-NLC exhibited either no significant difference in the uptake at 2 and 3 µg/ml or 
a significant reduction at 5 µg/ml when incubated with SVG P12 cell lines suggesting high 
selectivity of R-SA43-DTX-NLC towards the glioblastomas U87MG cell lines as compared 
to SVG P12. SA43-aptamer has demonstrated higher selectivity towards the U87MG cell 
line due to Ku 70 and Ku 80 overexpression in glioblastoma cells, and higher binding of 
SA43 to both proteins, and lower uptake with the SVG P12 cell line (Aptekar et al., 2015). 
Consequently, when this aptamer was conjugated to R-DTX-NLC it enhanced its uptake by 
U87MG cells over SVG P12 cells. This quality would solve a major obstacle in the anti-
cancer loaded NLC delivery to the cancer cells. A similar concept of concentration-
dependent uptake evaluation was reported by Gao et al., (2014a).   
 
 
Figure 4.25 MFI demonstrating the concentration-dependent uptake of U87MG cell lines 
treated with R-DTX-NLC, R-ALA-DTX-NLC, R-GLA-DTX-NLC, and R-SA43-DTX-NLC 
formulations. Data are mean and ± SD, (N=3). * p ˂  0.05, refers to a significant difference 































Figure 4.26 MFI demonstrating the concentration-dependent uptake of SVG P12 cell 
lines treated with R-DTX-NLC, R-ALA-DTX-NLC, R-GLA-DTX-NLC, and R-SA43-DTX-NLC 
formulations. Data are mean and ± SD, (N=3). * p ˂  0.05, refers to a significant difference 
when formulations were compared to R-DTX-NLC as the control in this case. 
 
The flow cytometer histograms displayed in figures 4.27 a, b, 4.28 a, b, c, d and 4.29 a, b 
for both cell line also indicated the concentration-dependent cell uptake as evidenced by 
the shift in the fluorescence intensities to the right over different concentration levels for 
both glioblastoma U87MG cell lines and the non-cancerous brain cell lines SVG P12. The 
four formulations R-DTX-NLC, R-GLA-DTX-NLC, R-ALA-DTX-NLC and R-SA43-DTX-NLC all 
exhibited high intense fluorescence, histogram shifts when U87MG were treated, in 
comparison with less intensive histogram peaks when the SVG P12 were treated under 
the same conditions.  
 
Figure 4.27 Flow cytometer histograms for the concentration-dependent uptake when 
R-DTX-NLC were incubated with 1, 2, 3, and 5 µg/ml (a) U87MG cell lines, (b) SVG P12 
cell lines. R4 representing a region around the untreated control cells, and R3 
representing a region around the shifted peaks as the fluorescence intensity increases 
the peaks shifting more to the right when the concentration was increased as evidence 
of increased uptake with the concentration. The control, in this case, was the untreated 




























Figure 4.28 Flow cytometer histograms for the concentration-dependent uptake when 
incubated with 1, 2, 3, and 5 µg/ml (a) U87MG cell lines treated with R-GLA-DTX-NLC, 
(b) SVG P12 cell lines treated with R-GLA-DTX-NLC. (c) U87MG cell lines treated with R-
ALA-DTX-NLC, (d) SVG P12 cell lines treated with R-ALA-DTX-NLC. R4 representing a 
region around the untreated control cells, and R3 representing a region around the 
shifted peaks as the fluorescence intensity increases the peaks shifting more to the right 
when the concentration was increased as evidence of increased uptake with the 
concentration. The control, in this case, was the untreated cell lines. Data are N=3. 
 
Figure 4.29 Flow cytometer histograms for the concentration-dependent uptake when 
R-SA43-DTX-NLC were incubated with 1, 2, 3, and 5 µg/ml (a) U87MG cell lines, (b) SVG 
P12 cell lines. R4 representing a region around the untreated control cells, and R3 
representing a region around the shifted peaks as the fluorescence intensity increases 
the peaks shifting more to the right when the concentration was increased as evidence 
of increased uptake with the concentration. The control, in this case, was the untreated 
cell lines. Data are N=3. 
 
Cells derived from patients (BTNW911 cell line)  
BTNW911 cell lines were treated with four formulations R-DTX-NLC, R-GLA-DTX-NLC, R-
ALA-DTX-NLC and R-SA43-DTX-NLC at 1 µg/ml for 6 h incubation time, to study the 
quantitative cell uptake. The MFI indicated a highly significant increase in the cell uptake 







BTNW911 were treated with the surface modified formulations under the same 
conditions (Figure 4.30). Though there was no noticeable difference in the peak shifting 
position of the flow cytometer histograms were laid on top of each other for all the four 
formulations.  It is also worth mentioning that R-GLA-DTX-NLC and R-ALA-DTX-NLC 
showed significantly lower peak size than R-DTX-NLC formulation (Figure 3.31). 
 
Figure 4.30 MFI demonstrating the BTNW911 uptake with one level concentration of 1 
µg/ml of R-DTX-NLC, R-ALA-DTX-NLC, R-GLA-DTX-NLC, and R-SA43-DTX-NLC 
formulations at 6 h incubation time. Data are mean and ± SD, (N=3). *** p ˂  0.001, refers 
to a very significant difference when formulations were compared to R-DTX-NLC as the 
control in this case. 
 
 
Figure 4.31 Flow cytometer histograms of the BTNW911 uptake with one level 
concentration 1 µg/ml of R-DTX-NLC, R-ALA-DTX-NLC, R-GLA-DTX-NLC, and R-SA43-DTX-
NLC formulations  , respectively. At 6 h incubation time. R4 
representing a region around the untreated control cells, and R3 representing a region 
around the shifted peaks as the fluorescence intensity increases the peaks shifting more 
to the right when the cells were incubated with different formulation at one 
concentration as evidence of increased uptake with different types of unmodified and 
surface modified R-DTX-NLCs. The control, in this case, was the untreated cell lines 
















4.5.4.3. Spheroids uptake 
3D U87MG spheroids were prepared to evaluate the uptake of four formulations R-DTX-
NLC, R-GLA-DTX-NLC, R-ALA-DTX-NLC and R-SA43-DTX-NLC at one level concentration of 
1 µg/ml for 6 h incubation time. A quantitative uptake evaluation was performed using 
the flow cytometer as described in section 4.4.9.3. The data obtained as flow cytometer 
histograms (Figure 4.33) showed two populations of cell uptake, one was designated as 
early uptake that was thought to be the uptake by the cells on the surface of the spheroids 
and the second was thought to be due to the late uptake phase which was indicated by 
the uptake of the cells in the core of the spheroids. Due to the fact that spheroids consist 
of shell and core cells so it was assumed in this experiment that the cells in the core of the 
spheroids will take a longer time to be penetrated with the treatment, hence the data 
were expressed as early and late uptake as shown in figure 4.33. The MFI indicated a 
highly significant increase in the cellular late uptake phase (p ˂ 0.001) when the spheroids 
were treated with R-DTX-NLC, that might be due to the high lipophilicity nature of this 
formulation in comparison to the other three formulations and that would explain the 
high potency of this formulation when examined for its antiproliferative effect in the 3D 
U87MG spheroids. A lower late uptake was shown when the spheroids were treated with 
the surface modified formulations under the same conditions (Figure 4.32), that might 
suggest that the surface modification of the DTX-NLC were not contributing to higher 
spheroids uptake due to their inability to transport to the inner core of spheroid cells. This 
correlates with a similar finding reported by Gao et al., (2012b) whereby different 
formulations were uptaken by the spheroid cells in variable intensity. Additionally, R-ALA-
DTX-NLC demonstrated a highly significant increase in the early uptake phase when 
compared with all three other formulations. Although there was no remarkable difference 
in the peak shifting position in the flow cytometer histograms for all the four formulations 






Figure 4.32 MFI demonstrating the 3D U87MG spheroids uptake at 1 µg/ml of R-DTX-
NLC, R-ALA-DTX-NLC, R-GLA-DTX-NLC, and R-SA43-DTX-NLC formulations at 6 h 
incubation time. Data are mean and ± SD, (N=3). *** p ˂ 0.001, refers to a very 





Figure 4.33 Flow cytometer histograms of the 3D U87MG spheroids uptake at 1 µg/ml 
of R-DTX-NLC, R-ALA-DTX-NLC, R-GLA-DTX-NLC, and R-SA43-DTX-NLC formulations 
, respectively at 6 h incubation time. R4 representing a region 
around the untreated control cells, and R3 representing a region around the shifted 
peaks as the fluorescence intensity increases the peaks shifting more to the right when 
the cells were incubated with different formulation at one concentration as evidence of 
increased uptake with different types of unmodified and surface modified R-DTX-NLCs. 

















4.5.5. Quantitative and qualitative endocytosis pathways analysis 
It is well known that the endocytosis is a general mechanism for the internalisation and 
trafficking of NPs and other extracellular particles into the cells by different, and multiple 
pathways (Sahay et al., 2010). In this study, four formulations were examined for their 
mechanism of internalisation in U87MG and SVG P12 cells, where the cells were exposed 
to several endocytosis inhibitors in order to distinguish the pathways each formulation 
exhibited to gain entry into the cells (section 4.4.10). The data were acquired and analysed 
for both qualitative and quantitative studies by using fluorescence microscopy for 
capturing and analysing the images and the flow cytometer to quantify the MFI, 
additionally, any peak fluorescence shifting towards the right was considered as evidence 
for cellular pathway mechanism, respectively.  
R-DTX-NLC, R-GLA-DTX-NLC, R-ALA-DTX-NLC, and R-SA43-DTX-NLC showed less 
fluorescence intensity under the microscope, when treated and incubated at 4 °C for 2 
and 4 h incubation time in both cell lines  and examined under the same conditions; 
indicating that for all four formulations, the uptake was thought to be an active energy-
dependent transport as evidenced by  low uptake at 4 °C (Figures 4.34 b, c, 4.35 b, c, 4.38 
b, c, 4.39 b, c, 4.42 b, c, 4.43 b, c, 4.46 b, c, 4.47 b, c). Moreover, the MFI results when the 
four formulations incubated at 4 °C with both cell lines (Figures 4.36, 4.40, 4.44, and 4.48) 
demonstrated a significant reduction in the MFI as compared to the incubation of same 
formulations at 37 °C. These results were in line with previous reports (Aptekar et al., 
2015, Wong et al., 2017). Figures 4.37 c, d, 4.43 c, d, 4.47 c, d, 4.49 c, d, respectively, also 
display the peak locations of the four formulations incubated at 4 °C was close to the 
peaks position of the untreated control cells vs. the peak positions of the similar 
formulations when incubated at 37 °C that was further to the right side. As previously 
explained by Kam et al., (2006) and Thurn et al., (2011), if the uptake process was 
hindered by incubating the treatment at a lower temperature (4 °C rather than 37 °C) 
indicates the uptake mechanism is the energy-dependent endocytosis process. In 
addition, to further determine whether clathrin-mediated pathway has a role for the 
internalisation of the four formulations, both cell lines were incubated with 0.45 M 
sucrose, pre- and during the incubation of cell lines with the four formulations. Any 
disruption of the uptake process when the cells are incubated under hypertonic 
environment suggest that NPs were internalised through clathrin-mediated pathway 
Sahay et al., (2010). Our findings indicate that clathrin pathway is one of the pathways 
that all four formulations exhibited to gain entry in both the cell line due to the fact that 




d, 4.39 d, 4.42 d, 4.43 d, 4.46 d, and 4.47 d) especially for SVG P12 cell lines and a highly 
significant reduction in MFI was displayed when both cells lines were incubated with the 
four formulations in the presence of sucrose vs the MFI of four formulations incubated 
without inhibitor (Figure 4.36). Additionally, the flow cytometer histograms for both cell 
lines also suggested a disruption in uptake, due to lower peaks intensity when compared 
to control untreated cell lines (Figures 4.37 a, b, 4.41 a, b, 4.45 a, b, 4.59 a, b). From these 
results, we gathered that clathrin-mediated pathway might strongly be one of the 
internalisation pathways that all four formulations exhibited. To assess the internalisation 
of all four formulations through caveolae/ lipid rafts pathway, both cell lines were treated 
with 5 µg/ml nystatin pre- and during treatment with the formulations. Nystatin disrupts 
the cholesterol distribution, it binds to cholesterol moiety and thus disrupts lipid raft in 
the cell membrane by directly inserting into the membrane and sequestering cholesterol 
into complexes and thus inhibit entry of molecule via caveolae-mediated endocytosis 
(Kam et al., 2006).  
Both cell lines were characterised by low fluorescence intensity under the microscope 
(Figures 4.34 f, 4.35 f, 4.38 f, 4.39 f, 4.42 f, 4.43 f, 4.46 f, and 4.47 f) with very noticeable 
results for SVG P12, and further confirmation that caveolae/ lipid rafts pathway might be 
another uptake pathway of all the four formulations. Similar results were also obtained 
with a significant reduction in MFI of both cell lines U87MG and SVG when pretreated 
with nystatin before treatment with the formulations.  
To clarify the involvement of micropinocytosis/phagocytosis in all four formulations 
uptake, both cell lines were treated with cytochalasin B (Cyto. B) pre- and during 
incubation of cell lines with the four formulations. Cytochalasin B depolymerises actin 
filaments which are important for the structure formation needed to enclose molecules. 
These actin filaments internalise particulate via macropinocytosis or phagocytosis. Thus, 
disruption of actin filament by cytochalasin B reduce the cell internalisation of the 
molecule (Martin et al., 2012). The data obtained from the fluorescence microscopy 
suggested lower fluorescence intensity when both cell lines were incubated with Cyto. B 
(Figures 4.34 d, 4.35 d, 4.38 d, 4.39 d, 4.42 d, 4.43 d, 4.46 d, and 4.47 d). Additionally, the 
MFI acquired from the flow cytometer revealed a very significant reduction in the MFI of 
the cells when incubated with Cyto. B in both cell lines when compared with MFI of 
untreated cells with the Cyto. B. The data clearly suggests that 
micropinocytosis/phagocytosis was one of the pathways that were involved in all four 
formulations of uptake mechanisms. Interestingly all the three pathways clathrin-, 




previous reports where lipid nanoparticles have shown to be internalised by more than 
one pathway (Thurn et al., 2011). 
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Figure 4.34 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) and 
the green fluorescence dye refers to the R-DTX-NLC (Rhodamine 123 (R) loaded within 
the DTX-NLC). (a) U87MG control untreated cells only stained with DAPI, (b) U87MG 
incubated for 2 h with R-DTX-NLC at 4 °C and the nuclei were stained with DAPI, (c) 
U87MG incubated for 4 h with R-DTX-NLC at 4 °C and the nuclei were stained with DAPI, 
(d) U87MG incubated with sucrose pre and during incubation with R-DTX-NLC for 4 h at 
37 °C, (e) U87MG incubated with Cyto. B (cytochalasin B) pre and during incubation with 
R-DTX-NLC for 4 h at 37 °C, (f) U87MG incubated with Nystatin pre and during incubation 
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Figure 4.35 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) and 
the green fluorescence dye refers to the R-DTX-NLC (Rhodamine 123 (R) loaded within 
the DTX-NLC). (a) SVG P12 control untreated cells only stained with DAPI, (b) SVG P12 
incubated for 2 h with R-DTX-NLC at 4 °C and the nuclei were stained with DAPI, (c) SVG 
P12 incubated for 4 h with R-DTX-NLC at 4 °C and the nuclei were stained with DAPI, (d) 
SVG P12 incubated with sucrose pre- and during incubation with R-DTX-NLC for 4 h at 
37 °C, (e) SVG P12 incubated with Cyto. B (cytochalasin B) pre- and during incubation 
with R-DTX-NLC for 4 h at 37 °C, (f) SVG P12 incubated with Nystatin pre and during 


























Figure 4.36 MFI for U87MG and SVG P12 cell lines treated with endocytosis pathways 
inhibitors pre and during incubation with R-DTX-NLC. Data are mean and ± SD, (N=3). 
*** p ˂ 0.000, refers to a very significant difference when all data were compared to R-
DTX-NLC incubated at 37 °C, as the control in this case. 
 
 
Figure 4.37 Flow cytometer histograms for U87MG and SVG P12 cell lines treated with 
endocytosis pathways inhibitors pre and during incubation with R-DTX-NLC where (a) 
U87MG treated with sucrose, Cyto. B, and Nystatin, (b) SVG P12 treated with sucrose, 
Cyto. B and Nystatin, (c) U87MG incubated with R-DTX-NLC at 4 °C and 37 °C, (d) SVG 
P12 incubated with R-DTX-NLC at 4 °C and 37 °C. T control, in this case, is the untreated 
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Figure 4.38 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) and 
the green fluorescence dye refers to the R-GLA-DTX-NLC (Rhodamine 123 (R) loaded 
within the DTX-NLC). (a) U87MG control untreated cells only stained with DAPI, (b) 
U87MG incubated for 2 h with R-GLA-DTX-NLC at 4 °C and the nuclei were stained with 
DAPI, (c) U87MG incubated for 4 h with R-GLA-DTX-NLC at 4 °C and the nuclei were 
stained with DAPI, (d) U87MG incubated with sucrose pre- and during incubation with 
R-GLA-DTX-NLC for 4 h at 37 °C, (e) U87MG incubated with Cyto. B (cytochalasin B) pre- 
and during incubation with R-GLA-DTX-NLC for 4 h at 37 °C, (f) U87MG incubated with 
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Figure 4.39 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) and 
the green fluorescence dye refers to the R-GLA-DTX-NLC (Rhodamine 123 (R) loaded 
within the DTX-NLC). (a) SVG P12 control untreated cells only stained with DAPI, (b) SVG 
P12 incubated for 2 h with R-GLA-DTX-NLC at 4 °C and the nuclei were stained with DAPI, 
(c) SVG P12 incubated for 4 h with R-GLA-DTX-NLC at 4 °C and the nuclei were stained 
with DAPI, (d) SVG P12 incubated with sucrose pre- and during incubation with R-GLA-
DTX-NLC for 4 h at 37 °C, (e) SVG P12 incubated with Cyto. B (cytochalasin B) pre- and 
during incubation with R-GLA-DTX-NLC for 4 h at 37 °C, (f) SVG P12 incubated with 



























Figure 4.40 MFI for U87MG and SVG P12 cell lines treated with endocytosis pathways 
inhibitors pre and during incubation with R-GLA-DTX-NLC. Data are mean and ± SD, 
(N=3). *** p ˂ 0.000, refers to a very significant difference when all data were compared 
to R-GLA-DTX-NLC incubated at 37 °C, as the control in this case. 
 
 
Figure 4.41 Flow cytometer histograms for U87MG and SVG P12 cell lines treated with 
endocytosis pathways inhibitors pre and during incubation with R-GLA-DTX-NLC where 
(a) U87MG treated with sucrose, Cyto. B, and Nystatin, (b) SVG P12 treated with sucrose, 
Cyto. B and Nystatin, (c) U87MG incubated with R-GLA-DTX-NLC at 4 °C and 37 °C, (d) 
SVG P12 incubated with R-GLA-DTX-NLC at 4 °C and 37 °C. T control, in this case, is the 
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Figure 4.42 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) and 
the green fluorescence dye refers to the R-ALA-DTX-NLC (Rhodamine 123 (R) loaded 
within the DTX-NLC). (a) U87MG control untreated cells only stained with DAPI, (b) 
U87MG incubated for 2 h with R-ALA-DTX-NLC at 4 °C and the nuclei were stained with 
DAPI, (c) U87MG incubated for 4 h with R-ALA-DTX-NLC at 4 °C and the nuclei were 
stained with DAPI, (d) U87MG incubated with sucrose pre- and during incubation with 
R-ALA-DTX-NLC for 4 h at 37 °C, (e) U87MG incubated with Cyto. B (cytochalasin B) pre- 
and during incubation with R-ALA-DTX-NLC for 4 h at 37 °C, (f) U87MG incubated with 
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Figure 4.43 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) and 
the green fluorescence dye refers to the R-ALA-DTX-NLC (Rhodamine 123 (R) loaded 
within the DTX-NLC). (a) SVG P12 control untreated cells only stained with DAPI, (b) SVG 
P12 incubated for 2 h with R-ALA-DTX-NLC at 4 °C and the nuclei were stained with DAPI, 
(c) SVG P12 incubated for 4 h with R-ALA-DTX-NLC at 4 °C and the nuclei were stained 
with DAPI, (d) SVG P12 incubated with sucrose pre- and during incubation with R-ALA-
DTX-NLC for 4 h at 37 °C, (e) SVG P12 incubated with Cyto. B (cytochalasin B) pre- and 
during incubation with R-ALA-DTX-NLC for 4 h at 37 °C, (f) SVG P12 incubated with 



























Figure 4.44 MFI for U87MG and SVG P12 cell lines treated with endocytosis pathways 
inhibitors pre and during incubation with R-ALA-DTX-NLC. Data are mean and ± SD, 
(N=3). *** p ˂ 0.000, refers to a very significant difference when all data were compared 
to R-ALA-DTX-NLC incubated at 37 °C, as the control in this case. 
 
 
Figure 4.45 Flow cytometer histograms for U87MG and SVG P12 cell lines treated with 
endocytosis pathways inhibitors pre and during incubation with R-ALA-DTX-NLC where 
(a) U87MG treated with sucrose, Cyto. B, and Nystatin, (b) SVG P12 treated with sucrose, 
Cyto. B and Nystatin, (c) U87MG incubated with R-ALA-DTX-NLC at 4 °C and 37 °C, (d) 
SVG P12 incubated with R-ALA-DTX-NLC at 4 °C and 37 °C. T control, in this case, is the 
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Figure 4.46 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) and 
the green fluorescence dye refers to the R-SA43-DTX-NLC (Rhodamine 123 (R) loaded 
within the DTX-NLC). (a) U87MG control untreated cells only stained with DAPI, (b) 
U87MG incubated for 2 h with R-SA43-DTX-NLC at 4 °C and the nuclei were stained with 
DAPI, (c) U87MG incubated for 4 h with R-SA43-DTX-NLC at 4 °C and the nuclei were 
stained with DAPI, (d) U87MG incubated with sucrose pre- and during incubation with 
R-SA43-DTX-NLC for 4 h at 37 °C, (e) U87MG incubated with Cyto. B (cytochalasin B) pre- 
and during incubation with R-SA43-DTX-NLC for 4 h at 37 °C, (f) U87MG incubated with 
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Figure 4.47 Endocytosis pathways evaluations by fluorescence microscopy imaging, 
where the blue colour refers to the stained nucleus with a fluorescence dye (DAPI) and 
the green fluorescence dye refers to the R-SA43-DTX-NLC (Rhodamine 123 (R) loaded 
within the DTX-NLC). (a) SVG P12 control untreated cells only stained with DAPI, (b) SVG 
P12 incubated for 2 h with R-SA43-DTX-NLC at 4 °C and the nuclei were stained with 
DAPI, (c) SVG P12 incubated for 4 h with R-SA43-DTX-NLC at 4 °C and the nuclei were 
stained with DAPI, (d) SVG P12 incubated with sucrose pre- and during incubation with 
R-SA43-DTX-NLC for 4 h at 37 °C, (e) SVG P12 incubated with Cyto. B (cytochalasin B) 
pre- and during incubation with R-SA43-DTX-NLC for 4 h at 37 °C, (f) SVG P12 incubated 





























Figure 4.48 MFI for U87MG and SVG P12 cell lines treated with endocytosis pathways 
inhibitors pre and during incubation with R-SA43-DTX-NLC. Data are mean and ± SD, 
(N=3). *** p ˂ 0.000, refers to a very significant difference when all data were compared 
to R-SA43-DTX-NLC incubated at 37 °C, as the control in this case. 
 
 
Figure 4.49 Flow cytometer histograms for U87MG and SVG P12 cell lines treated with 
endocytosis pathways inhibitors pre and during incubation with R-SA43-DTX-NLC where 
(a) U87MG treated with sucrose, Cyto. B, and Nystatin, (b) SVG P12 treated with sucrose, 
Cyto. B and Nystatin, (c) U87MG incubated with R-SA43-DTX-NLC at 4 °C and 37 °C, (d) 
SVG P12 incubated with R-SA43-DTX-NLC at 4 °C and 37 °C. The control, in this case, is 











































4.5.6. Cell cycle analysis  
The cell cycle distribution of DTX-NLC, GLA-DTX-NLC, ALA-DTX-NLC, and SA43-DTX-NLC 
was performed to understand whether the NLCs loaded with DTX will follow the same 
pattern of DTX G2/M cell cycle arrest phase. DTX is a well-known mitotic inhibitor, and it 
can suppress cell growth by inducing G2/M cell cycle arrest (Choi et al., 2015). Following 
24 h treatment of glioblastoma U87MG cell line with the above-mentioned formulations 
and DTX (Figures 4.50 and 4.51), the results demonstrated the distribution of the 
formulations into a different cell cycle phases with a very significant reduction in G0/G1 
phase when all formulations and DTX were compared to the G0/G1 phase of untreated 
U87MG as a control (Figure 4.51). The following order from higher to lower % cells in   
G0/G1 phase (Figures 4.50 and 4.51) U87MG untreated, ALA-DTX-NLC, DTX, DTX-NLC, 
GLA-DTX-NLC, and SA43-DTX-NLC (61.0, 20.43, 16.31, 10.54, 9.27, and 5.0 %), 
respectively. Phase S exhibited the order from higher to lower % cells in S phase (Figure 
4.50), ALA-DTX-NLC, U87MG untreated, GLA-DTX-NLC, DTX-NLC, DTX, and SA43-DTX-NLC 
(9.84, 8.24, 5.74, 4.17, 4.09, and 3.18 %) respectively, with a very significant difference in 
the S phase cell cycle distribution when all formulation and DTX were compared to the 
untreated U87MG cell line as a control. In addition, the G2/M phase which taxanes are 
widely known display was encountered in high % in DTX-NLC and all surface modified DTX-
NLC over a very significant reduction in the G2/M phase of the untreated U87MG as a 
control. The G2/M phase quantification is presented in figure 4.47 and followed the order 
from higher to the lowest G2/M phase, SA43-DTX-NLC, DTX-NLC, GLA-DTX-NLC, DTX, ALA-
DTX-NLC, and untreated U87MG cell line (91.62, 85.26, 84.13, 79.49, 69.69, and 29.24%), 
respectively. It is worth noting that SA43-DTX-NLC was showed the highest percent of 
G2/M cell cycle phase population amongst all other examined formulations and DTX, 
demonstrating that when the DTX-NLC was conjugated with SA43-aptamer it caused a 
concomitant increase in the G2/M phase, so consequently strong cell division and growth 
inhibition, and eventually faster cell arrest would be connected to the presence of the 
SA43-aptamer on the surface of the DTX-NLCs. Furthermore, GLA-DTX-NLC and DTX-NLC 
also demonstrated similar findings as for the SA43-DTX-NLC with slightly lower percent 
distribution in G2/M phase than the SA43-DTX-NLC  indicating that DTX-NLC surface 
modification with GLA had a similar effect as the DTX-NLC, and did not enhance the cell 
arrest due to no significant difference in G2/M phase between the two formulations. In 
contrast, ALA-DTX-NLC contributed less to effect on cell inhibition when the DTX-NLC was 
surface modified with ALA due to a highly significant reduction in G2/M phase by ALA-
DTX-NLC when compared to the G2/M phase arrest by DTX-NLC. At this point, it was highly 




inhibition, rather than the presence of PUFAs on the surface of the DTX-NLC, suggesting 
the SA43-DTX-NLC exhibited higher cell arrest in G2/M phase through breaking of the 
double-strain DNA and in theory damaging of the chromosome (Ree et al., 2006). It is also 
safe to say that all examined formulation followed DTX pattern as a drug-induced G2/M 
cell cycle arrest was demonstrated by all the formulations (figures 4.50 and 4.51).  
 
Figure 4.50 Percentage cell cycle distribution for U87MG cell lines following 24 h 
incubation with DTX, DTX-NLC, GLA-DTX-NLC, ALA-DTX-NLC, and SA43-DTX-NLC 
formulations. Data are mean and ± SD, (N=3). *** p ˂ 0.000, refers to a very significant 





























Figure 4.51 showing flow cytometer histograms for U87MG cell cycle following 24 h 
incubation with (a) control U87MG untreated cell lines (b) DTX (c) DTX-NLC (d) GLA-DTX-
NLC (e) ALA-DTX-NLC, and (f) SA43-DTX-NLC. Data are N=3. 
 
In summary, surface modification of DTX-NLC with PUFAs (GLA and ALA) improved the 
potency of DTX-NLC towards U87MG cell lines and demonstrated activity as good as DTX 
alone. ALA-DTX-NLC and GLA-DTX-NLC also exhibited more efficacy towards patient-
derived BTNW911 cells at all time points in comparison to DTX-NLC.  
Cellular internalisation and uptake were improved when DTX-NLC were surface modified 
with PUFAs and SA43-aptamer at all studied time points. In addition, SA43-DTX-NLC 
showed higher selectivity towards U87MG cell line than SVG P12. It was observed that the 
mechanism of cell uptake was through active transport due to binding SA43 to Ku 70 and 
Ku 80, and PUFAs ability to bind FABPs and the endocytosis was involved for 




arrest at G2/M phase, with a very significant increase in G2/M phase for the SA43-DTX-
NLC.  
Chapter Five 
































5.1.1. In-vitro BBB model and their role in CNS drug delivery system  
BBB models, especially tri-culture, represents the closest in-vitro model to the in-vivo 
neurovascular unit (Nakagawa et al., 2007). The advantages of the in vitro models 
compared to the in vivo models are lower cost, a lower amount of compound required for 
quantitation of BBB permeability, higher throughput capacity, and the lower number of 
animals required for downstream drug testing if early screens are more physiologically 
relevant (Lundquist et al., 2002). Hence in-vitro BBB model was investigated to establish 
as a proper and reliable model that can mimic all BBB functionalities for permeability, 
transport study and potential compound interaction with the BBB (Nielsen et al., 2011; 
Kumar et al., 2014; Bicker et al., 2014). Nakagawa et al., (2007) discovered that tri-culture 
models gave the highest TEER values when cells were seeded on a transwell insert, grown 
on the apical membrane to form a tri-culture. In this chapter we have used a tri-culture 
(3D in-vitro BBB model) that was established, characterised and validated in-house by Dr 
Alder research group (Kumar et al., 2014), where three primary cell lines of human origin 
were used in the reconstruction of all three BBB components for screening NPs, aptamers, 
and different compounds and evaluating their permeability through the 3D in-vitro BBB 
model (Kumar et al., 2014). 
5.1.2. Multidrug resistance  
Multidrug resistance (MDR) also known as a drug efflux transporter called P-gp or MDR1 
is highly expressed in the BBB. The P-gp pumps out the drug and compounds from the 
brain back to the blood side against concentration gradients, which comprises a 
substantial barrier in the treatment of CNS and malignant diseases (Kim 2002). In this 
study, we propose to encapsulate DTX a P-gp substrate (Loscher and Potschka, 2005) into 
NLCs to increase the DTX concentration in the brain (basolateral side of the 3D in-vitro 
BBB model) by using P-gp inhibitors Solutol® HS15 and Labrasol as surfactants during the 
fabrication of the DTX-NLCs. Furthermore, functionalisation of the DTX-NLCs with PUFAs 
ligands may potentially suppress the expression of the P-gp as indicated by Raghava and 






5.2. Aim and objectives  
The aim of this study was to evaluate the permeability of the developed DTX-NLC and 
surface modified DTX-NLCs with PUFAs  (GLA-DTX-NLC and ALA-DTX-NLC), and selective 
aptamer SA43-DTX-NLC through a 3D in-vitro BBB model, and to investigate their potential 
uptake by glioblastoma U87MG cells on the basolateral (brain) side of the transwell after 
passing through the BBB model for assessment of their potential in targeted delivery for 
treatment of glioblastoma.  
5.2.1. Objective 1 
Fluorescence labelled formulations R-DTX-NLCs, R-GLA-DTX-NLC and R-ALA-DTX-NLC, and 
R-SA43-DTX-NLC were evaluated for apparent permeability by measuring 
transendothelial resistance (TEER) and appearance of fluorescence of NLCs on the 
basolateral side of a 3D in-vitro BBB model of three primary cell lines of human origin. 
5.2.2. Objective 2 
DTX-NLC and DTX solution were assessed for apparent permeability through the BBB 
model and DTX concentration was quantified by a validated HPLC method that was 
developed for this purpose (Chapter two section 2.5.3.3). 
5.2.3. Objective 3 
3D BBB model in the presence of U87MG on the basolateral side was used for examining 
the BBB permeability and glioblastomas uptake of fluorescence labelled formulations R-
DTX-NLCs, R-GLA-DTX-NLC and R-ALA-DTX-NLC, and R-SA43-DTX-NLC through analysis 
using the flow cytometer. 
5.2.4. Objective 4 
Determination of the P-gp efflux pump activity for DTX-NLCs, GLA-DTX-NLC and ALA-DTX-







5.3. Equipment and materials  
5.3.1. Equipment 
EVOM-2 purchased from (Merck Millipore, Oxford, UK), Tecan GENios Pro® plate reader 
(Tecan, Theale, UK). Humidified incubator supplied with 5 % CO2 (Thermo Scientific Nunc, 
UK). Benchtop flow cytometer (Guava, Merck), and the data were analysed with Guava ® 
easyCyte software 3.1.1. (Guava, Merck). Benchtop centrifuge, at 179 x g for 5 min (ALC, 
Buckinghamshire, UK). Benchtop centrifuge was used for 30 min at 16300 x g (Spectrafuge 
24D, Jencons-Pls, UK). (Agilent HPLC 1260 Infinity, Agilent Technologies, USA).  
5.3.2. Materials 
Fibronectin, Phosphate buffered saline (PBS) 0.1 M (pH7.4), and all plastic-ware including 
tissue culture flasks, well plates, centrifuge tubes, and 1.5 ml tubes were purchased from 
Fisher Scientific, Leicestershire, UK. Foetal bovine serum (FBS), L-glutamine, sodium 
pyruvate, non-essential amino acid (NEAA) and phosphate buffer saline (PBS). RNAase 
free water from Fisher, UK. Propidium iodide (PI), Trypsin solution 10X, Trypan blue, and 
Evans blue dye (EBD) were purchased from Sigma Aldrich, the UK and all lab consumables 
were purchased from Sigma, Dorset, UK. Human serum (HS), Endothelial basal media 
(EBM-2)/(EGM-2), Astrocyte basal media (ABM-2)/(AGM-2) kit and Eagle’s minimum 
essential medium (EMEM), Hank’s balanced salt solution (HBSS) were purchased from 
Lonza, UK. Pericyte medium (PM), was purchased from Caltag Medsystems. Non-tissue 
culture 96 well plate/ V-shaped was purchased and TryPLE Express were from Fisher, UK. 
Insert 6.5 mm transwell polystyrene with 8.0 µm pore polycarbonate membrane TC-
treated sterile items were purchased from VWR, UK. 
5.3.3. Cell lines 
Human microvascular endothelial cells (HMBEC), human brain vascular pericytes (HBVP) 
and human astrocytes (HA) were purchased from (Sciencell, Buckingham, UK), passage 
number (p2-8) was used. U87MG (human glioblastoma cell line) grade IV, passage number 









All the experiments in this chapter were performed under sterile conditions and by using 
a class II laminar flow hood in a primary lab as described in chapter four section 4.4. 
Additionally, similar protocols mentioned in chapter four for cell line thawing (section 
4.4.2), subculturing (section 4.4.3), and cell counting (section 4.4.4) were followed in 
experiments reported in this chapter, where the only difference was PBS was used for 
washing instead of the HBSS, and TryPLE Express was used to detach the primary cell lines 
instead of the trypsin.  
5.4.1. Preparations 
5.4.1.1. Media preparation  
Endothelial basal media (EBM-2) was used for culturing HBMEC by using Endothelial 
Growth Media-2 Single quotes (EGM-2) kit, plus 2% human serum (HS), Astrocyte basal 
media (ABM-2) was used for culturing NHA by using Astrocyte Growth Media-2 Single 
quotes (AGM-2) kit, plus 3% HS, For HBVP culturing, Pericyte medium (PM), Pericyte 
Growth Supplement (PGS) and penicillin/streptomycin solution (P/S), plus 2% of HS, a 
detailed growth supplement summarised in chapter two (section 2.3.2). 
5.4.1.2. Coating inserts  
The plates were sprayed with 70% IMS and placed inside sterile laminar flow hood, the 
inserts were washed with HBSS, 0.5 ml in each insert was added, and incubated for 30 min 
by placing the plates in 37 °C humidified incubator under 5 % CO2 atmosphere. And the 
HBSS was aspirated from each insert gently then replaced with fibronectin placed on the 
apical side of the insert then the plates were incubated for 24 h in 37 °C humidified 
incubator under 5 % CO2.  
5.4.2. Tri-culture on transwell for 3D BBB model 
Prior to establishing the Tri-culture on transwell for 3D BBB model, the three primary cell 
lines were grown until reached confluency 85-90%, to develop a fully validated human 
cell line in-vitro BBB model (Kumar et al., 2014).  The inserts were coated prior to the 
seeding day as described in section 5.4.1.2. based on the primary cell lines 
characterisation, growth kinetics, and protocol established by Kumar et al., (2014), the 
NHA and HBVP were seeded on the apical outer part of the insert. The inserts were 
incubated for 4 h inside the hood, following the incubation period the inserts were placed 




added to the basolateral side. The plates were transferred into 37 °C humidified incubator 
under 5 % CO2 for 48 h incubation followed by seeding HBMEC on the apical inner part of 
the insert, 600 µl of media was added to the basolateral side. The plates were then 
incubated for 48 h at 37 °C in a humidified incubator under 5 % CO2 to form a tri-culture 
model. 
5.4.3. Testing the integrity of the 3D in-vitro BBB model 
There are several methods to determine the barrier properties of in-vitro models. The 
para-cellular permeability was monitored using a trans-endothelial electrical resistance 
(TEER) EVOM-2 instrument, which is the most widely used method to determine TEER on 
endothelial cells as mono-culture (Nakagawa et al., 2007) or as previously reported for tri-
culture (Kumar et al., 2014; Esposito et al., 2016). For the measurement of TEER, two 
electrodes were used, one being placed in the upper and the other in the lower chamber, 
and the results were expressed in Ohm/cm2 (Nakagawa et al., 2007). In this experiment, 
the TEER measurement was performed by recording at least three readings from different 
positions in each transwell for up to 14 days (Kumar et al., 2014).  
Another way to test the integrity of the BBB model was by using Evans blue dye (EBD) as 
an inert negative control, which is too large for paracellular transport (Kumar et al., 2014) 
by adding 1 µg/ml of EBD on apical side of the inserts, and incubated for up to 15 min at 
37 °C humidified incubator under 5 % CO2, and then 100 µl was sampled from the 
basolateral side of the insert and the absorption was measured at 595 nm using the plate 
reader. The EBD unknown concentration was calculated by plotting a standard curve 
generated from known concentrations. The integrity of the model was tested by EBD prior 
to and at the end of each experiment following the model highest TEER values. The TEER 
was also measured at different time intervals 0.25, 0.5, 1, 2, 4, and 6 h, in the presence of 
EBD in the apical side and without the EBD to establish if there is any interruption in the 
TEER values due to the presence of the EBD. 
5.4.4. Evaluation of the permeability of DTX-NLCs and surface 
modified DTX-NLCs across 3D in-vitro BBB model 
DTX-NLCs and DTX-NLCs surface modified were screened for apparent permeability across 
the developed 3D in-vitro BBB model, all cell lines were arranged on a three-dimensional 
scaffold as described in section 5.4.2. After 48 h, the tri-cultures were measured for their 
TEER using the EVOM-2 across three locations on the insert for each of the models every 
day, until the model was ready to start the experiment on the 7-8 day when the TEER 




DTX-NLC, R-GLA-DTX-NLC, R-ALA-DTX-NLC, and R-SA43-DTX-NLC were diluted in media to 
a final concentration of 0.5 and 1 µg/ml. The tri-cultures were incubated in standard tissue 
culture conditions and at different time intervals 0.25, 0.5, 1, 2, 4, and 6 h, TEER was 
measured and a 100 µl of media from the basolateral side of the trans-well insert was 
sampled for each time point and replaced by 100 µl of fresh media. The fluorescence of 
the sampled media was measured at excitation wavelength 485 nm and emission 
wavelength 535 nm using the plate reader. The integrity of the barrier was tested using 1 
µg/ml EBD prior to the experiment and in the end, to ensure that the model was intact 
during the incubation time and duration of the entire experiment. All data were obtained 
from three experimental replicates. The unknown concentration of Rhodamine123 (R) 
labelled DTX-NLCs were calculated using a standard curve that was established for each 
formulation, and the apparent permeability (Papp) was calculated using equation 5.1 as 







)                                             Equation 5.1 
where:  
V = Volume of basolateral compartment (0.6 ml) (0.5 cm3) 
 A = surface area of the polycarbonate membrane (0.3 cm2)  
C0 = Final concentration of R-DTX-NLCs in the apical side (1 or 0.5 µg/ml)  
dQ Change in the concentration of DTX-NLCs passing across the cell layer to the 
basolateral side (μg/ml)  
dt = Change in time (Sec). 
5.4.5. Evaluation of the permeability of DTX and DTX-NLC across 3D 
in-vitro BBB model using HPLC method 
The 3D in-vitro BBB model was prepared as described in section 5.4.2, and the free DTX 
from the DTX solution and the DTX-NLC that permeated through the model into the 
basolateral side of the insert was quantified. In this experiment, two level concentrations 
were used 1 and 2 µg/ml for DTX and DTX-NLC by diluting the sample with media and 
placing 200 µl from each concentration into the apical side of the insert, then incubated 
for 6 h in 37 °C humidified incubator under 5 % CO2. Following the incubation period, the 
experiment was terminated, and 0.45 ml was taken from each insert and placed in a 1.5 
ml tube then 50 µl of 0.1 µg/ml PTX as internal standard (IS) was added to each tube, 




extraction of DTX from the biological matrix, then vortexed again for 3 min. All tubes were 
then placed in the centrifuge, for 30 min at 16300 x g centrifugation speed as previously 
stated in chapter two (section 2.4.3.2.3) for sample preparation. 900 µl of the supernatant 
was taken from each tube and placed into an HPLC vial for HPLC analysis and 
quantification of DTX using the developed and validated method that previously detailed 
in chapter two (section 2.5.3.3), each sample was injected into the HPLC system three 
times, this experiment was a replica of three, after acquiring the free DTX concentration, 
then the Papp was calculated as per equation 5.1. The integrity of the barrier was tested 
using 1 µg/ml EB prior to the experiment and in the end, to ensure that the model was 
intact during the designated incubation period. 
5.4.6. Evaluation of DTX-NLCs and surface modified DTX-NLCs uptake 
by U87MG monolayer following the permeability across 3D in-vitro 
BBB model  
In this experiment for the quantification of Rhodamine 123 (R) labelled formulations  R-
DTX-NLC, R-GLA-DTX-NLC, R-ALA-DTX-NLC, and R-SA43-DTX-NLC  uptake by U87MG 
monolayer following the permeability across 3D in-vitro BBB model, where the flow 
cytometer was used for quantification of fluorescence labelled formulations. The 
following protocol was adopted and several steps were modified from a previously 
published paper where they used mono-culture BBB model from a mouse brain 
endothelial Bend.3 as summarised by Lin et al., (2016). In our experiment, a 3D in-vitro 
BBB model was prepared as described in section 5.4.2. The only addition to that protocol 
is the U87MG cells were seeded in a density of 20000 cells/ ml on the bottom of the plate 
(without the inserts), a day before the TEER reach to 260-290 Ω/ cm2, followed by 
transferring the inserts in each well (contains U87MG monolayer), and incubated for at 
least 2 h in 37 °C humidified incubator under 5 % CO2 . Then 200 µl from each formulation 
was added at 1 µg/ml concentration once the TEER increased over 300 Ω/ cm2. TEER was 
measured at different time intervals of 0.25, 1, 2, 4, and 6 h. Additionally, samples were 
withdrawn at 1, 2, 4, and 6 h from both apical 20 µl, then diluted with 80 µl mix media 
and from basolateral side of the insert a 50 µl was taken, then diluted with 50 µl mix 
media, without replacing the media. 
The experiment was terminated after the last incubation time point (6 h) followed by 
measuring the fluorescence of the sampled media at excitation wavelength 485 nm and 
emission wavelength 535 nm using the plate reader. As for the U87MG cell line, the cells 
were prepared for the uptake analysis using the flow cytometer following the protocol 




µg/ml EB prior to the experiment and in the end, to ensure that the model was intact 
during the incubation time. All data were obtained from three experimental replicates. 
The unknown concentration of Rhodamine123 (R) labelled DTX-NLCs were calculated 
using a standard curve that was established for each formulation, and the Papp was 
determined using equation 5.1. Additionally, for the fluorescence data acquired by the 
flow cytometer, the MFI was plotted against the incubation time and the flow cytometer 
histograms were examined for the peak shifting.  
5.4.7. Evaluation of DTX-NLCs and surface modified DTX-NLCs effect 
on P-gp efflux pump using 3D in-vitro BBB model  
The 3D in-vitro BBB model was prepared as described in section 5.4.2, and once the model 
reached maximum TEER measurements ranging between 260-300 Ω/ cm2. The media was 
removed from the apical side and replaced by 200 µl of the following samples  
(a) 10 µg/ml Rhodamine123 (R) at 37 °C 
(b) 10 µg/ml R at 4 °C 
(c) 10 µg/ml R+ 100 µM verapamil at 37 °C 
(d) 10 µg/ml R+ 22 µM vinblastine at 37 °C 
(e) 10 µg/ml R+ 1 µg/ml DTX-NLC at 37 °C 
(f) 10 µg/ml R+ 1 µg/ml GLA-DTX-NLC at 37 °C 
(g) 10 µg/ml R+ 1 µg/ml ALA-DTX-NLC at 37 °C 
(h) 10 µg/ml R+ 1 µg/ml SA43-DTX-NLC at 37 °C 
 
Then after 1 h incubation at 37 °C humidified incubator under 5 % CO2, 100 µl was sampled 
from the apical and basolateral side of each insert and analysed for the Rhodamine123 
fluorescence. The fluorescence was measured at excitation wavelength 485 nm and 
emission wavelength 535 nm using the plate reader, and the unknown concentration of 
Rhodamine123 (R) was calculated using a standard curve of Rhodamine123.  
5.4.8. Statistical data analysis 
The statistical analysis was performed using the Kolmornov-Smirnov test for normality 
followed by ANOVA (with post-hoc analysis Tukey and Dunnett test) by using statistical 
analyses were performed using the Statistical Package for the Social Sciences SPSS Version 
20 software (IBM company, USA) and the Microsoft Excel software for Microsoft office 
360 (Microsoft Corporation, USA). The analysis of variance was statistically significant 
difference when (*) P < 0.05 (confidence 95%), (**) P < 0.001 (confidence 99%), and (***) 
P < 0.000. The data are presented as the mean ± standard deviation for N=3 experiments 




5.5. Results and discussion  
5.5.1. Cell characterisation  
Primary cells morphology was observed under the light microscopy x10 magnification, on 
day 5 the endothelial cells HBMEC exhibited relatively higher growth and confluency in 
comparison with NHA and HBVP (Figure 5.1). HBMEC showed spindle-shaped 
morphology. The astrocytes NHA showed fibroblastic morphology with many elongated 
processes arising from each cell and less confluency in comparison to HBMEC and HBVP 
(Figure 5.1). The pericytes HBVP were observed as thin cells with elongated processes 
rising from each cell like a net shape (Figure 5.1), they were slow growing in comparison 
to the HBMEC. 
 
(a)                                          (b)                                               (c) 
Figure 5.1 Light microscopy images x 10 magnification of monolayer primary cell lines 
(a) HBMEC cell line; (b) NHA cell line, and (c) HBVP cell line. 
 
5.5.1. Testing the integrity of the 3D in-vitro BBB model 
In this study, the maximum TEER obtained was 300 Ω/cm2 on day 8, and the model was 
used when TEER was ranging between 260-300 Ω/cm2 on days 7, 8, and 9 (Figure 5.2 a). 
Previously, the integrity of the BBB cell culture model was deemed stable and intact for 
assessing drug transport, when a sufficiently high TEER value 250-300 Ω/cm2 was achieved 
(Esposito et al., 2016; Kumar et al., 2014). The integrity and barrier properties of the BBB 
model was also tested by addition of EBD in the apical side followed by measurement of 
EBD appearance in the apical side and TEER values, as described in section 5.4.3. Figure 
5.2 b confirmed that there was no disruption in the BBB at the designated time points, as 
TEER remained constant for the duration required for future experiments, and no EBD 
was detected by absorbance spectroscopy from media in the basolateral side, indicating 










Figure 5.2 Testing the integrity of the in-vitro model (a) To establish the barrier 
formation TEER was measured for up to 14 days, (b) TEER measurements of the 3D in-
vitro BBB model at different time intervals with and without EBD. Data are mean ± SD, 
(N=3). 
 
5.5.2. Evaluation of the permeability of DTX-NLCs and surface 
modified DTX-NLCs across 3D in-vitro BBB model using fluorescence 
detection 
As described in section 5.4.4, to test DTX-NLC and surface modified DTX-NLCs 
permeability, fluorescent probe Rhodamine123 (R) was encapsulated within the NLCs, 
and the rhodamine 123 fluorescence was used as a marker to determine whether the 
NLCs had permeated the BBB. Rhodamine123 is frequently used, in the case of this 
experiment the Rhodamine123 was encapsulated inside the NLC and was protected from 





































had shown that NLC did not release 40% contents until at least 2 h (Chapter three section 
3.5.10.2), therefore for the duration of this experiment, rhodamine detection on the 
basolateral side of the BBB was indicative of permeation of the NLCs. 
Each standard curve was obtained by measuring the Rhodamine 123 concentration within 
the NLCs by plotting a range of R-DTX-NLC, R-GLA-DTX-NLC, R-ALA-, and R-SA43-DTX-NLC 
concentrations vs their mean fluorescence intensity (MFI) to quantify the unknown 
concentration of samples that were withdrawn from the basolateral side of the insert. 
The fluorescence of 0.5 µg/ml R-DTX-NLC that was sampled from the basolateral side of 
the insert was converted to concentration using a standard plot (Figure 5.3 a).  In Figure 
5.4 a, the data acquired demonstrated a permeation of R-DTX-NLC through the 3D in-vitro 
BBB model starting from early time point 0.25 h and reaching the highest concentration 
at 2 h. The TEER value dropped from 275.05 ±19.41 Ω/cm² (control) to maximum low of 
173.33 ±12.46 Ω/cm² at 1 h, after which, TEER values started to increase and had returned 
to control values at 2 h, and until the termination of the experiment up to 6 h (Figure 5.4 
a). This decrease and recovery in TEER could be due to the opening of the TJs facilitating 
passage of NLC through the in-vitro BBB model. It is known that tight junctions can be 
opened only to a limited extent (Bazzoni 2006). A similar pattern was shown when a 
higher concentration of 1 µg/ml R-DTX-NLC was evaluated for its permeability (Figure 5.4 
b), where TEER values also dropped from 0.25 to 1 h and then returned to normal after 2 
h of incubation. The fluorescence of 1 µg/ml R-DTX-NLC that was sampled from the 
basolateral side of the insert was converted into concentration using the standard plot 
shown in figure 5.3 b, and the highest concentration was obtained at 2 h, which was higher 
than when 0.5 µg/ml R-DTX-NLC was tested. Interestingly, the R-DTX-NLC was still 
showing permeability even after TEER returned to normal values following the closing of 
the TJ, suggesting another transport mechanism other than paracellular transport was 
involved. Solutol® HS15 (a PEG copolymer/surfactant) was incorporated in the 
preparation of the R-DTX-NLC formulation to prolong circulation time (Chen et al., 2004). 
Permeation of the R-DTX-NLC may have continued due to the role of Solutol®HS15 as a 
resistance modification agent (RMA); consequently, it works as an efflux pump P-gp 
inhibitor to reverse the multidrug resistance (MDR) as demonstrated by Coon et al., 
(1991). Additionally, the Papp was calculated using equation 5.1 for both concentrations 
(Figure 5.4 c). Higher apparent permeability (Papp values) were displayed when 0.5 µg/ml 
R-DTX-NLC was examined at 0.25, 0.5, 1, and 2 h than the Papp of 1 µg/ml R-DTX-NLC, 
when almost similar Papp was observed at 4 and 6 h of incubation for both concentration 




Papp values correlated with when the TEER values dropped, indicating that the R-DTX-
NLC has the ability to pass through the BBB in-vitro model. The model was considered 
intact due to no EBD detectable in the basolateral side of the insert during and at the end 





Figure 5.3 Standard calibration plot for (a) 0.5 µg/ml R-DTX-NLC (b) 1 µg/ml R-DTX-NLC. 
Data are mean ± SD, (N=3). 
 


























































Figure 5.4 In-vitro BBB permeability of R-DTX-NLCs (a) Combo graph for the TEER 
measurements and fluorescence concentration for 0.5 µg/ml R-DTX-NLC, (b) Combo 
graph for the TEER measurements and fluorescence concentration for 1 µg/ml R-DTX-
NLC, (c) scatter graph for the Papp values plotted with time of 0.5 and 1 µg/ml R-DTX-

































































































As shown in figure 5.6 a and b, when R-GLA-DTX-NLC was evaluated at two-level 
concentrations, the TEER values started to drop from 286.5 ±2.5 Ω/cm² (control) to 233.5 
±0.83 Ω/cm² at 1 h for 0.5 µg/ml R-GLA-DTX-NLC (Figure 5.6 a), and, 197.44 ±31.82 Ω/cm² 
at 2 h, when 1 µg/ml of RGLA-DTX-NLC was examined (Figure 5.6 b). Additionally, the 
concentration of 0.5 and 1 µg/ml R-GLA-DTX-NLC that were sampled from the basolateral 
side of the inserts was calculated from fluorescence measurements using the standard 
plots shown in figure 5.5 a and b, respectively. The highest concentrations were displayed 
for both the tested concentrations of R-GLA-DTX-NLCs at the 6 h time point. The 
fluorescence permeated from 1 µg/ml R-GLA-DTX-NLC was two-fold higher than the 
maximum fluorescence shown when 1 µg/ml bare R-DTX-NLCs without surface 
modification was examined at 6 h incubation time. This indicates that when the 
formulation was functionalised with GLA it caused a higher permeation of the R-GLA-DTX-
NLC through the BBB model. The Papp values for both concentrations 0.5 and 1 µg/ml R-
GLA-DTX-NLC (Figure 5.6 c) exhibited low permeability at the early time point, followed 
by reaching the highest value at 1 h incubation, then the Papp values were reduced at 4 
and 6 h of incubation. It was reported in literature that upon administration of GLA 
reactive oxygen species (ROS) were generated (Leaver et al., 2002a), that led to the 
suppression of P-gp expression, and eventually to P-gp inhibition (Yuan et al., 2008), which 
in turn caused efflux pump inhibition and which explains the high fluorescence level of R-
GLA-DTX-NLC that was permeating through the 3D in-vitro BBB model, even when the 
TEER values returned to normal values, demonstrating the termination of the transit 
opening for the TJ period. Another mechanism for the permeation of R-GLA-DTX-NLC 
through the BBB model might be due to GLA on the surface of the NLC binding to the brain 
FABP7 receptors (Elsherbiny et al., 2013; Shimizu et al., 1997). Fatty acids have the ability 
to enter the brain by passive diffusion and proteins-mediated transport by the 
membrane-associated proteins, like fatty acid transport proteins and fatty acid 









Figure 5.5 Standard calibration plot for (a) 0.5 µg/ml R-GLA-DTX-NLC (b) 1 µg/ml R-GLA-
DTX-NLC. Data are mean ± SD, (N=3). 
 






































































































Figure 5.6 In-vitro BBB permeability of R-GLA-DTX-NLCs (a) Combo graph for the TEER 
measurements and fluorescence concentration for 0.5 µg/ml R-GLA-DTX-NLC, (b) Combo 
graph for the TEER measurements and fluorescence concentration for 1 µg/ml R-GLA-
DTX-NLC, (c) scatter graph for the Papp values plotted with time of 0.5 and 1 µg/ml R-
GLA-DTX-NLCs. Data are mean ± SD, (N=3). 
 
Figure 5.8 a and b represents R-ALA-DTX-NLC permeation through the 3D in-vitro BBB 
model through the transient opening of the TJ, indicated by the reduction in the TEER 
values from 286.5 ±2.5 Ω/cm² for the control to 243.66 ±0.33 Ω/cm² at 1 h, when 
incubated with 0.5 µg/ml R-ALA-DTX-NLC (Figure 5.8 a); and to 243.11 ±4.14 Ω/cm² at 2 h 
when 1 µg/ml R-ALA-DTX-NLC was incubated (Figure 5.8 b). The permeation of 
fluorescence-tagged ALA-DTX-NLCs concentration of 0.5 and 1 µg/ml R-ALA-DTX-NLCs 
that were sampled from the basolateral side of the insert was calculated using the 



























































0.5 and 1 µg/ml R-ALA-DTX-NLCs permeation were exhibited at 6 h incubation (Figure 5.8 
a, b). Additionally, the calculated Papp values for both tested concentrations of R-ALA-
DTX-NLCs showed high apparent permeability at an early time point followed by a 
reduction in the Papp values when the higher concentration was examined at 1 h, and 
until the termination of the experiment at 6 h incubation time, while at a lower 
concentration the Papp reached the highest level at 2 h incubation followed by lower Papp 
values at 4 and 6 h incubation time (Figure 5.8 c). Similar mechanisms that were discussed 
for the permeation of R-GLA-DTX-NLCs might be exhibited by R-ALA-DTX-NLCs 
permeation as well, due to the fact that they are both PUFAs and might bind to similar 
receptors. To the best of our knowledge, both R-GLA-DTX-NLCs and R-ALA-DTX-NLCs are 
newly developed NLCs for brain-targeted therapy, and no previous reports have been 





Figure 5.7 Standard calibration plot for (a) 0.5 µg/ml R-ALA-DTX-NLC (b) 1 µg/ml R-ALA-
DTX-NLC. Data are mean ± SD, (N=3). 





























































Figure 5.8 In-vitro BBB permeability of R-ALA-DTX-NLCs (a) Combo graph for the TEER 
measurements and fluorescence concentration for 0.5 µg/ml R-ALA-DTX-NLC, (b) Combo 
graph for the TEER measurements and fluorescence concentration for 1 µg/ml R-ALA-
DTX-NLC, (c) scatter graph for the Papp values plotted with time of 0.5 and 1 µg/ml R-












































































































To test the permeability of the R-DTX-NLC after functionalisation with selective SA43-
aptamer, one level concentration was examined at 1 µg/ml R-SA43-DTX-NLC. A drop in 
the TEER values was observed from 294.77 ±5.17 Ω/cm² for the control to 255.33 ±24.09 
Ω/cm² at 4 h incubation time (Figure 5.10 a). These values indicated that the BBB took a 
longer time to recover when it was incubated with R-SA43-DTX-NLC, as compared to the 
other three formulations discussed earlier (R-DTX-NLC, R-GLA-DTX-NLC, and R-ALA-DTX-
NLC). Additionally, the calculated concentration was higher after 6 h incubation time, as 
calculated by using the standard plot in figure 5.9 for R-SA43-DTX-NLC. Interestingly, the 
Papp values calculated for 1 µg/ml R-SA43-DTX-NLC at different time intervals indicated a 
lower Papp (Figure 5.10 b), and a different pattern compared to the other three 
formulations, where the highest Papp was achieved at 0.5 h and remained almost 
constant until the termination of the experiment at 6 h. The free SA43-aptamer has 
previously been evaluated for its permeation through the 3D in-vitro BBB model, where a 
temporary drop in the TEER values indicated the transit opening of the TJ, and an apparent 
permeability of 4.32 ± 3.90 x10−9 cm/min was reported (Aptekar et al., 2015). Aptekar et 
al., (2015) found staining of patient glioblastomas tissue sections revealed that SA43 
aptamer binding to endothelial cells was variable, therefore the process of permeability 
was uncertain as to whether it was transcellular or via an endothelial specific protein. 
While the mechanism of the SA43-aptamer passing through the BBB is still unknown at 
this stage, several mechanisms might be involved in crossing through the BBB, that could 
be attributed to transcellular transport, or the variable binding to endothelial cells may 
suggest that the aptamer is able to bind to endothelial specific ligands within the cell 
(Aptekar et al., 2015).  
 
Figure 5.9 Standard calibration plot for 1 µg/ml RSA43-DTX-NLC. Data are mean ± SD, 
(N=3). 


































Figure 5.10 In-vitro BBB permeability of R-SA43-DTX-NLCs (a) Combo graph for the TEER 
measurements and fluorescence concentration for 1 µg/ml R-SA43-DTX-NLC, (b) scatter 
graph for the Papp values plotted with respect to time for the evaluation of 1 µg/ml R-
SA43-DTX-NLCs. Data are mean ± SD, (N=3). 
 
There was no significant difference in the Papp values of all the four formulations when 
compared with one another at 1 h incubation time at of concentration 1 µg/ml as 
demonstrated the Papp values were 2x 10-3, 1.8x 10-3, 1.9x 10-3, 1.02x 10-3 cm/Sec for R-
DTX-NLC, R-GLA-DTX-NLC, R-ALA-DTX-NLC, and SA43-DTX-NLC, respectively. 
Furthermore, no significant difference was exhibited when 0.5 µg/ml concentration of R-
DTX-NLC, R-GLA-DTX-NLC, and R-ALA-DTX-NLC was evaluated, the Papp were 2.9x 10-3, 
3x10-3, and 4.1x 10-3 cm/Sec, respectively. Though significantly higher concentrations 
permeated to the basolateral side for R-GLA-DTX-NLC and R-ALA-DTX-NLC in comparison 
to the R-DTX-NLC at 6 h incubation, indicating that both PUFA surface modified 


























































that all four formulations permeated through the BBB model in a similar manner at the 
examined time point (1 h) for each designated concentration. In this study, the Papp is 
not a time-dependent or concentration-dependent variable as demonstrated in figures 
5.4c, 5.6 c, 5.8 c, and 5.10 b, as higher Papp values were shown for lower concentration 
0.5 µg/ml when R-DTX-NLC, R-GLA-DTX-NLC, and R-ALA-DTX-NLC were evaluated. 
All four formulations displayed permeation through the BBB model that might be due to 
the transient opening of the TJs allowing the NLCs to pass through the BBB model by 
paracellular diffusion, as previously reported some molecules have the ability to diffuse 
through the BBB, by passing through the TJ (Patel et al., 2013; Kumar et al., 2014). In 
addition to the transient opening of the TJ, there are different mechanisms for the NLCs 
penetration across the BBB, it might be attributed to the type of surfactants that were 
used for the fabrication of the NLCs that facilitated the passage through the BBB. As 
indicated by a previous study that the size and surface charge of NPs had no influence on 
BBB permeation, and it was the surfactant that affected the BBB permeation (Voigt et al., 
2014).  Soy lecithin (Lipoid S75), was used for fabrication of the SLN reported by 
Manjunath and Venkateshwarlu (2006), for enhancing the BBB uptake. Likewise, for 
Solutol® HS15 (Singh et al., 2013). These two surfactants were used for the fabrication 
and development of the NLCs which could have contributed to BBB permeation of NLCs. 
Also, the lipophilicity of the NLCs might contribute to their ability to pass through the 3D 
in-vitro BBB model as indicated in literature lipidic particles with low molecular weight 
drugs can pass the BBB by trans-cellular diffusion (Patel et al., 2013). Moreover, enhancing 
of NPs phagocytosis by monocytes can be considered as an unconventional approach to 
deliver NPs-loaded drugs to the brain, after phagocytosis of NPs may transport their cargo 
into the brain (Afergan et al., 2008). The mechanism for BBB permeability and uptake of 
NPs was thought to be receptor-mediated endocytosis by the brain capillary endothelial 
cells, followed by transcytosis (Gabathuler, 2010). The PUFAs functionalised NLCs (R-GLA-
DTX-NLC and R-ALA-DTX-NLC) might permeate through the BBB model through binding to 
FABP7 receptors (Elsherbiny et al., 2013; Shimizu et al., 1997). Moreover, Fatty acids have 
the ability to enter the brain by passive diffusion and proteins-mediated transport by the 
membrane-associated proteins, like fatty acid transport proteins and fatty acid 
translocases (CD36) as indicated by Chen et al., (2008). As far as we know the SA43 may 
have the ability to bind to endothelial specific ligands that might lead to R-SA43-DTX-NLC 
permeation through the BBB, in addition to other mentioned mechanisms listed above 




evaluation of all four formulations, due to no EBD detectable in the basolateral side of the 
insert during and at the end of the experiment.   
5.5.3. Evaluation of the permeability of DTX and DTX-NLC across 3D 
in-vitro BBB model using HPLC method 
DTX-NLC is a newly developed carrier aimed for targeted delivery and enhances 
therapeutic for the treatment of glioblastoma, therefore the evaluation of its permeability 
through the BBB is a necessary and essential step at this stage as previously recommended 
by Doan et al., (2002) and Kikuchi et al., (2013). Additionally, there are few reports of in-
vitro models for testing the permeability of different compounds using the HPLC method 
for quantification, a monoculture model established from HBMEC, and tri-culture 
cultivated from rat primary cell lines as detailed by Moradi-Afrapoli et al., (2016), likewise 
a tri-culture in-vitro BBB model of rat origin was also used by Jahne et al., (2014). As 
described in section 5.5.2 DTX-NLCs showed high permeation through the 3D in-vitro BBB 
model established from all human origin primary cells, due to the high Papp values 
quantified using fluorescence labelled DTX-NLCs. The gold standard for separation and 
quantification of compounds in the pharmaceutical industry is HPLC with an appropriate 
detection technique such as UV or tandem mass spectrometry.  We have developed and 
validated a specific HPLC-UV method for quantification of DTX in a biological matrix 
comprising of a mixture of culture media used in the in in-vitro BBB model. Experiments 
as described in section 5.4.5, for the DTX and DTX-NLCs were repeated using a different 
method of quantification (HPLC-UV) and evaluated for permeation through the BBB 
model at two level concentrations. Formulations used in this study were not labelled with 
a fluorescence marker. Compared to the higher sensitivity of fluorescence, there was 
concern that detection of DTX on the basolateral side of the model would be lower than 
the LOD for the HPLC method (Chapter two, Section 2.5.3.3.7). Therefore, DTX-NLCs were 
studied at 1 and 2 µg/ml concentrations. Figure 5.11 showed the TEER values dropping 
from 330.33 ±13.38 Ω/cm² (control) to 296.66 ±7.76 and 309.66 ±5.13, Ω/cm² at 0.25 and 
1 h respectively, when incubated with 1 µg/ml DTX-NLC, then the TEER values returned to 
normal values following 2 h incubation. When 2 µg/ml DTX-NLC was evaluated the TEER 
values took a longer time to recover. TEER values for the control 330.33 ±13.38, then 
reduced to 308.66 ±9.50, 299 ±18.08, and 300.88 ±19.29 Ω/cm² at 0.25, 1, and 2 h 
incubation that indicated the transient opening of the TJ (Figure 5.11 a). The similar 
pattern was notable when 1 µg/ml of DTX solution was evaluated through the model as 
the TEER values were 333.33 ±10.38 Ω/cm² for the control and followed by dropping at 




2 µg/ml DTX solution was tested TEER values 333.33 ±10.38 Ω/cm² for the control, were 
followed by fluctuation in the TEER, till it decreased to 290.66 ±5.03 Ω/cm² at final 
incubation time (6 h) as shown in figure 5.11 b. It would seem that the BBB model did not 
recover and TEER values remained decreased even at 6 h after adding a high 
concentration of DTX, though the integrity of the model was still intact, as measured by 
EBD evaluation at the end of the experiment. The model was considered intact when 
there is no detectable EBD in the basolateral side of the insert. This unbalanced and 
variation in the TEER values might be attributed to the fact that DTX at higher 
concentration might cause toxicity to the tri-culture cells.  
      
(a)                                                                   (b)        
Figure 5.11 TEER measurements over 6 h (a) for 1 and 2 µg/ml DTX-NLC, (b) 1 and 2 
µg/ml DTX solution, where the control is the tri-culture cell lines without treatment. 
Data are mean ± SD, (N=3). 
 
DTX exhibited a high potency and toxicity in normal and cancerous cell lines as we 
previously determined in Chapter Four (Section 4.5.2.1), and it would appear that the BBB 
model lost barrier function when it came into direct contact with the DTX alone. The Papp 
values for 1 µg/ml for DTX-NLC and DTX after 6 h incubation period was 40 x10-3 and 25x 
10-3 cm/Sec respectively, showing a highly significant difference between the two 
treatments. When 2 µg/ml of DTX-NLC and DTX were examined there was no significant 
difference between the Papp. DTX is a CNS negative drug (P-gp substrate) (Loscher and 
Potschka, 2005), but our data indicated the ability of DTX to pass through the BBB on 
prolonged incubation, though that high concentration of DTX damaged the stability of the 










































 To our knowledge, no previous reports have been published for testing the permeation 
of DTX through a 3D in-vitro BBB model. Our data indicated that the permeability is not a 
concentration-dependent variable as also shown in section 5.5.2 when two level 
concentration were examined with a fluorescence labelled DTX-NLCs. Additionally, the 
higher values of Papp that were acquired after quantifying DTX from the biological matrix 
by HPLC showed a more efficient way and better method to determine the actual Papp 
values. due to a high extraction recovery % as the extraction recovery was ranging 
between 100.02 and 90.03 % as detailed earlier in chapter two (section 2.5.3.3.5).   
5.5.4. Evaluation of DTX-NLCs and surface modified DTX-NLCs uptake 
by U87MG monolayer following the permeability across 3D in-vitro 
BBB model  
To explore the fate of four formulations, R-DTX-NLC, R-GLA-DTX-NLC, R-ALA-DTX-NLC, and 
R-SA43-DTX-NLC after passing through the 3D in-vitro BBB model as detailed in section 
5.5.2, we propose to determine these four formulations uptake by a glioblastoma U87MG 
monolayer. In addition, to evaluate the effect of the presence of U87MG with the 3D in-
vitro BBB model, the TEER, concentration by fluorescence quantification from the 
basolateral side and Papp were calculated. As summarised in section 5.4.6, the U87MG 
cells were seeded on the bottom of the plate then the tri-culture BBB model was 
introduced to glioblastoma cells once the TEER values were high enough ranging between 
260-290 Ω/ cm2.  
The TEER was 297.66 ±24.2 Ω/cm² for the control (untreated cells), then followed by a 
maximum drop in the TEER values to 253.66 ±7.96Ω/cm² at 1 h, when R-DTX-NLC 1 µg/ml 
was incubated. The TEER gradually returned close to the control values (Figure 5.12 a). A 
similar pattern was displayed by both R-GLA-DTX-NLC and R-ALA-DTX-NLC, the lowest 
TEER value was obtained after 1 h incubation for 1 µg/ml R-ALA-DTX-NLC and R-GLA-DTX-
NLC (Figure 5.12 b and c). While for the R-SA43-DTX-NLC the TEER measurements 
indicated that the BBB model exhibited a longer time to retain normal TEER values as the 
TEER values were 261.77 ±14.43, 243.4 ±23.29, 257 ±30.94, and 255.33 ±24.09 Ω/cm² 
when incubated for 0.25, 1, 2, and 4 h, respectively (Figure 5.12 d). All four formulations 
indicated a change in the TEER values (Figure 5.12 e) which in turn proposed that they 
interact with the TJs proteins in the endothelial barrier causing them to open transiently 
and might suggest the permeation of those formulations through the paracellular 
diffusion as discussed in details in section 5.5.2. When comparing the four ligands there 
was no significant difference between them as to which caused the largest decrease in 




U87MG cells in the BBB model due to the virtually similar pattern were shown when the 
four formulation tested with the absence of the U87MG in the BBB model as detailed in 
section 5.2.2. This may be explained by the fact that BBB cells were not grown in the 
presence of the U87MG glioblastomas. In vivo, glioblastoma is known to grow behind 
intact BBB, as well as causing a leaky BBB in nearby vessels (On et al., 2013). The focus of 
this thesis was to improve the permeability of CNS therapeutics, therefore the intact BBB 
model was grown in the absence of U87MG cells, and the 3D insert was only exposed to 
the glioblastoma U87MG monolayer for 2 h during the experiment, to ensure that 
compounds from the glioblastoma secretome did not disrupt the barrier, skewing the 
apparent permeability of test formulations.  
 
         
(a)                                                                      (b) 
        










































































Figure 5.12 TEER measurements over 6 h time intervals for (a) 1 µg/ml R-DTX-NLC, (b) 1 
µg/ml R-DTX-NLC and R-GLA-DTX-NLC, (c) 1 µg/ml R-DTX-NLC and R-ALA-DTX-NLC,(d) 1 
µg/ml R-DTX-NLC and  R-SA43-DTX-NLC, and (e) combined data for 1 µg/ml R-DTX-NLC, 
R-GLA-DTX-NLC, R-ALA-DTX-NLC, and R-SA43-DTX-NLC . Data are mean ± SD, (N=3). 
 
In addition to measuring the TEER values, we quantified the concentration for the samples 
that were collected from the basolateral side of the insert,reading fluorescence values 
from the standard plot shown in figures 5.13 a, b, c, and d for the R-DTX-NLC, R-GLA-DTX-
NLC, R-ALA-DTX-NLC, and R-SA43-DTX-NLC, respectively (Figure 5.14).  
The concentration of DTX-NLCs permeated in the presence of the U87MG in the 3D in-
vitro BBB model was significantly higher than the fluorescence concentration examined 
with BBB model in absence of the U87MG cells for all the all four formulations R-DTX-NLC, 
R-GLA-DTX-NLC, R-ALA-DTX-NLC, and R-SA43-DTX-NLC, respectively at 1 µg/ml (figures 5.4 
b, 5.6 b, 5.8 b, and 5. 10). 
Data showed a higher concentration passing through the BBB model, with a slight increase 
with respect to time, and R-SA43-DTX-NLC fluorescence concentration showed a highly 
significant difference in comparison to R-DTX-NLC and R-GLA-DTX-NLC, and no significant 
difference when compared with R-ALA-DTX-NLC at 1 h incubation time. All formulations 
demonstrated a permeation through the BBB model even when the TEER returned to 
normal values, leading to the conclusion that there may be different mechanisms that 


























































































Figure 5.13 Standard calibration plots 1 µg/ml of (a) R-DTX-NLC, (b) R-GLA-DTX-NLC, 
(c)R-ALA-DTX-NLC, and (d) R-SA43-DTX-NLC. Data are mean ± SD, (N=3). 
 
 


























































Figure 5.14 Fluorescence concentrations for 1 µg/ml of R-DTX-NLC, R-GLA-DTX-NLC, R-
ALA-DTX-NLC, and R-SA43-DTX-NLC, respectively, that were sampled from basolateral 
side (B) of the insert at 1, 2, 4, and 6 h. Data are mean ± SD, (N=3). 
 
The apparent permeability for all formulations was calculated using equation 5.1 and 
plotted with respect to time (Figure 5.15), the Papp indicated a higher value at 1 h 
incubation time for all four formulations, additionally, the Papp of R-SA43-DTX-NLC was 
significantly higher then Papp of R-DTX-NLC, and no significant difference between R-
SA43-DTX-NLC when compared with R-GLA-DTX-NLC and R-ALA-DTX-NLC. Furthermore, a 
significant increase in Papp was displayed when R-GLA-DTX-NLC and R-ALA-DTX-NLC were 
compared with R-DTX-NLC at 1 h incubation time. The Papp values were high at 1 h 
incubation then started to reduce over time. From this results we gather that the Papp 
values were high due to the opening of the TJ and it was reduced when the TEER values 
returned close to normal values indicating the close of the TJ gap, and due to the fact that 
the TEER values of R-SA43-DTX-NLC took longer time to return to normal values than the 



















































increase of R-SA43-DTX-NLC permeation and resulted in high Papp value at 1 h incubation 
(Figure 5.15).  
 
 
Figure 5.15 Expressing the for the Papp values in a scatter graph plotted with respect to 
different time intervals, for 1 µg/ml of R-DTX-NLC, R-GLA-DTX-NLC, R-ALA-DTX-NLC, and 
R-SA43-DTX-NLC. Papp was calculated for samples collected from the basolateral side 
of the insert for each formulation at 1, 2, 4, and 6 h. Data are mean ± SD, (N=3). 
 
To determine the uptake of all four formulations by U87MG after passing through the BBB 
model the U87MG cells were collected from the bottom of the plate after 6 h incubation 
with the four formulations, then samples were prepared and analysed using the flow 
cytometer to quantify the amount of the formulations that were uptaken by U87MG. The 
MFI indicated no significant difference when all four formulations were compared with 
each other (Figure 5.16 a), suggesting that the ligands attached to the surface of the NLCs 
might need to be increased to enhance the uptake of the formulation after passing the 
BBB model. There was an enhanced rate of permeation of the NLCs when it was surface 
modified with the SA43-aptamer. The flow cytometer histograms in figures 5.16 b and c 
showed the peak shifting towards the right side, due to U87MG uptake in all four 




























   
(b)                                                                     (c) 
Figure 5.16 U87MG uptake data following penetration through the BBB model (a) MFI 
at 6 h incubation with 1 µg/ml R-DTX-NLC, R-GLA-DTX-NLC, R-ALA-DTX-NLC, and R-SA43-
DTX-NLC, respectively. Data are mean ± SD, (N=3), (b) flow cytometer histograms 
demonstrating the U87MG uptake, and peak shifts for 6 h incubation time of 
control (untreated U87MG cells), and 1 µg/ml of R-DTX-NLC, R-GLA-
DTX-NLC, and R-ALA-DTX-NLC, respectively and (c) flow cytometer histograms 
demonstrating the U87MG uptake, and peak shifts for 6 h incubation time of  
control (untreated U87MG cells) and  1 µg/ml of R-SA43-DTX-NLC, respectively. 
Data are (N=3). 
 
Generally, Papp was considered high in case Papp ˃  60 × 10−6 cm/min according to Amidon 
et al., (1995); Esposito et al., (2016) and Kumar et al., (2014). It is worth mentioning that 
GB cells exhibit overexpression of vascular endothelial growth factor (VEGF), which is an 
angiogenesis factor. VEGF might be related to the increase in the paracellular permeability 
in a BBB model (Miao et al., 2014; Dwyer et al., 2012). The brain tumour barrier model 
























permeability (Kumar et al., 2014). In our case, the increase in paracellular permeability 
might lead to the excess NLCs permeating through the BBB model in the presence of the 
U87MG cells, suggesting the existence of glioblastoma promotes endothelial permeability 
in brain microvascular endothelial cells as previously demonstrated by Dwyer et al., 
(2012). Additionally, other mechanisms might be involved in higher permeation of R-GLA-
DTX-NLC and ALA-DTX-NLC, such as the capacity to promote the NLCs to bind to the brain 
FABP7 receptors. PUFAs (GLA and ALA) have been reported to bind to these receptors 
(Elsherbiny et al., 2013; Shimizu et al., 1997). The ability of SA43-aptamer to bind to Ku 
70 and Ku 80 and also to bind to endothelial specific ligands within the cell (Aptekar et al., 
2015) might cause the higher permeability of this three formulation through the BBB 
model in presence of U87MG more than the permeability that have been shown to same 
formulation when tested in the same model without the presence of U87MG, 
glioblastoma induce permeability, through its receptor CXCR2 on brain endothelial 
(Dwyer et al., 2012). 
 
5.5.5. Evaluation of DTX-NLCs and surface modified DTX-NLCs effect 
on P-gp efflux pump using 3D in-vitro BBB model  
For the purpose of evaluating the efflux inhibition potential of DTX-NLC, GLA-DTX-NLC, 
ALA-DTX-NLC, and SA43-DTX-NLC, rhodamine 123 efflux pump activity in the presence 
and absence of the four formulations relative to verapamil and vinblastine were 
evaluated, as detailed in section 5.4.7. Rhodamine123 (R) a well known cell-permeable 
and was used for examining membrane transport, Rhodamine 123 is a P-gp substrate 
efflux transport (Yang et al., 2015).  was used in 10 µg/ml concentration in combination 
with all samples. A standard plot of R was generated to quantify its concentration in the 
basolateral side of the insert.  
Efflux activity of R  was significantly reduced when incubated at 4° C compared to R 
concentration when incubated at 37 °C. Additionally, when efflux activity of 10 µg/ml R 
(no P-gp inhibitors) was compared to 10 µg/ml R concentration in the presence of P-gp 
inhibitors verapamil and vinblastine, a significantly higher concentration of R, was 
measured on the basolateral side, confirming verapamil and vinblastine effect as P-gp 
inhibitor (Figure 5.17) these results were in line with previous research by Yang et al., 






A significantly lower concentration of R was seen when DTX-NLC formulation was 
incubated with 10 µg/ml R at 37 °C suggesting that DTX-NLC, might be not an active efflux 
inhibitor, or might need longer incubation time to display its effect. Some NPs in the 
literature have been found to act as P-gp inhibitors depending on their compositions 
(Bansal et al., 2009a).  Solutol HS-15 and Labrasol have the ability to inhibit the P-gp 
functions and enhance drug accumulation, through their ability to insert themselves 
between the plasma membrane lipid tails of the lipid bilayer and fluidise the membrane. 
Also, they might interact with the bilayers polar head groups and modify the hydrogen 
bond or ionic bond forces which may add on to the inhibitory effect of P-gp inhibitors (Lo 
2003). Both of these surfactants were used for the fabrication of our DTX-NLC 
formulation. Notably, the absence of any P-gp inhibition may be due to a lower 
concentration of excipients (Figure 5.17). 
GLA-DTX-NLC also had a similar effect as the DTX-NLC. Some PUFAs have a role as P-gp 
expression suppressor as previously reported by Srivalli and Lakshmi, (2012) and  Yuan et 
al., (2008), through elevated levels of ROS, but it is known that changing gene expression 
needs a long time to be achieved, hence GLA-DTX-NLC did not express a notable change 
in the R concentration when samples were collected from the basolateral side of the BBB 
model. While ALA-DTX-NLC and SA43-DTX-NLC demonstrated no significant increase in R 
concentration when compared to the 10 µg/ml R at 37 °C (Figure 5.17), which suggest that 
their effect as P-gp inhibitors might appear on prolonging incubation time or considering 






Figure 5.17 Papp values for 10 µg/ml Rhodamine123 (R) at 37 °C, 10 µg/ml R at 4 °C, 10 
µg/ml R+ 100 µM verapamil at 37 °C, 10 µg/ml R+ 22 µM vinblastine at 37 °C, 10 µg/ml 
R+ 1 µg/ml DTX-NLC at 37 °C, 10 µg/ml R+ 1 µg/ml GLA-DTX-NLC at 37 °C, 10 µg/ml R+ 
1 µg/ml ALA-DTX-NLC at 37 °C, 10 µg/ml R+ 1 µg/ml SA43-DTX-NLC at 37 °C after 1 h 
incubation. All samples were compared to 10 µg/ml R at 37 °C. * P < 0.05, ** P < 0.001 
and *** P < 0.000 refers to the significant difference. Data are mean ± SD, (N=3). 
 
In summary, the Papp suggested that ligands improved permeation of the DTX-NLC 
formulation due to the ability of PUFAs to enter the brain by passive diffusion and 
proteins-mediated transport by the membrane-associated proteins, like fatty acid 
transport proteins and fatty acid translocases (CD36) as indicated by Chen et al., (2008), 
but this does not seem to have been achieved by P-gp inhibition, leading to the conclusion 
that the attached ligands may be masking the P-gp inhibiting groups of the NLC. The 
additional active transport mediated mechanism, such as receptor-mediated endocytosis, 
may be involved as PUFAs might enable the DTX-NLC binding to the brain FABP7 
receptors, and the ability of SA43-aptamer to Bind to Ku 70 and Ku 80, thus increasing the 
permeability of DTX-NLC through the 3D in-vitro BBB model, which makes these 
formulations suitable as a carrier system of chemotherapeutic drug docetaxel for brain 





































































The main aim of this project was to enhance selectivity and therapeutic efficacy of an 
anticancer drug docetaxel (DTX) for targeting and treating glioblastomas, by examining 
the glioblastoma cell lines proliferation, internalisation, uptake, cell cycle distribution and 
permeation through 3D in-vitro BBB model that was set up from human origin cell lines. 
 This was achieved by enhancing permeation through the BBB of the poorly water-soluble 
drug DTX, by incorporating it into nanostructure lipid carrier (NLC) as a delivery system 
composed of biodegradable excipients and increasing its selective uptake by glioblastoma 
cells by use of novel aptamer and polyunsaturated fatty acids (PUFAs) as targeting ligands.  
 
6.1.1. Analytical methods development and validation  
• HPLC method was developed and validated for quantification of DTX from NLCs to 
determine total DTX content and its entrapment efficiency within the DTX-NLCs. THF 20% 
and 80% mobile Phase (Acetonitrile and water, 50:50), was found to be a suitable organic 
solvent system to completely dissolve the DTX-NLCs. Optimum chromatographic 
separation was achieved by a mobile phase consisting of acetonitrile and water (50:50, 
v/v), used at a flow rate of 1.0 ml/min. The method demonstrated high linearity in the 
range of 1 to 10 µg/mL with a coefficient of regression 0.9994. The minimum detectable 
concentration of DTX (LOD) was 0.013 µg/ml and the minimum concentration that the 
HPLC method is able to quantify (LOQ) was 0.041 µg/ml. The method was found to be 
highly sensitive, specific, repeatable and reproducible with accuracy ranging between 99 
% to 100.6 %, All validated parameters were well within the acceptable values of the ICH 
and FDA guidelines.  
• Moreover, HPLC methods were also developed and validated successfully for 
quantification of DTX released from the NLCs into the two-dissolution media. This method 
was used for quantifying and establishing the release kinetics of the DTX from the 
developed DTX-NLCs. The method revealed high linear regression with an R2 value of 
0.999, this method was precise and accurate with high specificity and sensitivity with all 
validated parameters well within the acceptable values of the ICH and FDA guidelines.  
• Also, a new HPLC method was developed for the quantification of DTX in a biological 
matrix containing a mixture of three primary cell culture media consisting of proteins and 
human serum. Paclitaxel was used as an internal standard. Retention time for DTX and 
PTX were found at 7.2min and 7.7 min respectively with no interference from the 




concentration range of 0.05 to 2 µg/ml and was accurate, repeatable and precise with 
high extraction recovery ranging from 90.03-100.02 %. This method was used for 
quantification of DTX and DTX-NLC that permeated through the physiological 3D in-vitro 
BBB model. All validated parameters were well within the acceptable values of the ICH, 
FDA, and EMA guidelines. This method would be of a great value and contribution for 
future research as to the best of our knowledge there is no method developed for the DTX 
and DTX-NLC extraction and quantification in BBB culture media.  
6.1.2. DTX-NLCs development, functionalisation and 
characterisation 
• DTX loaded NLCs (DTX-NLC) were successfully developed using hot homogenisation 
technique using probe sonication. DTX was successfully encapsulated in the NLCs using 
solid lipid triglyceride Dynasan®114 (D114) with a combination of three liquid lipids to 
enhance DTX solubility and stabilised using a combination of surfactants that not only 
reduced the interfacial tension and produced stable NLCs but also act as P-gp inhibitors 
and would possibly improve BBB permeation.  
• During development, both product and process parameters were thoroughly optimised 
initially using one-factor-at-a-time approach followed by 32 factorial design. Amongst the 
process parameters, the temperature was found to be a critical parameter affecting DTX 
stability and required to be controlled during the production of NLCs. In product 
parameters, lipid and surfactant concentration affected the critical quality parameters 
(Particle size, PDI, zeta potential, total drug, entrapment efficiency) of the DTX-NLCs and 
stable formulation could be identified with the response surface methodology.   
• DTX-NLC was characterised by low particle size (136 nm), uniform distribution (0.23), 
spherical shape, high drug entrapment efficiency (99.1 %) and desirable drug release over 
the period of 24 h. This formulation also exhibited high zeta potential (ZP) -32 mV, which 
aided in its stability. DSC, XRD and FTIR confirmed the presence of the entrapped drug in 
an amorphous state in NLCs.  
• Successful functionalisation of DTX-NLC with two PUFAs (GLA and ALA), and one novel 
SA43-aptamer could be achieved using EDC-NHS chemistry. It was established that the 
free amine group (FAG): GLA ratio of 1: 1/5, ALA ratio of 1: 1/6 and FAG: the SA43-aptamer 
ratio of 1:8 were the most favourable ratios for conjugation of GLA, ALA, and SA43-
aptamer respectively to DTX-NLCs. To the best of our knowledge, these ligands were not 
previously reported for their conjugation with NLCs as ligands for treatment of 
glioblastoma. These surface modified DTX-NLCs would contribute to the ongoing research 




DTX-NLC, and SA43-DTX-NLC  formulations exhibited low particle size and fairly uniform 
particle size distribution with high drug entrapment efficiency. FTIR spectral analysis, 
Raman spectroscopy and reduction of free surface amines confirmed the covalent 
bonding of ligands.  
•  DTX-NLC could be successfully lyophilised to produce a free-flowing product by using 10% 
trehalose as a cryo-protectant. Remarkably a low particle size could be achieved on 
reconstitution with only 13 nm increase in particle size from the original DTX-NLC before 
the lyophilisation. The freeze-dried form showed good stability for up to six months when 
stored at a temperature of 4 °C and -20 °C. Further, DTX-NLC in liquid dispersion form 
demonstrated good colloidal stability in water and dextrose 5% physiological media for 
up to 24 h. 
 6.1.3. In-vitro cell lines and 3D spheroids studies 
• Cell proliferation studies illustrated enhanced DTX-NLCs potency by surface modification 
of the DTX-NLC with PUFAs when treated with U87MG glioblastoma cells.  Both GLA-DTX-
NLC and ALA-DTX-NLC displayed similar activity towards U87MG at 24 h and highly 
significant low IC50 value than bare DTX-NLC. ALA-DTX-NLC demonstrated higher potency 
than GLA-DTX-NLC when incubated for 48 h with U87MG, while both formulations 
displayed higher activity than DTX-NLC at 48 h. The ligand density had an impact on cell 
proliferation as well as the presence of antioxidants in the NLCs. The SA43-DTX-NLC 
displayed lower toxicity towards U87MG cell lines as compared to DTX and DTX-NLCs. 
• DTX-NLC demonstrated less toxicity towards SVG P12 than DTX at 24 and 48 h respectively 
signifying its lower toxicity to the non-cancerous cells at early time points. GLA-DTX-NLC 
and ALA-DTX-NLC both showed lower cell toxicity towards SVG P12 at 24 h. Interestingly 
GLA-DTX-NLC exhibited less toxicity towards SVG P12 at 48 h than the ALA-DTX-NLC. 
However, all the three formulations showed no significant difference in their activity 
towards SVG P12 at 72 h. SA43-DTX-NLC exhibited the least toxicity towards SVG P12 than 
all the tested samples, therefore, can be considered the safest formulation to non-
cancerous cells. 
• When tested on patient-derived glioblastoma BTNW911 cell lines, ALA-DTX-NLC displayed 
higher activity (significantly low IC50) than both DTX-NLC and GLA-DTX-NLC at all time 
points, and GLA-DTX-NLC, in turn, exhibited more potency (significantly lower IC50) than 
DTX-NLC at all time points when treated with BTNW911 cell). Thus DTX-NLC potency 
increased when surface modified with PUFAs due to the tumoricidal effect of PUFAs 




The SA43-DTX-NLC showed lower activity than DTX-NLCs probably due to lack of any 
therapeutic effect of the SA43. 
• Delivery of DTX using NLCs showed favourable cytotoxicity towards the 3D U87MG 
spheroids than treatment with the native drug, which might be due to the higher cellular 
uptake of DTX-NLC by spheroid cells as confirmed from the FACS data. Interestingly GLA-
DTX-NLC demonstrated less toxicity towards U87MG spheroids while ALA-DTX-NLC and 
SA43-DTX-NLC elicited similar potency as DTX. 
• Fluorescence microscopy and FACS analysis also confirmed the preferential uptake of 
NLCs by glioblastoma cells in comparison to normal cells (p<0.05) when the DTX-NLCs 
were surface modified with GLA, ALA, and SA43-aptamer. The obtained data also indicate 
that SA43-DTX-NLC showed higher selectivity towards U87MG cell lines rather than non-
cancerous brain cells SVG P12. 
The internalisation mechanisms showed both time and concentration-dependent cellular 
uptake when U87MG cell lines were treated with all four formulations with notably less 
uptake by SVG P12 cells. All four formulations were uptaken by patient-derived cell line 
BTNW911. Additionally, 3D U87MG spheroids demonstrated higher uptake with DTX-NLC, 
and surface modification of DTX-NLCs did not enhance the 3D U87MG spheroids. Longer 
incubation time might be required in case of 3D U87MG spheroids uptake. 
• Fluorescence microscopy and FACS analysis for endocytosis pathway study demonstrated 
that all four formulations internalised through multiple pathways (clathrin-mediated 
pathway, caveolae/ lipid rafts pathway, and involvement of 
micropinocytosis/phagocytosis). Additionally, it was observed that the mechanism of cell 
uptake might be through active transport due to lower uptake of formulations at 4 °C. 
• Cell cycle distribution results in U87MG cells demonstrated all examined formulations 
followed DTX pattern and clearly showed arrest at drug-induced G2/M phase. 
 
6.1.4. 3D in-vitro BBB model for evaluation of NLCs permeability  
• 3D in-vitro BBB model of all human cell lines illustrated high TEER value of 300 Ω/cm2 
obtained on day 8, exhibiting integrity of the model. This model was used for screening 
the permeability of DTX, DTX-NLC and surface modified DTX-NLCs.  
DTX-NLCs and all three surface modified DTX-NLCs demonstrated high permeation 
through the model, with apparent permeability ranging between 1.02x 10-3 - 2x 10-3- 
cm/Sec which, might be due to paracellular diffusion. Notably, when DTX-NLC was 
functionalised with GLA and ALA, it caused a high concentration permeation of the 




receptors. SA43-DTX-NLC displayed similar permeability as DTX-NLC when studied using 
in-vitro BBB model.  
• However, in the tumour presence model where a layer of U87MG was grown on the 
basolateral side of in-vitro BBB model, R-SA43-DTX-NLC, R-GLA-DTX-NLC and R-ALA-DTX-
NLC fluorescence concentrations showed a highly significant increase in comparison to R-
DTX-NLC (at 1h), suggesting that surface modification of the R-DTX-NLC with selective 
SA43-aptamer and PUFAs contributed to higher circulating concentration on the 
basolateral side of the 3D insert. Also, FACS data confirmed that all four formulations were 
uptaken by the U87MG cells after passing through the 3D in-vitro BBB model.  
• DTX-NLC and surface modified DTX-NLCs formulations were not active P-gp inhibitors 
leading to the conclusion that the attached ligands might be masking the P-gp inhibiting 
groups of the NLC. The active transport via transcytosis might be the mechanism 
responsible for the permeation of the DTX-NLCs through the BBB model due to the 
notably lower concentration at 4°C which indicates an energy-dependent process. The 
receptor-mediated transcytosis, may be involved as PUFAs might enable the DTX-NLC 
binding to the brain FABP7 receptors, and the ability of SA43-aptamer to bind to Ku 70 
and Ku 80, thus increasing the permeability of DTX-NLC through the 3D in-vitro BBB 
model, which makes these formulations suitable as a carrier system of chemotherapeutic 
drug DTX for brain delivery treatment. 
6.1.5. General conclusion 
In conclusion, we have achieved the aim of this project of using NLCs as a carrier system 
for delivery of chemotherapeutic drug DTX for treatment of glioblastoma and improving 
its potency with increased toxicity towards glioblastoma cell lines by surface modification 
of the DTX-NLC with PUFAs (GLA and ALA). DTX-NLC was characterised by low particle size 
and uniform particle distribution with negative surface charge and lyophilised formulation 
stable for up to six months. 
All three-surface modified formulations demonstrated high uptake by glioblastoma 
U87MG cells, and notably less cellular uptake with non-cancerous brain cells (SVG P12), 
with distinguishing selectivity against glioblastoma cell line U87MG. 
DTX permeability through 3D in-vitro BBB model could be enhanced by encapsulation of 
DTX within the NLCs and further, the permeation was found to increase by surface 
modification of DTX-NLC with ligands (GLA, ALA and SA43-aptamer). Distinctive increase 
in the apparent permeability through the in-vitro tumour model in the presence of 




uptake by U87MG cells for all the three-surface modified DTX-NLCs, as compared to bare 
DTX-NLC acclaims not only their enhanced BBB permeability but also, improved cellular 
internalisation and selective uptake which merits their potential in future glioblastomas 
therapy. Our data will open the door for new carrier system that uses a selective and 
targeted therapy by surface modifying the nanoparticles with novel ligands comprising of 
polyunsaturated fatty acids and aptamer. Additionally, incorporation of docetaxel with a 
combination of solid and liquid lipids showed a down gradation of toxicity towards the 
non-cancerous brain cells while enabling the docetaxel nanoparticles to permeate 
through the in-vitro BBB model which indicates the possibility of solving the limitation of 
inability of docetaxel to penetrate the BBB and reduce its non-specific toxicity. 
6.2. Future work 
The present study involved the development of NLCs as a carrier system for 
chemotherapeutic drug docetaxel for enhancing its brain permeability and targeted 
delivery for treating glioblastomas. Several challenges still remain to be discovered to 
achieve more selective and higher potency within one single formulation. Additionally, 
further studies are required to exploit these systems for their potential use in 
glioblastoma therapy Given below is an outline of some of the ideas proposed for future 
work: 
• A long-term stability study of the DTX-NLCs according to ICH guidelines would need to be 
carried out to explore if they have any potential for commercial application.  
• Scale-up studies and understanding the effect of scale-up on critical quality attributes of 
the formulation. 
• The present studies on cytotoxicity and selectivity are based on in vitro studies, a detailed 
pharmacokinetic and biodistribution are required to understand the in vivo fate of the 
developed nanoparticulate formulations. 
• Also, efficacy studies in orthotropic glioblastomas model in nude mice would be one of 
essential next steps for proof of concept in vivo studies. 
• Presently the effect of PUFAs (GLA and ALA) and the SA43-aptamer have been studied 
individually for enhancing drug efficacy, cellular uptake, selectivity and permeability 
through the 3D in-vitro BBB model, it would be interesting to evaluate their effectiveness 





• Further studies are also required to evaluate the glioblastoma cell apoptosis mechanism 
for the developed NLCs and surface modified NLCs and also conduct experiments in the 
hypoxic chamber and evaluate the difference between non- hypoxic environments.  
• Since we established that the NLCs has the ability to permeate through the 3D in-vitro 
BBB model and also up taken by glioblastoma cells after passing the model, it would 
worthwhile to delineate the mechanism of transport of the NLCs and surface modified 
NLCs across the BBB model, and deciphering whether the permeability of the NLCs and 
surface modified NLCs was paracellular or transcellular.  
• Another aspect of future studies would be to study the systems in an advanced 3D in-vitro 
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Project Title: Developing Docetaxel lipid Nano-particle and Functionalised Lipid 
Nano-Particles Formulations for targeting brain tumours 
 
Is the application for samples to support the project being made to: 
Brain Tumour North West  (BTNW) Tissue Bank / Walton Research Tissue Bank 




Is the funding for the project   a) external (eg funded through a grant application) 
b) internal (eg funded from a researchers laboratory or 
institutional budget) 
                c) other (please give details) 
C) Self-funded project   
 
If the project has been submitted as a grant application for external funding?     
Was the application successful?    Yes / no  
Was the project externally peer-reviewed?   Yes / no 
 
External Funding body: None 
 
Details of Funding:  Total £ …………… (staff …………………and consumables 
…………) 
 





Does the project have ethics approval? No 
If yes, please supply reference number ……………….and date of approval ………….. 
 
Both Tissue Banks have generic ethical approval to supply tissue/data for projects conducted by internal 
applicants, without the need for further ethics approval. External researchers wishing to use tissue or data 






a) Are the applicants employed by NHS establishment(s)?             no 
b) Does the project involve research activity using the anonymised samples/data in an 
NHS establishment?        no 
 
If yes to a or b, the project may require research governance approval and applicants should consult the 
Research Governance Manager at their hospital 
 
Co-applicants:  Name      Affiliation 
Not applicable  
 
Outline of Project   
 
Please give a brief outline of the project under the headings below (not more than 1-3 A4 




Docetaxel (DTX) is a hydrophobic anticancer drug with poor water solubility and 
considerable systemic toxicity. This has limited its clinical application. In recent decades, 
the emergence of nanotechnology has provided new drug delivery systems for DTX, 
which can improve its water solubility, minimize the side effects and increase the 
tumour targeting. To improve the therapeutic potential of DTX, this study aims to 
develop a nanostructured lipid carrier (NLC) of DTX (DTX-NLC) that can pass the blood-
brain barrier (BBB) and target glioblastoma (GBM). 
 
Hypothesis and Study Aim  
Aims: 
1- To test designed DTX-NLC and functionalised DTX-NLCs with short-term culture 
cells 
2- To study the uptake of DTX-NLC and functionalised DTX-NLCs with short-term 
culture cells  
Plan of Project  
Conducting Cytotoxicity study and uptake study for designed DTX-NLC and 
functionalised DTX-NLCs with short-term culture cells 
 






To determine the effect of DTX, DTX-NLC, B-NLC, and functionalised DTX-NLCs on short-
term culture, cell viability study will be performed. When the cells reached confluency 
(Figure 7) cells will be seeded at a density of 2500 cells/90 µl/well in a 96-well plate. The 
cells will then culture for 24 hours prior to drug treatment concentrations (2.5, 5, 10, 25, 




the viability assay by adding 10 µl/well of Presto Blue following 24, 48 and 72 hours of 
incubation of cells treated with the drug to measure the cell viability. Media without any 
cells was used as a blank and cells and media without a treatment were used as a 
control. Plate reader (Genios Pro microtiter plate reader, Tecan, Austria) was used for 
detection of fluorescence response for PrestoBlue at an excitation wavelength of 535 
nm and an emission wavelength of 612nm. This experiment was repeated three times 
and a percentage of mean cell viability will be calculated using the following equation: 
% Cell Viability= (fluorescence of each concentration- fluorescence of the blank/ 
fluorescence of the control- fluorescence of the blank) *100          
A 50 % inhibition concentration (IC50) values for DTX, DTX-NLC and B-NLC were obtained 
and a concentration versus % mean cell viability was plotted using the Prism5 software. 
Uptake study 
It is proposed to analyse the cellular internalisation mechanism for entry of R123 
(Rhodamine 123)-DTX-NLC and functionalised R123-DTX-NLCs into short-term culture 
using flow cytometry (MERKE). The samples will be incubated at variable time points at 
concentrations with each cell line and analysed with a Guava Flow software. 
 
Data Analysis and Statistics 
 
Samples will be tested for normality distribution and an SPSS software for statistical 
analysis will be used. One way ANOVA will be performed on samples depending on a 
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fresh frozen tissue, the cellular component of blood, plasma or serum and how many 
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Primary cells  
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Please indicate if all samples are required at the start of the project or if further 
applications for samples will be made in the light of initial findings. 




Please also provide a brief lay summary (maximum 200 words) 
 
Due to previous results (unpublished data) the data have clearly demonstrated 




and uniform distribution. DTX-NLC and functionalised DTX-NLCs were 
characterised by high drug content and encapsulation efficiency, which exhibited 
more potency than DTX solution towards glioma cell lines and safety for non-
cancerous cell line. DTX-NLC and functionalised DTX-NLCs have the ability to 
pass through the in-vitro BBB model and up-taking fast by cancerous cells.  
The upcoming plan is to test DTX-NLCs and functionalised Aptamers and 
linolenic acids with DTX-NLC as potential targeting for brain tumour cells in short-
term culture, study viability for all generated NLCs with ligands will be performed 
and uptake study using flow cytometer on all validated DTX-NLCs and 
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